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CHAPTER 1 
 
INTRODUCTION 
 
1.1. The Colorful History of the Prodigiosin Alkaloids. 
The prodigiosin pigments are known for their bright colors and various biological 
activities.
1,2
 These bright red natural products have a long and ‘colorful’ history. The 
deep red color of these compounds is due to the pyrrolylpyrromethene core, in which 
three pyrrole units make up a system with substantial extended conjugation (Figure 
1.1).
1,3
 
 
 
Figure 1.1. Structures of the prodigiosin alkaloids. 
 
Various acyclic and cyclic substitutions can be incorporated onto the C-ring by 
different bacterial species. Nonylprodigiosin is completely cyclic, with an alkyl chain that 
2 
 
extends from the C-ring to connect to the A-ring. Roseophilin is another prodiginine 
alkaloid that incorporates a methoxyfuran in place of the methoxypyrrole of the 
prodigiosins and incorporates a strained macrocyclic motif that contains the azafulvene 
moiety. This strained macrocyclic azafulvene has been the focus of numerous total and 
formal syntheses.
1 
The prodigiosin alkaloids are secondary metabolites produced by a number of 
Gram-negative and Gram-positive bacteria, including Serratia spp., actinomycetes (such 
as Streptomyces coelicolor A(3) 2), and various marine bacteria, including Hahella 
chejuensis, Pseudoalteromonas dentrificans, and KCTC 2396 (Figure 1.2, Panel A).
4,5
 
Since the bacteria strains producing the prodigiosin closely resembled drops of blood 
(Figure 2A), it was hypothesized that this pigment may have been responsible for the 
many miraculous events recorded throughout history.
1,4
 The compound was named 
prodigiosin for this observation
1,6
  Prodigious is an adjective used to describe a noun that 
is extraordinary in size, amount, extent, degree, or force. It can also be used to describe 
something which is wonderful, marvelous, or miraculous. The etymology is the Latin 
prodigiosis from prodigium, which means omen. For the Romans, a prodigium was a 
literally a sign about the future that came from the gods.
7 
This 'prodigious’ pigment has been proposed to be responsible for the miraculous 
phenomenon of the bleeding host in the European Middle Ages.
1,4,8 
 The Mass of Bolsena 
was one of the most famous cases which was commemorated as the festival of Corpus 
Christi and was immortalized by Raphael in 1508, when he was commissioned to 
decorate the papal apartments of Julius II in the Vatican (Figure 1.2, Panel C). Even 
before the Middle Ages, prodigiosin alkaloids had been implicated by historians as early 
3 
 
as 332 BC. At the Siege of Tyre, Alexander the Great predicted victory based on the 
‘bloody’ bread served throughout the camp.1,4  Since the ‘blood’ was inside the bread, not 
on the outside, Alexander’s seer predicted that the omen meant the besieged city would 
bleed from the inside. Tyre was considered an impregnable island fortress off the coast of 
modern Lebanon, situated about one half mile off the mainland, surrounded by 18 feet 
deep water, and with walls 150 feet high. Alexander’s army started to build a 200 yard 
wide land bridge from the mainland to the island in January of 332 BC. These endeavors 
took seven long months, but the ensuing struggle of the Tyrians was short-lived. Today, 
Tyre is still connected to mainland by this manmade causeway (Figure 1.2, Panel D). 9 
 
Figure 1.2. Panel A: Streptomyces coelicolor producing the blood red prodigiosin pigment. Panel 
B: Structure of prodigiosin.  Panel C: Raphael’s “Mass of Bolsena” fresco in the Vatican.1 Panel 
D: Present-day Google Earth image of the island of Tyre and Alexander the Great’s land bridge 
that now connects the island to the mainland and completely altered the coastal currents. 
 
4 
 
While the prodigious prodigiosins produced by bacteria were the subject of 
miracles and signs from God, until the late 1900s, the true nature of their ability to 
perform ‘miracles’ would be unknown. During this time, the biological properties of the 
prodigiosins and their potential to become life-saving therapeutics would begin to be 
realized. 
 
1.2. Biosynthetic Origins of Prodigiosin Alkaloids. 
In 1960, the structure of prodigiosin was confirmed through chemical synthesis by 
Rapoport and Holden.
10
 Over the next 50 years, biosynthetic studies to identify the gene 
clusters responsible for prodigiosin production would prove challenging yet rewarding. 
The first major milestone was the confirmation that the biosynthesis is a bifurcated 
pathway that combines an alkyl pyrrole (MAP, 2-Methyl-3-n-Amyl-Pyrrole in 
prodigiosin) with the 4-Methoxy-2,2’-Bipyrrole-5-Carbaldehyde (MBC) through an 
enzymatic condensation.
11
 Feeding studies revealed that proline, serine, acetate, glycine, 
and S-adenosylmethionine were the required components necessary for the biosynthesis 
of prodiginines.
4,12 
 Once the genomes of prodigiosin-producing bacteria were sequenced, 
the gene clusters for pigment production were identified by inactivation and measurement 
of accumulated biosynthetic intermediates. It became evident that gene clusters 
responsible for production of MBC were highly conserved throughout the prodiginine-
producing bacteria. However, gene clusters responsible for MAP or other alkyl pyrrole 
formation, were completely different. This difference may be explained by the need to 
incorporate different starter units to construct slightly different monopyrroles. 
Undecylprodigiosin biosynthetic cluster components were abbreviated red, whereas the 
5 
 
prodigiosin biosynthetic gene clusters of Serratia sp. ATCC 39006 and S. marcescens 
ATCC274 were abbreviated pig. A summary of our current knowledge of the 
biosynthetic pathways of prodiginine natural products is described in Figure 1.3.
4
  
 
Figure 1.3. Biosynthesis of Prodigiosin, Undecylprodigiosin, and Butyl-meta-
cycloheptylprodigiosin.
4
 (adapted from Williamson 2006). 
 
 
1.3. Biomimetic Syntheses of Prodigiosin Alkaloids. 
At the time of the first total synthesis of prodigiosin in 1962, the bifurcate 
pathway had been identified and a biomimetic approach, which involved synthesizing 
MBC and subsequent condensation with MAP, was the route chosen for the early 
endeavors in prodiginine chemical synthesis. 
4,13
 
6 
 
 
Scheme 1.1. First total synthesis of prodigiosin 1.1 by Rapoprt and Holden.
10 
 
The 1962 Rapoport Holden synthesis began with the condensation of the sodium 
salt of diethyl N-ethoxycarbonyl glycinate 1.9 with diethyl ethoxymethylenemalonate 
1.10 to give diethyl 3-hydroxypyrrole-2,4-dicarboxylate 1.11.
10
 O-alkylation with 
diazomethane and subsequent selective hydrolysis of the more reactive ester at C4 
followed by decarboxylation of the resulting acid afforded pyrrole 1.13 which was 
condensed with imine 1.14 to provide pyrrole-pyrrolidine 1.15 in very low yield. 
Dehydrogenation of the pyrrolodine ring was achieved with Pd/C to give ester 1.16, 
7 
 
which was transformed to aldehyde 1.17 through McFayden-Stevens reduction. 
Condensation of aldehyde 1.17 with alkyl pyrrole 1.18 completed the first total synthesis 
of prodigiosin (1.1). This route highlighted the difficulty of pyrrole synthesis and the 
methods available at the time, namely, condensation reactions and thermal 
decarboxylations and fragmentations with variable yields. In the last 50 years, subsequent 
routes to access the tripyrrole prodiginine cores have led to considerable advances in 
heterocyclic chemistry.  
 
Scheme 1.2. First generation synthesis of MBC 1.17 by Wasserman and co-workers.
14 
 
Wasserman and co-workers developed a method for the synthesis of MBC 1.17 
based on cyclization of a vicinal tricarbonyl intermediate (1.22) (Scheme 1.2).
14
 
8 
 
Aldeyhde 1.19 was treated with dianion 1.20. The most basic, terminal anion reacts with 
the aldehyde and subsequent acidic work-up quenched the second anion and provided the 
elimination product of the addition, the -keto ester 1.21. Oxidation of the activated 
methylene with N,N-dimethyl-p-nitrosoaniline provided tricarbonyl 1.22. Reaction with 
benzylamine 1.23 proceeds through a 1,2-addition to the highly electrophilic center 
carbonyl and subsequent intramolecular 1,4-addition. Acidic dehydration provides the 
aromatic bipyrrole 1.24. O-alkylation and removal of the dimethoxy benzyl protecting 
group gave ester 1.16. McFayden-Stevens reduction provided the desired aldehyde 1.17 
 
Scheme 1.3. Second generation synthesis of MBC 1.17 by Wasserman and co-workers.
15 
 
In a second-generation synthesis by Wasserman and co-workers, an oxidative 
method was used to combine the two pyrrole units (Scheme 1.3).
15
 Treatment of ester 
1.25 with methylene blue and irradiation with a tungsten halogen lamp under an oxygen-
rich atmosphere provided peroxide 1.26. Addition of pyrrole to the reaction mixture traps 
the intermediate peroxide generating the t-butyl ester bipyrrole 1.27. McFayden-Steven’s 
9 
 
reduction afforded aldehyde 1.17. Both of these routes relied upon the inefficient, 
McFayden-Stevens reduction, resulting in low overall yields. Nevertheless, Wasserman 
and co-workers were able to use their routes to achieve the synthesis of prodigiosin, 
undecylprodigiosin, and metacycloprodigiosin in addition to several unnatural 
analogues.
15-19
  
 
Scheme 1.4. Synthesis of MBC 1.17 by Boger and co-workers featuring a key inverse-electron-
demand Diels-Alder reaction.
20
 
 
 Boger and co-workers prepared the MBC core through a key inverse-electron-
demand Diels-Alder reaction between 1,2,4,5 tetrazine 30 and 1,1-dimethoxy ethane to 
give the resulting pyridazine 1.29 in excellent yield (94%) (Scheme 1.4).
20
 Ring 
contraction with zinc dust and acetic acid provided the 2,5-dimethylcarboxylate pyrrole 
10 
 
1.30 in good yield. Hydrolysis of the more sterically-accessible and electrophilic C5 ester 
and iodine-mediated decarboxylation provided the diiodo intermediate 1.32. 
Hydrogenolysis provided pyrrole 1.33 and acylation gave urea 1.35, which was subjected 
to oxidative coupling with stoichiometric polymer-supported palladium acetate. 
Hydrolysis of the urea tether and subsequent conventional, yet low-yielding, McFayden-
Stevens reduction provided MBC 1.17 in 34 % yield. Boger and co-workers used the 
MBC 1.17 in various condensation reactions to probe the structure-activity relationship 
(SAR) of this class of compounds and the parameters responsible for cytotoxic and 
antibacterial activities.  
While routes to achieve the total synthesis of prodigiosin heavily focused on the 
generation of MBC 1.17, the synthesis of variously substituted alkyl mono-pyrroles, 
especially the cyclic pyrrole congeners, proved a considerable synthetic challenge. 
Wasserman and co-workers were the first to access the strained macrocyclic 
pyrrolophanes for the total synthesis of metacycloprodigiosin (Scheme 1.5).
19
 
Cyclododecanone was transformed into the brominated derivative 1.38 through routine 
manipulations. Elimination and deprotection provided enone, 1.39, which then underwent 
several reaction to achieve transposition and provide enone 1.40. Conjugate addition of 
cyanide anion to transposed enone 1.40, protection of the carbonyl, reduction of the 
cyano moiety to the aldehyde, and subsequent deprotection provided 1,4-dicarbonyl 1.41. 
Paal-Knorr condensation completed the synthesis of the desired 12-membered 
pyrrolophane macrocycle (1.42) in 1.4 % yield over 13 steps. Biomimetic condensation 
with MBC 1.17 provided metacycloprodigiosin (1.6).  
11 
 
 
Scheme 1.5. Synthesis of metacycloprodigiosin by Wasserman and co-workers.
19
 
 
Fürstner and co-workers achieved the synthesis of the 12-memebered 
pyrrolophane core of metacycloprodigiosin by utilizing an intramolecular Tsuji-Trost 
reaction of the vinyl epoxide 1.43 to provide the highly-functionalized 12-membered ring 
(1.44) (Scheme 1.6).
21
 Functional group manipulations and base-induced elimination of 
the sulfone provided 1,4-dicarbonyl 1.45. Paal-Knorr condensation with benzyl amine 
gave the protected pyrrole (1.46).  Additional steps led to the formation of the benzyl-
protected pyrrolophane moiety in 1.6 % yield over 14 steps.  
 
12 
 
 
Scheme 1.6. Synthesis of the metacycloprodigiosin pyrrolophane core by Fürstner and co-
workers.
21 
 
The Paal-Knorr condensation has proven a very effective method of generating 
the alkyl-substituted pyrrolophane cores of prodigiosin alkaloids. However, in Fürstner 
and co-workers’ synthesis of streptorubin B, a novel ring expansion reaction was utilized 
to generate the 10-membered ring pyrrolophane core (1.55) (Scheme 1.7).
22
 Allylic 
amination of cyclooctene 1.48 provided amine 1.49, which underwent alkylation with 
propargyl bromide and subsequent acylation of the acetylide with butanoyl chloride to 
provide enyne 1.50. The ring expansion reaction is a formal “enyne metathesis” reaction 
catalyzed by platinum (II) chloride that is hypothesized to occur through a nonclassical 
carbocation intermediate (1.51-1.53), based on observed byproducts, to yield macrocycle 
1.54. Subsequent transformations provided the alkyl pyrrole component (1.55) of 
streptorubin B (1.7) in 9 steps from cyclooctene and 13.5 % overall yield.  
 
 
13 
 
 
Scheme 1.7. Fürstner and co-workers’ ‘Enyne metathesis” route to prepare the C-ring pyrrole of 
streptorubin B (1.7). 
22 
 
 
 This ring expansion reaction also proved highly successful at accessing the 12-
membered pyrrolophane core of metacycloprodigiosin (1.6) from cyclodecene in 9 steps 
and 3.4 % yield (Scheme 1.8). 
22 
 
Scheme 1.8. Synthesis of the C-ring pyrrole of metacycloprodigiosin (1.6) by Fürstner and co-
workers utilizing their developed ring-expansion reaction.
22 
 
 
 
 
14 
 
1.4. Cross-Coupling Reactions in the Synthesis of Prodigiosin Alkaloids. 
 D’Alessio and co-workers were the first to move away from the biomimetic 
condensation of MBC 1.17 and an alkyl pyrrole. Instead of combining the A and B rings 
to form MBC 1.17 and incorporating the C-ring in the condensation reaction, D’Alessio 
and co-workers condense the B and C ring and incorporate the A ring through a Suzuki 
cross-coupling reaction (Scheme 1.9).
23,24
 Aldehyde 1.59 underwent base-mediated 
condensation with commercially available pyrrolinone 1.60 to give enelactam 1.61. 
Treatment with triflic anhydride provided triflate 1.62, which was used in a Suzuki cross-
coupling reaction with 1-Boc-pyrrole-2-boronic acid (1.60) to provide 
undecylprodigiosin (1.2) in 3 steps and 45.6 % yield from aldehyde 1.59.  This great 
improvement yield and the requirement for significantly fewer steps highlights the 
importance and impact of the development of cross-coupling reactions as a means of 
forming C-C bonds, especially in heterocyclic, aromatic systems.  
 
Scheme 1.9. D’Alessio et al. total synthesis of undecylprodigiosin utilizing a key Suzuki cross-
coupling reaction for the generation of the bipyrrole moiety.
23,24
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The methods developed by D-Alessio and co-workers were incorporated into the 
first total synthesis of nonylprodigiosin by Fürstner and co-workers (Scheme 1.10).
25
 By 
employing the basic condensation of formylated alkyl pyrrole 1.64 and pyrrolinone 1.60, 
triflate formation, and Suzuki cross-coupling, a mixture of E (1.68) and Z (1.69) isomers 
about the methylene bond was obtained. Ring-closing metathesis (RCM) with ruthenium-
based catalyst 1.70 could only occur with the Z-isomer (1.68). As the Z-isomer reacts to 
form the macrocyclic product, the preequilibrium is constantly shifting to form more of 
the minor Z-isomer in solution, which is subsequently intercepted in the metathesis 
reaction. Hydrogenation of the presence of Wilkinson’s cationic rhodium catalyst 
completed the first total synthesis of nonylprodigiosin (1.4). The convergent nature of 
this route has enabled the synthesis of many unnatural analogs with heterocyclic variants 
for SAR studies.
26,27 
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Scheme 1.10. Fürstner and co-worker’s synthesis of nonylprodigiosin (1.4) utilizing a key RCM 
reaction.
25 
 
 
Diari and co-workers developed a highly scalable route for the synthesis of an 
unnatural prodigiosin analog, obatoclax, for clinical trials (Scheme 1.11).
28
 Diari’s route 
is based on D’Alessio’s route, which incorporates a key Suzuki cross-coupling reaction.25 
However, Diari’s route utilizes the Suzuki reaction to form the C-C bond between the A-
ring and B-ring and includes the biomimetic acid-mediated condensation reaction to 
17 
 
incorporate the C-ring pyrrole. A Vilsmeier-Haack haloformylation is utilized to generate 
bromoenamine 1.72, and subsequent Suzuki cross-coupling with the N-protected indole 
boronic acid 1.73 provides the MBC analog 1.74. Acidic condensation with 2,4-
dimethylpyrrole (1.75) completes the synthesis of obatoclax (1.76) in 3 steps from 
commercially available starting material. 
 
Scheme 1.11. Diari and co-workers route for the large-scale synthesis of obatoclax (1.76) 
for clinical trials. 
28 
 
 
Recently, a Meldrum’s acid route that allows easy access to prodigiosin analogues 
with variations at the A, B, and C ring has been developed by McNab and co-workers 
(Scheme 1.12).
29
 Starting from known 1.77 analogs, flash vacuum pyrolysis (FVP) is 
employed to generate ketone 1.78, which was immediately methylated to provide methyl 
ether 1.79. Vilsmeier formylation conditions were utilized to provide the aldehyde 1.80. 
Phosphoryl chloride catalyzed condensation of aldehyde 1.80 with 2-unsubstituted 
pyrrole 1.84 provided prodigiosin unnatural analogs 1.85. By altering the 3 core rings to 
incorporate various heterocycles, they hope to develop detailed structure-activity 
relationships to better understand the prodigiosin bioactivity. The Meldrum’s acid route is 
18 
 
unique in the fact that it enables variation at all 3 pyrrole rings, not just at the C-ring, 
which is available from the condensation routes, or the A-ring, with is available from the 
cross-coupling routes.  
 
Scheme 1.12 Meldrum’s acid route to prodigiosin analogues developed by McNab and co-
workers.
29 
 
 
1.5. Enantioselective Syntheses of Prodigiosin Alkaloids. 
While there have been numerous efforts to achieve the total synthesis of 
prodigiosin alkaloids, it was not until 2009 that the first enantioselective total syntheses 
of a tripyrrole prodiginine natural product wwas achieved by Thomson and co-workers.
30 
Thomson and Clift utilized a stereoselective, merged 1,4-addition/oxidative 
coupling process to achieve the total synthesis of metalocycloprodigiosin (1.6) and the 
recently isolated prodigiosin R1 (1.8) (Scheme 1.13).
3
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Scheme 1.13. Merged 1,4 addition/oxidative coupling for the synthesis of metacycloprodigiosin 
(1.6) and prodigiosin R1 (1.8) by Thomson and Clift
30 
 
 
Using conditions developed by Feringa and co-workers, Thomson and Clift began 
the synthesis of metalocycloprodigiosin (1.6) by regio- and stereoselective copper-
catalyzed 1,4-addition of ethylmagnesium bromide to enone 1.83 followed by enolate 
trapping with chlorosilane 1.84 to give silyl bis-enol ether 1.85 as a mixture of enol 
isomers (Scheme 1.14). Using conditions developed in Thomson’s lab for oxidative bond 
formation, dione 1.86 was generated in 35% yield over two steps from enone 1.83. RCM, 
hydrogenation, and Paal-Knorr condensation provided the chiral, saturated, C-ring 
pyrrole, and methyl oxidation with DDQ provided aldehyde 1.87. Aldehyde 1.87 was 
then utilized in a trimethylsilyltriflate-mediated aldol condensation reaction with 
pyrrolinone 1.60 to give conjugated lactam 1.88. Triflation, Suzuki cross-coupling with 
boronic acid 1.63, and Boc-deprotection afforded metalocycloprodigiosin (1.6) in 11 
steps from enone 1.83 and proceeded in 13% overall yield. This enantioselective strategy 
was also applied to the first total synthesis of prodigiosin R1 (1.8) in 11 steps and 7% 
overall yield (Scheme 1.15).
30
 These two syntheses represent the first time that any 
members of the tripyrrole prodigiosin alkaloids have been prepared in enantioenriched 
form.  
20 
 
 
 
 
 
Scheme 1.14. Enantioselective total synthesis of  metalocycloprodigiosin (1.6) by 
Thomson and Clift.
30
 
 
 
 
Scheme 1.15. Enatioselective total synthesis of prodigiosin R1 (1.8) by Thomson and 
Clift.
30 
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In 2011, Thomson and coworkers once again designed an enatioselective route for 
the preparation of a prodigiosin analogue, streptorubin B (1.7) (Scheme 1.16).
31
 After 
attempts to incorporate their previously developed methodology, they found that the 
RCM used to form the 12-memebred ring of metalocycloprodigiosin (1.6) and 
prodigiosin R1 (1.8) was not a viable option for the formation of the 10-membered ring in 
streptorubin B (1.7). In light of this discovery, they investigated alternative routes to 
achieve the enantioselective synthesis of this highly strained prodigiosin alkaloid. The 
synthesis began with the oxidative cleavage of cycloheptene 1.89 to form dialdehyde 
1.90, which underwent a one-pot enantioselective aldol/Wittig reaction to provide alcohol 
1.91 in 10:1 dr and 98:2 er. Swern oxidation followed by addition of vinyl anion 1.92 
gave alcohol 1.93, the precursor to an anionic oxy-Cope rearrangement in 97:3 er. 
Exposure of alcohol 1.93 to KHMDS and 18-crown-6 produced the desired 10-memebred 
ring (1.95) in 85% yield. Alkene reduction and concomitant benzyl ether cleavage, 
oxidation of the liberated alcohol to the aldehyde, and Paal-Knorr condensation provided 
pyrrole 1.55. Using chemistry developed in our lab based on the work of Diari and co-
workers,
29,33
 Thomson and co-workers completed the first enantioselective synthesis of 
streptorubin B (1.7) in 9 steps and 20% overall yield.
31
 After comparing the Circular-
Dichroism (CD) spectra of the natural and synthetic streptorubin B (1.7), it was 
determined that the S-enantiomer is the naturally-occurring stereoisomer, which is unique 
from the 12-membered pyrrolophane, metalocycloprodigiosin (1.6), which was 
determined to naturally occur as the R-enantiomer. 
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Scheme 1.16. Enantioselective total synthesis of streptorubin B (1.7) by Thomson and co-
workers, incorporating a tandem aldol/Wittig sequence and a key anionic oxy-Cope 
rearrangement.
31
 
 
 
The evolution of synthetic, heterocyclic chemistry is clearly evident in the 
preparation prodigiosin alkaloids. From the condensations and decarboxylations of 
Rapoport and Holden in 1960, to RCM, Suzuki cross-coupling, and enantioselective 1,4 
conjugate additions of the twenty-first century; alkaloid synthesis has come a long way.  
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1.6. Biological Activity of Prodigiosin Alkaloids and Unnatural Analogs.  
The interest in prodiginine natural products is not simply due to the synthetic 
challenges offered by the unique structures. This class of natural products exhibits many 
interesting biological activities, from immunosuppression, to anticancer activity, to 
antimicrobial and antimalarial activity.
1,4
 In many cases, these activities occur at 
nanomolar concentrations with a considerable therapeutic window. 
 
 
Figure 1.4. Numerous actions of the prodigiosin by different pathways. The prodigiosin 
alkaloids have been shown to facilitate an apoptotic scenario by 4 alternative routes.
33
(adapted 
from Pérez-Tomás 2003). 
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The prodigiosin alkaloids have been implicated to exert biological activities 
through numerous possible mechanisms of action in various cell types and disease states 
(Figure 1.4).
33
 Prodigiosin alkaloids possess considerable hydrophobic components and 
are highly unstable in aqueous solutions. These compounds may diffuse rapidly through 
membranes and interact with DNA with a preference for the AT sites at the minor groove 
promoting copper-mediated dsDNA cleavage. Cells respond to this DNA damage by 
activating cell-cycle arrest, DNA repair, or triggering apoptosis (Route 1).
34-36
  
Prodiginine compounds may be incorporated into the lipid bilayer of the plasmatic 
membrane, where by endocytosis they reach the endosome compartment and uncouple 
vacuolar H
+
-ATPase (V-ATPase) through promotion of the H
+
/ Cl
-
 symporter. This 
causes neutralization of acidic compartments within the cells, thus inducing intracellular 
acidification and triggering autophagy-induced cell death and eventually apoptotic cell 
death (Route 2).
 37-40
 A prodiginine compound may activate an unidentified prodigiosin 
receptor or a known death receptor, inducing caspase 8 activation and consequently, 
apoptosis (Route 3). Prodigiosin alkaloids may diffuse freely through membranes and 
interact with the mitochondrial outer membrane, uncoupling Fo-F1-ATPase and triggering 
apoptosis (Route 4).
41,42
 The pathway followed by a particular prodiginine compound 
would depend very much on the cell type studied, the drug concentration within the cell, 
the uncharacterized hierarchy of the prodiginine targets, and the interaction between 
distinct pathways.
33 
In human neuroblastoma cell lines prodigiosin (1.1) acts as a proton sequestering 
agent that destroys the intracellular pH gradient, and it has been proposed that the main 
cytotoxic effect could be related to action on mitochondria, where it exerts an uncoupling 
25 
 
effect on the electronic chain transport of protons to mitochondrial ATP synthase.
43 
Nonylprodigiosin-HCl has been shown to inhibit apoptosis in PC12-RasN17 cells 
through Ras and the activation of the Ras-PI3K-Akt pathway.
44
 Acidification of 
cytoplasm, DNA damage, suppression of NF-kappa beta, and sustained JNK activity 
could all activate Ras and initiate a protective effect in this cell line; however, to date, 
this is the first example of prodigiosins exhibiting an antiapoptotitc effect in any cancer 
cell line. 
Prodigiosins have also been shown to uncouple lysosomal vacuolar-type ATPase 
through promotion of H
+
/ Cl
-
 symport. Prodigiosin (1.1), metacycloprodigiosin (1.6), and 
undecylprodigiosin (1.2) all raise intralysosomal pH through inhibition of lysosomal 
acidification driven by vacuolar (V-)-ATPase without inhibiting ATP hydrolysis in a 
dose-dependent manner with IC50 values of 30-120 pmol/mg of protein.
45
  
Prodigiosin (1.1) has also demonstrated induction of p21, a negative cell-cycle 
regulator, in a p-53 independent manner as prodigiosin induced p21 in MCF-7 cells with 
both mutated and dominant negative p53.
46
 The p53 protein is mutated in most human 
cancers and this mutation prevents cancer cells from suffering the cytostatic and/or 
cytotoxic effects of anticancer drugs.
47
 Since prodigiosin (1.1) does not require the 
presence of this protein to exert its effect on cancer cells, this could make prodiginine 
compounds a promising lead for treatment of p53-mutant cancer cell lines. 
 In vitro, prodiginine alkaloids have been shown to intercalate DNA with a 
preference for the AT sites in the minor groove.
34
 Prodiginine compounds display 
oxidative copper-promoted dsDNA-cleavage and the superior copper-nuclease activity 
correlates to superior anticancer properties in leukemia (HL-60) cell line. Through SAR 
26 
 
studies, it has been found that a nitrogen-containing A-ring and the B-ring methoxy 
substituent are required for potent cytotoxicity.
20,23,48,49
 
X-ray crystallography has revealed that prodigiosin binds to copper in a 1:1 Cu (I) 
complex ( 1.98) and that all 3 nitrogens coordinate to the metal atom (Scheme 1.5).
48
 The 
C-pyrrole ring is oxidized and contains an OH group attached to C1 to generate an sp
3
-
hybridized carbon atom and a new double bond between N1 and C4. Coordination with 
Zn forms a 1:2 Zn(I)2 complex (1.97) where prodigiosin has not undergone oxidation. 
Also, the A-ring does not participate in Zn (II) binding. These results indicate that all 3 
nitrogens of the tripyrrole core of the prodigiosins is required for oxidative dsDNA 
cleavage. 
 
 
Figure 1.5. Crystal structures of prodigiosin (1.1) bound to zinc as a dimeric species (left) and 
copper as a monomeric species (right).
48
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Replacement of the A-ring with substituted indoles and unnatural alkyl pyrrole 
substituents has produced new antiproliferative prodigiosin analogs.
49
 However, 
substitution of the A-ring with thiophene, furan, or phenyl decreases nuclease activity and 
abolishes anticancer activity. One of the most important and successful unnatural 
prodiginine alkaloids is a synthetic compound named obatoclax (1.76), which was 
developed by GeminX Pharmaceuticals and was described as a BH3 mimetic drug.
50
 
However, the molecular target of the majority of prodiginine derivatives remains 
unidentified and the pathways involved in observed biological activities uncharacterized. 
In 2012, Pérez-Tomás, R. and co-workers discovered a new molecular target for 
prodigiosin (1.1) and obatoclax (1.76), the mammalian target of rapamycin (mTOR) 
(Figure 1.6).
51
 mTOR is an evolutionarily conserved serine/threonine protein kinase 
which is constituted of two signaling complexes: mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2). Both complexes have specific effects on distinct cellular 
functions, such as controlling mRNA translation, ribosome biogenesis, autophagy, and 
metabolism.
52-54
 It was discovered that the two prodiginine alkaloids inhibit both 
mTORC1 and mTORC2 and thus counteract S6K-1/IRS-1 negative feedback loop in 
melanoma.
51
 Melanoma is notoriously resistant to cytotoxic reagents, and the 
development of this resistance has been related to the presence of different feedback 
loops that link both P13K/AKT/mTOR and mitogen activated protein kinase (MAPK) 
pathways. These pathways are critical to melanoma progression and both are deregulated 
in melanoma, but not in normal cells.
 55,56
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Figure 1.6. Structures of prodigiosin (1.1) and obatoclax (1.76). 
 
Pérez-Tomás, R. and co-workers discovered that prodigiosin (1.1) and obatoclax 
(1.76)  both induced activation of autophagic-dependent and apoptotic cell death and that 
induction of autophagy actually occurred before apoptosis.
51
 Kinetics and affinity 
evaluation revealed high-affinity binding between mTOR and the two prodigiosin 
alkaloids. In silico modeling was performed to identify key interactions between each of 
the prodiginine compounds and mTOR. In the induced fit prodigiosin-mTOR complex, 
the hydrophonic environment around the pentyl side chain includes Ile2500, Ile2559, and 
Val2504 (Figure 1.7). Stacking interactions were observed between His2340 and PG 
pyrrole rings. The “H-bond ring” created by the alcohol chain of Ser2342 and the two 
extreme pyrrole nitrogens in the A-ring and C-ring appeared to be a key interaction. 
Obatoclax-mTOR complex has a key H-bond interaction between the C-ring pyrrole and 
a glutamine residue (Figure 1.7). The indole moiety appears to be involved in 
hydrophobic interactions between I2559 and I2500. The lack of a key H-bonding 
interaction between the indole ring and residues within the mTOR binding site is 
surprising since it has been shown that a nitrogen containing A-ring is necessary for 
activity.
20,23,48,49
 The role of the B-ring in mTOR binding is not evident from the in silico 
models. Clearly, prodiginine research could benefit from biological testing of additional 
29 
 
analog libraries to elucidate the molecular mechanisms and targets of these interesting 
molecules. With both of these compounds in Phase I/II clinical trials, it would be highly 
desirable to generate compounds with known mechanisms of action and improved 
chemical properties to facilitate bioavailability and the development of oral 
formulations.
51
 
 
 
Figure 1.7. In silico induced fit models of prodigiosin-mTOR complex (top) and obatoclax-
mTOR complex (bottom).
51
 (adapted from Pérez-Tomás 2012). 
 
 
The anticancer activity of the prodigiosin alkaloids alone makes them intriguing 
synthetic targets; however, the immunosuppressive properties of prodiginine compounds 
30 
 
have been receiving a large amount of attention due to the need of compounds with this 
activity and novel mechanisms of action. Cyclosporin A (CsA), FK 506, and rapamycin 
are currently the immunosuppressive drugs utilized to prevent allograft rejection in organ 
and tissue transplants and to treat autoimmune diseases.
2,57
 Prodigisin alkaloids have been 
shown to suppress cytotoxic T-cells without affecting B cell-mediated immune functions, 
which is unique from the traditional immunosuppressants.
57
 In another sturdy, co-
treatment with prodigiosin and CsA in mice that have undergone bone marrow 
transplants provided a more effective treatment than either drug dosed alone. Prodigiosin 
(1.1)  inhibited only IL-2R expression, but not IL-2 expression; whereas CsA inhibited 
both.
58
 Exogenously added IL-2 reversed the suppressive activity of CsA, but not that of 
prodigiosin (1.1). These results indicated that prodigiosin (1.1) and CsA have similar 
inhibitory potencies but different modes of action that warrant additional investigation. It 
is of great interest to generate prodiginine analogs that ‘dial out’ anticancer activity and 
increase immunosuppressant activity in order to investigate their potential to treat 
autoimmune diseases and to prevent allograft rejection. D’Alessio and coworkers 
identified PNU-156804, a compound which prevented heart allograft rejection in mice in 
a dose-dependent fashion (Figure 1.8).
23
  
 
Figure 1.8. Structure of PNU-156804 (1.99) synthesized by D’Alessio and co-workers.23 
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The ability to uncouple the anticancer and immunosuppressive activity of these 
compounds is highly desirable in the search for clinically relevant drug candidates. In the 
last decade, numerous diseases have been identified to result from immune system 
deregulation, such as lupus, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, 
Psoriasis, and Diabetes mellitus type 1.
59
 These diseases are included in a class known as 
autoimmune diseases, and could potentially be treated by selective immunosuppressant 
agents.  
If immunosuppression and anticancer activity are able to be optimized or ‘dialed-
out’, then one could also imagine optimizing the observed antimalarial activity over other 
biological activities to obtain effective therapeutics for eradication of the Plasmodium 
falciparum parasite. While synthetic prodigiosin analogs have shown potent antimalarial 
activity, dose-limiting toxicity is still a problem and additional compounds will need to 
synthesized and further SAR developed.
61
 Reynolds and co-workers have synthesized 
extensive libraries of unnatural prodigiosin analogs and have found that the A-ring 
pyrrole is critical for antimalarial activity, as has been observed in numerous other SAR 
studies of various biological activities. Variation of the C-ring by incorporating 
hydrophobic groups of various size and length proved integral to activity enhancement in 
vitro and in mouse models. 
60
 
 
1.7. Summary. 
The prodigiosin alkaloids possess a rich history, and have been the focus of 
numerous synthetic endeavors.
10-31
 These natural products are produced by various 
bacteria species, and have been shown to possess antibacterial, antimalarial, anticancer, 
32 
 
and immunosuppressant activities.
33-60
  The interesting and numerous biological activities 
of the prodiginine alkaloids are the main reason these natural products have been the 
subject of numerous synthetic endeavors and SAR studies over the past 50 years and will 
continue to intrigue chemists and biologists for many years to come. 
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CHAPTER 2 
 
PROGRESS TOWARD THE TOTAL SYNTHESIS OF MARINEOSINS A & B 
 
2.1. Isolation and Structure Elucidation of Marineosins A & B.  
 Marineosins A and B (2.1 and 2.2) were isolated by Fenical and co-workers in 
2008 from cultures of a marine sediment-derived actinomycete related to the genus 
Streptomyces.
1
 The key structural features common to the marineosins are the spiroiminal 
center, two pyrrole moieties, and a 12-membered macrocyclic ring (Figure 2.1).  
 
Figure 2.1.  Structures of marineosins A & B (2.1 & 2.2) and prodigiosin 2.3.
1 
 
The marineosins appear to be derived from unknown modifications of 
prodigiosin-like bacterial pigment pathways. A biosynthetic route suggested by Fenical 
and co-workers (Figure 2.2),
1
 begins with the condensation of 2.4, the known primary 
precursor bipyrrole aldehyde (MBC) of the prodigiosin alkaloids, with a novel 2-keto-
undec-3-enylpyrrole 2.5 to give 2.6. Enone 2.6 could then undergo an intramolecular, 
inverse-electron-demand hetero-Diels-Alder cyclization to form the tetrahydropyran ring 
and spiroiminal simultaneously.  
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Scheme 2.1. Possible biosynthesis of 2.1 and 2.2 via an inverse-electron-demand hetero-Diels-
Alder cyclization. 
 
 
2.2. Biological Activity of Marineosins A & B. 
Following isolation and structure elucidation through 1D and 2D NMR 
techniques, the marineosins were tested for their ability to arrest cell division in the HCT-
116 human colon tumor cell line.
1
 Marineosin A exhibited an IC50 value of 0.5 M in the 
HCT-116 cytotoxicity assay. In contrast, marineosin B showed considerably weaker 
cytotoxicity with an IC50 value of 46 M. Testing of marineosin A in the National Cancer 
Institute (NCI) 60 cell line panel showed considerable selectivity against melanoma and 
leukemia cell lines. Due to the unprecedented spiroiminal core and the potential of 
marineosin A as an anticancer therapeutic, these new members of the prodiginine family 
of natural products are intriguing synthetic targets.  
By synthesizing marineosin analogs and performing biological assays for 
anticancer activity, immunosuppression, and antimalarial activity, we hope to identify the 
minimal pharmacophore necessary for each of these activities, to prepare simplified 
analogs based on the knowledge of the key structural feature required for activity, and to 
optimize compounds that display one activity preferentially over the other activities. 
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Once we have obtained these selective compounds, gene-expression profiling can be 
performed to reveal candidate pathways involved in the observed activities and RNAi 
modifier studies can be utilized to identify which proteins in a signaling pathway are 
putative targets for our compounds. We can also perform affinity chromatography 
experiments to identify protein targets and determine specificity. This knowledge would 
prove invaluable to prodiginine research, as well as cancer, immunology, and malaria 
research.  
 
2.3. The Diels-Alder Reaction in Organic Synthesis.  
 
2.3.1. Discovery of the Diels-Alder Reaction 
In 1928 Otto Diels and Kurt Alder published their landmark paper describing the 
[4+2] cycloaddition of cyclopentadiene and quinone (Scheme 2.2).
2
 After several key 
theoretical breakthroughs, such as Alder’s endo rule and Woodward’s prediction of 
regiochemistry based on the electronic nature of diene and dienophile sbstituents, the 
synthetic utility of this reaction, which effectively couples a conjugated diene and an 
olefin (dienophile), became evident.
3-5
 The ability to generate complex cyclohexene-
containing products with excellent regio- and stereoselectivity at multiple stereocenters 
makes this reaction one of the most valuable tools available to synthetic chemists.
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Scheme 2.2. The Diels-Alder reaction is a concerted [4+2] pericyclic reaction. Otto Diels and 
Kurt Alder discovered the reaction when they identified the products formed from reaction of 
cyclopentadiene (2.8) and quinone (2.9) in 1928. They received the Nobel Prize in 
chemistry in 1950 for this reaction.
2,3 
 
2.3.2 Theoretical Framework for Regio- and Stereochemical Outcomes of the 
Diels-Alder Reaction. 
 
The Diels-Alder reaction is a pericyclic [4+2] reaction which is characterized by a 
cyclic transition state where three  bonds are broken concomitantly forming two  
bonds and a  bond in a single concerted step (Scheme 2.2). Frontier molecular orbital 
theory (FMO) and symmetry considerations predict that the key orbital interactions in the 
Diels-Alder reaction are the highest occupied and lowest unoccupied molecular orbitals 
(HOMO and LUMO) (Figure 2.2).
6,7
 Decreasing the energy gap between the HOMO and 
LUMO orbitals will cause the reactivity of the system to increase. Orbital coefficients 
derived from FMO theory predict the regiochemistry of the reaction, which can be 
exploited by incorporating electron-donating and electron-withdrawing substituents into 
the reactants.
7,8 
 Incorporation of these substituents changes the energy of the system and  
creates geometric asymmetries in the key frontier molecular orbitals, which affects the 
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synchronicity of bond formation in the transition state,
 
thus affecting  the regio- and 
stereoselectivity of the reaction.
9
 The favored transition state will be the one that arises 
from complementing orbital coefficients of the diene-dienophile pair, which leads to the 
formation of pseudo-ortho substituted products and precludes the formation of possible 
pseudo-meta substituted products with C1 substituted dienes. By the same reasoning, C2 
substituted dienes will preferentially form pseudo-para adducts over the corresponding 
pseudo-meta adducts.
8,9 
Formation of the kinetically favored endo transition state is rationalized by 
invoking secondary orbital bonding interactions between the diene and dienophile to 
form the syn product (Figure 2.2).
3
 The thermodynamically favored anti product, 
obtained from the exo transition state, may also be isolated in some systems when steric 
interactions become increasingly important. However, by incorporating suitable 
conjugating substituents into the dienophile, the endo transition state is considerably 
more energetically favorable.
3,8
  
The Diels-Alder reaction is classified by the flow of electrons. A normal-electron-
demand Diels-Alder reaction is characterized by a reaction between an electron-rich 
diene and an electron-poor dienophile, where the HOMO of the diene and the LUMO of 
the dienophile are the key frontier molecular orbital interactions in this class of pericyclic 
reaction. The opposite polarization, an electron-rich dienophile and electron-poor diene, 
is also possible and the reaction is classified as an inverse electron-demand Diels-Alder 
reaction (Figure 2.2).
9,10 
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Figure 2.2. Frontier molecular orbitals involved in the normal-electron-demand and inverse-
electron demand Diels-Alder reaction. Regio- and stereochemical outcomes of the Diels-Alder 
reaction with 1- and 2-sunstituted dienes. (D =electron-donating substituent, W = electron- 
withdrawing substituent).
3, 8-10 
 
 
The formation of stereogenic chiral elements is predictable in a relative sense 
since the Diels-Alder reaction is regioselective, stereospecific and diastereoselective due 
to the orbital coefficients of the reactants from FMO theory and Alder’s endo rule.3 The 
high level of control and predictability makes the Diels-Alder reaction a powerful 
transformation in modern organic synthesis; however, the ability to achieve absolute 
stereocontrol and not just relative control of stereogenic outcomes will continue to be an 
important topic of future Diels-Alder research. The development of reagent-controlled 
methods of stereoselectivity could provide access to Diels-Alder adducts that could not 
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be achieved through substrate-controlled methods and will make the Diels-Alder reaction 
an even more powerful tool for modern organic synthesis. 
 
2.3.3. The Elusive “Diels-Alderase”. 
The existence of “Diels-Alderases”, enzymes that catalyze Diels-Alder reactions 
in nature, is a subject of great speculation.
11
 There are certainly numerous cases of Diels-
Alder retrons in natural products that could indeed arise from enzyme catalysis and have 
been predicted to involve a Diels-Alder reaction in proposed biosynthetic routes (Figure 
2.3).
3,11
 However, despite numerous biosynthetic proposals that incorporate the Diels-
Alder reaction, the isolation of an enzyme that performs this reaction or identification of 
a gene cluster with a Diels-Alderase domain has yet to occur.
11 
 
Figure 2.3. Examples of natural metabolites for which biosynthetic Diels-Alder transformations 
have been proposed. 
3,11
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Macrophomate Synthase (MPS) is the most extensively studied of all the putative 
Diels-Alderases.
11,14,15
 However, quantum and molecular mechanics support a stepwise 
sequence of a Michael-addition followed by an aldol reaction (Scheme 2.3).
16
 Solution of 
the crystal structure of MPS revealed a similar tertiary to 2-dehydro-3-deoxygalactarate 
(DDG) aldolase, despite weak sequence identity (20%). Both enzymes generate pyruvate 
enolate in the active site; MPS by decarboxylation of oxaloacetate 2.20 and DDG 
aldolase by deprotonation of pyruvate.
15,17,18
 It was initially proposed that MPS utilizes 
the pyruvate enolate to bicyclic intermediate 2.23 en route to macrophomic acid 2.15 by 
either an inverse-electron-demand Diels-Alder reaction or a sequential Michael-aldol 
mechanism (Scheme 2.3).
19,12,14
 Hilvert and co-workers demonstrated that, like DDG 
aldolase, once MPS generates the pyruvate enolate, it efficiently mediates an aldol 
reaction with a variety of aldehyde substrates.
20
 These results certainly support the 
stepwise Michael-aldol pathway as the most likely mechanism employed by this enzyme.  
 
Scheme 2.3. Proposed biosynthetic mechanisms for macrophomate acid synthase: The Michael-
Aldol mechanism (top) and the Diels-Alder Mechanism (bottom).
11-14,19
 (adapted from Kelly 
2008). 
 
 
2.3.4. The Diels-Alder Reaction in Complex Natural Product Synthesis. 
There have been numerous synthetic endeavors that incorporate a ‘biomimetic’ 
intramolecular Diels-Alder reaction to impart stereoselectivity and stereospecificity to 
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highly-substituted cyclic cores.
3,11,21-24
 Shown in Scheme 2.4 are a few relevant examples 
where a Diels-Alder cycloaddition is a key transformation in the synthetic route to access 
a complex natural product.
3,11, 
 These transformations are examples of intramolecular 
Diels-Alder reactions (IMDA) and/or transannular Diels-Alder reactions, common 
synthetic strategies increasingly associated with the biosynthetic origins of various 
secondary metabolites.
3,11  
Many of these routes exemplify creativity in organic synthesis 
and have proven highly successful in practice.
21-24
 
 
 
Scheme 2.4. Incorporation of biomimetic Diels-Alder reactions into the syntheses of complex 
natural products.
21-24 
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The possibility of the existence of a Diels-Alderase in the thousand-year-old 
prodigiosin biosynthetic pathway is very exciting and we eagerly anticipate the 
development of routes to synthesize compounds to test this biosynthetic hypothesis for 
the synthesis of marineosins A and B (Scheme 2.5). 
 
Scheme 2.5. Fenical’s biosynthetic proposal of marineosins A and B. 
 
 
2.4. Snider’s Synthesis of the Spiroiminal Core of the Marineosins and Proposal of 
an Alternative Biosynthetic Route. 
 
In 2010, Snider and co-workers published a model synthesis of the novel 
spiroiminal core (2.39) of the marineosins in 7 steps from lactone 2.37( Scheme 2.6).
25
  
 
Scheme 2.6. Snider and co-workers route to the novel spiroiminal core of marineosins A 
and B.
25 
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In addition to preparing the spiroiminal core of the marineosins through a non-
Diels-Alder-based route, Snider suggests an alternative to the Diels-Alder biosynthetic 
proposal (Scheme 2.7).
25
 Undecylprodigiosin (2.40), a likely precursor in Streptomyces 
sp., could undergo oxidation of the methylene group to a radical or cation by a RedG 
homologue that is a nonheme iron-dependent dioxygenase. This radical or cation 2.42 
could then add to the exocyclic double bond to give macrocyclic radical 2.43. RedG is 
responsible for conversion of undecylprodigiosin (2.40) to butyl-meta-
cycloheptylprodigiosin (2.42) by C-H activation/oxidation to a radical or cation and 
subsequent intramolecular Friedel-Crafts reaction to pyrrole to form 2.42.
26-28
 In the case 
of marineosins, radical 2.43 could then undergo 1,5 hydride shift would provide 
macrocycle 2.44, with the radical in close proximity to the enzyme active site where the 
molecule was first oxidized. A second one-electron oxidation would provide alcohol 
2.45. 2H- pyrrole 2.45 could then undergo a 1,5 sigmatropic hydride shift to generate 3H-
pyrrole 2.46, which would rapidly undergo cyclization to give enamine  2.47. 
Isomerization to the imine should provide marineosins A and B. A 1,5 sigmatropic shift 
could also provide the 1H-pyrrole 2.48, but for cyclization occur, the aromaticity of the 
resulting pyrrole would have to be broken, which would be a very energetically 
unfavorable process. For this reason, it is hypothesized that the unstable 3H-pyrrole 2.46 
would lead to product formation.  
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Scheme 2.7. Snider and co-workers’ alternative biosynthetic proposal.25 (adapted from 
Snider 2010). 
 
Snider’s synthesis began with the addition of vinyl magnesium bromide to lactone 
2.37 and quenching with TESCl to form enone 2.49. Reaction of 2.49 with oxime 2.50 in 
aqueous sodium hypochlorite provided isoxazoline 2.38. Hydrogenolysis of the 
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isoxazoline over Raney Nickel and subsequent methylation gave iminal 2.51. Exposure 
of the iminal to acidic conditions provided various amounts of all possible marineosin 
diastereomers 2.52 as described in Scheme 2.8. Removal of the SEM protecting groups 
from the three diastereomers obtained after 2-3 weeks of equilibration proceeded 
smoothly to provide the deprotected analogs 2.53-2.55.  
 
Scheme 2.8. Snider and co-workers’ synthesis of the spiroiminal core of marineosin A and B.25 
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Snider and co-workers conclude that incorporation of the fused macrocycle 
should force the equatorial methyl group to the proper axial conformation and that 
interaction between the macrocyclic ring and the methoxy substiuent should favor the 
formation of marineosin A and B isomers over all other isomers.  
 
2.5. Marineosins A & B as Intriguing Synthetic Targets. 
Despite the debated biosynthetic route, the marineosins appear to belong to the 
family of prodigiosin pigments, and the evolution of synthetic, heterocyclic chemistry is 
evident in the rich history of these alkaloids. From the condensations and 
decarboxylations of Rapoport and Holden in 1962, to ring-closing metathesis, Suzuki 
cross-coupling, and enantioselective 1,4 conjugate additions of the twenty-first century; 
alkaloid synthesis has come a long way. It is obvious why the marineosins, prodigiosin-
like alkaloids containing an unprecedented number of stereogenic centers (5), would 
provide an intriguing framework to explore current methods of asymmetric synthesis and 
to catalyze the development of novel methods for the challenging synthesis of alkaloids 
containing electron-rich pyrrole moieties. 
The prodigiosin alkaloids possess a rich-array of biological activities. Anticancer, 
antibacterial, antimalarial, and immunosuppressive properties have been observed in 
many prodiginine natural products and unnatural analogs. The ability to fine-tune one 
particular activity over another makes this group of natural products an intriguing study 
in structure-activity relationships. Synthesis of the marineosins, preparation of unnatural 
analogs and subsequent biological testing will add to the SAR knowledge of the 
prodigiosin alkaloids. Of particular interest will be the role of the transformed B-ring of 
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the spiroiminal center. While a nitrogen-containing A-ring is required for biological 
activity and variations in the C-ring are well-tolerated in most cases, the role of the 
azafulvene B-ring in the biological activity of the prodigiosin alkaloids has yet to be 
investigated in detail.
29
 In addition, the prodigiosin alkaloids have been shown to possess 
a wide variety of ‘tunable’ biological activities, but the mechanisms of action behind 
many of these activities have yet to be discovered and will be a future goal within our 
laboratory. 
 
Although the existence of a naturally occurring Diels-Alderase is still in question, 
a stepwise process for marineosin formation in the prodigiosin biological pathway could 
explain the Diels-Alder retron. A RedG homologue could be responsible for C-H 
activation in the alkyl chain, followed by addition to the pyrrolomethene core of the 
tripyrrole pigment. This mechanism would be consistent with the biosynthesis of other 
cyclic prodigiosin natural products, such as metalocycloprodigiosin, prodigiosin R1, and 
streptorubin B, and the fact that RedG has been predicted to catalyze oxidative 
cyclization of undecylprodigiosin (1.2) to form butyl-meta-cycloheptylprodigiosin (1.3) 
in S. coelicolor A3 (2).
25-28
 With these possibilities in mind, we set out to achieve the 
total synthesis of marineosins A and B by incorporating a key intramolecular inverse-
electron-demand hetero-Diels-Alder reaction.  
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2.6.Synthesis of the Prodiginine Substrate and the Intramolecular Diels-Alder 
Reaction. 
As outlined in Scheme 2.9, the retrosynthetic analysis of marineosins A and B begins 
with chemoselective hydrogenation of the electron-rich carbon-carbon double bonds in 
the Diels-Alder adduct 2.7. 
 
Scheme 2.9. Retrosynthetic analysis of marineosins A and B (2.1 and 2.2).(Nuc = nucleophile, 
LG = leaving group, R = protecting group or H). 
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Acid-mediated condensation between aldehyde 2.4 and enone 2.5 gives the Diels-
Alder substrate 2.6. Aldehyde 2.4 is synthesized via Vilsmeier-Haack haloformylation of 
4-methoxy-3-pyrrolin-2-one 2.58 and subsequent Suzuki coupling of bromoenamine 2.56 
with N-Boc-pyrrole-2-boronic acid 2.57. The key reactions that provide the carbon 
framework of enone 2.5 are a cross metathesis (CM) and an alkylation to form the C13-
C14 bond or the C14-C15 bond.  
The synthesis of aldehyde 2.4 was very straightforward following known methods 
utilized in the synthesis of the structurally similar BH3 mimetic obatoclax by Diari and 
co-workers.
30
 
 
The Vilsmeier-Haack haloformylation of 4-methoxy-3-pyrrolin-2-one 2.58 
was carried out with phosphorous oxybromide and N,N-diethyl formamide to yield 
bromoenamine 2.56 in 59% yield (Scheme 2.10). Suzuki cross-coupling of 
bromoenamine 2.56 with N-Boc-pyrrole-2-boronic acid gave Boc-protected aldehyde 
2.64 in 48% yield. According to the literature procedures, the deprotected aldehyde (2.4) 
was expected to be the major product; however, it was only isolated in 10% yield. 
Isolated 2.4 proved to be relatively unstable and polymerized even when stored at 0 
o
C 
under argon, so it was decided to use the Boc-protected 2.64 in the acid-mediated 
condensation and allow deprotection to occur in situ. 
 
Scheme 2.10. Synthesis of aldehyde 2.64. 
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 The synthesis of enone 2.5 proved to be significantly more challenging and began 
with attempts to form the C13-C14 bond to combine the pyrrole and alkyl chain moieties. 
Deprotonation at the 2-position of pyrrole 2.65 was achieved using lithium 2,2,6,6-
tetramethylpiperidide (LTMP) at -78 
o
C (Scheme 2.11). Unfortunately, the 
nucleophilicity of the pyrrolyl anion 2.66 was too low to react with alkyl bromide 2.67.
31 
Displacement also failed to occur with the alkyl mesylate 2.68. Deprotonation was not 
the problem, since the anion could be quenched by adding iodine, a much hotter 
electrophile, to the reaction mixture.  
 
Scheme 2.11. Attempted alkylation of N-Boc pyrrole 2.65 to form alkyl pyrrole 2.69. 
 
 At this point, we decided to form the C14-C15 bond to provide alkyl pyrrole 2.69. 
In this alkylation route, the pyrrole fragment would now be the electrophilic partner and 
the alkyl chain the nucleophile. Polymer-supported borohydride reduction of N-Boc-
pyrrole-2-carboxaldehyde 2.71 resulted in quantitative conversion to alcohol 2.72 with 
required no purification (Scheme 2.12). The polymer-bound reagent was simply removed 
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by filtration and the solvent was removed in vacuo to give alcohol 2.72. Mesylation of 
the alcohol was carried out at 0 
o
C with methanesulfonylchloride and triethylamine. 
Unfortunately, the major product obtained was quaternary ammonium salt 2.73, which 
resulted from displacement of the mesylate by triethylamine. In order to overcome this 
problem, polymer-supported diisopropylethylamine was used instead. Under these 
conditions, formation of mesylate 2.74 was successful (74% yield).  
 
Scheme 2.12. Formation of mesylate 2.74 from N-Boc-pyrrole-2-carboxaldehyde 2.71. 
 
To perform the cuprate addition, 8-bromo-1-octene (2.67) was first converted to 
the Grignard reagent and then added to a solution of the mesylate 2.74 and catalytic 
Li2CuCl4 (Scheme 2.13).
32
 The cuprate addition proved unsuccessful, and only starting 
material was recovered. Upon warming to room temperature, the starting material 
decomposed and no discernible product was observed upon work-up and purification. 
The displacement was then attempted with the Grignard reagent alone, but this method 
gave no desired product and no starting material could be recovered. This was most likely 
a result of addition to the t-butyl carbamate protecting group, followed by decomposition 
of a highly unstable, deprotected pyrrolylmesylate. In light of these observations, it was 
concluded that the Boc-protected pyrrole may not be the best electrophilic substrate for 
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this type of addition.  
 
Scheme 2.13. Unsuccessful SN2 displacement of mesylate to form alkylpyrrole 2.69. 
 
In order to explore the reactivity of differentially substituted pyrrole systems, the 
8-bromo-1-octene Grignard reagent was simply added to N-Boc-pyrrole-2-
carboxaldehyde (2.71). Incorporation of aldehyde 2.71 as the electrophilic reagent, 
should take advantage of the Grignard reagent’s preference for 1,2-addition to the most 
electrophilic center.  As expected, the desired 1,2-addition was observed; however, the 
only isolable product was oxazolidinone 2.75, which resulted from transesterification of 
the Boc-carbamate t-butyl ester by the alkoxide generated upon 1,2-addition of the 
Grignard reagent  (Scheme 2.14). Since opening of the oxazolidinone would require 
additional steps, a different protecting group was explored. 
 
Scheme 2.14. Unexpected cyclization of Grignard addition product to form oxazolidinone 2.75. 
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  The commercially available 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde was 
chosen as a desirable protecting group. It was hypothesized, based on the observation that 
the Boc protecting group could be converted to a cyclic carbamate, that the sulfonate 
protecting group of 2.76 could be transferred to the alkoxide  2.77 and eliminated upon 
treatment with sodium borohydride and heat to give intermediate 2.79 (Scheme 2.15). 
Addition of a second equivalent of hydride should provide anion 2.80 and mildly acidic 
work-up generate alkylpyrrole 2.69 in one step. There is also literature precedence for 
this type of reaction. In 1985 Muchowski et. al showed that alkylpyrroles could be 
synthesized by the reduction of acylpyrroles with sodium borohydride in refluxing 
isopropanol.
33
 
 
Scheme 2.15. Hypothesized one-pot addition, rearrangment, deoxygenation, deprotection to form 
an alkylpyrrole from a sulfonamide-protected acylpyrrole. 
 
Following addition of the 8-bromo-1-octene Grignard reagent at 0 
o
C to 1-
(phenylsulfonyl)-2-pyrrolecarboxaldehyde (2.81), the reaction mixture was stirred 4 h at 
room temperature. Sodium borohydride in methanol was then added and the solution was 
heated to reflux. After 72 h, minimal formation of alkyl pyrrole 2.69 had occurred. The 
major product was the secondary alcohol 2.82, not the alkylpyrrole 2.69 (Scheme 2.16).  
57 
 
 
Scheme 2.16. Unsuccessful One-pot addition, rearrangment, deoxygenation, and deprotection to 
give alkyl pyrrole 2.69. 
 
 
After isolating alcohol 2.82, we treated it with sodium borohydride in refluxing 
isopropanol to determine if the rearrangement could occur with the already reduced 
alcohol, or if the ketone had to be reduced and in situ rearrangement occur to facilitate 
elimination (Scheme 2.17).  
 
Scheme 2.17.  Attempted sodium borohydride-mediated deoxygenation/deprotection of alcohol 
2.82 to give alkylpyrrole 2.69. 
 
Unfortunately, no product formation was observed, so a Ley oxidation was 
performed to oxidize alcohol 2.82.
34
 After purification to remove any ruthenium, 
acylpyrrole 2.83 was obtained in 86% yield. Acylpyrrole 2.83 was suspended in 
isopropanol, treated with excess sodium borohydride, and refluxed for 24 hours. At this 
time, the reaction had reached completion, and after purification, the desired alkylpyrrole 
2.69 was obtained in 94% yield. Scheme 2.18 describes the current synthesis of 
alkylpyrrole 2.69. 
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Scheme 2.18. Current synthesis of alkylpyrrole 2.69. 
 
 The next step in the current synthesis is the cross metathesis of alkylpyrrole 2.69 
with 3-buten-2-one using the Grubbs’ second generation catalyst.35 When the reaction 
was refluxed in dichloromethane for 12 hours, the major product was not the expected 
enone 2.5, but a pyrrole alkylated at the 2-position by the 3-buten-2-one Michael acceptor 
(2.84) (Scheme 2.19).  
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Scheme 2.19.  Minimization of the unexpected Michael adducts 2.84 and  2.85 in the cross 
metathesis of alkenylpyrrole 2.69 and 3-buten-2-one to form enone 2.5. 
 
The presence of this unexpected by-product reveals that the Grubb’s catalyst may 
act as a Lewis acid that activates the Michael acceptor to attack by the electron-rich 
pyrrole. In order to minimize this side reaction, a higher catalyst loading was used (30 
mol %) and the reaction was carried out at room temperature. After 6 h, the side product 
had begun to form, so the reaction was stopped although conversion was only 70 %. 
After purification, enone 2.5 was isolated in 40% yield.  
Although the yield was low, the reaction sequence was simply performed on a 10 
gram scale in order to produce a large quantity of the Diels-Alder substrate for catalyst 
screening. The complete synthetic route to access enone 2.5 is described in Scheme 2.20. 
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Scheme 2.20.  Current synthesis of enone 2.5. 
 
 The acid-mediated condensation of enone 2.5 with aldehyde 2.64 was carried out 
using 2 equivalents of HCl at a 0.87 M concentration in methanol according to procedure 
used in the synthesis of Obatoclax by Dairi et. al.
30
 After 10 minutes the reaction had 
reached completion and the conversion was quantitative. The reaction was quenched with 
excess ammonium hydroxide, which readily removed the carbamate protecting group, 
giving Diels-Alder substrate 2.6 (Scheme 2.21). 
 
Scheme 2.21. Acid-mediated condensation of enone 2.5 with aldehyde 2.64 to give Diels-Alder 
substrate 2.6. 
 
With the Diels-Alder substrate in hand, it was time to screen conditions to 
catalyze the [4+2] cycloaddition. The various conditions for the catalyst screen are 
outlined in Table 2.1. Unfortunately, none of the Lewis acids that are commonly used for 
inverse electron-demand hetero Diels-Alder reactions gave any product formation.
36 
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Table 2.1. Lewis Acids and conditions used to catalyze the intramolecular hetero Diels-Alder 
reaction. 
 
Catalyst Equiv. 
(mol%) 
Solvent Temperature 
(
o
C) 
Time (h) Result 
Eu(FOD)3 20 Cylcohexane 80 72 No rxn 
Eu(FOD)3 20 Cyclohexane 25 96 No rxn 
Yb(OTf)3 20 CH2Cl2 25 96 No rxn 
Sc(OTf)3 20 CH2Cl2 25 96 No rxn 
SnCl4 100 CH2Cl2 25 4, 12 Decomposed 
Me2AlCl 100 CH2Cl2 25 4, 12 Decomposed 
AcOH xs EtOH (1:1) 120 (mw) 0.25, 0.5 No rxn 
AcOH xs EtOH (1:1) 150 (mw) 0.5 No rxn 
AcOH xs Neat 160 (mw) 0.5 No rxn 
HCl xs Dioxane (1:1) 120 (mw) 0.5 No rxn 
TFA xs DCE 120 (mw) 0.25, 0.5 Decomposed 
Me2AlCl 500 CH2Cl2 -78 2, 4, 6, 
16, 24, 
48 
No rxn 
SnCl4 500 CH2Cl2 -78 2, 4, 6, 
16, 24, 
48 
No rxn 
SnCl4 500 CH2Cl2 -78 to -45 24 Decomposed 
BBr3 400 CH2Cl2 -78 2 Decomposed 
Me2AlCl 500 CH2Cl2 -20 4, 8, 16, 
24, 48, 
72, 96, 
108 
No rxn 
--- --- Mesitylene 215 1 Decomposed 
Methylene blue 
h 
100 CH2Cl2 25 4, 8, 12 No rxn 
ZnCl2 100 CH2Cl2 25 6, 12, 
24, 48 
No rxn 
ZnCl2 800 CH2Cl2 25 12, 24, 
48 
No rxn 
 
Without any promising leads, it was concluded that Diels-Alder substrate 2.6 was 
fairly unreactive. In order to make the heterodiene more reactive as an inverse electron-
demand Diels-Alder substrate, we decided to add an electron-withdrawing group to the 
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enone, namely, an -keto ester. This would provide a more electron-deficient, and thus 
more reactive, heterodiene. In light of the conjugate addition observed during the cross 
metathesis of 3-buten-2-one with alkylpyrrole 2.69, we thought that a Wittig-type 
reaction might prove more effective when incorporating the pyruvate moiety. This 
required either cleaving one carbon from the alkyl chain during the synthesis of this 
fragment or incorporating a carbon chain that is one carbon shorter in the Grignard 
reaction and then generating an aldehyde following a hydroboration/oxidation sequence. 
The new retrosynthesis is described in Scheme 2.22.  
 
Scheme 2.22. Retrosynthesis of Diels-Alder substrate 2.91 via synthesis of aldehyde 2.86 by 
either an oxidative cleavage or hydroboration/oxidation route. 
 
Ozonolysis was the first method used to synthesize aldehyde 2.86 from 
alkylpyrrole 2.69. Unfortunately, these conditions also resulted in cleavage of the 
electron-rich pyrrole to form a terminal amide. Dihydroxylation and subsequent oxidative 
cleavage proved unsuccessful as well due to incomplete dihydroxylation and production 
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of complex reaction mixtures during oxidative cleavage.  
It was finally decided that 7-bromo-1-heptene would be used in the Grignard 
addition (Scheme 2.23). After Ley oxidation of the resulting alcohol (2.92), acylpyrrole 
2.93 underwent sodium borohydride-mediated reduction, deoxygenation, and 
deprotection to give alkylpyrrole 2.87. Hydroboration and oxidation of 2.87 gave 
quantitative conversion to alcohol 2.94 with a 96% yield following purification. Ley 
oxidation of alcohol 2.94 gave clean conversion to aldehyde 2.86, which was purified by 
filtration of the reaction mixture through a celite plug and rinsing with dichloromethane. 
This method of aldehyde formation provided good yields (73% over two steps from 
alkylpyrrole 2.87) and has become the method of choice.  
 
Scheme 2.23. Synthesis of -keto ester 2.90. 
 
Reaction of aldehyde 2.86 with ethyl(triphenylphosphoranylidene)pyruvate (2.95) 
to give  -keto ester 2.90proved unsuccessful. The stabilized ylide is so highly stabilized 
that it is fairly unreactive. After refluxing in dichloromethane overnight, the ylide was 
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still present and the aldehyde had decomposed, possibly as a result of polymerization 
through a series of condensation reactions (Scheme 2.24.).  
 
Scheme 2.24. Unsuccessful Wittig olefination of aldehyde 2.86 to generate -keto ester 2.90. 
 
The next approach to generate -ketoester 2.90 was to use phosphonate 2.97 in a 
Horner-Wadsworth-Emmons olefination as a hotter reagent than the phosphoranylidene. 
Ethyl bromopyruvate (2.96) was treated with triethylphosphite at room temperature, 
resulting in a highly exothermic reaction (Scheme 2.25). After cooling to room 
temperature, TLC determined that all the starting material had been consumed, and LC-
MS confirmed that the product had the correct mass. However, H
1
 and C
13
 NMR revealed 
that the product was not the desired phosphonate 2.97 but was vinyl phosphate 2.98. 
According to an extensive review of the Michaelis–Arbuzov rearrangement by 
Bhatacharya and Thyagarman,
37
 the vinylphosphate is the major product with -chloro 
ketones and -bromo ketones. With the addition of an electron-withdrawing ester, it is 
logical that the ethyl -bromopyruvate would form the vinylphosphate product 
exclusively, as was observed.  
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Scheme 2.25.  Formation of undesired vinyl phosphate 2.98. 
 
Bhatacharya and Thyagarman report that -iodo ketones form the phosphonate 
exclusively. Ethyl iodopyruvate (2.99) is not commercially available, but it was easily 
synthesized from 2.96 in 91% yield using a Finkelstein reaction (Scheme 2.26).  
 
Scheme 2.26. Attempted preparation of Horner-Wadsworth-Emmons reagent, phosphonate 2.97. 
 
Addition of triethylphosphite to ethyl iodopyruvate 2.99 should result in the 
desired phosphonate 2.97. Unfortunately, iodination of bromopyruvate and subsequent 
Michaelis-Arbuzov reaction failed to provide phosphonate 2.97. Once again, vinyl 
phosphate 2.98 was the only product observed, presumably a result of the increased 
acidity of the -carbon due to the presence of the -keto ester. This result was undesired 
but not entirely unexpected, since Bhatacharya and Thyagarman investigated -iodo 
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ketones, not -iodo--ketoesters. 
If phosphonate formation had been successful, the final step in the synthesis of -
ketoester 2.90 would have been a Horner-Wadsworth-Emmons reaction with aldehyde 
2.86 performed in the presence of lithium chloride and DBU in acetonitrile, conditions 
developed by Roush and Masamune for base-sensitive substrates.
38
 These conditions 
were chosen since the deprotected pyrrole would most likely be problematic if sodium 
hydride is used. Without-ketoester 2.90, further investigation of an intramolecular 
Diels-Alder route to produce the marineosins was not possible. Due to the failure to 
produce the desired phosphonate 2.97 and the inherent instability of aldehyde 2.86, this 
route was abandoned in favor of one with more stable intermediates.  
In summary, Diels-Alder substrate 2.6 has been successfully synthesized. 
However, 2.6 did not undergo a [4+2] cycloaddition in the presence of various Lewis 
acids. We decided to derivatize 2.6 by adding an -ketoester to the enone in order to 
make substrate 2.90, a more electron-deficient heterodiene, which would be more likely 
to undergo the desired cycloaddition based on reactivity. To date, the relatively unstable 
aldehyde 2.86 has been synthesized; however, incorporation of the pyruvate moiety 
through an olefination reaction proved unsuccessful, which has led to the exploration of 
alternate routes. 
 
2.7. Intermolecular Diels-Alder Reaction. 
 
  
In light of the difficulty encountered with olefination reactions to produce 2.90 
and the unreactive nature of Diels-Alder substrate 2.6, an alternative synthesis has been 
developed that incorporates many of the key reactions from previous routes. The two 
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notable changes are the RCM to form macrocycle and an intermolecular inverse electron 
demand hetero Diels-Alder (Scheme 2.27). 
 
Scheme 2.27. Restrosynthetic analysis of intermolecular hetero Diels-Alder route. 
 
 The alternative route starts from commercially available, (tert-
butyldimethylsilyloxy)-acetaldehyde (2.100). This compound has a high boiling point 
(165-167
o
C) and no extraneous, deprotected, highly reactive functional groups, so we 
hypothesized that unlike aldehyde 2.86, it should not decompose in the conditions 
necessary to activate the highly stabilized ethyl (triphenylphosphoranylidene) pyruvate 
(2.95). After refluxing in toluene overnight, heterodiene 2.101 was readily obtained 
(Scheme 2.28). 
68 
 
 
Scheme 2.28. Synthesis of heterodiene 2.101. 
 
 The synthesis of silylether 2.102 is very straightforward (Scheme 2.29). Most of 
the steps have been accomplished before in the synthesis of aldehyde 2.86. The route 
begins with Grignard addition to 1-(phenylsulfonyl)-pyrrole-2-carboxaldehyde (2.81), the 
only difference is that the Grignard reagent was prepared from 5-bromo-1-pentene, to 
give alcohol 2.106 in 76% yield. Ley oxidation and subsequent sodium borohydride-
mediated reduction, deoxygenation, and deprotection yielded alkylpyrrole 2.108 (81% 
over 2 steps). Hydroboration and oxidation of 2.108 gave alcohol 2.109, which was 
immediately subjected to TBDPS protection yielding silylether 2.102 (82% over 2 steps).  
 
Scheme 2.29. Synthesis of silylether 2.102. 
 
 Instead of immediately subjecting silylether 2.102 to acid-mediated condensation 
with aldehyde 2.64 to give dieneophile 2.103 (Scheme 2.27), we decided to construct a 
simpler model system to save our starting material and simplify NMR interpretation. This 
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model system was synthesized by condensation of aldehyde 2.64 with commercially 
available 2-ethylpyrrole to yield the Diels-Alder model substrate 2.110 (Scheme 2.30).   
  
Scheme 2.30. Condensation of 2-ethylpyrrole with aldehyde 2.2 to give model dienophile 2.110. 
 
At this point, we began to screen different Lewis acids for their ability to catalyze 
a [4+2] cycloaddition between heterodiene 2.101 and model dienophile 2.110 to generate 
Diels-Alder adduct 2.111 (Table 2.2).  
 
Table 2.2.  Lewis Acids and conditions used to catalyze the intermolecular Diels-Alder reaction. 
 
Catalyst Equiv.  Solvent Temperature 
(
o
C) 
Time (h) Result 
Eu(FOD)3 0.2 Cyclohexane 25 72 No rxn 
Yb(OTf)3 0.2 Cyclohexane 25 72 No rxn 
Sc(OTf)3 0.2 CH2Cl2 25 72 No rxn 
Me2AlCl 1 CH2Cl2 0 12 No rxn 
SnCl4 1 CH2Cl2 0 12 Decomposed 
BBr3 1 CH2Cl2 -78 2 Decomposed 
ZnCl2 10 CH2Cl2 0 4 Reacted 
 
Finally, a positive result was obtained using ZnCl2 (10 equiv.) in CH2Cl2 at 0 
o
C. 
The mass of the resulting adduct as determined by LC-MS matched the expected mass of 
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the Diels-Alder product 2.111. Also, 
1
HNMR and 
13
CNMR revealed the correct number 
of proton and carbon atoms with similar shifts as would be expected for the Diels-Alder 
adduct. However, the splitting patterns in the 
1
HNMR were slightly unexpected; 
therefore, HMBC and HSQC spectra were obtained for the compound. Based on HMBC 
correlations, it was determined that the Diels-Alder reaction had not occurred, but instead 
the ZnCl2 had catalyzed a conjugate addition between the A-ring pyrrole of the 
dienophile (2.110) and the ,-unsaturated -keto ester (2.101) (Scheme 2.31).  
 
Scheme 2.31. ZnCl2-mediated conjugate addition of dienophile 2.110 to heterodiene 2.112. 
 
In light of this result with the pyruvate heterodiene 2.101, we decided to 
investigate the intermolecular Diels-Alder reaction further by experimenting with 
different heterodienes and by incorporating a carbamate-protected dienophile 2.113 
(Scheme 2.32). The methyl ketone (2.114) and ethyl ester (2.115) heterodienes were 
prepared from commercially available Wittig reagents and (tert-butyldimethylsilyloxy)-
acetaldehyde 1.100 in the same manner as heterodiene 2.101 was prepared (Scheme 
2.28). Unfortunately, the methyl ketone (2.114) and ethyl ester (2.115) heterodiene 
derivatives failed to react with dienophile 2.110 under any of the conditions previously 
described in Table 2.2. Not even the conjugate addition adduct was observed. When the 
A-ring pyrrole of dienophile 2.110 was protected as the t-butyl carbamate (2.113), no 
reaction occurred with pyruvate heterodiene 2.101 in the presence of ZnCl2. Although 
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carbamate protection efficiently prevented the conjugate addition reaction, it did not 
facilitate the desired [4+2] cycloaddition.  
 
Scheme 2.32. Reaction of various heterodienes and protected/deprotected dienophiles in the 
presence of Lewis acids from Table 2.2 in an attempt to initiate an intermolecular Diels-Alder 
cycloaddition. 
 
Since none of the prepared heterodienes reacted in the desired manner, it was 
finally concluded that dienophile 2.110 was not a competent partner for a Diels-Alder 
reaction.  
 
2.8. Molecular Modeling of the Prodigine Substrate for the Intramolecular Diels-
Alder Reaction. 
 
In light of the difficulties encounter with facilitating the Diels-Alder reaction, we 
enlisted molecular modeling in an attempt to understand this lack of reactivity in both the 
intramolecular and the intermolecular variants. Molecular mechanics sampling for the 
intramolecular substrate 2.6  was conducted starting from the hypothesized transition 
state geometry using both stochastic and systematic conformer searches and gradient 
energy minimization with the Merck MMFF94 forcefield as implemented in the MOE 
software package (Chemical Computing Group).
39
  Analysis of the top 10,000 
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conformers with the lowest relative energies (20kcal from lowest energy conformer) 
indicated a failure to identify favorable Diels-Alder transition state geometries. Out of 
10,000 systematic search conformers generated for 2.6, less than 15% of the structures 
sampled have a folded topology, and the key atoms remained separated by almost five 
angstroms (Figure 2.4). Of those conformers with a folded topology, only 15% form 
intramolecular hydrogen bonds. Thus, as a result of intramolecular hydrogen bonds and a 
large degree of conformational flexibility present in the long, alkyl linker moiety, the 
intramolecular Diels-Alder mechanism is likely energetically disfavored. Moreover, since 
attempts at intermolecular variants proved equally unsuccessful, it was concluded that the 
key olefin of the extended poly-pyrrole π-system is not a competent dienophile. This 
extended conjugation removes electron density from the olefin, which needs to be 
electron-rich in order to raise the alkene HOMO to a state that is energetically favorable 
for an inverse demand Diels-Alder reaction to occur. With this information, we 
concluded that a Diels-Alder cycloaddition is not a viable synthetic route for the 
synthesis of Marineosins A & B in the laboratory.
40
 However, this does not rule out an 
enzyme-templated process in nature that could impart the correct electronic state and 
conformation in order to catalyze the reaction. 
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Figure 2.4.  Most favored Merck MMFF94 minimized conformer 2.6. 
 
 In summary, we constructed various heterodienes in an attempt to catalyze an 
intermolecular inverse electron-demand hetero-Diels-Alder reaction with model 
dienophile 2.111. Unfortunately, no reaction occurred with any of the substrates except 
the pyruvate derivative, which underwent a conjugate addition reaction with the A-ring 
pyrrole of model dienophile 2.110. Through organic synthesis and computational 
modeling, we have concluded that the biosynthetic proposal of an inverse electron-
demand hetero-Diels-Alder reaction is not a viable method for the synthesis of 
Marineosins A & B. Therefore, we have decided to pursue the synthesis of these marine 
alkaloids by alternative routes that do not proceed through a tripyrrole prodigiosin 
alkaloid intermediate. 
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2.9. Acid-catalyzed Intramolecular N-Acyliminium Cyclization for the Synthesis of 
Marineosin A. 
 
 After many unsuccessful attempts to synthetically validate the proposed 
biomimetic route to Marineosins A & B, we decided to investigate other ways to 
synthesize spiroaminal centers in alkaloid natural products. One of the most 
straightforward and amenable routes involves Grignard addition to a chiral hydroxy-
malimide, readily prepared from (S)-2-hydroxysuccinic acid, followed by acid-catalyzed 
intramolecular N-acyliminium cyclization to form the spiroaminal core (Scheme 2.33). 
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Scheme 2.33. Preparation of aza-spiropyran 2.123. by Huang and coworkers.
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 This key reaction could easily provide the core structure of Marineosin A as 
described by the retrosynthesis outlined in Scheme 2.34 
 
2.9.1. Addition of an -Nucleophilic Pyrrole to (S)-Hydroxy Malimide. 
The key aspect of this new route is the formation of an -nucleophilic pyrrole, 
which should add regioselectivly to the (S)-hydroxy malimide 2.119 to form the 
spriocyclic core. Marineosin A (2.1) is obtained from lactam spiroaminal 2.124 by 
deprotection/hydrogenation, stereocenter inversion, triflate formation, and a Suzuki cross 
coupling to install the final pyrrole moiety. Metalation and addition of bromide 2.125 to 
malimide 2.119, followed by acid-catalyzed imtramolecular N-acyliminium cyclization 
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will provide lactam spiroaminal 2.124 as the thermodynamically favored product. 
Malimide 2.119 is readily obtained from (S)-2-hydroxy-succinic acid (2.126) by a known 
procedure.
42-44 
Bromide 2.125 is synthesized by reduction, subsequent bromination, and 
ring-closing metathesis of acylpyrrole 2.127. Addition of the pyrrolylanion of 
alkylpyrrole 2.130 to the pyridylthioester of acid 2.128 followed by sulfonamide 
protection will provide acylpyrrole 2.127. Alkylpyrrole 2.108 is accessed through 
previously described transformations (Scheme 2.29), beginning with Grignard addition of 
5-bromo-1-pentene to 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde 2.81. Acid 2.128 is 
obtained through stereoselective alkylation of lactone 2.129, lactone hydrolysis, and silyl 
protection of the resulting alcohol.  
 
Scheme 2.34. Retrosynthesis of marineosin A utilizing N-acyliminium spirocyclization. 
  
Malimide 2.119 was prepared in 73% overall yield by a known method which 
begins with a 3-step-1-pot sequence to give the malimide core (Scheme 2.35).
42-44
 (S)-2-
hydroxy-succinic acid (2.126) was suspended in excess acetylchloride and heated to      
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50 
o
C for 2 hours, then the mixture was concentrated and excess benzylamine in THF was 
added at the resulting oil. This mixture was stirred at room temperature for 4 hours, and 
then the solution was concentrated a second time. The remaining residue was 
resuspended in excess acetylchloride and heated at 50 
o
C for 18 hours. After 
concentrating the mixture a final time, the resulting oil was purified by flash 
chromatography to give acetate-protected hydroxy-malimide 2.130 in 87 % yield. Acid-
catalyzed transesterification of malimide 2.130 with acetylchloride in ethanol, gave 
hydroxy malimide 2.131 in 98 % yield. The free hydroxyl group was subsequently 
protected using benzylbromide and silver (I) oxide to give benzyl ether 2.119 (85 %). 
 
Scheme 2.35. Synthesis of malimide 2.119  from (S)-2-hydroxy-succinic acid. 
 
 Lactone 2.129 was readily obtained following a procedure developed by White 
and coworkers (Scheme 2.36).
45
 Regioselective, basic epoxide-opening of commercially 
available (S)-2-methyloxiriane was achieved with the dianion of (phenylthio)acetic acid 
2.132 yielding hydroxy-acid 2.133. Acid-catalyzed lactonization of hydroxy-acid 2.133 
with catalytic p-TSA gave thiophenyllactone 2.134 in 71% yield over 2 steps. Raney 
nickel desulfurization completed the synthesis of lactone 2.129 (86% yield).   
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Scheme 2.36. Synthesis of lactone 2.129 from (phenylthio)acetic acid and (S)-2-methyloxirane. 
 
In order to access acid 2.138, lactone 2.129 was first treated with lithium 
hexamethyldisilazide then allyl iodide at -78 
o
C to afford -allyl lactone 2.135 in 6:1 dr 
(anti:syn) and 80 % yield (Scheme 2.37). Hydrolysis of -allyl lactone 2.135 with 1.1 
equivalents of lithium hydroxide in THF/H2O (7:1 v/v) at 0 
o
C for 10 hours provided 
hydroxy-acid 2.136 in 98% yield with essentially no racemization of the stereocenter. 
Extra equivalents of base or higher temperatures decreased the reaction time but led to 
considerable racemization. Hydroxy-acid 2.136 was then bis-protected as 
silylether/silylester 2.137 which was immediately purified and then chemoselectively 
deprotected to give acid 2.138 in 93 % yield over 2 steps. 
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Scheme 2.37. Synthesis of acid 2.138 from lactone 2.129. 
 
With acid 2.138 in hand and alkylpyrrole 2.108, which was prepared as 
previously described in Scheme 2.29, it was time to start considering coupling conditions 
to yield acylpyrrole 2.140. Since the ketone was the desired product following 
pyrrolylanion addition, utilization of a Weinreb amide was investigated first. Weinreb 
amide 2.139 was easily prepared from acid 2.138 by amide coupling with N,O-
Dimethylhydroxylamine hydrochloride in 86 % yield (Scheme 2.38). Unfortunately, the 
amide proved to be completely unreactive to addition of the pyrrolylanion of alkylpyrrole 
2.108, even at room temperature and for extended reaction times. 
 
Scheme 2.38. Unsuccessful addition of pyrrolylanion 2.108 to Weinreb amide 2.139 to form 
acylpyrrole 2.140. 
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. 
In light of this result, we decided to prepare a more reactive acylating reagent, a 
thioester. Thioester 2.141 was prepared from acid 2.138, 2,2’-dipyridyldisulfide, and 
triphenylphosphine in 92 % yield (Scheme 2.39).
44
 Thioester 2.141 was very stable; it 
could be purified by column chromatography and stored at 0 
o
C for three months without 
any appreciable decomposition. Addition of the pyrrolylanion 2.108 to thioester 2.141 in 
toluene at -78 
o
C gave the desired acylpyrrole 2.140 in 85 % yield. Attempts to combine 
the thioester formation and pyrrolylanion addition into a one-pot procedure were 
unsuccessful. Only unreacted thioester 2.141 and alkylpyrrole 2.108 were recovered from 
the reaction mixture; however, when the thioester was purified and then treated with 
pyrrolylanion 2.108, addition proceeded smoothly with complete conversion. 
 
Scheme 2.39. Synthesis of acylpyrrole 2.140 by pyrrolylanion addition to thioester 2.141. 
 
The next step was to protect the pyrrole nitrogen of acylpyrrole 2.140 with a 
suitable protecting group that would be compatible with organometallic reagents. Choice 
of a proper protecting group is critical since acylpyrrole 2.140 will become bromide 
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2.125 that must undergo oxidative addition to become the Grignard reagent. Since the 
phenylsulfonamide protecting group had proven robust in previous organometallic 
reactions, it was chosen as the ideal protecting group. Also, an electron-withdrawing 
protecting group should deactivate the electron-rich alkylpyrrole thus making it less 
likely to undergo undesirable side reactions. Traditional protection conditions were 
employed with acylpyrrole 2.140 (Scheme 2.40); however, no reaction occurred under 
these conditions.  
 
Scheme 2.40. Attempt to protect acylpyrrole 2.140 using traditional protection conditions. 
 
A model system was then designed in order to test protection conditions and to 
save the advanced intermediate acylpyrrole 2.140 (Scheme 2.41).  
 
Scheme 2.41. Synthesis of model acylpyrrole 2.146 from butyl levulinate 2.142. 
Synthesis of the model system began with Corey-Bakshi-Shibata (CBS) reduction 
of butyl levulinate 2.142 to give alcohol 2.143 in 92 % yield but only 60 % ee (as 
determined by Mosher ester analysis)
47
. Since this was only a model system to determine 
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protection conditions, we decided to carry on with this modest enantiomeric excess. The 
free alcohol was protected to give silylether 2.144 (100 %) and then the ester hydrolyzed 
to give acid 2.145 in 98 % yield. Acid 2.145 was then treated with 2,2’-dipyridyldisulfide 
and triphenylphosphine to give the thioester, and the pyrrolylanion of commercially 
available 2-ethylpyrrole was added in situ giving model acylpyrrole 2.146 in 88 % yield 
for the one-pot procedure. With model acylpyrrole 2.146 in hand, we began investigating 
different protecting groups and conditions as listed in Table 2.3.  
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Table 2.3.  Trial conditions for the protection of model acylpyrrole 2.146. 
 
Entry Base Solvent Electrophile Additive Method
a
 
Yield 
(%)
b
 
1 NaH DMF PhSO2Cl --- A 0 
2 NaH DMF TolSO2Cl --- A 0 
3 NaH DMF TolSO2OO2STol --- A 0 
4 NaH DMF PhSO2Cl --- B 0 
5 NaH THF PhSO2Cl --- A 0 
6 NaH THF PhSO2Cl 15-crown-5 C 0 
7 NaH DMF MeSO2Cl --- A 0 
8 KOtBu THF MeSO2Cl 18-crown-6 C 0 
9 Collidine DCM MeSO2Cl --- A 0 
10 BuLi THF TolSO2OO2STol --- D 0 
11 BuLi THF PhSO2Cl --- D 0 
12 LiHMDS THF TolSO2OO2STol --- D 0 
13 LiHMDS THF PhSO2Cl --- D 0 
14 DBU DCM PhSO2Cl --- A 0 
15 Cs2CO3 MeCN PhSO2Cl --- E 0 
16 Et3N MeCN TolSO2Cl DMAP F 0 
17 NaH DMF BnBr --- A 95 
a
 Method A: Base is added to solution of pyrrole at rt and stirred for 0.5 h, then electrophile is 
added and stirred at rt for 2 h. Method B: Same as A, except stirred 8 h after addition of 
electrophile. Method C: Base is added to a solution of pyrrole and additive at rt and stirred for 0.5 
h, then electrohphile is added and stirred at rt for 2 h. Method D: Base is added to solution of 
pyrrole at 0 
o
C and stirred for 0.5 h, then electrophile is added the reaction is warmed to rt and 
stirred for 2 h. Method E: Same as method A, but instead of stirring at rt, the mixture is heated to 
80 
o
C. Method F: Same as method B, but reaction was stirred for 16 h.  
b
 isolated yield of desired protected product. 
 
Protection of the acylpyrrole 2.146 with an electron-withdrawing sulfonamide 
group proved highly unsuccessful; however, Entry 17 shows that protection as the 
benzylamine was not only successful, but high yielding (95 %). With N-
benzylacylpyrrole 2.147 in hand, we decided to investigate reduction conditions with this 
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readily available model system to provide alcohol 2.148. Unfortunately, every reduction 
attempted (NaBH4, L-selectride, CBS) resulted in the elimination product 2.149 as the 
only isolated product (Scheme 2.37). Noyori transfer hydrogentation gave no product 
formation even after extended reaction times (7 days).  
 
Scheme 2.42. Attempted reduction of N-benzylacylpyrrole 2.147 to alcohol 2.148. 
 
In light of these results, it was concluded that the benzyl protecting group was not 
suited for these transformations. All of the sulfonamide protection conditions (Entries 1-
16) for the model system listed in Table 2.3 were then tried with the actual system 
(acylpyrrole 2.140). When none of the conditions successfully protected the pyrrole, we 
tried reducing acylpyrrole 2.140 to the alcohol with no protecting group. This, too, only 
resulted in the elimination product.  
Prior to adjusting the synthesis further, we decided to develop a model system to 
test the validity of the key core-forming addition to malimide 2.119 followed by acid-
catalyzed spirocyclization. The inclusion of a sulfonamide protected-pyrrole was crucial, 
since a naked benzene or furan could not adequately represent the electronic and steric 
properties of a benzenesulfonamide-protected pyrrole (Scheme 2.43). Bromide 2.76 is a 
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simplified version of bromide 2.125 (Scheme 2.34). The model bromide lacks the 
macrocyclic ring, so it requires a much simpler synthesis. Also, bromide 2.152 contains a 
primary alcohol instead of a secondary alcohol, so there are no diastereomers to 
complicate NMR interpretation.  
 
Scheme 2.43. Retrosynthetic analysis for model synthesis of the spiroiminal core 2.150 of 
marineosin A. 
 
As outlined in Scheme 2.43, model marineosin A (2.150) is obtained from 
spiroaminal 2.151 through a Mitsunobu inversion, triflate formation and Suzuki cross-
coupling. Spiroaminal core 2.151 is prepared by Grignard addition of bromide 2.152 to 
malimide 2.119 and subsequent acid-catalyzed spirocyclization of the intermediate N-
acyliminium ion. Malimide 2.119 is readily available from 2-(S)-hydroxysuccinic acid 
2.126 (Scheme 2.35). Bromide 2.152 is synthesized by addition of 
allylmagnesiumbromide to 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde 2.81, followed 
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by hydroboration/oxidation, and mono-silylether protection of the resulting primary 
alcohol.  
The seemingly straightforward synthesis of bromide 2.152 proved to be quite a 
challenge. Grignard addition of allylmagnesiumbromide to 1-(phenylsulfonyl)-2-
pyrrolecarboxaldehyde 2.81 provided homoallylic alcohol 2.153 in 93 % yield (Scheme 
2.44). Subsequent hydroboration/oxidation sequence gave diol 2.154 in excellent isolated 
yield (98 %). Mono-protection of the primary alcohol as the tert-butyldimethylsilylether 
yielded alcohol 2.155 as the only product (89 %). 
 
Scheme 2.44. Synthesis of alcohol 2.155 from 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde 2.81. 
 
In order to prepare bromide 2.152, alcohol 2.155 was added to a solution of 
carbon tetrabromide and triphenylphosphine in dichloromethane. Unfortunately, the only 
product obtained in quatitative yield was tetrahydrofuran 2.156 (Scheme 2.45).  
 
Scheme 2.45. Formation of tetrahydrofuran 2.156  as an undesired side product in an attempted 
bromination of alcohol  2.155. 
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The observed product formation is a result of silylether cleavage by hydrogen 
bromide formed in situ and subsequent cyclization by intramolecular displacement of the 
resulting bromide, or the phosphonium salt intermediate, by the free primary alcohol. In 
light of this occurrence, an investigation of bromination conditions was initiated (Table 
2.4). 
 
Table 2.4. Investigation of bromination conditions.  
 
 
Substrate Conditions 
Product Distribution 
A : B : C 
2.155 PPh3, CBr4, CH2Cl2 0 : 100 : 0 
2.155 Ph3PBr2, THF:pyr (6:1) 0 : 15 : 85 
2.155 DPPE, Br2, CH2Cl2 0 : 0 : 100 
2.155 Ph3PCl2, CH2Cl2 0 : 10 : 90 
2.157 PPh3, CBr4, CH2Cl2 0 : 0 : 100 
2.157 Ph3PBr2, THF:pyr (6:1) 0 : 0 : 100 
2.157 DPPE, Br2, CH2Cl2 0 : 0 : 100 
2.157 Ph3PCl2, CH2Cl2 0 : 0 : 100 
 
Attempted bromination with triphenylphosphine dibromide in the presence of 
pyridine as a proton sponge inhibited tetrahydrofuran formation; however, none of the 
desired product was formed. Instead of bromide 2.152, alkene 2.161 was the major 
product with minor tetrahydrofuran formation. The next bromination conditions tested 
were 1,2-Bis(diphenylphosphino)ethane (DPPE) (0.5 equiv) and bromine (1 equiv) in 
dichloromethane. The use of DPPE instead of triphenylphosphine generally results in 
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simpler purification and decreased elimination side products.
48 
Unfortunately, these 
conditions still gave alkene 2.161 as the sole product. An attempt to use neutral 
chlorination conditions also failed to deliver the desired halogenated product 2.158. The 
tert-butyldimethylsilyl ether protecting group was then replaced by a tert-
butyldiphenylsilylether (2.157), which is much more robust in acidic media. 
Unfortunately, the TBDPS group only served to prevent tetrahydrofuran formation 
completely and to provide the undesired elimination product, alkene 2.162 as the only 
product.  
With these results, it was decided that if the -bromide could actually be formed, 
it would be unstable and possess a highly thermodynamically stable elimination pathway. 
Also, if this sp
3
 bromide was subjected to magnesium metal to undergo oxidative 
addition, the resulting organometallic reagent would possess a highly favorable 
elimination pathway. In light of these conclusions, it was decided to take advantage of 
the stability of alkene 2.161 by preparing an -pyrrolo-vinylbromide that could later be 
hydrogenated to provide marineosin core 2.151. A Shapiro reaction was chosen as the 
key reaction to provide the vinyl bromide since the required hydrazone could readily be 
synthesized using conditions that have already been optimized for this pyrrole substrate. 
The modified retrosynthetic route is described in Scheme 2.44.  
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Scheme 2.46. Retrosynthesis of  model marineosin core 2.151 by Grignard addition of 
vinylbromide 2.164. 
 
 Vinylbromide 2.164 will undergo a Grignard reaction with malimide 2.119 to 
provide unsaturated spiroaminal 2.163, which can be hydrogenated to the desired model 
marineosin core 2.151. The substrate for the Shapiro reaction, tosylhydrazone 2.165, is 
synthesized by hydroboration/oxidation of ketone 2.166, silyl protection of the primary 
alcohol, and subsequent hydrazone formation. Ketone 2.166 is prepared by Grignard 
addition of allylmagnesium bromide to 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde 2.81 
and oxidation of the resulting alcohol. 
 The synthesis of tosylhydrazone 2.165 proved straightforward and highly efficient 
(Scheme 2.47). Grignard addition of allylmagnesium bromide to 1-(phenylsulfonyl)-2-
pyrrolecarboxaldehyde 2.81 gave the secondary homoallylic alcohol 2.167 in 88 % yield. 
Ley oxidation rapidly provided ketone 2.166 in 91 % yield, and hydroboration/oxidation 
of the terminal alkene gave a 96 % yield of primary alcohol 2.168. Protection as the 
silylether (2.169) proceeded in 86 % yield and subsequent condensation with 
tosylhydrazide gave tosylhydrazone 2.165 in 83 % yield.  
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Scheme 2.47. Synthesis of tosylhydrazone 2.165 from 1-(phenylsulfonyl)-2-
pyrrolecarboxaldehyde 2.81. 
  
 With tosylhydrazone 2.165 in hand, it was time to experiment with conditions for 
the Shapiro reaction (Scheme 2.48). 
 
 
Scheme 2.48. Shapiro reaction with tosylhydrazone 2.165 in an attempt to form vinylbromide 
2.164 or vinyliodide 2.170 
 
  Unfortunately, every temperature, solvent, and electrophile combination failed to 
provide the desired vinylbromide 2.164 or vinyliodide 2.170. It was concluded that 
perhaps the hydrazone was too sterically hindered or simply too stable to undergo the 
required fragmentation reaction, since in every case, only starting material was recovered, 
with no evidence of the desired vinylbromide or even the alkene that would result from 
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hydrogen abstraction and/or unsuccessful electrophilic attack.  
At this point, we decided to rethink the use of an -nucleophilic pyrrole for the 
regioselective addition to (S)-hydroxy malimide 2.119 to form the spriocyclic core. 
 
2.9.2. Hydroamination for Late-Stage Pyrrole Formation. 
 With all the problems encountered performing simple tranformations on pyrrole-
based substrates, we decided to develop a synthetic approach that called for a late-stage 
pyrrole installation.  
 In 2010, Zheng and Hua reported conditions for the formation of 1,2,5-
trisubstituted pyrroles from 1,3 diynes using cuprous chloride and a primary amine 
(Scheme 2.49).
49 
Since this was the necessary pyrrole substitution pattern and a 1,3-diyne 
could easily be incorporated into a previously established route, this method was ideal.  
 
Scheme 2.49. 1,2,5-substituted pyrrole synthesis by intermolecular hydroamination followed by 
intramolecular hydroamination. 
 
2.9.3. Addition of a Diyne to (S)-Hydroxy Malimide. 
Using this hydroamination methodology, a diynyl bromide would replace the -
bromopyrrole as the Grignard reagent in this new synthesis as outlined in Scheme 2.51. 
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Scheme 2.51. Retrosynthesis of marineosin A (2.1) from a 1,3-diyne pyrrole precursor 2.173. 
 
 Unsaturated marineosin core 2.171 could be prepared using Zheng-Hua diyne 
hydroamination strategy followed by a ring-closing methathesis reaction.
49
 Spiroaminal 
2.172 would be achieved through Grignard addition of diynyl bromide 2.173 to malimide 
2.119. diynyl bromide 2.172 could be provided by addition of the deprotonated acetylide 
2.175 to aldehyde 2.174, which is prepared from lactone 2.129. Diyne 2.175 is prepared 
by a copper-catalyzed Cadiot-Chodkiewicz alkyne-alkyne cross-coupling with 
ethynyltrimethylsilane 2.177 and iodoacetylene 2.176 followed by silane deprotection. 
Lithium acetylide (2.178) addition to 6-bromo-1-hexene 2.179) followed by iodination 
should provide iodoacetylene 2.176.
 
 The forward synthesis began with the preparation of aldehyde 2.174 
(Scheme 2.52) from previously prepared (Scheme 2.37) TBS ester 2.137. Ester 2.137 is 
treated with diisobutylaluminumhydride (DIBAL-H) to provide alcohol 2.180 in 93 % 
yield. Parikh-Doering oxidation of alcohol 2.180 completed the synthesis of aldehyde  
2.174 (81% yield). 
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Scheme 2.52. Preparation of aldehyde 2.174 from previously prepared ester 2.137. 
 
The synthesis of 1,3-diyne 2.175 proved equally as straightforward (Scheme 
2.53). Nucleophilic substitution of 6-bromo-1-hexene 2.179 with commercially available 
lithium acetylide ethylenediamine complex 2.178 gave terminal acetylene 2.181. 
Iodination of the terminal acetylene by deprotonation with n-butyl lithium and quenching 
of the resulting anion with iodine provided iodoacetylene 2.176 in 59 % yield over 2 
steps. A Cadiot-Chodkiewicz cross-coupling of iodoacetlyene 2.176 and 
ethynyltrimethylsilane 2.177 with Alami’s improved conditions gave the TMS-protected 
1,3-diyne 2.182 in excellent yield (89 %).
50
 Silane deprotection by basic methanolysis 
provided the terminal 1,3-diyne (2.175) in 95 % yield. Treatment of 1,3-diyne 2.175 with 
a ethyl magnesium bromide provided the acetylide Grignard reagent, which was then 
added to aldehyde 2.174 at 0 
o
C to provide diynyl alcohol 2.174 in 85 % isolated yield 
(1:1 dr). At this point in the synthesis the diastereomers from the allylation reaction are 
easily separated and the reported yield of 85 % is for the major diastereomers syn, syn, 
anti and syn, syn, syn). The configuration of the stereocenter formed in the addition of 
diyne 2.175 to aldehyde 2.174 is not important, since this center will become the 
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nucleophilic center of the Grignard reagent. Since Grignard reactions can follow anionic 
or radical addition pathways, it is very likely that this stereocenter will racemize. 
Bromination of diynyl alcohol 2.183 with carbon tetrabromide, triphenylphosphine, and 
pyridine in dichloromethane readily provided diynyl bromide 2.173 in 82 % isolated 
yield (Scheme 2.53). It is important to note that without the pyridine additive (4 equiv.), 
the silylether was cleaved and the cyclized tetrahydrofuran was the only product 
observed, as with the pyrrole substrate (Scheme 2.45).  
 
Scheme 2.53. Synthesis of 1,3 diyne 2.175, subsequent addition to aldehyde 2.174, and 
bromination of the resulting alcohol 2.183 to provide diynyl bromide  2.173. 
 
Diynyl bromide 2.173 was only stable at room temperature for approximately 4 
days. After one week, the bromide had completely decomposed. Fortunately, if kept at      
-35 
o
C, the bromide was stable for about three weeks. With diynyl bromide 2.173 in 
hand, it was time to begin exploring conditions for the addition to malimide 2.119. 
Since work by Huang had shown that numerous Grignard reagents could 
regioselectively add into malimide 2.119,
41
 we first chose to convert diynyl bromide 
2.173 to a magnesium Grignard reagent. Stirring the 2.173 with magnesium metal in THF 
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at -78 
o
C followed by addition of malimide 2.119 provided no product formation. diynyl 
bromide 2.173 and malimide 2.119 were the only compounds recovered (Figure 2.5). 
Such a low temperature was chosen to avoid -elimination once the organometallic 
complex had formed. Since a highly conjugated ene-diyne compound would be formed 
upon -elimination, it was considered to be a very likely side reaction. The elimination 
product was not observed at -78 
o
C, and since the reaction failed to initiate, the decision 
was made to raise the temperature. At 0 
o
C in THF and diethyl ether, the same result was 
observed. Since the lack of reactivity was caused by an inability to initiate, the 
magnesium/diynyl bromide 2.173/THF or ether solutions were heated to reflux for 1 hour 
and then cooled to 0 
o
C and malimide 2.119 was added. Unfortunately, no addition was 
observed with these reactions either. However, instead of recovering diynyl bromide 
2.173, only des-bromo diyne 2.184 was obtained (Scheme 2.54). Interestingly, none of 
the -elimination product was recovered, only the dihydro diynyl compound 2.184. Since 
this side reaction could be due to hydrogen abstraction from the solvent, it was decided to 
use a Barbier method of addition. Although the Grignard reagent was forming, it was 
given enough time to abstract a hydrogen atom before the electrophile was added.  If the 
two reagents were combined, then as soon as the Grignard reagent forms, it should react 
with the electrophile available in solution.diynyl bromide 2.173 and malimide 2.119 were 
combined in THF and added to magnesium metal. This solution was rapidly stirred and 
heated to reflux for 2 hours. Unfortunately, the same result was observed: des-bromo 
diyne 2.184 and malimide 2.119 were the only isolated products.  
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Scheme 2.54. Summary of diynyl bromide (2.173) additions to malimide 2.119 and reduced 
malimide 2.185. 
 
Since malimide 2.119 is much less reactive than a traditional electrophile, like an 
aldehyde, it was theorized that the diynyl Grignard was forming, but the hydrogen 
abstraction pathway proceeds much faster than addition to the sterically hindered imide. 
To test this theory, malimide 2.119 was replaced with p-methoxybenzaldehyde. 
Surprisingly, none of the expected alcohol was observed, only des-bromo diyne 2.184 
and p-methoxybenzaldehyde were isolated. At this point, it was concluded that diynyl 
bromide 2.173 was the main problem, since it was unable to react with a simple 
electrophile. It was decided to investigate different types of additions besides the 
traditional Grignard. First, Rieke magnesium was used to generate the organometallic 
reagent using a Grignard addition procedure and a Barbier addition procedure, both 
carried out at -78 
o
C. Rieke magnesium is traditionally used for difficult Grignard 
reagents, such as secondary benzyl and allyl halides, so it was chosen for these 
properties. Unfortunately, the only isolated products were malimide 2.119 and des bromo 
diyne 2.184. This time, the des-bromo compound 2.184 was observed at -78 
o
C, which 
was not the case with magnesium ribbon where no reaction occurred. So it was concluded 
that the Grignard reagent was able to initiate at a much lower temperature with Rieke 
magnesium, but that hydrogen abstraction was still the favored pathway. The next 
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approach was described by Kobayashi where zinc dibromide is added to magnesium 
metal, propargyl bromide, and ether at room temperature.
51
 These conditions are 
optimized to make a hydrogen abstraction pathway less favorable by preventing 
magnesium bromide salts from irreversibly crashing out of solution; however, these 
conditions did not work with our system. Once again, the dihydro diynyl compound 
2.184 was isolated. The next conditions tested were developed by Kim and Han for use 
with propargyl halide additions to cyclic imides.
52
 Diynyl bromide 2.173, malimide 
2.184, zinc dust, and lead II bromide were suspended in THF and stirred at room 
temperature. After 48 hours, only starting material was recovered. Once it was 
determined that the Kim-Han procedure was unsuccessful, a method by Jiang and Tian 
that utilizes propargyl zincates to displace acetate from a reduced hydroxymalimde 
(2.185) was utilized.
53
 The diynyl bromide 2.173 was combined with acetoxyamide 2.185 
and zinc dust in THF and heated to reflux for 18 hours (Scheme 2.54). When the reaction 
was quenched, the only isolated product was deprotected hydroxymalimide 2.186. No 
diynyl bromide was recovered, so it is highly likely this relatively unstable starting 
material decomposed under the reaction conditions. In light of these results, it was 
concluded that the instability of diynyl bromide 2.173 combined with its steric bulk were 
preventing it from successfully undergoing addition to the malimide 2.119 
. The addition/acid-catalyzed N-acyliminium intramolecular spirocyclization 
method for spiroaminal synthesis may highly successful with substrates like primary 
halides that do not readily eliminate, undergo rapid abstraction pathways, or have 
significant steric bulk. Unfortunately, our diynyl bromide 2.173 proved incompatible 
with the conditions necessary to achieve this addition. Since this route to access the 
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marineosin core structure has proven unsuccessful to date, a new synthesis that involves 
acyclic key intermediates and a late-stage lactamization of a hydroxyketoamide has been 
envisaged. 
 
2.10 Acid-catalyzed Spirocyclization of a Hydroxyketoamide for the Synthesis    
        of Marineosin A. 
 
 
 Cyclization of hydroxyketoamides to form spiroaminals containing amide 
moieties has proven highly successful in the synthesis of complex natural products.
54,55
. 
These routes generally involve concomitant removal of acid labile protecting groups to 
reveal the reactive functional groups and subsequent acid-catalyzed spirocyclization, 
which can significantly improve the efficiency of a complex synthesis.
55
 
 
Scheme 2.55. Mechanism of the acid-catalyzed lactamization of a hydroxyketoamide.  
 
As described in Scheme 2.55, the spirocyclization reaction begins by treating 
protected hydroxyketoamide 2.187 with acid to remove the acid-labile alcohol protecting 
group. The free alcohol then adds to the activated carbonyl to preferentially form ketal 
2.189.  Subsequent loss of water generates oxonium ion 2.190, which is quenched by 
intramolecular attack of the primary amide to give spiroaminal 2.191. 
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One caveat of this method of spirocyclization is that the conformation of the 
spiroaminal center cannot be controlled; the compound will adopt the most 
thermodynamically stable conformation. If the natural product does not exist as the most 
stable conformer, then this method of spirocyclization would be ineffective. Molecular 
modeling studies can assist in determining the ability of this methodology to provide the 
desired compound by predicting the most stable conformations, and are commonly 
employed for this task.
55
 
 
Scheme 2.56. Marineosins A (2.1) and B (2.2) and alternative spirocenter conformations (2.1’ 
and 2.2’). 
 
 
In the case of marineosins A (2.1) and B (2.2), marineosin A should be the most 
thermodynamically favored product. In both marineosin diastereomers, the trans-fused 
macrocyclic ring is placed in the equatorial position in the chair conformation of the 
cyclohexane ring. Also, the methoxy substituent is positioned away from the macrocyclic 
ring in both marineosin A and B, which may favor formation of these two stereoisomers 
over the other two possible diastereomers (2.1’ and 2.2’). Finally, the nitrogen of the 
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spiroiminal center of marineosin A is placed in the axial position and stabilized by the 
anomeric effect, making this conformation more favorable than one in which the nitrogen 
is in the non-anomerically stabilized equatorial position (2.1’). This should facilitate 
formation of the desired marineosin A isomer as the most thermodynamically favored 
product in our acid-catalyzed spirocyclization. Preference for formation 2.2 over 2.2’ 
may prove more difficult due to the balance between decreasing the steric hindrance by 
adapting a conformation that positions the methoxy group away from the macrocyclic 
ring (2.2) versus the electronic stabilization provided by of the anomeric effect (2.2’). By 
enantioselectively preparing the hydroxyketoamide for the formation of the marineosin A 
isomer (which differs from marineosin B at the methoxy chiral center and spirocenter), 
we should obtain the desired, biologically active, marineosin A stereoisomer upon acidic 
spirocyclization. 
 
2.10.1. Diyne Substrates for Hydroxyketoamide Synthesis. 
 
 Based on the success of acid-catalyzed spirocyclizations of hydroxyketoamides to 
produce spiroaminals in the total synthesis of natural products, a route was devised which 
incorporates this key reaction to provide marineosin A (Scheme 2.57). 
Unsaturated marineosin A core structure 2.192 can be prepared by the key acid-
catalyzed spirocyclization of hydroxyketoamide 2.193 and an RCM reaction. 
Hydroxyketoamide 2.193 is prepared using the hydroamination methodology developed 
by Hua and co-workers with a 1,3 diyne,
49
 which is accessed by oxidation and amide 
formation from diol 2.194. Diol 2.194 is derived from allylic alcohol 2.195 through an 
asymmetric epoxidation, methylation, and concomitant pivolate deprotection/epoxide 
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opening to the 1,2-diol with DIBAL-H.
56
 Allylic alcohol 2.195 can be prepared from 
hydroxyepoxide 2.196 by epoxide opening with sodium bis(2-methoxyethoxy)aluminum 
hydride (Red-Al) to give the 1,3-diol and subsequent pivolate protection of the primary 
alcohol.
56
 Reduction of ester 2.197 and asymmetric epoxidation should provide epoxide 
2.196. Ester 2.197 could readily be obtained from previously prepared diynyl alcohol 
2.183 by oxidation and olefination of the resulting ketone.  
 
 
Scheme 2.57. Retrosynthesis of marineosin A (2.1) by spirocyclization of hydroxyketoamide 
2.193. 
 
The forward synthesis of hydroxyketoamide 2.193 began with Ley oxidation of 
diynyl alcohol 2.183 to give diynyl ketone 2.198 in 83 % yield (Scheme 2.58). A Horner-
Wadsworth-Emmons reaction with phosphonate 2.199 and n-butyllithium was employed 
to access ester 2.197. Unfortunately, ester 2.197 was only obtained in 31 % yield. It was 
decided to continue with the route, but to simultaneously investigate alternative 
101 
 
olefination conditions in order to obtain improved yields. Reduction of ester 2.197 with 
DIBAL-H gave allylic alcohol 2.200 in 86 % yield; however, subsequent epoxidation of 
allylic alcohol 2.200 using modified Sharpless conditions
 
proved unsuccessful.
57
 After 1 
week at -20 
o
C, no product formation was observed. The reaction was allowed to warm to 
room temperature, but after stirring for 3 days, only starting material remained. Attempts 
to utilize dimethyldioxirane (DMDO), meta-chloroperoxybenzoic acid (mCPBA), or 
vanadyl acetoacetonate, or basic methods (H2O2, NaOH or Triton B) resulted in 
decomposition of the starting material and/or non-selective olefin oxidation. 
 
Scheme 2.58. Synthesis of epoxide 2.196 from diynyl alcohol 2.183. 
 
The absence of any product formation led to the conclusion that the reactivity of 
the alkene was being attenuated by the extended conjugation. Mechanistically, an 
epoxidation reaction is an electrophilic substitution of an alkene. Electron-rich alkenes 
react very quickly and electron-deficient alkenes react very slowly, if at all. 
Unfortunately, our system, with substantial delocalization of electron density through the 
highly conjugated diene/diyne system, proved unreactive to epoxidation with mild, 
stereoselective conditions and decomposed upon exposure to more reactive conditions. In 
addition to this difficulty with the epoxidation, olefination of ketone 2.198 continued to 
102 
 
be low-yielding with a variety of conditions. Aspects of this route, such as the late-stage 
installation of the electron-rich pyrrole and the acid-catalyzed spirocyclization, were 
appealing; however other aspects were undesirable, like low-yielding olefinations, 
unsuccessful epoxidations, and a very long linear sequence of reactions. In light of these 
results and observation, this route was modified to remove the troublesome reactions and 
provide a more convergent synthesis of the required hydroxyketoamide 2.193.  
Excluding the sequential asymmetric epoxidation reactions by preparing terminal 
alkene 2.202 for cross metathesis (CM) with a methylene derivative of diynyl ketone 
2.183 would not only remove a troublesome reaction sequence, but would also provide a 
more convergent route (Scheme 2.59).  
 
Scheme 2.59. RCM/CM route to incorporate allylic methoxy fragment, alkene 2.202. 
 
Macrocycle 2.201 could be obtained through a CM reaction between terminal 
alkene 2.202 and geminal alkene 2.203, which is prepared from ketone 2.198 by a RCM 
reaction and a simplified olefination. Grubbs and co-workers have put an extensive 
amount of work into discerning the reactivity differences of alkenes in cross metathesis 
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reactions with the Grubb’s second-generation catalyst.58 Type 1 olefins undergo rapid 
homodimerization and the homodimers are consumable, whereas Type 2 alkenes undergo 
slow homodimerization, and the homodimers are sparingly consumable. Type 3 olefins 
do not homodimerize, and type 4 olefins are spectators that are inert to cross metathesis. 
Alkene 2.202 is a terminal alkene with a secondary allylic alcohol protected by a small 
group, which makes it a type 2 alkene. Geminal alkene 2.203 is a type 3 olefin since it is 
a 1,1-disubstituted olefin, so cross metathesis between 2.202 and 2.203 should proceed 
smoothly if type 2 alkene 2.202 is added slowly to minimize homodimerization. Since 
type 3 olefin 2.203 does not homodimerize, it will not be a problem to have a high 
concentration of this alkene in solution.  
Alkene 2.202 would be readily prepared from vinyl epoxide 2.204 by directed 
epoxide-opening to the 1,3-diol, mono-protection of the primary alcohol as the pivolate, 
and subsequent methylation of the free secondary alcohol. Vinyl epoxide 2.204 could be 
synthesized from cis-2-butene-1,4-diol 2.205 through mono-protection, epoxidation, 
oxidation of the free alcohol to the aldehyde, Wittig olefination, and deprotection of the 
alcohol. 
Before finalizing the changes to access diol 2.133 (Scheme 2.56), it was necessary 
to investigate the reactivity of the three key functional handles of d ketone 2.113. It was 
crucial to determine whether pyrrole formation followed by RCM then olefination would 
work better than RCM, pyrrole formation, then olefination. Since olefination of diynyl 
ketone 2.198 was low-yielding, it was decided to approach functionalization of the other 
two reactive groups of 2.198 first, the terminal alkene or 1,3-diyne moieties, in order to 
determine if olefination would proceed more smoothly when these groups were absent.  
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Ring-closing metathesis of diynyl ketone 2.198 appeared to proceed smoothly. 
TLC showed formation of a single product spot and consumption of all starting material 
and LC-MS data revealed that a compound with the correct mass had indeed formed. 
However, 
1
HNMR revealed a very different story. The compound that had formed was 
actually 1,5-diene-3-yne 2.207.
59 
 
Scheme 2.60. Attempted ring-closing metathesis of diynyl ketone 2.198. 
 
This formation of this compound can be explained by envisioning a RCM-
induced metallotropic [1,3-shift] as described by Lee and coworkers to produce a 1,5-
diene-3-yne (Scheme 2.61).
59
 First, enyne metathesis occurs generating alkylidene 
intermediate 2.208. This intermediated can then undergo a [1,3] metallotropic shift, 
which can be considered a special case of enyne metathesis where there is no tether 
between the ene and the yne counterparts. This shift results in the rearranged alkylidene 
2.209, which can then undergo RCM with the remaining alkene to give the observed 1,5-
diene-3-yne 2.207. 
105 
 
 
Scheme 2.61. Formation of 1,5-diene-3-yne  2.107 from attempted RCM of ketone 2.198 with 
Grubbs II catalyst.
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Since RCM could not be achieved with the diyne in place, we decided to use a 
pyrrole derivative in the RCM reaction. Since pyrrole 2.140 had already been synthesized 
and could be successfully protected as N-benzylpyrrole 2.210 (Scheme 2.62), it was 
simply used for the RCM because the preparation was already optimized and the 
compound had been stored and was immediately available. Interestingly, after refluxing 
at 40 
o
C for 24 hours, only starting material was recovered. Changing the solvent to 
toluene and refluxing at 100 
o
C provided no improvement. 
 
Scheme 2.62. Unsuccessful RCM with N-benzylpyrrole 2.140. 
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Even with a protected pyrrole, it appeared that the catalyst was being poisoned. 
This was unexpected since the pyrrole nitrogen had been protected and the pyrrole was 
substituted at the 2-position by an electron-withdrawing acyl substituent. One possible 
explanation is that protection of the pyrrole nitrogen with an alkyl group (benzyl) actually 
increases the basicity of the amine, as is seen with simple alkyl amines. If this is the case, 
the more basic pyrrole would actually chelate to the catalyst more efficiently than the 
deprotected pyrrole. To test this theory, ring-closing metathesis was attempted with 
deprotected pyrrole 2.140. Unfortunately, no reaction was observed with this substrate 
either. However, this does not discount the hypothesis that the benzyl-protected pyrrole 
nitrogen would be more basic. The deprotected pyrrole may be an efficient chelator as 
well, since the nitrogen is less hindered and more open for chelation.  
 Routes to achieve the synthesis of the required hydroxyketoamide for the acid-
mediated spirocyclization have proven unsuccessful so far in our progress toward the 
total synthesis of marineosin A. Our major focus to achieve the synthesis of the requisite 
hydroxyketoamide has been on the preparation of a diyne and then incorporating it into 
the molecule as a single unit, followed by a ring-closing reaction to form the macrocycle. 
Considering the results of these endeavors, we decided to investigate the formation of the 
diyne for the ring-closing reaction. 
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2.10.2  Intramolecular Alkyne-Alkyne Coupling for Hydroxyketoamide Synthesis.                 
In light of the problems encountered with electron-rich pyrrole intermediates and 
reactive diynes, a route to achieve the synthesis of the key hydroxyketoamide without 
these components was designed. We decided to investigate the possibility of forming an 
alkyne within a stereochemically advanced intermediate, followed by subsequent 
intramolecular Hay alkyne-alkyne coupling (Scheme 2.63).
60
 Hydroamination of diyne 
2.212 could incorporate the C-ring pyrrole into the macrocycle forming intermediate 
2.211, which can provide the hydroxyketoamide following a few functional group 
interconversions.
61
 Intramolecular Hay coupling of two terminal alkynes would provide 
the requisite diyne 2.212. Regioselective epoxide opening with an acetylide could 
provide the first terminal alkyne and deprotection, oxidation, and homologation could 
provide the second terminal alkyne of dialkyne 2.212. Epoxide 2.214 is generated from 
stereoselective reduction of enone 2.215 and subsequent asymmetric epoxidation. Enone 
2.215 is obtained from cross metathesis of an easily accessed enone 2.216 and a mono-
substituted terminal alkene 2.217.   
 
108 
 
 
Scheme 2.63. Retrosynthesis of marineosin A (2.1) incorporating a key Hay coupling to form the 
diynyl macrocycle 2.212. 
 
 
 Enone 2.216 was prepared from 1,3-propanediol (2.218), which was mono-
protected to give benzyl ether 2.219 and oxidized to -hydroxy aldehyde 2.220 under 
Parikh-Doering conditions (Scheme 2.64).
62
 Addition of vinyl magnesium bromide to the 
aldehyde and subsequent Ley oxidation provided the desired enone 2.216 in 31 % overall 
yield.  
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Scheme 2.64. Synthesis of enone 2.216 from 1,3-propanediol (2.218). 
 
 
Preparation of terminal alkene 2.217, which contains the required stereochemical 
elements, was not as straightforward (Scheme 2.65). Stereoselective alkylation with alkyl 
iodide 2.221 of lactone 2.129 proceeded slowly (12 h) and in low yield (39 %) with the 
addition of DMPU to breakup lithium aggregates. Without DMPU, the reaction showed 
no evident conversion to alkyl lactone 2.222.  Since the diastereoselectivity was good 
(7:1), this route was carried forward. Careful hydrolysis of lactone 2.129, subsequent bis-
protection as the TBDPS ether/ester, and finally DIBAL-H reduction of the ester 
provided the primary alcohol (2.223) in 50 % yield over 3 steps. Parikh-Doering 
oxidation to aldehyde 2.224 and Wittig olefination gave the required terminal olefin 
2.217.
62,63
 Unfortunately cross metathesis with the prepared vinyl ketone 2.216 proved 
unsuccessful. Only 5 % conversion to product was observed, even after 5 days and 
addition of 60 mol % of catalyst. 5 days at 100 
o
C in toluene resulted in no noticeable 
increase in conversion.   
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Scheme 2.65. Attempted synthesis of enone 2.215 from lactone 2.129.  
 
 
Since there are numerous methods for the synthesis of-unsaturated ketones, 
we decided to explore the Horner-Wadsworth-Emmons (HWE) reaction to prepare this 
intermediate.
64
 In order to use this method, we had to prepare the required -
ketophosphonate 2.225. This was achieved in a three-step sequence (Scheme 2.66), 
beginning with Jones oxidation of mono-benzyl ether 2.226 and subsequent esterification 
of the resulting carboxylic acid. Deprotonation of methyl-dimethylphosphonate 2.227 and 
treatment with the prepared -hydroxy ester 2.228 provided the necessary phosphonate 
2.225.  
 
Scheme 2.66. Synthesis of -ketophosphonate 2.225. 
 
Using the conditions developed by Roush and co-workers for the HWE reaction 
with base-sensitive substrates, phosphonate 2.225 was treated with barium hydroxide in 
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THF at room temperature.
64
 After 1 h, aldehyde 2.224 was added as a solution in 
THF:H2O (40:1 v/v) at room temperature. The HWE reaction provided the desired enone 
2.215 in 46 % yield (58 % yield brsm) with no noticeable racemization.  
 
Scheme 2.67. HWE reaction of aldehyde 2.224 and phosphonate  2.225 to provide enone 2.215. 
 
While exploring conditions for the preparation of the enone 2.215, efforts were 
underway to optimize the stereoselective alkylation of lactone 2.129. Based on previous 
alkylation studies with allyl iodide, it was decided to use a substituted allylic iodide 
(2.230) in the alkylation reaction. Following optimization of iodination conditions, the 
route described in Scheme 2.68 was utilized to prepare the required allylic iodide 2.230. 
 
Scheme 2.68. Synthesis of alkyl iodide 2.230 from 6-hepten-1-ol (2.226). 
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6-hepten-1-ol (2.226) was protected as the TBS ether (2.227), and the resulting 
alkene underwent CM with ethyl acrylate to provide the -unsaturated ester 2.228 
which was reduced to allylic alcohol 2.229 with DIBAL-H. Subsequent iodination with 
iodine, triphenylphosphine, and imidazole provided allylic iodide 2.230 in excellent yield 
(64 % over 4 steps with purification). Allylation of lactone 2.129 with allylic iodide 
2.230 proceeded in the absence of DMPU, much more rapidly (2 h), and with better yield 
(82%) of the allylated lactone 2.231 than alkylation with the alkyl iodide 2.221 (Scheme 
2.69).  
 
Figure 2.69. Synthesis of chiral allylic alcohol 2.237 from lactone 2.129. 
 
Careful hydrolysis of lactone 2.231, TBDPS bis-protection, and subsequent 
reduction of the TBDPS ester gave primary alcohol 2.233 in 85 % yield over 3 steps. 
Parikh-Doering oxidation and hydrogenation gave the saturated aldehyde 2.235 for the 
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HWE reaction. The HWE reaction proceeded in 45 % yield (69 % brsm) to give enone 
2.236. Stereoselective reduction of enone 2.236 was achieved using the Corey-Bakshi-
Shibata (CBS) catalyst 2.238 and a method optimized by Drummond and Sutherland to 
give the desired secondary allylic alcohol 2.237  in 94% yield and greater than 20:1 
dr.
65,66
 
The CBS catalyst 2.238 is synthesized from proline and is utilized to 
enantioselectively reduce ketones to alcohol. The enantioselectivity is derived from 
transition state 2.240 where the larger substituent is positioned away from the large R 
group on the catalyst. Internal hydride delivery from borane results in formation of the S 
enantiomer 2.241  in good to excellent ee based on the size difference of R1 and R2.
65 
 
Scheme 2.70. Mechanism of the CBS reduction. 
 
Kinetic resolution utilizing Sharpless asymmetric epoxidation (SAE) conditions 
(Scheme 2.71) is an effective way to generate a chiral allylic alcohol from a racemic 
mixture.
67-69
 By utilizing the reagent control provided by the chiral catalyst, one is able to 
choose which enantiomer of the allylic alcohol is obtained in > 95% ee. The other 
enantiomer will be converted to the erythro epoxy alcohol due to its faster reaction rate. 
The alcohol with the fastest reaction rate is the one that minimizes the A1,2 strain between 
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the R group of the secondary alcohol and the geminal substituent on the double bond 
(Scheme 2.72). If (+)-DET is chosen as the chiral reagent, the R enantiomer decreases 
this strain, so it is the fastest to react, leaving the S enantiomer as unreacted, 
enantiomerically-enriched allylic alcohol.
67 
 
Scheme 2.71. Mnemonic for determining facial selectivity in the SAE reaction. 
 
 
Scheme 2.72. Rational for observed kinetic resolution utilizing SAE. 
 
The stereoselectivity of the CBS reduction was confirmed by Sharpless kinetic 
resolution to form the desired epoxide 2.242 (Scheme 2.73). (+)-DET gave complete 
conversion to the epoxide product, which confirmed that the reduction had indeed 
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occurred exclusively from the face to give the (S) stereoisomer of the alcohol (2.237). 
If considerable addition had occurred from the face, then unreacted (R)-allylic alcohol 
would have been recovered from the epoxidation reaction.
67 
 
Scheme 2.73. Kinetic resolution of alcohol 2.237 and synthesis of -methoxy epoxide 2.244. 
 
Since the threo isomer was required and the erythro isomer is obtained from the 
Sharpless asymmetric epoxidation, we inverted the alcohol stereocenter of hydroxyl 
epoxide 2.242 using Mitsunobu conditions to provide the desired R-hydroxy epoxide 
2.243. Subsequent soft methylation with trimethyloxonium tetrafluoroborate and proton 
sponge provided the methyl ether 2.244 in excellent yield (87%). 
70 
At this point, it was time to investigate conditions to regioselectively open the 
epoxide by addition of mono-TMS-protected acetylene. We began by treating epoxide 
2.244 with diethyl aluminum chloride, which has been shown to provide regioselective 
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epoxide-opening of hindered substrates.
71
 We hoped the methoxy substitutent would 
chelate to the epoxide and increase the electrophilicity of the C9 carbon to facilitate 
addition at this center. TMS-acetylene 2.177 was deprotonated with n-butyl lithium at -78 
o
C and the resulting solution added to the epoxide at -78 
o
C. After stirring for 12 h with 
no reaction, the solution was warmed to 0 
o
C and stirred for an additional 12 h. After 
observing no reaction, the mixture was warmed to room temperature and stirred for 24 h. 
At this point, there was still no evidence of conversion to product, so additional diethyl 
aluminum chloride was added at room temperature. After 8 h, all starting material had 
been consumed and TLC revealed conversion to a single product that was more polar 
than the starting epoxide 2.244. Upon inspection of 
1
H NMR and 
13
C NMR data, it was 
concluded that the epoxide had indeed been opened regioselectively at the desired 
position. However, the nucleophile responsible was not acetylide 2.177, it was the 
chloride anion from the Lewis acid additive to provide chloro-alcohol 2.245. Subsequent 
oxidation to ketone 2.246 provided a cleaner spectrum with clear coupling constants and 
shifts, thus corroborating the identity of the nucleophile as the chloride anion. 
 
Scheme 2.74. Undesired regioselective opening of epoxide 2.244 with chloride anion to form 
chloro-alcohol 2.245. 
 
 
Attempts to open the epoxide 2.244 with a relevant nucleophile proved futile. 
Various Lewis acids, solvents, nucleophiles, temperatures, and orders of addition were 
studied as outlined in Scheme 2.75. The only addition to occur successfully was the 
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chloride anion addition which resulted from treating the epoxide with excess diethyl 
aluminum chloride. At this point it was concluded that this route would be unable to 
provide the desired hydroxyketoamide and that substantial alterations would have to be 
made to incorporate the C9 stereocenter.  
 
Scheme 2.75. Attempts to form alkyne 2.247 by regioselective addition to epoxide 2.244. 
 
2.10.3 Intermolecular Alkyne-Alkyne Coupling for Hydroxyketoamide  Synthesis. 
We began to consider alternative disconnections to achieve the hydroxyketoamide 
core, and in light of our previous success with the Cadiot-Chodkiewicz hetero alkyne-
alkyne cross-coupling, we decided to incorporate an intermolecular diyne formation and 
still utilize an intermolecular/intramolecular hydroamination reaction to generate the 
pyrrole followed by an RCM reaction to form the macrocycle (Scheme 2.76).
72-75
 We had 
experienced successful cross-metathesis reactions with an electron-rich, deprotected alkyl 
pyrrole in our work with the proposed biosynthetic route of the marineosins (Chapter 2, 
Section 2.6), and we believe that this pyrrole will display similar reactivity.
76
 The 
spiroiminal center will still be formed by an acid-mediated cyclization of a 
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hydroxyketoamide intermediate, followed by installation of the final pyrrole moiety.  
As described in Scheme 2.76, a readily available iodoalkyne 2.256 will be 
coupled to a highly derivatized terminal alkyne 2.251 to provide the diyne for pyrrole 
formation and subsequent cyclization. Alkyne 2.251 can be prepared by a stereoselective 
1,4-addition, followed by an stereoselective aldol reaction directed by the same acylated 
oxazolidinone 2.252. The opportunity to utilize a single auxiliary to direct the formation 
of three stereocenters, including the elusive C9 stereocenter, was highly appealing.
77-79 
 
Scheme 2.76. Retrsynthesis of marineosin A 2.1 through key intermolecular Cadiot-
Chodkiewwicz hetero alkyne-alkyne cross coupling and a Michael addition/aldol reaction 
sequence. 
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The acylated oxazolidinone was readily prepared starting from (S)-methyl oxirane 
2.254 by the regioselective addition of vinyl cuprate to the least substituted position of 
the epoxide (Scheme 2.77). Protection of the resulting, crude alcohol 2.257 as the TBDPS 
ether provided the product 2.258 in 81% yield over 2 steps. Cross metathesis with methyl 
acrylate and subsequent hydrolysis of the methyl ester 2.259 provided the required 
carboxylic acid 2.260 in excellent yield.  
 
Scheme 2.77. Synthesis of carboxylic acid 2.259 from (S)-methyl oxirane 2.254. 
 
Acid 2.260 was then treated with trimethylacetyl chloride and triethylamine to 
form the mixed anhydride in situ which was added to a solution of lithiated (R)-4-Benzyl-
2-oxazolidinone 2.255 to provide acylated oxazolidinone 2.253 for the conjugate addition 
(Scheme 2.78). To our delight, the 4-benzyl oxazolidinone proved to be an excellent 
substrate for the conjugate addition, providing a single diastereomer in 84 % yield and 
greater than 20:1 dr. 
79 
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Scheme 2.78. Acylation of oxazolidinone 2.255 with acid 2.260 and subsequent conjugate 
addition to provide 2.261. 
 
 
This excellent stereoselectivity is a result of the rigid, chelate transition state 
2.262 described in Scheme 2.79.
79
 The benzyl substituted oxazolidinone has historically 
shown inconsistent and undesirable results for facial selectivity in conjugate addition 
reactions. However, Williams and co-workers have shown that in the case of conjugate 
addition with allyl cuprate, the benzyl substrate displays excellent stereoselectivity.
79
 The 
more active allyl cuprate species appears to react more quickly than other cuprates at -78 
o
C
 
and with preferential formation of the adduct resulting from chelated transition state 
2.262, as opposed to open-chain transition state 2.263, which is the common reactive 
chelate in aldol reactions with oxazolidinone auxiliaries (vide infra), and has been used to 
explain the typical, opposite stereoselection (2.264) of benzyl-substituted versus phenyl-
substituted derivatives. Williams and co-workers observed that the benzyl-substituted 
auxiliary only showed modest selectivity in the conjugate addition reaction. However, 
when allyl cuprate was utilized as the nucleophile under the same reaction conditions, 
they observed excellent stereoselectivity for the formation of the same stereoisomer as 
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the phenyl-substituted auxiliary. In light of the poor stereoselectivity of the phenyl-
substituted oxazolidinones in aldol reactions, we decided to use the benzyl-substituted 
auxiliary for the conjugate addition reaction with allyl cuprate, so that the subsequent 
aldol reaction could be performed with the same auxiliary. In this manner, we will 
effectively set three stereocenters with one chiral auxiliary.  
 
Scheme 2.79. Possible transition states for conjugate addition reaction with an oxazolidinone 
auxiliary.
79 
 
With the completion of the highly successful conjugate addition reaction, it was 
time to investigate the subsequent aldol reaction. The -methoxy aldehyde was prepared 
as described in Scheme 2.80. 3-buten-1-ol (2.265) was protected as the benzyl ether 
(2.266), and cross metathesis provided the unsaturated ester (2.267) which was reduced 
to the allylic alcohol (2.268) with DIBAL-H. Sharpless asymmetric epoxidation provided 
epoxide 2.268 in excellent yield. Regioselective, europium–mediated solvolysis of the 
epoxide provided an excellent yield of the 1,2 diol 2.269 (94 %, >20:1 1, 2 : 1, 3).
80 
Oxidative cleavage of 2.269 provided the desired -methoxy aldehyde 2.270 for the aldol 
reaction.  
122 
 
 
Scheme 2.80. Preparation of -methoxy aldehyde 2.270 from 3-buten-1-ol (2.265). 
 
In order to choose the correct conditions to facilitate the aldol reaction and 
promote formation of the desired stereoisomer, it was necessary to investigate the theory 
behind stereoselection in the aldol reaction. This theory is based upon the Zimmerman-
Traxler transition state model which explains that the factors controlling stereoselectivity 
are the preference for placing substituents equatorially in six-membered ring transition 
states and the avoidance of 1, 3-diaxial interactions.
81,82 
In the aldol reaction, two new stereocenters are set. To account for all 
combinations, there is a possibility of forming 2
x
 diastereomers, where x is the number of 
new stereocenters formed in the reaction. In the case of the aldol reaction, x = 2, so there 
are four possible diastereomers. Formation of the Z-enolate (2.272) and reaction with an 
aldehyde can form a syn or anti aldol adduct (Scheme 2.81). Formation of the E-enolate 
(2.273) will provide the enantiomers of the syn or anti adducts that result from the Z-
enolate. The stereocontrol in this case is a result of the 1, 3-diaxial interaction between 
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the R2 group of the aldehyde and the R1 substituent of the enolate in the Zimmerman-
Traxler transition states 2.275 and 2.277. Minimization of this interaction places the 
aldehyde R2 group in a pseudoequatorial position (2.274 and 2.276) and results in the 
formation of syn aldol adducts (2.278) from Z-enolates and anti-aldol adducts (2.280) 
from E-enolates.  
 
Scheme 2.81. Four diastereomers are possible in the aldol reaction. Avoidance of 1,3 diaxial 
interactions precludes formation of  two of the diastereomers (2.279 and 2.281), resulting in the 
formation of anti adducts from E-enolates (2.280) and syn adducts (2.278) from Z-enolates.
81,82
 
(adapted from Li 2009). 
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Incorporation of the Evan’s oxazolidinone forces the transition state to adopt the 
conformation described in Scheme 2.82, where the polar imide of the oxazolidinone 
points away from the acyl moiety and aldehyde coordinated to the metal, thus forming a 
dipole. In order to prevent the chiral benzyl substituent of the oxazolidinone from 
experiencing unfavorable 1,3-diaxial interactions with the metal ligands in transition state 
2.285, this substituent is oriented away from the reactive components of the aldol 
reaction. This removes the possibility of forming a syn relationship between the auxiliary 
substituent and the -substituent, and controls the formation of the anti-relationship 
between the auxiliary and the -substituent, known as the Evan’s syn product (2.286). 
Formation of a product with the syn relationship between the auxiliary and the -
substituent is known as the non- Evan’s syn product (2.287) which is achievable through 
alternative reagents and reaction conditions. 
 
Scheme 2.82. Dipole Model of auxiliary control to provide Evan’s syn adol products (2.286) 81,82 
(adapted from Li 2009).
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 Utilization of soft enolization conditions will favor formation of the Z-enolate 
over the E-enolate as described in Scheme 2.83. Chelation between the Lewis acid 
additive and the imide and amide carbonyls occurs first, followed by deprotonation. The 
Z-enolate 2.291 is favored by removing the gauche interaction between the enolate 
substituent and the chiral auxiliary in transition 2.289. As a result, the chirality of the-
carbon is set, and it is trans to the auxiliary substituent, as predicted by the Zimmerman-
Traxler transition state model. 
 
Scheme 2.83. Soft enolization conditions favor the formation of Z-enolates.
 81,82
 (adapted 
from Li 2009).
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By choosing the correct chirality for the oxazolidinone and utilizing soft 
enolization conditions to favor formation of the Z-enolate 2.293, we should be able to 
control the stereoselectivity of the aldol reaction to give the desired product 2.252 as 
highlighted in Scheme 2.84 
 
Scheme 2.84. Zimmerman-Traxler transition state for the formation of aldol adduct 2.252. 
 
 
Aldol procedures requiring boron as the chelation metal proved unsuccessful and 
only facilitated removal of the TBDPS protecting group. Titanium conditions developed 
by Crimmins and co-workers proved to be much more substrate-tolerant in our case.
78 
Unfortunately, the aldol reaction failed to occur with the methoxy aldehyde, and only 
starting materials were recovered.  
In addition to stereocontrol provided by avoidance of 1,3-diaxial interactions in 
the transition state, enolate geometry, and auxiliary chirality, with an -chiral aldehyde 
one must also consider the effect of this stereocenter on the transition state. To better 
understand this phenomenon we have to consider the Felkin-Ahn model of carbonyl 
addition (Figure 2.5). 
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Figure 2.5. Felkin-Ahn Model for addition to -chiral carbonyl compounds.83 
 
In the Felkin-Ahn model, typically the largest substituent is placed perpendicular 
to the carbonyl and antiperplanar to the incoming nucleophile (Figure 2.5). The larger the 
nucleophile and RL, the greater the Felkin selectivity.
83,84
  
 
Figure 2.6. Felkin-Ahn Model predicts stereochemically distinct products based on enolate 
geometry (top). Desired product 2.252 could be formed through the Z-enolate if size-based 
assignments are made (bottom).
84 
128 
 
  
As described in Figure 2.6, formation of the Z-enolate should provide the syn, syn Felkin 
product, which is the desired product, if we consider R = CH2CH2OBn the large group 
and R = OCH3 the medium group. However, the incorporation of an -polar substituent 
(such as an -methoxy) affects the Felkin transition state in which RL is always placed 
anti to the incoming nucleophile. This -polar substituent effect is known as the 
antiperiplanar effect, which maximizes separation between the incoming anionic 
nucleophile and the electronegative α-substituent.. The effect is based on the preference 
to align the best acceptor * orbital parallel to the  and * orbitals of the carbonyl and 
antiperiplanar to the incoming anion, thus stabilizing the incoming anion (Figure 2.7).
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Figure 2.7. Felkin-Ahn antiperiplanar effect (left) can lead to anti-Felkin selectivity if X (the 
electronegative substituent) is not also the largest substituent (right).
85-87 
 
 
With -methoxy aldehyde 2.271, RM = OCH3 and RL = CH2CH2OBn; however, 
the antiperiplanar effect will place the -methoxy substituent away from the incoming 
nucleophile and the large R group next to the carbonyl and closer to the incoming 
nucleophile (Figure 2.8). In our case, the nucleophile and RL are very large, which 
typically makes Felkin selectivity very favorable. However, minimization around RL 
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places the electronegative -methoxy substituent into the path of the incoming anionic 
nucleophile, which is electronically very unfavorable. Consideration of the 
electronegative -substituent would predict the anti-Felkin product would be favored 
based on the antiperiplanar effect. However, this places the large RL substituent into the 
path of the very large, incoming nucleophile, thus resulting in significant steric repulsion.  
 
 
Figure 2.8. Analysis of aldehyde 2.271 based on Felkin-Ahn theory. 
 
This analysis led to the conclusion that neither of the possible reaction pathways 
is particularly favorable, and this is very likely the reason for the observed lack of 
reactivity. 
To investigate whether the combined steric and electronic liabilities of the -
methoxy aldehyde were responsible for this lack of reactivity, the aldol reaction was 
performed with a non-branched aldehyde, 6-hexanal. In this case, the aldol product was 
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readily formed, so it was concluded that the aldol reaction must be performed with a 
simpler substrate that does not experience opposing steric and electronic effects.  
Unsaturated aldehyde 2.298, possessing a flat and sterically undemanding surface, 
was chosen as a suitable substrate and was easily prepared in two steps. Mono-protection 
of 1,4-cis-buten-diol 2.296 with PMB chloride and subsequent oxididation/isomerization 
with excess manganese dioxide provided aldehyde 2.298 for use in the aldol reaction.   
 
 
Scheme 2.84. Synthesis of sterically-undemanding aldehyde 2.296 from cis-butenediol 2.294. 
 
Aldehyde 2.298 should provide the aldol product 2.252, and subsequent 
stereoselective epoxidation, regioselective epoxide opening, and functional group 
manipulations will provide the required hydroxyketoamide core 2.249 as described in 
Scheme 2.85. A key asymmetric epoxidation reaction, regioselective opening of the 
epoxide with Red-Al, and subsequent methylation will provide the chiral methoxy 
substituent of intermediate 2.300 that was unable to be directly incorporated as an -
methoxy aldehyde in the aldol reaction.  
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Scheme 2.85. Incorporation of aldehyde 2.298 into the retrosynthesis of marineosin A. 
 
Fortunately, the simplified, unsaturated aldehyde 2.298 proved to be an excellent 
partner in the aldol reaction, providing the desired syn isomer 2.299 in 65% yield and 
10:1 dr (Scheme 2.86). Recovered starting material (25%) was easily separated and 
resubmitted to improve the yield (78%, one resubmission). The success of the conjugate 
addition/aldol reaction sequence is an important milestome, since this is the first time we 
have been able to stereoselectively form the C9 stereocenter of marineosin A.  
 
Scheme 2.86. Aldol reaction with sterically undemanding aldehyde 2.298. 
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Intermediate 2.299 contains the three stereocenters that are the same in both 
marineosin A and marineosin B. Although our main focus is currently on the synthesis of 
the biologically active marineosin A diastereomer, one could envision a route to 
marineosin B which simply uses alternative asymmetric epoxidation conditions to 
prepare the other diastereomer (Scheme 2.87). Acid-catalyzed spirocyclization would not 
benefit from anomeric stabilization, but the inverted methoxy sbstituent could provide 
enough steric repulsion to orient this substituent away from the bulky, electron-rich 
pyrrolophane to favor formation of the non-anomerically stabilized spiroiminal. 
 
Scheme 2.87. C7-epi-2.300 could be prepared from aldol adduct 2.299 using an asymmetric 
epoxidation to provide marineosin B (2.2).  
 
After successfully optimizing the conjugate addition/aldol sequence, auxiliary 
removal proved to be a daunting task. In addition to the desired diol, two by-products 
were formed, namely, the retro-aldol product 2.261 and the amido alcohol 2.302 resulting 
from hydride addition to the oxazolidinone auxiliary. After trying numerous conditions, 
only lithium borohydride and methanol in THF provided any of the desired diol product 
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2.301. It was concluded that these conditions provided the best and most consistent yield 
of diol 2.301 (36-42%) and that the isolated retro-aldol product (2.261) could be 
resubmitted to the aldol conditions to provide additional starting material (2.299) 
 
Scheme 2.88. Auxiliary removal to give diol 2.301 and by products. 
 
The 42% of material lost as the amido alcohol 2.302 was unfortunate, so we 
decided to look into the other auxiliaries for the conjugate addition/aldol sequence. We 
tried three different auxiliaries (phenyl oxazolidinone, benzyl thiazolidinethione, and 
benzyl oxazolidinthione), and found the reaction sequence unsuccessful in all cases due 
to lack of stereoselectivity in the aldol reaction (phenyl), cuprate addition to the auxiliary 
(thiazolidinethione), or opening of the auxiliary to give amido alcohol 2.302 when treated 
with LiBH4 (oxazolidinthione).  At this point it was decided that a 36-42% yield of diol 
2.299 was acceptable at this stage of the synthesis, and the route was continued. 
Diol 2.301 was protected as the bis-TES ether (2.303) and the PMB protecting 
group was oxidatively removed by treatment with DDQ to give the primary allylic 
alcohol 2.304. Surprisingly, Sharpless’ asymmetric conditions for the epoxidation of 
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allylic alcohol 2.304 provided 0% conversion to product, even after a 7 day reaction time 
and the addition of stoichiometric amounts of reagents. It was concluded that the olefin 
was most likely too sterically crowded to undergo the desired reaction. The secondary 
TES ether may be blocking the face of the alkene and thus preventing any product 
formation due to the facial selectivity of the reactants.  
 
Scheme 2.89. Attempted asymmetric epoxidation of alkene  2.304. 
 
We decided to explore the effects of different protecting groups and oxidation 
states of diol 2.301 as summarized in Scheme 2.90.  
Although diol 2.01 could be selectively oxidized with manganese dioxide to 
provide enone 2.306, subsequent protection of the primary alcohol as the benzyl ether, 
pivolate ester, and benzoate ester was unsuccessful. Dioxolane protection of the hindered, 
enone 2.306 was also unsuccessful. The primary alcohol of enone 3.206 was found to be 
efficiently reactive with TBSCl to provide the TBS ether; however, subsequent acidic 
conditions required for the dioxolane protection were incompatible with the primary TBS 
ether. By manipulating the primary alcohol of diol 2.301 first, it was found that it could 
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selectively be protected as the pivolate ester over the secondary alcohol. Pivolate ester 
2.308 was oxidized to enone 2.309, but subsequent reactions to form he dioxolane ketal 
all failed. Since we were unable to protect the hindered enone derivatives (2.306, 2.307, 
and 2.309) and remove the steric bias within our molecule, we decided to exploit the 
presence of the chiral secondary alcohol and the inherent steric bulk of alkene 2.304 by 
attempting a substrate-directed asymmetric epoxidation. 
 
Scheme 2.90. Attempts to remove the steric bias of diol 2.301 by oxidation and dioxolane 
protection. 
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First, diol 2.301 had to be mono-protected to leave the secondary alcohol free for 
chelation. This was accomplished with TBSCl and imidazole to provide mono-TBS ether 
2.310 in 96 % yield (Scheme 2.91). With chiral allylic alcohol 2.310 in hand it was time 
to analyze the conformation of the substrate and decide what strategy would give the 
desired stereoselectivity.    
 
Scheme 2.91. Mono-protection of allylic alcohol 2.310 for substrate-controlled 
epoxidation. 
 
Due to the reliability, chemoselectivity, and stereoselectivity associated with 
vanadyl acetoacetonate, this reagent was chosen for the substrate-controlled epoxidation. 
Typically, excellent, substrate-controlled stereoselectivity is observed in metal-catalyzed 
epoxidations by exploiting the A1,2 strain within a molecule (Figure 2.9).
88 
In the case of vanadyl acetoacetonate, the role of the geminal substituent is 
crucial.
88,89
 If the germinal substiuent is sufficiently large, it can control the epoxidation 
to generate solely the erythro product. However, if the geminal substituent is very small, 
A1,2 strain becomes less important. If Rcis or R is very large, A1,3 strain will become the 
controlling factor.  
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Figure 2.9. Vanadyl acetoacetonate epoxidation and rational for the observed stereochemical 
outcomes.
88,89 
 
In our case, the geminal substituent is a hydrogen atom, which is very small, and 
R is very large. As explained by the Newman projections in Figure 2.10, the more 
favorable conformation is the one in which A1,3 strain is minimized by placing the very 
large R group away from the double bond and gauche with the geminal hydrogen. This 
conformation should provide the desired threo product. One could easily see how a 
methyl geminal substituent could increase A1,2 strain and lower the stereocontrol of A1,3 
strain. It is also evident that a large cis substituent could improve the stereocontrol by 
maximizing the A1,3 strain. In our case, we are expecting the A1,3 strain to be the 
controlling factor. The only question remaining is how strong that control will be.  
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Figure 2.10. Analysis of A1,3 strain within allylic alcohol 2.310 and predicted outcome of 
epoxidation reaction. 
 
Treatment of allylic alcohol 2.310 with tert-butyl hydrogen peroxide (TBHP) and 
vanadyl acetoacetonate at 0 
o
C resulted in 100% conversion to a single diastereomer 
(>20:1 by NMR) in only 4 hours.  
 
Scheme 2.92. Substrate-controlled stereoselective epoxidation of allylic alcohol 2.310 with 
vanadyl acetoacetonate. 
 
A crystal structure was unable to be obtained from the viscous oil; however, 
molecule modeling agrees with the assignment of the product as threo isomer 2.311. The 
energy-minimized conformation of allylic alcohol 2.310 reveals that the most favored 
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conformation is indeed the one that minimizes the A1,3 strain. This leaves the -face of 
the alkene open for epoxidation in the most energetically favored conformation, as 
predicted.   
.  
Figure 2.11. Most favored energy minimized conformation of allylic alcohol 2.310. 
Lowest energy conformation reveals open bottom face of C6-C7 alkene in agreement with 
minimization of A1,3 strain. 
 
 
With threo epoxide 2.311 in hand, it was time to choose protecting groups and 
investigate the regioselective epoxide-opening. Protection of the free secondary alcohol 
as the TBS ether was unsuccessful with TBSCl and imidazole; however, the more 
reactive TBSOTf and pyridine facilitated complete conversion to silyl ether 2.312 
(Scheme 2.93). The PMB protecting group was oxidatively removed using DDQ, 
revealing the free primary alcohol (2.313). The alcohol was then treated with Red-Al to 
regioselectively open the epoxide through chelation with the free alcohol and internal 
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hydride delivery to provide 1,3-diol 2.314.
56
 Unfortunately, the TBS groups proved too 
labile under the strongly basic conditions and mixed regioisomers of tetra-ols were 
obtained.  
 
Scheme 2.93. Undesired protecting group removal in regioselective epoxide-opening. 
 
. The protecting group strategy was reassessed, and the primary alcohol of diol 
2.301 was chemoselectively protected as the TIPS ether (2.315). Epoxidation proceeded 
smoothly with this highly hindered substrate to provide the threo epoxide (3.316) as 
before. The secondary alcohol of 3.316 was carefully protected as the benzyl ether by 
adding sodium hydride as 0 
o
C, immediately followed by addition of excess benzyl 
bromide and catalytic TBAI. The mixture was allowed to slowly warm to room 
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temperature once all of the reagents were combined. These precautions were taken in 
order to avoid an intramolecular Payne rearrangement considering the steric crowding at 
this position in the molecule. Fortunately, the reaction proceeded in 91 % yield to provide 
benzyl ether 3.317 with no evidence of a Payne rearrangement by NMR analysis.
91 
 
Scheme 2.94. Preparation of alcohol 2.318 for regioselective epoxide-opening. 
 
The PMB ether of 2.317 was oxidatively cleaved to reveal the desired 2,3-epoxy 
alcohol (2.318), which was treated with Red-Al. After 4 hours, the reaction was near 
completion, but removal of the TIPS protecting group was becoming apparent by LCMS. 
The reaction was quenched, extracted, and purified to provide the desired 1,3-diol 2.319 
as the major product (63%), recovered starting material 2.318 (15%), and the TIPS 
removal product as a minor by-product (<5%). None of the 1,2 diol was observed by 
NMR. The primary alcohol was selectively protected as the pivolate ester (2.320), and the 
secondary alcohol subjected to soft methylation conditions to provide the fully protected 
intermediate 2.321, as a single diastereomer. 
In order to incorporate the alkyne, it was necessary to identify conditions that 
could selectively deprotect a primary TIPS ether in the presence of a secondary TBDPS 
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ether. The chosen conditions would need to be acidic since TIPS ethers are slightly more 
acid labile than a TBDPS ether. In general, it should also be easier to remove a primary 
acid-labile protecting group over the secondary, more acid-stable protecting group. 
Previous research indicated that chemoselective removal of silyl ethers was possible with 
dilute HCl in MeOH and other protic solvents.
91,92
 In light of these successes, 2.321 was 
treated with 0.01 M HCl in MeOH, and after 5 hours, all starting material had been 
consumed. Upon purification and NMR analysis, it became evident that the secondary 
TBDPS ether had been selectively deprotected under these conditions to provide the free 
secondary alcohol 2.323 in 91% yield.  
Scheme 2.95. Chemoselective deprotection of a primary TIPS ether in the presence of a 
secondary TBDPS ether. 
 
 
 These results were disheartening, but conditions were fortuitously revealed that 
could successfully remove the TBDPS protecting group from the protected 
hydroxyketoamide in the acid-catalyzed spirocyclization step. After unsuccessful 
experiments with several organic acids, we decided to test Lewis acids. According to rate 
studies performed by Mabic and Lepoittevin, TBDPS ethers are stable to BF3OEt2 in 
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CH2Cl2; however, TIPS ethers should be hydrolyzed within 1 h.
93
 In our hands, treatment 
of intermediate 2.321 with BF3OEt2 in CH2Cl2 at room temperature resulted in complete 
conversion to the desired deprotected primary alcohol 2.322 in 0.5 hours and 94 % 
isolated yield. The hindered primary alcohol was readily oxidized under Parikh-Doering 
conditions to provide the desired aldehyde 2.324 in 79 % yield with no racemization.
 
However, excess reagents were needed in order for the reaction to reach completion 
within the average 4-6 hour reaction time commonly observed for these conditions. Since 
aldehyde 2.324 proved sensitive to air oxidation to the carboxylic acid, it was stored at     
-20 
o
C under argon and used within 1 week, or stored at 0 
o
C under argon and carried on 
to the next reaction within 24 hours. 
 
Scheme 2.96. Attempted homologation to form alkyne 2.325 
 
Aldehyde 2.324 was then subjected to Ohira-Bestmann conditions for 
homologation to alkyne 2.325.
95
 Unfortunately, the only observed product was the -
hydroxy elimination product 2.326. Corey-Fuchs homologation proved unsuccessful as 
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well; formation of the geminal dibromide intermediate never occurred at room 
temperature and gently heating the reaction mixture resulted in decomposition of the 
starting material.
96
 
Our inability to generate the advanced alkyne intermediate 3.325 prevented 
further pursuit of the total synthesis of marineosin A through completion of the route 
described in Scheme 2.97. Since the hydroamination route for pyrrole formation was no 
longer a viable route, alternative methods of pyrrole formation would need to be 
explored.  
 
Scheme 2.97. Summary of unsuccessful intermolecular alkyne-alkyne coupling/hydroamination 
route. 
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2.10.4. Model Synthesis of the Fully-Functionalized Core of Marineosin A. 
Due to the challenge of installing the pyrrolophane C-ring of marineosin A, we 
decided to exclude this moiety and complete a model synthesis of marineosin A based on 
the acid-catalyzed spirocyclization strategy. Completion of a model synthesis of the fully-
functionalized spiroiminal core of marineosin A will provide a chance to optimize the 
reaction sequence for the total synthesis of marineosin A once the pyrrolophane moiety is 
completed. A model system will also enable investigation of the late-stage 
spirocyclization in order to determine the viability of our current route to achieve the total 
synthesis of marineosin A. The marineosin A model (2.331) will not contain the 
macrocycle or the C-ring pyrrole, but will contain functional group handles that enable 
their installation. 2.331 will be prepared by the acid-mediated spirocyclization from 
hydroxyketoaminde 2.332, which will be obtained from the stereocehmically advanced 
alcohol 2.321. 
 
Scheme 2.98. Retrosynthetic analysis of marineosin A model 2.331 from previously synthesized 
TIPS alcohol 2.321. 
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The TIPS-protected alcohol 2.321 was utilized for initial model studies. Pivalate 
reductive removal with DIBAL-H proceeded smoothly to give the primary alcohol 2.333, 
which was oxidized with Parikh-Doering conditions to give aldehyde 2.334. Pinnick 
oxidation rapidly provided carboxylic acid 2.335, which was coupled to ammonium 
chloride with traditional amide coupling conditions to provide the primary amide 2.336.
96
 
Hydrogenolyisis of the benzyl ether and concomitant hydrogenation of the double bond 
provided alcohol 2.337, which was oxidized to the hydroxyketoamide (2.338) with Ley 
conditions. 
 
Scheme 2.99. Completion of the synthesis of the fully-functionalized sprioiminal core of 
marineosin A. 
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Keeping in mind the undesired deprotection of the TBDPS ether (Scheme 2.95), 
0.01 M HCl in MeOH was chosen to facilitate the cyclization. Unfortunately, the TIPS 
ether was hydrolyzed under these conditions and replaced by a methyl ether, as 
confirmed by 1D and 2D NMR experiments. The major product was obtained as a single 
diastereomer in 81 % yield. HMBC, HSQC, COSY, and NOESY experiments confirmed 
the absolute structure of the product as the marineosin A isomer based on the 
stereochemistry relative to the axial methyl group within the pyran ring, which was 
incorporated from (S)-methyl oxirane in our synthetic route.  
 
Figure 2.12. Key NOESY and HMBC correlations of marineosin model 2.340 confirming 
connectivity and absolute stereochemistry. 
 
 
Suspension of the spirocyclic lactam 2.340 in pyrrole and treatment with 
phosphorous oxychoride, provided the spiroiminal core 2.240.
97
 However, the product 
was unable to be separated from the pyrrole solvent by chromatography due to the 
considerable polarity of the two components and the instability of the product to reverse-
phase chromatography. Once appreciable material has been prepared, this reaction will be 
attempted on a larger scale (> 1.5 mg) to enable additional purification efforts and full 
characterization. 
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Lactam 2.339 will also be treated with triflic anhydride to provide triflate 2.341, 
which can be coupled to 1-Boc-2-pyrrole boronic acid and other boronic acids to generate 
a library of unnatural analogs for biological testing (Scheme 2.100). 
 
 
Scheme 2.100. Planned synthesis of unnatural analogs of marineosin A. 
 
In order to prevent ionization of the TIPS ether and reaction with methanol, we 
decided to replace this protecting group with the more stable p-methoxyphenyl (PMP) 
ether. This way the PMP group can be selectively removed to incorporate additional 
derivatization (Scheme 2.101). 
After optimizing conditions for the Mitsunobu reaction to incorporate the PMP 
protecting group, PMP ether 2.342 was carried through the same reaction sequence as 
TIPS ether 2.321 to successfully prepare the required hydroxyketoamide 2.348 (Scheme 
2.101).  
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Scheme 2.101. Synthesis of the sprioiminal core of marineosin A with a PMP primary alcohol 
protecting group. 
 
 
Exposure to acidic methanol gave surprising results. Pyran 2.350 was formed as 
the exclusive product. The PMP group was removed by the acidic reaction conditions, 
and the intermediate ion was quenched by methanol. The primary amide underwent 
methanolysis to provide a methyl ester and the oxonium ion was quenched by an 
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elimination reaction in the absence of a primary amide moiety to capture the electrophilic 
intermediate. It is unclear why the two very stable protecting groups (TIPS and PMP) are 
removed in such dilute acidic conditions and why these two very similar substrates 
produce very different products through divergent reaction pathways. Clearly, in order to 
generate a stable and predictable marineosin A model for derivatization and biological 
evaluation, we will need to incorporate an alcohol substituent that it not designed for 
subsequent removal as a protecting group. 
 
2.11 Future Work. 
 
2.11.1 Completion of Marineosin A Macrocyclic Model System. 
In light of the difficulties encountered with protecting groups in the acid-mediated 
spirocyclization, we plan to alkylate the primary alcohol 2.322 with a substituent that is 
not designed for removal as a protecting group (Scheme 2.102). After preparing allylic 
iodide 2.351, this electrophile will be used to alkylate primary alcohol 2.322. Alkylation 
with commercially-available 7-bromo-1-heptene was unsuccessful, but the allylic iodide 
2.351 should be considerably more reactive, as we have observed in previous 
experiments with the alkylation of lactones (Chapter 2, Scheme 2.69).  
After O-alkylation to form ether 2.352, a 12-membered ring containing the alkyl 
ether will be formed by RCM (Scheme 2.102). Macrocycle 2.353 will then undergo the 
series of optimized reactions to provide hydroxyketoamide 2.357 for the acid-mediated 
spirocyclization to provide lactam 2.358. Acylation of lactam 2.358 with pyrrole will 
provide the fully derivatized model core 2.359 of marineosin A. 
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Scheme 2.102. Planned route for completion of the model system of marineosin A. 
 
Hopefully, the alkyl group/macrocycle will prove more stable than the TIPS and 
PMP protecting groups and will provide the desired marineosin A isomer. We then plan 
to make unnatural analogs as previously described in Scheme 2.100 and hope to identify 
the minimal pharmacophore for biological activity. In this model system, the only 
missing piece will be the pyrrole moiety within the macrocycle. The oxygen within the 
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macrocyclic ring is still a hydrogen bond acceptor and could have the same role in cells 
as the pyrrole. Of course the pyrrole can function as a hydrogen bond donor or acceptor, 
so these macrocyclic ethers could highlight the role of the C-ring pyrrole in the observed 
biological activity. If the macrocyclic ethers prove completely inactive, this could 
indicate that the C-ring pyrrole serves primarily as a hydrogen bond donor. Retained 
activity with ether replacements could indicate the C-ring pyrrole is primarily a hydrogen 
bond acceptor.  Either result will reveal interesting information about the SAR of these 
structurally-complex natural product analogs. SAR studies have implicated that the 
pyrrole A ring is key for activity; 
29
 however, numerous prodigiosins with alternative C-
rings have maintained or improved biological activity and these derivatives have been 
used to tune the activity to favor one biological process over another.
29,98
 We are hopeful 
that our macrocyclic etherlibrary will also possess anticancer, antimalarial, antibacterial, 
or immunosuppressive activity as so many of the prodigiosin alkaloids do and that we 
will be able to identify derivatives to modulate these potential, variable activities.  
 
 
2.11.2 Total Synthesis of Marineosin A 
 In addition to our plans to complete a model system of the fully-derivatized 
spiroiminal core of marineosin A (Scheme 1.102), we also plan to complete the total 
synthesis of this intriguing natural product and to synthesize derivatives with various 
nitrogen-containing heterocycles as the A-ring. Our plan for the completion of the 
synthesis will include an intermolecular Stetter reaction as a key carbon-carbon bond 
forming reaction (Scheme 2.103).
99 
In the Stetter reaction, triazolium salt 2.360 is deprotonated to form a Wittig-type 
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reagent (2.361), which then adds into the aldehyde component to give alkoxy 
intermediate 2.362. A hydride shift then occurs to give the acyl anion intermediate 2.363.  
 
Scheme 2.103.The mechanism of the Stetter reaction. 
 
This is an example of umpolung chemistry, where the activity of a functional 
group is reversed. In this case, the electrophilic aldehyde is transformed into a 
nucleophilic acyl anion (2.363), which then adds to a -unsaturated carbonyl through a 
conjugate addition to provide the 1,4 dione (2.365) following collapse of the tetrahedral 
intermediate (2.364) and regeneration of the Wittig salt 2.361. 
The Stetter reaction will be incorporated into the conjugate addition/aldol route 
(Scheme 2.85) starting from aldehyde 2.324. Addition of vinyl magnesium bromide and 
subsequent oxidation of the resulting allylic alcohol with manganese dioxide will provide 
enone 2.366 (Scheme 2.103). Intermolecular Stetter reaction with enone 2.366  and 
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aldehyde 2.367 will provide 1,4-dione 2.368, which can then undergo a ring-closing 
metathesis reaction to form macrocyclic 1,4-dione 2.369. 
 
 
Scheme 2.103. The intermolecular Stetter reaction will be a key carbon-carbon bond forming 
reaction for the completion of the total synthesis of marineosin A. 
 
Dione 2.369 can then be utilized in a Paal-Knorr condensation reaction with 
ammonium acetate to provide the 2,5-disubstituted pyrrole 2.370 (Scheme 2.104).
100-102
  
 
Scheme 2.104. Paal-Knorr pyrrole synthesis to provide the  2,5-disubstituted pyrrole 2.370 of 
marineosin A. 
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Performing the RCM prior to pyrrole synthesis will circumvent any undesirable 
interaction between the ruthenium catalyst and the electron-rich pyrrole, which has been 
known to poison the metathesis catalyst and prevent the desired ring-closing reaction 
from occurring (Chapter 2, Scheme 2.19 and 2.62). Following pyrrole formation, the 
resulting pyrrolophane 2.370 will be subjected to the same series of reactions optimized 
in our model studies to generate marineosin A as a single diastereomer (Scheme 2.105).  
 
Scheme 2.105. Completion of the total synthesis of marineosin A.   
 
With marineosin A in hand, we plan to generate unnatural A-ring analogs through 
triflate formation and Suzuki cross-coupling with various commercially-available 
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heterocyclic boronic acids as outlined in Scheme 2.100 for library generation around the 
model system. These compounds will be tested in viability, proliferation, and invasion 
assays in the HCT-116 colon cancer cell line, as well as various other cell lines. We are 
also interested in the immunosuppressive and antimalarial properties of prodigiosin 
analogs and will investigate these activities through various collaborations. Hopefully, 
future studies will enable identification of a minimal pharmacophore and the design and 
optimization of a second-generation, simplified synthesis for the preparation of this 
pharmacophore. A simplified synthesis could provide rapid access to larger libraries of 
unnatural analogs for optimization of various biological properties and mechanism of 
action studies. 
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CHAPTER  3 
 
TOTAL SYNTHESIS AND BIOLOGICAL EVALUATION OF TAMBJAMINE K 
AND A LIBRARY OF UNNATURAL ANALOGS 
 
 
3.1. Tambjamine Alkaloids. 
 
The tambjamines A–J (3.1–3.10) are a 2,2’-bipyrrolic class of cytotoxic alkaloids 
with diverse aliphatic termini isolated from marine invertebrates, such as bryozoans, 
nudibranchs, and ascidians, and are related to the prodigiosin 3.11 family of alkaloids 
(Figure 3.1).
1–8
  
 
Figure 3.1. Structures of the tambjamines A–J (3.1–3.10), prodigiosin (3.11).1-8 
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Figure 3.2. Structures of the tambjamine alkaloid relatives BE-18591 (3.12) and YP1 (3.13).
 
 
BE-18591 (3.12) and YP1 (3.13) are the only tambjamine alkaloids not isolated 
from marine invertebrates, but are instead produced by bacterial strains.
9
 
Pseudoalteromonas tunicata, is a marine bacterium that produces a range a biologically 
active products, including YP1 (3.13). BE-18591 (3.12) is the only tambjamine alkaloid 
isolated from a terrestrial bacterium, Streptomyces BA18591.  
 
 3.2. Identification of the Tam Biosynthetic Pathway. 
The gene cluster encoding for the biosynthesis of tambjamine YP1 (3.13) has 
been identified, and this knowledge proves that the prodigiosin alkaloids and tambjamine 
alkaloids share similar biosynthetic pathways.
9
 Proline, malonyl Co-A, and serine are 
incorporated into the synthesis of MBC as described by Williamson and co-workers in 
the biosynthesis of prodigiosin.
10
 AfaA activates dodecenoic acid, TamT introduces the 
double bond between the and  carbons, and TamH transfers an amino group from an 
amino acid.
9
 The resulting dodec-3-en-1-amine is condensed with MBC by TamQ to 
form YP1 (3.13).  
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Scheme 3.1. Biosynthetic pathway for the production of tambjamine alkaloid YP1 
(3.13).
9
 (adapted from Burke 2007). 
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Of the 19 proteins encoded in the Tam cluster, 12 were found to have high 
sequence homology to the Red proteins responsible for undecylprodigiosin synthesis in 
Streptomyces coelicolor A3(2) and Pig proteins involved in the biosynthesis of 
prodigiosin in Serratia sp. Table 3.1 highlights the Tam  proteins with sequence 
similarity to the Red and Pig proteins.
9-11
 The Red and Pig proteins involved in MBC 
biosynthesis are marked by and (M). The relationship between these two families of 
natural products is evident in the biosynthetic origins of these alkaloids. 
 
Table 3.1. Tam proteins, predicted functions, and Pig and Red proteins that possess sequence 
homology.
9
 (adapted from Burke 2007). 
 
 
3.3. Biological Activity of the Tambjamine Alkaloids. 
Members of the tambjamine class of alkaloids have demonstrated a wide range of 
biological activities including antitumor, antimicrobial, and immunosuppressive 
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properties. For tambjamines D (3.4) and E (3.5), the antitumor properties have been 
correlated with DNA intercalation and oxidative cleavage of single-strand DNA.
12
 Much 
like the prodigiosin family of alkaloids, this DNA cleavage is induced in the presence of 
copper without activation by an external reductant. This implies that Cu (I) is formed 
reductively through the concomitant oxidation of the tambjamine to a -radical cation. 
This species may damage DNA through an electron transfer mechanism with the DNA 
bases, resulting is apoptosis.
13 
Tambjamine C (3.3), E-J (3.5-3.10), BE-18591 (3.12), and YP1 (3.13) have 
shown useful antimicrobial and cytotoxic effects, and SAR studies have revealed that the 
more lipophilic compounds show greater potency in both settings.
14
 Unfortunately, none 
of the significantly cytotoxic compounds showed selectivity for the cancer cell lines over 
non-transformed cell lines. However, this limitation may be overcome by generating 
unnatural analogs for biological testing in an attempt to ‘dial out’ this undesirable lack of 
selectivity. 
The tambjamines have also shown activity as ionophores.
15,16
 Although they have 
been shown to induce apoptosis by oxidative DNA damage, they can effectively increase 
intracellular pH, which can also lead to apoptosis. BE-18591 (3.12) has displayed 
especially interesting activity.
16
 This compound shows reversible inhibition of the 
lysosomal proton pump (V-ATPase), the mitochondrial proton pump (F-ATPase), and the 
ATP-dependent proton pump (P-ATPase) in rabbit gastric mucosa with IC50 values from 
1-80 nM. Coupled to its antibacterial activity against Heliobacter pylori, this alkaloid 
could prove highly useful in the treatment of stomach ulcers. BE-18591 (3.12) has also 
shown immunosuppressive activity at nanomolar concentrations. However the selectivity 
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for T-cell proliferation over B-cell proliferation was less than the selectivity of 
prodigiosin.
16
 However, the potential for developing unnatural compounds with desirable 
biological activity based on the structure of the tambjamine alkaloids is very promising.  
 
3.4. Isolation of Tambjamine K. 
In early 2010, Gavagnin and co-workers described the isolation and 
characterization of a new member of the tambjamine family, tambjamine K (3.14), 
isolated from the Azorean nudibranch Tambja ceutae.
17 
Like other members of this 
family, 3.14 displayed antiproliferative and cytotoxicity against tumor (CaCo-2, IC50 
=3.5 nM, HeLa IC50 = 14.6 M, C6 IC50 = 14 M, H9c2 IC50 = 2.7 M, and 3T3-L1 IC50 
= 19 M) and non-tumor cell lines. Interestingly, 3.14 displayed differential effects 
across these tumor cell lines with a variance of >5000-fold (CaCo-2 vs 3T3-L1).
10
 Based 
on these data and our own efforts in related areas, we initiated an effort for the total 
synthesis and biological evaluation of 3.14 along with a library of unnatural analogs with 
unprecedented diversity in the eastern C7 position to survey moieties other than aliphatic 
alkyl chains.  
 
Figure 3.3. Structure of newly isolated tambjamine alkaloid, tambjamine K (3.14).
17
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3.5. Total Synthesis of Tambjamine K. 
Interest in the tambjamine family originated in our evaluation
18
 of Fenical’s 
biosynthetic proposal
19 
for the synthesis of marineosin A via an intramolecular inverse-
electron-demand Diels–Alder reaction with prodigiosin analog 3.15 (Figure 3.4). Like 
3.1–3.14, marineosin A displayed potent cytotoxic activity against HCT116 cells (IC50 = 
500 nM).
18,19  
 
Figure 3.4. Proposed biosynthesis of Marineosin A via and inverse electron-demand Diels-Alder 
reaction with prodigiosin analog 3.15. 
 
Our synthetic approach to access 3.12 was similar to that which we employed for 
the synthesis of 3.13.
18,20
 As shown in Scheme 3.2, a Vilsmeier–Haack haloformylation 
was performed on 4-methoxy-3-pyrrolin-2-one 3.16 to provide bromoenamine 3.17 in 
59% yield. Suzuki cross-coupling with Boc-1H-pyrrol-2yl boronic acid 3.18 delivered the 
Boc-protected analog 3.19 in 48% yield. Finally, an acid mediated condensation between 
3.19 and isopentyl amine
16
 afforded tambjamine K (3.14) in 65% yield and 18% overall 
yield for the three step sequence. Synthetic 3.14 was identical in all aspects to the natural 
product (Table 3.2). 
169 
 
 
Scheme 3.1. Total synthesis of tambjamine K.
20
 
 
 
Table 3.2. Comparison of NMR data from natural product isolate to synthetic natural product. 
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3.6. Biological Activity of Tambjamine K and Prodiginine Unnatural Analogs. 
While 3.14 was studied in a number of tumor cell lines, it was not evaluated in 
cell viability assays with HCT116 colorectal carcinoma or MDA-MB-231 breast 
carcinoma cell lines—tumor lines of interest to our lab.21 Moreover, we had not yet 
evaluated 3.15 or another related prodigiosin analog 3.20 we employed as a template for 
an intermolecular inverse-electron demand Diels–Alder (IEDDA) reaction to access the 
marineosin A core.
18
 Concentration-response curves (CRCs) were generated for viability 
of the HCT116 and MDA-MB231 cell lines upon treatment with compounds 3.14, 3.15, 
and 3.20 (Figure 3.5).  
 
Figure  3.5. Viability  concentration -response  curves for tambjamine K (3.14) and prodigiosin 
alkaloids 3.15 and 3.20  in HCT116 colonrectal cancer cell line (left) and MDA-MB-231 breast 
cancer cell line (right). 
 
 
As summarized in Table 3.3, tambjamine K (3.14) displayed weak cytotoxicity 
against HCT116 (IC50 =13.7 M) and MDA-MB-231 (IC50 = 15.3 M). In contrast, the 
Intramolecular IEDDA prodigiosin analog 3.15 was more potent with IC50 values of 3.5 
M for both tumor lines. The intermolecular IEDDA prodigiosin analog 3.20 was found 
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to be extremely potent, with IC50 values of 146 nM and 362 nM, for HCT116 and MDA-
MB-231 cell lines, respectively.  
 
Table 3.3.  Structures and activities of tambjamine K and unnatural analogs. 
 
a
 8000 cells/well in 96 well plate followed by 24 h for attachment. Added vehicle or compounds 
in RPMI 1640 plus 10% FBS + penicillin-streptomycin. Cells allowed to grow for 48 h, then 
viability was assessed. 
 
Figure 3.6 shows the HCT-116 cellular populations for the vehicle, and 
compounds 3.14, 3.15, 3.20 after 48 hour treatment at two concentrations. 
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Figure 3.6. HCT116 cell populations after 48 h treatment with vehicle (left), and 
compounds 3.14, 3.15 and 3.20 (center and right). 
 
3.7. Synthesis of a Library of Unnatural Tambjamine Analogs. 
These data prompted us to synthesize and evaluate a library of unnatural 
tambjamine analogs
 
to capitalize on the SAR observed for this class of natural products 
akin to our earlier work developing unnatural analogs with activities beyond the natural 
product.
22-24
  
Importantly, Quinn and co-workers
25
 previously prepared a combinatorial library 
of 10 unnatural tambjamine analogs, but all possessed limited R diversity and aliphatic 
side chains dominated. Our library was designed to incorporate functionalized benzyl, 
heteroaryl moieties and other previously undescribed analogs with varying degrees of 
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lipophilicity and basicity to further develop SAR.  
The library was prepared as shown in Scheme 3.2, and differed from the route to 
access 3.14 only in extended reaction time, as several amines proved sluggish in their 
conversion to unnatural tambjamine analogs 3.21; however, all analogs were successfully 
prepared in yields ranging from 35% to 88%. 
 
Scheme 3.2. Library synthesis of tambjamine unnatural analogs 3.21. 
 
3.8. Biological Activity of a Library of Unnatural Tambjamine Analogs.  
We triaged the library of analogs 3.21 by a employing a 10 M single point 
screen in the standard 48 hour viability assay using both HCT116 and MDA-MB-231 
cells.
21 
The majority of analogs, especially the benzyl congeners, 3.21m–3.21w, had no 
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effect on viability in either tumor cell line. Figures 3.7 and 3.8 show the single point data 
for the analogs 3.21 in these assays, and it is important to note that differential activity 
was observed between the two tumor cell lines (Figure 3.7 and 3.8). The most potent 
analog was 3.21b, a racemic 1,2,3,4-tetrahydronaphthalene congener, which significantly 
decreased HCT116 viability (<10% viability) while having only marginal effect on 
MB231 (40% viability). Other unnatural analogs 3.21c, 3.21e, 3.21f, and 3.21g decreased 
HCT116 cell viability to less than 20%, with minimal effect on MB231 viability. Clearly, 
constraining the benzyl amine moiety in 3.21b, 3.21e, and 3.21f into a bicyclic ring 
system is important for activity relative to the inactive benzyl derivatives 3.21m–3.21w.  
 
Figure 3.7. Single point (10 M) screen of library of analogs 3.21. 48 h cell viability assay with 
HCT116 colorectal carcinoma line 
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Figure 3.8. S ingle point (10 M) screen of library of analogs 3.21. 48 h cell viability assay with 
MDA-MB-231 breast carcinoma line. 
 
Based on the promising single point data, we then determined IC50 values for 
3.21b in both cell lines. 3.21b displayed moderately potent cytotoxicity against HCT116 
cells (IC50 = 1.8 M) with the CRC reaching baseline (0% viability at 10 M dose) 
(Figure 3.9). In contrast, 3.21b displayed weak cytotoxicity in the MDA-MB-231 cells 
(IC50 = 4.0 M) with the CRC only achieving ~50% decrease in cell viability at the 
highest (10 M) dose; therefore, the calculated IC50 is for a partial response. The results 
of the CRCs are summarized in Table 3.10. Most importantly, in our standard 
cytotoxicity assay in non-transformed cells, 3.21b displayed no toxicity.  
 
176 
 
 
Figure 3.9. Viability concentration-response curves for tambjamine unnatural analog 
3.21b in the HCT116 cell line (left) and the MDA-MB-231 cell line (right). 
 
 
Table 3.4. Structure and activity of tambjamine unnatural analog 3.21b. 
 
 
 
Based on these data, we then evaluated select unnatural analogs with activity in 
the HCT116 cell viability assay and evaluated them in standard 48 hour cell proliferation 
assays (Figure 3.10) using another colorectal line (SW620) and a non-small cell lung 
carcinoma (NSCLC) line (H520). Interestingly, 3.20, the most potent tambjamine analog 
in both the HCT116 (IC50 = 146 nM) and MDA-MB-231 (IC50 = 362 nM) viability 
assays, had no effect on proliferation in either the SW620 or the H520 cell lines. 
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However, unnatural analog 3.21b, displayed a significant effect on inhibiting 
proliferation in both tumor cell lines, while other analogs showed varying effects.  
 
Figure 3.10. Single point (10 M) screen of select unnatural tambjamine analogs in 48 h cell 
proliferation assays. (A) Proliferation assay with SW620 colorectal carcinoma line; (B) 
proliferation assay with H520 NSCLC line. 
 
As both unnatural tambjamine analogs 3.20 and 3.21e displayed minimal to no 
effect on proliferation (viability) in SW620 cells, we examined their ability to block 
invasion in this tumor line, as the ability of tumor cells to invade into the surrounding 
microenvironment is the defining step in tumor progression.
 
As shown in Figure 3.11, 
both 3.20 and 3.21e significantly blocked invasion, with 3.20 completely inhibiting 
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invasion. Moreover, both analogs displayed minimal or no cytotoxicity in this colorectal 
tumor cell line, further highlighting the value of unnatural analog synthesis.  
 
         
Figure 3.11. Single point (10 M) screen of select unnatural tambjamine analogs in 24 h cell 
invasion assay in the SW620 colorectal carcinoma line. 
 
 
3.9. Conclusions and Future Work. 
In summary, we completed the first total synthesis of tambjamine K (3.14) in 18% 
overall yield coupled with evaluation in viability assays in both colon (HCT116) and 
breast cancer (MDA-MB-231) cell lines. We also prepared a library of unnatural 
tambjamine analogs with unprecedented diversity and improved biological activity 
against a number of tumor cell lines in viability, proliferation and invasion assays. This 
effort demonstrated that subtle changes to the tambjamine core afford varying degrees of 
selectivity against different tumor cell lines. These data argue for further exploration of 
the tambjamine scaffold coupled with evaluation (viability, proliferation, and invasion) in 
additional human tumor cell lines. Current efforts are focused on synthesizing a second-
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generation library including the discrete enantiomers of 3.21b and 3.21e, chiral -methyl 
congers of the benzylic analogs 3.21m–3.21w and more focused analogs based on 3.20. 
In parallel, we are working to identify the molecular target(s) for these unnatural analogs 
by evaluating 3.20, 3.21b, and 3.21e against large panels of kinases, growth factors, and 
phosphatases as a primary approach. After investigating the SAR of the selective 
anticancer activity, we also plan to test our unnatural analogs for immunosuppressive 
properties, since this activity has been observed in tambjamine and prodiginine alkaloids. 
Resent literature has shown that prodiginine unnatural analogs possess potent antimalarial 
activity, but suffer from problems with general cytotoxicity.
26
 We plan to test our 
tambjamine unnatural analogs that show insignificant general toxicity for the ability to 
eradicate the Plasmodium falciparum parasite that is responsible for nearly all malaria 
deaths. Hopefully, this scaffold will prove as rich in tunable biological activity as the 
closely-related prodiginine alkaloids. 
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CHAPTER 4 
 
TECHNOLOGY ENABLED SYNTHESIS AND BIOLOGICAL EVALUATION 
OF 3,6-DISUBSTITUTED-[1,24]-TRIAZOLO[4,3-b]PYRIDAZINES AS M1 
ANTAGONISTS FOR TREATMENT OF DYSTONIAS. 
 
4.1. Introduction. 
 
4.1.1. Dystonias. 
 4.1.1.1. Symptoms. 
Dystonia is a movement disorder in which sustained muscle contractions cause 
twisting and repetitive movements or abnormal postures.1 While not widely known, 
dystonia affects an estimated 300,000 people in North America alone.2  
Two major categories of dystonias exist, primary and secondary.1 Primary 
dystonias develop spontaneously in the absence of any associated disease or apparent 
cause and show no other neurological symptoms, except tremor and myoclonus.1 These 
dystonias have a genetic component, and symptoms are typically irreversible once they 
appear. Early onset primary dystonias are rare, frequently have a genetic basis, and can 
progress to affect multiple body parts, which is known as generalized dystonia. Late-
onset dystonias are much more common and are typically focal in nature, meaning they 
affect one specific body part. Hand dystonia (writer’s cramp) and cervical dystonia 
(torticollis) are two of the most common examples of focal dystonias. These late-onset 
cases can also have a heritable predisposition.  
Secondary dystonias occur when dystonic symptoms result from other disease 
states or a brain injury.1 Many neurodegenerative diseases have dystonic symptoms, 
183 
 
including Huntington’s disease, Parkinson’s disease, and Rett syndrome. Brain lesions 
caused by trauma, vascular injury, viral infection or demyelination can also result in 
dystonic symptoms.  
Since dystonias are not one disease with one cause, but multiple diseases and even 
symptoms of other diseases, it would prove very difficult to determine the cause of each 
dystonia and design treatments to address each cause. In the case of dytonias, it would be 
much more reasonable to develop a symptomatic treatment that addresses the dystonic 
symptoms and successfully alleviates these symptoms in patients. Such a therapeutic 
could then be utilized to ameliorate all primary dystonias and even secondary dystonias 
resulting from a completely unique brain injury. 
4.1.1.2. Current Treatment Options. 
While symptomatic treatment is the currently available method, there are many 
negative aspects of these treatments.3,4 Most pharmacological treatments, such as anti-
cholinergics, GABA agonists, and dopaminergic agents, have severe dose-limiting side 
effects due to lack of selectivity. Botulinum toxin (Botox) injection works very well for 
focal dystonias. However, the toxin has to be directly injected into the affected area, so 
this is not an effective treatment for generalized dystonia. The effects are only temporary 
and multiple injections will be required. Also, immunity to the toxin develops overtime, 
rendering it useless as a treatment over time. Some neurosurgical treatments have proven 
very effective. Deep Brain Stimulation (DBS) of the globus pallidus is an option for 
generalized dystonias, but is not effective in all cases. Also, this is a highly invasive brain 
surgery that places electrodes in the patient’s brain to stimulate certain neurons to relieve 
symptoms. Ideally, an effective pharmacotherapy could be designed that is orally 
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available and capable of treating a wide range of dystonic symptoms with minimal side 
effects.  
 
4.1.2. Muscarinic Acetylcholine Receptor (mAChR) Subtype 1 (M1) as a target for 
treatment of dystonias 
 
 4.1.2.1. The Role of Acetycholine as a Neurotransmitter. 
 
  Acetylcholine (ACh) is a non-amino acid derived small molecule that plays 
essential roles in both the mammalian central nervous system (CNS) and peripheral 
nervous system (PNS) as a neurotransmitter.5-10 Cholinergic signaling within the 
autonomic arm of the PNS occurs at the pre-ganglionic sympathetic and parasympathetic 
synapses, the post-ganglionic parasympathetic synapses, and at a subset of postganglionic 
sympathetic synapses in skin and sweat glands. ACh is also released at the skeletal 
neuromuscular junction, where it stimulates muscle contraction. In the CNS, Cholinergic 
neuronal signaling also plays a key role; its release controls a multitude of integral brain 
functions, motor control and regulation, reward behavior, sleep/wake cycles, metabolism, 
learning and memory, and attention. 
 4.1.2.2. Muscarinic Acetylcholine Receptors. 
mAChRs are Type I rhodopsin-like G-protein coupled receptors (GPCRs) that 
exist as five distinct subtypes (M1-M5) and share a high degree of homology, especially 
among the orthosteric Ach-binding sites.6,9,12-14 M1, M3, and M5 exhibit higher homology 
to each other than to M2 and M4, which share the highest homology with each other.
6,9  
Synaptic localization patterns as well as downstream signaling pathways are generally 
similar for M1, M3, and M5 subtypes versus M2 and M4.
13,14 The former three are 
considered stimulatory or excitatory due to predominantly post-synaptic localization and 
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coupling to the Gαq/phospholipase-C (PLC)/inositol triphosphate (IP3)/Ca
2+ pathway, 
while the latter two are regarded as inhibitory with predominantly pre-synaptic 
localizations and coupling to the Gαi/adenylyl cyclase (AC)/cyclic adenosine 
monophosphate (cAMP)/protein kinase A (PKA) effector system.13,14 M1, M4, and M5 
subtypes are predominantly localized within the CNS, while the M2 and M3 subtypes are 
expressed throughout the CNS and the periphery.  
4.1.2.3. M1 as a Potential Target for Dystonia Therapy. 
M1 has been implicated as a potential target for dystonia therapy due to its post-
synaptic expression on medium spiny GABA-ergic neurons (MSNs) of the dorsal 
striatium (Figure 4.1).15-17 Activation of M1 receptors on the MSNs leads to increased 
excitation of these neurons, which ultimately results in increased muscle contraction.  
Antagonism of striatal M1 receptors by selective small molecules would lead to decreased 
excitation of the MSNs, which could ultimately alleviate the motor dysfunction present in 
patients with dystonia. However, no subtype selective antagonists for the M1 receptor 
have been reported, and therefore discovery of such ligands is clearly required in order to 
pharmacologically test this therapeutic hypothesis. Current pharmacological treatments 
for dystonia commonly display off-target activity at multiple mAChR subtypes.3,4 If a 
therapeutic agent could be designed that selectively targets one subtype over all of the 
others, it could potentially ameliorate dystonic symptoms without complications from 
dose-limiting side effects. 
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Figure 4.1. Localization of M1 and other receptors within the CNS.
15 
 
4.2. Discovery of an HTS lead for M1 Antagonism. 
In the course of our program in small molecule probe development for the 
Molecular Library Screening Center Network (MLSCN),
18
 a high-throughput screen 
identified the 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazine scaffold 4.1 as an 
attractive hit for muscarinic receptor subtype 1 (M1) antagonism (Figure 1.1). While 
numerous reports describe syntheses of 1.1, yields are typically moderate (<50%) with 
prolonged reaction times at high temperatures (steps requiring 18 to >60 h at reflux).
19-22
 
In order to employ an iterative analog library synthesis approach for the lead optimization 
of 4.2, a weak, but selective muscarinic acetylcholine receptor antagonist (M1 IC50 = 22 
M, M4 IC50 >150 M), significant refinements were required in the synthetic protocols 
for delivering analogs 4.1, with diversity at both C3 and C6.
19-22
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Figure 4.2. Generic structure of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazine 4.1 and our M1 
antagonist screening lead 4.2. 
 
As many of the leads identified from HTS campaigns are small heterocyclic 
compounds, our laboratory has devoted significant effort to develop efficient protocols 
for the preparation of diverse heterocyclic templates employing microwave-assisted 
organic synthesis (MAOS).
23-29
 In recent reports, we have described general, high-
yielding MAOS protocols for the expedient synthesis of 1,2,4-triazines 4.3,
23
 imidazoles 
4.4,
24
 quinoxalines 4.5,
25
 pyrazinone 4.6,
26
 5-aminooxazoles 4.7,
27
 quinoxalinones 4.8,
28 
pyrazolo[1,5-a]pyrimidines 4.9,
29
 and pyrazolo[3,4-d]pyrimidines 4.10
30
 from simple 
starting materials (Figure 4.3). Therefore, application of MAOS to develop a general, 
high-yielding, and expedient synthesis of the 3,6-disubstituted-[1,2,4]triazolo[4,3-
b]pyridazine scaffold 4.1 seems warranted (Scheme 4.1). 
 
Figure 4.3. Heterocyclic templates accessed through MAOS in our laboratory.
23-30 
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4.3. Methodology Development for Expedited Library Synthesis. 
Classical conditions for the synthesis of 3,6-disubstituted-[1,2,4]triazolo[4,3-b] 
pyridazines 4.1 involve refluxing 3,6-dichloropyridazine 4.11 with an acylhydrazide 4.12 
in toluene for 16 h, or more typically for 60 h, to provide the 3-aryl-6-chloro-
[1,2,4]triazolo[4,3-b]pyridazine 4.13 in yields less than 50% (Scheme 1.1).
20-22 
Introduction of the amino moiety in the 6-position was accomplished through an SNAr 
reaction employing either neat or steel bomb conditions at 100–140oC for 8–30 h to 
deliver analogs 4.1 in yields ranging from 40% to 70%.
21-23
 Moreover, previous efforts 
were focused on traditional medicinal chemistry approaches and the development of 
structure–activity relationships (SARs), with little concern for achieving high chemical 
yields or reaction generality for either the heterocycle synthesis or the SNAr reaction. 
Indeed, the 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazine scaffold 4.1 has been an 
important pharmacophore for the development of GABAA receptor agonists at the 2/3-
subunit.
20-22 
 Interestingly, microwave-assisted organic synthesis has never before been 
applied to this heterocyclic system, and even more surprising when one considers a 1–6 
day reaction time to deliver a single derivative of 4.1. 
 
Scheme 4.1. Classical synthesis of 3,6-disubstituted-[1,2,4]triazolo 4,3-b]pyridazines 4.1. 
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By varying solvent and temperature parameters, microwave conditions were 
rapidly developed to accelerate and generalize the synthesis of the 3-phenyl-6-chloro-
[1,2,4]triazolo[4,3-b]pyridazine 4.13 core employing 3,6-dichloropyridazine 4.11 and 
acylhydrazide 4.12 (Table 4.1). When acetic acid was employed as a solvent or catalyst, a 
corresponding acetylated phenyl acylhydrazide 4.14 was obtained in varying quantities. 
Optimal acetic acid conditions employed 5% HOAc/EtOH at 150 
o
C for 10 min to afford 
the desired 4.13, along with 4.14 in an 85:15 ratio (Table 4.1, entry 9). Despite the side 
product, the conversion to 4.13/4.14 was quantitative and isolated yields of 4.13 exceeded 
82%. Application of the same MAOS conditions, but replacement of acetic acid with 5% 
4 N HCl in dioxane, afforded 100% conversion to 4.13 in 95% isolated yield without 
producing 4.14 (Table 1.1, entry 13). Thus, a reaction that previously required up to 60 h 
of conventional heating to provide <50% yield,
20-22
 now afforded 95% yield of the 
desired product 4.13 in 10 minutes by virtue of MAOS—a 360-fold reduction in reaction 
time.  
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Table 4.1. Optimization of MAOS conditions to produce 4.13. 
 
 
Entry T (
o
C) Solvent Time (min) 4.13:4.14
a 
1 
140 HOAc 10 42:58 
2 160 HOAc 10 28:72 
3 180 HOAc 10 24:76 
4 200 HOAc 10 13:87 
5 150 50% HOAc/EtOH 10 78:22 
6 170 50% HOAc/EtOH 10 64:36 
7 150 10% HOAc/EtOH 10 79:21 
8 170 10% HOAc/EtOH 10 74:26 
9 150 5% HOAc/EtOH 10 85:15 
10 170 5% HOAc/EtOH 10 77:23 
11 135 5% HOAc/EtOH 20 80:20 
12 135 EtOH
b 
10 -- 
13 150 5% HCl/EtOH
c 
10 100:0 
a
 Ratio determined by analytical LCMS and 
1
H NMR; conversion >95%. 
b
 No product formed without acid catalysis. 
c
 5% 4 N HCl/dioxane. 
 
191 
 
 
Attention was now directed at the application of these new MAOS conditions to a 
diverse array of acylhydrazides to ensure that this new protocol would indeed be general. 
As shown in Table 4.2, the MAOS protocol, employing either catalytic HOAc (Method 
A) or HCl (Method B), proved to be general with respect to a wide range of electron-rich 
(entry 4.13g), electron-deficient (entry 4.13f), and hindered acylhydrazides (entry 4.13a) 
as well as heterocyclic congeners (entries 4.13h, 4.13i) affording the desired 3-
aryl/heteroaryl-6-chloro-[1,2,4]-triazolo-[4,3-b]pyridazines 4.13 in isolated yields 
ranging from 74% to 97% in 10 min at 150 
o
C. 
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Table 4.2. Generality of the MAOS protocol to deliver analogs 4.13. 
 
 
Compound            R Yield
a
 (%) Yield
b
 (%) 
 
4.13a 
 
 
79 
 
92 
 
4.13b 
 
 
77 
 
93 
 
4.13c 
 
 
81 
 
91 
 
4.13d 
 
 
87 
 
96 
 
4.13e 
 
 
80 
 
95 
 
4.13f 
 
 
75 
 
97 
 
4.13g 
 
 
74 
 
96 
 
4.13h 
 
 
70 
 
88 
 
4.13i 
 
 
72 
 
86 
            a
 5% HOAc/EtOH, remaining mass balance congeners or 4.14. 
            b 
5% 4 N HCI/dioxane. All yields for isolated, analytically pure materials. 
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Developing a general MAOS-mediated SNAr protocol for the reaction of diverse 
amines with analogs 4.13 to deliver 3-aryl, 6-amino-[1,2,4]triazolo[4,3-b]pyridazines 4.1 
proved more difficult. Nucleophilic amines (benzyl, aliphatic, piperidines, and 
piperazines) reacted smoothly in EtOH at 170 
o
C for 10 min to produce analogs 4.1 in 
yields ranging from 73% to 92% (Scheme 4.2). Less nucleophilic amines, such as 
anilines, required K2CO3 in DMF with microwave irradiation for 15 min at 180
o
C to 
produce analogs 4.1 in yields exceeding 65%. Furthermore, analogs 4.13 readily 
participated in general microwave-assisted Sonogashira and Suzuki cross-coupling 
reactions to afford analogs 4.15 and 4.16 in yields exceeding 80% in every case examined 
(Scheme 4.2). 
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Scheme 4.2. MAOS protocols to functionalize 3-aryl-6-chloro-[1,2,4]-triazolo-[4,3-b]pyridazine. 
4.13. 
  
 
4.4. Resynthesis of the Lead Compound and Plan for Library Synthesis  
Utilizing these new MAOS protocols, we resynthesized the M1 versus M4 
selective antagonist HTS hit 4.2 (Scheme 4.3). Beginning with 4.13, delivered in 95% 
yield (Table 4.1), an SNAr reaction with Boc-piperazine provided 4.17, which was then 
deprotected using 1:1 TFA:DCM to afford 4.18 in 80% yield for the two steps. 4.18 was 
then acylated employing standard polymer-supported reagents and scavengers to generate 
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the original HTS hit 4.2 in 70% yield.
13
 Evaluation of 4.2 against M1–M5 in a functional 
cell-based assay indicated that 4.2 was indeed a weak but selective M1 antagonist (M1 
IC50 = 22 M, M2–M5 IC50 >> 50 M). Prior to this discovery there was only one other 
M1 selective small molecule antagonist,
30
 and prior to its discovery, the only M1 selective 
antagonist was MT7, a 71 amino acid peptide toxin from the green mamba snake.
31
 
Encouraged by this result, we employed an iterative parallel synthesis approach, 
employing our new MAOS protocols, to rapidly develop structure–activity relationships 
in an attempt to improve the M1 antagonist potency while maintaining selectivity for M2–
M5. 
 
Scheme 4.3. Application of MAOS protocols for the resynthesis of the M1 antagonist HTS hit 
4.2. 
 
As shown in Figure 4.4, we plan to vary the substituents at the C-3 and C-6 
positions, synthesizing small 12- to 24-member libraries employing the synthetic routes 
depicted in Scheme 4.3 and Figure 4.4. We will incorporate alternative aryl moieties into 
the eastern portion of the molecule by utilizing various aryl acylhydrazides in the initial 
condensation reaction. Alternative amides will be synthesized by acylation of the 
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secondary amine with acid chloride and activated carboxylic acids or anhydrides. Finally, 
we plan to replace the amide linkage with a non-hydrolysable bond through incorporation 
of different amines in the SNAr reaction.  
 
Figure 4.4. Synthetic plan to optimize 4.2 for M1 antagonist potency, while maintaining 
selectivity versus M2–M5. 
 
 
4.5. Biological Activity of Analog Libraries  
The first library was prepared by variation of the eastern portion of the molecule 
through incorporation of various electron-rich, electron-poor, and electron-neutral aryl 
acylhydrazides (4.2A-I). Analogs of 4.2 were triaged in a cell-based functional single-
point (10 M) screen for the compounds’ ability to decrease the response to an EC80 
concentration of acetylcholine (Figure 4.5). Three compounds (4.2C, 4.2G, 4.2I) were 
found to have greater M1 antagonist efficacy than the original HTS lead (4.2B) in the 
single point assay.  
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Figure 4.5. Single point 10 M screen for M1 antagonism.by analogs 4.2A-I. 
 
Concentration-response curves (CRCs) were generated for these three compounds 
to determine the potency of the analogs (Figure 4.6). 4.2C and 4.2I displayed IC50 values 
of 4.1 M and 3.6 M, respectively. 4.2G was determined to have an IC50 of 10 M. 
Further library development will be performed with the meta-methoxy analog 4.2I, since 
SAR indicates that it is the most active compound. 
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Figure 4.6. Concentration-response curves for M1 antagonism by analogs 4.2C, 4.2G, and 4.2I in 
a calcium mobilization mobilization assay using recombinant M1-expressing CHO cells. 
 
 
We next investigated the selectivity of our compounds for the M1 receptor over 
the other subtypes (M2-M5). Cell lines individually expressing M2-M5 were treated with 
various concentrations of compounds 4.2B, 4.2C, and 4.21 followed by an EC80 of ACh 
in order to generate CRCs (Figure 4.7).  
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Figure 4.7. Selectivity for M1versus M2-M5 for analogs 4.2B, 4.2C, and 4.2I. 
 
In light of these promising results, we began to generate additional libraries with 
various appendages in the western portion. Alternative amides were prepared according 
to Figure 4.8 by acylation with various acid chloride with diversity at R1. We also 
prepared various pyridyl and pyramidyl piperazines by performing the SNAr reaction with 
these piperazines.   
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Figure 4.8. Single point 10 M screen for M1 antagonism.by analogs 4.2J-AA. 
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SAR for this series was rather ‘flat’, with subtle changes leading to a complete 
loss of M1 inhibitory activity. Out of all of the analogs, only four demonstrated 
significant M1 antagonism; however, we managed to improve upon HTS hit 4.2. As 
summarized in Figure 4.9, exploration of the C3 position identified both the 3-OMe 
phenyl derivative 4.2I and the 4-Me phenyl congener 4.2C as engendering more potency 
(M1 IC50 = 3.59 M and 4.09 M, respectively), while maintaining selectivity (M2–M5 
IC50 >> 50 M). When holding the 3-OMe phenyl moiety constant at C3 and exploring 
alternatively functionalized piperazines for the bromofuranoic amide at C6, we identified 
two pyridyl piperazine analogs, 4.2J and 4.2L, which maintained M1 antagonism (M1 
IC50 = 3.99 M and 6.64 M, respectively) and selectivity (M2–M5 IC50 >> 50 M). 
Moreover, these latter analogs, with basic amines, afforded improved solubility and 
physiochemical characteristics. 
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Figure 4.9 Optimized analogs of 4.2 as highly selective M1 antagonists with improved M1 
inhibitory activity as compared to HTS hit 4.2. 
 
4.6. Summary.  
We have applied MAOS to the preparation of 3,6-disubstituted-[1,2,4]-triazolo-
[4,3-b]pyridazines 4.1, and developed general and high-yielding protocols with over a 
360-fold acceleration in reaction rate. For both the heterocyclic synthesis and the 
subsequent SNAr steps, reaction time, yield, and overall reaction generality were 
dramatically improved under these MAOS protocols; more importantly, these new 
protocols allow for an iterative analog library synthesis approach for lead optimization to 
be employed for the rapid synthesis of large numbers of analogs of 4.2. Employing these 
new MAOS protocols, a lead optimization campaign centered on the selective, but weak 
M1 antagonist hit 4.2 (M1 IC50 = 22 M) delivered two analogs, 4.2J and 4.2L, with over 
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a 6-fold increase in M1 inhibitory activity (M1 IC50 = 3.99 M and 6.64 M, respectively) 
while maintaining selectivity versus M2–M5 (IC50 >> 50 M). These compounds 
represent a novel chemotype of selective, small molecule M1 antagonists, and hold 
promise as leads for potential new therapeutic agents for dystonias.
33
  
 
Figure 4.10 Optimized analogs of 4.2 as highly selective M1 antagonists with improved M1 
inhibitory activity as compared to HTS hit 4.2.
34 
 
While further derivatization around the triazolopyridazine scaffold did not 
provide a significant increase in potency, the SAR mapping of our scaffold led to the 
development of a much more potent M1 orthosteric anatagonist, VU0255035, (Figure 
4.10) with the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).
34
 This 
scaffold maintains the 4-pyridylpiperazine moiety evident in one of our most potent 
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compounds. It also incorporates a bicyclic nitrogen-containing heterocyclic moiety 
reminiscent of the triazolopyridazine core. VU0255035 is highly selective for M1 with an 
IC50 of 133 nM at M1 and greater than 75x selectivity versus the other four muscarinic 
acetylcholine receptor subtypes. VU0255035 is the first highly selective M1 antagonist 
with nanomolar potency and will serve as a very important tool compound for the study 
of selective M1 antagonism, the role this activity plays within the nervous system, and the 
potential of this receptor as a therapeutic target for the treatment of dystonias and other 
movement disorders.  
 
4.7. Future Work. 
 Future work could include the development of an in vitro phenotypic assay for   
dystonia subtypes with known genetic mutations responsible for the errant phenotype. 
Once an assay is developed these compounds could be tested for their ability to alleviate 
the cellular phenotype. In vivo mouse models could also be developed and could provide 
excellent insight into the potential of these compounds to treat dystonic symptoms in an 
intact nervous system.  
 In addition to dystonia, these selective M1 antagonists could be utilized to study 
the role of M1 in other disease states, such as Parkinson’s disease. Until now, there have 
been no means to selectively antagonize M1 over the other receptor subtypes, therefore, 
when M1 has been implicated in disease states, its involvement has been unable to be 
definitively determined.
16,17
 The availability of these compounds will not only aid future 
research within our lab and the VCNDD, but also within the greater scientific community 
of neurological research.  
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CHAPTER 5 
 
EXPERIMENTAL METHODS 
 
5.1. General  
All 
1
H & 
13
C NMR spectra were recorded on Bruker DRX-500 (500 MHz), 
Bruker AV-400 (400 MHz) or Bruker AV-NMR (600 MHz) instrument. Chemical shifts 
are reported in ppm relative to residual solvent peaks as an internal standard set to δH 
7.26 or δC 77.0 (CDCl3) and δH 3.31 or δC  49.0 (CD3OD). Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m 
= multiplet), integration, coupling constant (Hz). IR spectra were recorded as thin films 
and are reported in wavenumbers (cm
-1
). Low resolution mass spectra were obtained on 
an Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra were 
recorded on a Waters Qtof-API-US plus Acquity system. The value Δ is the error in the 
measurement (in ppm) given by the equation Δ = [(ME – MT)/ MT] × 106, where ME is 
the experimental mass and MT is the theoretical mass. The HRMS results were obtained 
with ES as the ion source and leucine enkephalin as the reference. Optical rotations were 
measured on a Perkin Elmer-341 polarimeter. Analytical thin layer chromatography was 
performed on 250 μM silica gel 60 F254 plates. Visualization was accomplished with UV 
light, and/or iodine chamber and the use of ninhydrin, anisaldehyde ceric ammonium 
molybdate, and potassium permanganate solutions followed by charring on a hot-plate. 
Chromatography on silica gel was performed using Silica Gel 60 (230-400 mesh) from 
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Sorbent Technologies. Analytical HPLC was performed on an Agilent 1200 analytical 
LCMS with UV detection at 214 nm and 254 nm along with ELSD detection. Solvents 
for extraction, washing and chromatography were HPLC grade. All reagents were 
purchased from Aldrich Chemical Co. and were used without purification. All polymer-
supported reagents were purchased from Biotage, Inc. Flame-dried (under vacuum) 
glassware was used for all reactions. All reagents and solvents were commercial grade 
and purified prior to use when necessary. Mass spectra were obtained on a Micromass Q-
Tof API-US mass spectrometer was used to acquire high-resolution mass spectrometry 
(HRMS) data. 
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5.2. Progress Toward the Total Synthesis of Marineosins A & B. 
 
 
(E)-N-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-N-ethylethanamine (2.56). 
A 100 mL round bottom flask was charged with N,N-diethylformamide (2.86 g, 28.29 
mmol) and 23 mL of dichloromethane. The solution cooled to 0 
o
C in an ice bath, and a 
solution of phosphorous oxybromide (10.14 g, 35.36 mmol) in dichloromethane (7 mL) 
was added slowly over 20 minutes. After addition was complete, the reaction mixture 
was stirred for an additional 20 minutes. A solution of 4-methoxy-3-pyrrolin-2-one (2.00 
g, 17.68 mmol) in dichloromethane (18 mL) was added dropwise over 10 minutes, and 
the mixture was stirred for an additional 20 minutes. The flask was then removed from 
the ice bath, transferred to an oil bath, and refluxed (42
o
C) for 3.5 hours. The reaction 
mixture was then transferred to a 500 mL round bottom flask and cooled to 0
o
C in an ice 
bath. Water (20 mL) was added dropwise over 10 minutes, followed by 15 wt% sodium 
hydroxide (230 mL) over 40 minutes. The reaction was stirred for an additional 20 
minutes and then transferred to a separatory funnel. The layers were separated and the 
aqueous layer was extracted with dichloromethane (3 x). The combined organic layers 
were dried over sodium sulfate and concentrated in vacuo. The resulting yellow oil was 
subjected to flash chromatography (4:1 Hex:EtOAc) to give 2.56 as an oil that solidified 
upon standing at 20 
0
C to give a tan solid (2.67 g, 59%). 
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1
H NMR (CDCl3, 400 MHz)  (ppm): 1.29 (t, J = 7.2 Hz), 1.30 (t, J = 7.2 Hz), 3.40 (q, J 
= 7.2 Hz, 2H), 3.76 (s, 3H), 4.13 (q, J = 7.2 Hz, 2H), 5.59 (s, 1H), 6.99 (s, 1H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 12.4, 14.5, 44.5, 51.0, 57.9, 96.4, 120.7, 133.6, 138.5, 165.3. 
IR (KBr) max 2975, 2934, 1629, 1529, 1408, 1290, 1264, 1195, 1116, 1072, 906, 737 
cm
-1
. HRMS: C10H16N2OBr, Calculated: [M+H]+, 259.0446, Found: [M+H]+, 259.0448. 
 
tert-butyl 5'-formyl-4'-methoxy-1H,1'H-2,2'-bipyrrole-1-carboxylate (2.64). 
Pd(PPh3)4 was generated in situ by adding triphenylphosphine (1.22 g, 4.64 mmol) to a 
magnetically stirred suspension of Palladium II Acetate (0.23 g, 1.03 mmol) in degassed 
toluene (5.0 mL) then heating the ensuing mixture at 70 
o
C for 20 minutes under at 
atmosphere of argon. A solution of N-Boc-pyrrole-2-boronic acid (3.26 g, 15.46 mmol) 
and bromoenamine 2.56 (2.67 g, 10.31 mmol) in H2O/1,4-dioxane (1:9 v/v, 86 mL) was 
degassed, purged with argon gas and added to the solution of Pd(PPh3)4 in toluene. 
Anhydrous sodium carbonate (3.28 g, 30.93 mmol) was added and the reaction mixture 
stirred at 85
o
C. After 3 hours, the mixture was cooled and poured into water (150 mL). 
The mixture was reduced to pH 7 using 2 M HCl and transferred to a separatory funnel. 
The solution was partitioned with dichloromethane and extracted (4 x). The organic 
layers were combined, dried over sodium sulfate, and condensed in vacuo to give a 
brown residue that was purified by flash chromatography (4:1 Hex:EtOAc) affording 
aldehyde 2.64 as an orange solid (1.44 g, 48%). 
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1
H NMR (CDCl3, 400 MHz)  (ppm): 1.61 (s, 9H), 3.88 (s, 3H), 6.07 (d, J = 3.5 Hz, 1H), 
6.24 (t, J = 3.5 Hz, 1H) 6.66 (dd, J = 3.5 Hz, 1.76 Hz, 1H), 7.33 (dd,  J = 3.4, 1.80 Hz, 
1H), 9.53 (s, 1H), 10.73 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 27.8, 57.8, 85.7, 
94.7, 111.4, 116.8, 118.2, 124.5, 125.9, 130.2, 149.6, 157.6, 174.3. IR (KBr) max 3221, 
2979, 2833, 1735, 1623, 1549, 1502, 1433, 1370, 1330, 1287, 1255, 1140, 1021 cm
-1
. 
HRMS: C15H19N2O4, Calculated: [M+H]+,.291.1345, Found: [M+H]+,.291.1345. 
 
1-(oct-7-enyl)pyrrolo[1,2-c]oxazol-3(1H)-one (2.75). Magnesium ribbon (54.8 mg, 2.25 
mmol) was flame-dried in a 50 mL round bottom flask fit with a reflux condenser. 
Anhydrous THF (10 mL) and a small crystal of iodine were then added to the flask. 8-
bromo-1-octene (352.4 mg, 1.84 mmol) was added dropwise at room temperature, and 
then the solution was heated to reflux. After 2 hours, the mixture was cooled to 0
o
C and a 
prepared solution of N-Boc-pyrrole-2-carboxaldehyde (0.1 M in THF, 10 mL) was added 
to the prepared Grignard reagent. The solution was stirred at room temperature for 1 
hour, cooled to 0 
o
C, and quenched with 1M HCl until the pH was neutral. The mixture 
was extracted with dichloromethane (3x), washed with brine, dried over sodium sulfate, 
and condensed in vacuo to give a brown residue. The residue was purified by flash 
chromatography (10:1 Hex:EtOAc) and condensed under reduced pressure to give 2.75 as 
a clear yellow oil (185 mg, 78%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.31-1.40 (m, 6H), 1.44-1.50 (m, 2H), 1.86-1.92 
(m, 2H), 2.03 (q, J = 7.0 Hz, 2H) 4.93 (dt, J = 10.2, 1.0 Hz, 1H), 4.99 (ddd,  J = 17.1, 3.5, 
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1.6 Hz, 1H), 5.43 (t, J = 6.4 Hz, 1H), 5.74-5.84 (m, 1H),  6.00 (dd, J = 1.8, 1.3 Hz, 1H), 
6.43 (t, J = 3.1 Hz, 1H), 7.04 (d, J = 3.0 Hz, 1H) 
13
C NMR (CDCl3, 100 MHz)  (ppm): 
24.0, 28.6, 28.7, 28.9, 33.6, 34.5, 79.3, 102.4, 112.2, 114.3, 118.1, 136.6, 138.8, 150.0. 
IR (KBr) max 2927, 2856, 1797, 1467, 1416, 1404, 1322, 1267, 1096, 906, 754, 712 cm
-
1
. LRMS: m/z = 234.1 [M+H]+.  
 
1-(1-(phenylsulfonyl)-1H-pyrrol-2-yl)non-8-en-1-ol (2.82). Magnesium ribbon (2.07 g, 
85 mmol) was cut into small pieces, placed in a 500 mL, 2-neck schlenk flask fit with a 
reflux condenser, and flame-dried under vacuum. A small crystal of iodine was added 
and the flask was flushed with argon. The magnesium was suspended in anhydrous THF 
(250 mL) and vigorously stirred. 8-bromo-1-octene (11.78 g, 61.6 mmol) was added to 
the solution dropwise at room temperature. The resulting mixture was then heated to 
reflux (65 
o
C) for 2 hours. 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde (10.0 g, 42.5 
mmol) was added to a 500 mL flame-dried, schlenk flask. Anhydrous THF (105 mL) was 
added and the mixture was stirred and cooled to 0 
o
C in an ice bath. After refluxing for 2 
hours, the prepared Grignard reagent was cooled to room temperature and cannulated into 
the aldehyde solution over a 30 minute period. The resulting brown slurry was stirred at 0 
o
C for an additional 30 minutes and was then allowed to warm to room temperature. After 
3 hours, 2 M HCl was slowly added to the vigorously stirred solution until it reached pH 
7. The mixture was then transferred to a separatory funnel, diluted with water, partitioned 
with dichloromethane, and extracted (4 x). The combined organic layers were combined, 
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dried over sodium sulfate, and condensed under reduced pressure to give a brown 
residue. This residue was purified by flash chromatography (3:1 Hex:EtOAc) and dried in 
vacuo to afford alcohol 2.82 as a viscous, orange oil (9.08 g, 62%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.21-1.26 (m, 4H), 1.29-1.36 (m, 4H), 1.71-1.84 
(m, 2H), 2.01 (q, J = 7.2 Hz, 2H), 2.72 (d, J = 4.0 Hz, 1H), 4.80 (td, J = 7.2, 4.0 Hz, 1H), 
4.93 (dt, J = 10.4, 1.2 Hz, 1H), 4.98 (ddd, J = 17.2, 3.6, 1.6 Hz, 1H), 5.74-5.85 (m, 1H), 
6.26 (t, J = 3.2 Hz, 1H), 6.28 (dd J = 5.2, 3.2 Hz, 1H), 7.31 (dd J = 3.2, 2.0 Hz, 1H), 7.51 
(t, J = 8.0 Hz, 2 H), 7.61 (tt J = 8.0 Hz, 1.2 Hz, 1H), 7.79 (d J = 8.0 Hz, 2H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 26.0, 28.8, 28.9, 29.1, 33.7, 35.0, 65.2, 111.7, 112.4, 114.2, 
123.5, 126.5, 129.4, 133.9, 138.3, 139.1, 139.3. IR (KBr) max 3567, 2928, 2856, 1448, 
1366, 1177, 1152, 1090, 1056, 726, 685 cm
-1
. HRMS: C19H26NO3S, Calculated: 
[M+H]+,.348.1633, Found: [M+H]+,.348.1632. 
 
1-(1-(phenylsulfonyl)-1H-pyrrol-2-yl)non-8-en-1-one (2.83). TPAP (0.84 g, 2.39 
mmol) was added to a 250 mL flame-dried round bottom flask containing a stirred and 
cooled (0
o
C) solution of alcohol 2.82 (8.3 g, 23.9 mmol), NMO (5.6 g, 47.8 mmol), and 4 
amgstrom molecular sieves (12 g) in dichloromethane (100 mL). The reaction was 
warmed to room temperature and stirred for 4 hours. The reaction mixture was filtered to 
remove the molecular sieves, diluted with dichloromethane, and partitioned with water. 
The mixture was washed with 1 M HCl (1 x) and water (2 x). The organic layer was dried 
over sodium sulfate and condensed under reduced pressure to give a black oil. The oil 
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was purified by flash chromatography (4:1 Hex:EtOAc) and dried in vacuo to afford 2.83 
as a clear, colorless oil (7.08 g, 86%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.24-1.27 (m, 4H), 1.31-1.36 (m. 2H), 1.59 (quin. 
J = 7.2 Hz, 2H), 2.00 (q, J = 6.8 Hz, 2H), 2.66 (t, J = 7.2 Hz, 2H), 4.92 (d, J =10.0 Hz, 
1H), 4.97 (dd, J =16.8, 2.0 Hz, 1H), 5.73-5.83 (m. 1H) 6.34 (t, J = 3.6 Hz, 1H), 7.31 (dd, 
J = 3.6, 1.6 Hz, 1H) 7.52 (t, J = 7.6 Hz, 2H), 7.60 (t, J = 7.2 Hz, 1H), 7.80 (dd, J = 3.2, 
1.6 Hz, 1H), 8.00 (dd, J = 7.2 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 24.7, 28.6, 
28.7, 28.9, 33.6, 39.3, 110.3, 114.2, 123.2, 128.0, 128.6, 130.0, 133.4, 133.5, 138.9, 
139.0, 188.9. IR (KBr) max 2928, 2856, 1676, 1448, 1440, 1367, 1175, 1144, 1089, 
1062, 751, 726, 684 cm
-1
. HRMS: C19H24NO3S, Calculated: [M+H]+,.346.1477, Found: 
[M+H]+, .346.1481.  
 
2-(non-8-enyl)-1H-pyrrole (2.69).  Sodium borohydride (3.1 g, 81.88 mmol) was added 
to a flame-dried, 500 mL round bottom flask fit with a reflux condenser. The flask was 
purged with argon and anhydrous 2-propanol (150 mL) was added. Acylpyrrole 2.83 
(5.64 g, 16.29 mmol) was suspended in 120 mL of anhydrous 2-propanol, and this 
solution was added dropwise to the sodium borohydride solution at room temperature. 
After addition was complete, the mixture was heated to reflux (82 
o
C) for 24 hours. The 
reaction was cooled to room temperature and the excess sodium borohydride was 
quenched by slowly adding water to the stirring solution. When no more hydrogen gas 
evolved, the reaction was partitioned with dichloromethane, and extracted (3 x). The 
216 
 
organic layers were combined, dried over sodium sulfate, and concentrated under reduced 
pressure to give a yellow oil. This oil was purified by flash chromatography (5:1 
Hex:EtOAc) and concentrated in vacuo to afford 2.69 as a clear, yellow oil (2.94 g, 94%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.32-1.41 (m, 8H), 1.62 (quin, J = 7.6 Hz, 2H), 
2.04 (dd, J =7.6 Hz, 6.8 Hz, 2H), 2.59 (t, J = 7.6 Hz, 2H), 4.93 (dt, J = 10.0 Hz, 1.2 Hz, 
1H), 4.99 (ddd, J = 17.0 Hz, 4.0 Hz, 1.6 Hz, 1H), 5.76-5.86 (m, 1H), 5.91 (d, J = 0.8 Hz, 
1H), 6.13 (dd, J = 5.6 Hz, 3.2 Hz, 1H), 6.66 (dd, J = 4.4 Hz, 2.8 Hz, 1H), 7.89 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 27.7, 28.9, 29.0, 29.2, 29.3, 29.6, 33.8, 104.8, 
108.2, 114.1, 115.9, 132.8, 139.2. IR (KBr) max 3391, 2927, 2855, 1640, 1569, 1465, 
1438, 1095, 1025, 994, 910, 784, 712 cm
-1
. HRMS: C13H22N, Calculated: [M+H]+, 
192.1752, Found: [M+H]+, 192.1752.  
 
4-(5-(non-8-enyl)-1H-pyrrol-2-yl)butan-2-one (2.84). 3-buten-2-one (100 mg, 1.44 
mmol) was added to a flame-dried, 100 mL round bottom flask containing alkylpyrrole 
2.69 (125 mg, 0.65 mmol) and dichloromethane (3.5 mL). Grubb’s second-generation 
catalyst (28 mg, 0.033 mmol) was added in one portion at room temperature. The mixture 
was stirred for 12 hours at reflux, condensed in vacuo, and immediately purified by flash 
chromatography (3:1 Hex:EtOAc) affording 2.84 as a pale yellow oil (73 mg, 43%).
1 
1
HNMR (CDCl3, 400 MHz)  (ppm): 1.28-1.39 (m, 8H), 1.55-1.62 (m, 2H), 2.04 (q, J = 
6.8 Hz, 2H), 2.16 (s, 3H), 2.52 (t, J = 7.6 Hz, 2H), 2.76-2.83 (m, 4H), 4.03 (s, 3H), 4.93 
                                                        
1
 A 4:2:1 mixture of 2.84:2.5:2.85 was formed by this reaction. The major isomer 2.84 and 
desired product 2.5 were isolated and fully characterized. The identity and ratio of 2.85 were 
determined by crude 
1
HNMR of 2.84:2.85 mixture and LRMS. 
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(dt, J = 10.4 Hz, 1.2 Hz, 1H), 4.99 (ddd, J = 17.2 Hz, 3.6 Hz, 1.6 Hz 1H), 5.71-5.75 (m, 
2H), 5.74-5.87 (m, 1H), 8.14 (s, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 21.4, 27.8, 
28.9, 29.0, 29.2, 29.3, 29.6, 30.1, 33.8, 44.3, 104.2, 105.0, 114.1, 129.8, 132.0, 139.2, 
209.7. LRMS: m/z = 262.2 [M+H]+. 
 
(E)-11-(1H-pyrrol-2-yl)undec-3-en-2-one (2.5). 3-buten-2-one (1.21 g, 17.25 mmol) 
was added to a flame-dried, 100 mL round bottom flask containing alkylpyrrole 2.69 (1.5 
g, 7.84 mmol) and dichloromethane (60 mL). Grubbs’ second-generation catalyst (2 g, 
2.35 mmol) was added in one portion at room temperature. The mixture was stirred for 6 
hours, condensed in vacuo, and immediately purified by flash chromatography (3:1 
Hex:EtOAc) affording 2.5 as a clear colorless oil (725 mg, 40%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.31-1.33 (m, 6H), 1.46 (quin, J =2.4 Hz, 2H), 
1.62 (quin, J = 2.8 Hz, 2H), 2.22 (q, J = 7.2 Hz, 2H), 2.25 (s, 3H), 2.60 (t, J = 7.6 Hz, 
2H), 5.91 (d, J = 0.8 Hz, 1H), 6.07 (dt, J = 16 Hz, 1.6 Hz, 1H), 6.13 (dd, J = 5.6 Hz, 2.8 
Hz, 1H), 6.67 (dd, J = 4.0 Hz, 2.4 Hz, 1H), 6.80 (dt, J =16 Hz, 6.8 Hz, 1H), 7.95 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 26.8, 27.7, 28.0, 29.0, 29.1, 29.2, 29.6, 32.4, 
104.9, 108.2, 116.0, 131.3, 132.7, 148.5, 198.8. IR (KBr) max 3383, 2928, 2855, 1670, 
1624, 1457, 1429, 1362, 1257, 1024, 977, 784, 713 cm
-1
. HRMS: C15H24NO, Calculated: 
[M+H]+, 234.1858, Found: [M+H]+, 234.1856. 
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(E)-11-(5-((E)-(3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-1H-
pyrrol-2-yl)undec-3-en-2-one (2.6).  Aldehyde 2.64 (627 mg, 2.16 mmol) was 
suspended in anhydrous methanol (21 mL) in a flame-dried, 100 mL round bottom flask 
and cooled to 16 
o
C in a tap water bath. Pyrrolylenone 2.5 (605 mg, 2.59 mmol) was 
suspended in anyhydrous methanol (26 mL) and added to the aldehyde solution, followed 
by 0. 87 M HCl in methanol (3.73 mL, 3.24 mmol). The reaction mixture immediately 
turned a deep red color, and LCMS showed that the reaction had reached completion in 
less than 15 minutes. Ammonium hydroxide (6 mL) was added and the reaction was 
stirred for 2 hours. 2 M HCl was added until the solution reached pH 7 and then the 
mixture was transferred to a separatory funnel, diluted with water, partitioned with 
dichloromethane, and extracted (3 x). The combined organic layers were then filtered 
through a phase separator to remove any excess water and condensed in vacuo to give a 
black residue. This residue was purified by reverse phase chromatography using 
acetonitrile and 0.1% TFA/water (gradient: 35:65 to 85:15) to afford 2.6 as a viscous, 
deep red oil (805 mg, 92%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.31-1.38 (m, 6H), 1.49 (quin, J = 6.8 Hz, 2H), 
1.72 (quin, J = 7.2 Hz, 2H), 2.23 (q, J = 7.2 Hz, 2H), 2.25 (s, 3H), 2.81 (t, J = 7.8 Hz, 
2H), 4.03 (s, 3H),  6.06 (d, J = 16 Hz, 1H), 6.13 (s, 1H), 6.22 (d, J = 3.6 Hz, 1H), 6.39 (t, 
J = 1.8 Hz, 1H), 6.79 (dt, J = 16 Hz, 7.0 Hz, 1H), 6.87 (s, 1H), 6.99 (s, 1H), 7.03 (s, 1H), 
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7.29 (s, 1H). 
13
C NMR (MeOD, 100 MHz)  (ppm): 25.2, 27.6, 28.58, 28.61, 28.63, 
28.7, 32.0, 58.6, 93.6, 111.8, 112.3, 113.8, 114.4, 116.6, 117.4, 121.7, 123.2, 126.3, 
126.5, 127.6, 130.6, 149.6, 150.4, 167.7, 200.0. IR (KBr) max 3250, 3127, 2929, 2856, 
1674, 1630, 1604, 1549, 1517, 1457, 1411, 1374, 1288, 1254, 1201, 1184, 1138, 1043, 
990, 960, 837, 800, 748, 720 cm
-1
. HRMS: C25H32N3O2, Calculated: [M+H]+, 406.2495, 
Found: [M+H]+, 406.2494. 
 
1-(1-(phenylsulfonyl)-1H-pyrrol-2-yl)oct-7-en-1-ol (2.92). Magnesium ribbon (0.88 g, 
36.3 mmol) was cut into small pieces, placed in a 250 mL, 2-neck schlenk flask fit with a 
reflux condenser, and flame-dried under vaccum. A small crystal of iodine was added and 
the flask was flushed with argon. The magnesium was suspended in anhydrous THF (112 
mL) and vigorously stirred. 7-bromo-1-heptene (5.00 g, 28.24 mmol) was added to the 
solution dropwise at room temperature. The resulting mixture was then heated to reflux 
(65 
o
C) for 2 hours. 1-(phenylsulfonyl)-2-pyrrolecarboxaldehyde (4.75 g, 20.17 mmol) 
was added to a 250 mL flame-dried, schlenk flask. Anhydrous THF (50 mL) was added 
and the mixture was stirred and cooled to 0 
o
C in an ice bath. After refluxing for 2 hours, 
the prepared Grignard reagent was cooled to room temperature and cannulated into the 
aldehyde solution over a 30 minute period. The resulting brown slurry was stirred at 0 
o
C 
for an additional 30 minutes and was then allowed to warm to room temperature. After 3 
hours, 2 M HCl was slowly added to the vigorously stirred solution until it reached pH 7. 
The mixture was then transferred to a separatory funnel, diluted with water, partitioned 
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with dichloromethane, and extracted (4 x). The combined organic layers were combined, 
dried over sodium sulfate, and condensed under reduced pressure to give a brown 
residue. This residue was purified by flash chromatography (3:1 Hex:EtOAc) and dried in 
vacuo to afford alcohol 2.92 as a viscous, light orange oil (4.15 g, 62%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.20-1.36 (m, 6H), 1.74-1.83 (m, 2H), 1.99 (dd, J 
= 14.2 Hz, 6.8 Hz, 2H) 2.73 (d, J = 4.2 Hz, 1H), 4.80 (m, 1H), 4.92 (dt, J = 10.2 Hz, 1.0 
Hz, 1H), 4.97 (ddd, J = 17.1 Hz, 3.4 Hz, 1.8 Hz, 1H), 5.72-5.83 (m, 1H), 6.26 (t, J = 3.4 
Hz, 1H), 6.27 (dd, J = 5.0 Hz, 3.4 Hz, 1H), 7.30 (dd, J = 4.0 Hz, 1.8 Hz, 1H), 7.50 (t, J = 
7.4 Hz, 2H), 7.60 (tt, J = 7.4 Hz, 1.0 Hz, 1H), 7.78 (d, J =7.4 Hz, 2H). 
13
C NMR (CDCl3, 
100 MHz)  (ppm): 25.8, 28.7, 33.6, 35.0, 65.1, 111.6, 112.3, 114.2, 123.4, 126.5, 129.4, 
133.9, 138.3, 138.9, 139.3.  
 
1-(1-(phenylsulfonyl)-1H-pyrrol-2-yl)oct-7-en-1-one (2.93). TPAP (0.42 g, 1.19 mmol) 
was added to a 100 mL flame-dried round bottom flask containing a stirred and cooled (0 
o
C) solution of alcohol 2.92 (3.95 g, 11.85 mmol), NMO (2.78 g, 23.69 mmol), and 4 A 
molecular sieves (6 g) in dichloromethane (60 mL). The reaction was warmed to room 
temperature and stirred for 4 hours. The reaction mixture was filtered to remove the 
molecular sieves, diluted with dichloromethane, and partitioned with water. The mixture 
was washed with 1 M HCl (1 x) and water (2 x). The organic layer was dried over 
sodium sulfate and condensed under reduced pressure to give a black oil. The oil was 
purified by flash chromatography (4:1 Hex:EtOAc) and dried in vacuo to afford 2.93 as a 
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clear, colorless oil (3.36 g, 86%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.24-1.31 (m, 2H), 1.35 (quin, J = 7.2 Hz, 2H), 
1.60 (quin, J = 7.4 Hz, 2H), 2.00 (q, J = 7.2 Hz, 2H), 2.66 (t, J = 7.6 Hz, 2H), 4.92 (dt, J 
= 10.0 Hz, 1.0 Hz, 1H), 4.97 (ddd, J = 7.1 Hz, 3.4 Hz, 1.6 Hz, 1H), 5.71-5.82 (m, 1H), 
6.34 (t, J = 3.5 Hz, 1H), 7.03 (dd, J = 3.8 Hz, 1.7 Hz, 1H), 7.52 (t, J = 7.8 Hz, 2H), 7.59 
(tt, J = 7.4 Hz, 1.2 Hz, 1H), 7.80 (dd, J = 3.2 Hz, 1.7 Hz, 1H), 7.99 (d, J =7.3 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 24.6, 28.50, 28.53, 33.4, 39.3, 110.3, 114.3, 
123.2, 128.0, 128.6, 130.0, 133.4, 133.5, 138.8, 139.0, 188.9. 
 
 2-(oct-7-enyl)-1H-pyrrole (2.87). Sodium borohydride (2.95 g, 44.50 mmol) was added 
to a flame-dried, 250 mL round bottom flask fit with a reflux condenser. The flask was 
purged with argon and anhydrous 2-propanol (135 mL) was added. Acylpyrrole 2.23 
(2.96 g, 8.90 mmol) was suspended in 40 mL of anhydrous 2-propanol, and this solution 
was added dropwise to the sodium borohydride solution at room temperature. After 
addition was complete, the mixture was heated to reflux (82 
o
C) for 24 hours. The 
reaction was cooled to room temperature and the excess sodium borohydride was 
quenched by slowly adding water to the stirring solution. When no more hydrogen gas 
evolved, the reaction was transferred to a separatory funnel, partitioned with 
dichloromethane, and extracted (3 x). The organic layers were combined, dried over 
sodium sulfate, and concentrated under reduced pressure to give a yellow oil. This oil 
was purified by flash chromatography (5:1 Hex:EtOAc) and concentrated in vacuo to 
afford 2.24 as a clear, yellow oil (1.48 g, 94%). 
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1
H NMR (CDCl3, 400 MHz)  (ppm): 1.33-1.42 (m, 6H), 1.64 (quin, J = 7.6 Hz, 2H), 
2.05 (q, J = 7.0 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H), 4.94 (dt, J = 10.2 Hz, 1.0 Hz, 1H), 5.00 
(ddd, J = 17.1 Hz, 3.5 Hz, 1.6 Hz, 1H), 5.76-5.87 (m, 1H), 5.92 (d, J = 0.6 Hz, 1H), 6.14 
(dd, J = 5.7 Hz, 2.8 Hz, 1H), 6.67 (dd, J = 4.1 Hz, 2.6 Hz, 1H), 7.90 (bs, 1H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 27.6, 28.7, 28.8, 29.1, 29.5, 33.7, 104.8, 108.2, 114.2, 115.9, 
132.7, 139.0. 
 
8-(1H-pyrrol-2-yl)octan-1-ol (2.94). To a 100 mL, flame-dried round bottom flask, was 
added alkylpyrrole 2.87 (600 mg, 3.39 mmol) and 34 mL of anhydrous THF. The 
solution was cooled to 0 
o
C in an ice bath and a solution of 9-BBN (17.6 mL, 0.5M in 
THF) was slowly added. After 1 hour, the ice bath was removed and the mixture stirred 
overnight. After 24 hours, the reaction mixture was cooled to 0
o
C, and 3 M NaOH (5.5 
mL) was added dropwise, followed by dropwise addition of hydrogen peroxide (5.5 mL). 
The reaction was slowly warmed to room temperature after 1 hour and stirred 24 hours. 
The reaction was transferred to a separatory funnel and slowly diluted with water. The 
solution was partitioned with dichloromethane, extracted (5 x), dried over sodium sulfate, 
and condensed under reduced pressure to give a brown oil. This oil was purified by flash 
chromatography (6:1 Hex:EtOAc) and condensed in vacuo  to afford 2.94 as a pale 
yellow oil (635 mg, 96%).    
1
HNMR (CDCl3, 400 MHz)  (ppm): 1.28-1.39 (m, 10H), 1.53-1.64 (m, 4H), 2.59 (t, J 
=7.6 Hz, 2H), 3.64 (t, J =6.6 Hz, 2H), 5.91 (d, J =0.6 Hz, 1H), 6.13 (dd, J = 5.7 Hz, 2.8 
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Hz, 1H), 6.66 (dd, J = 4.1 Hz, 2.6 Hz), 7.95 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  
(ppm): 25.6, 27.6, 29.18, 29.22, 29.3, 29.5, 32.7, 63.0, 104.8, 108.1, 115.9, 132.7. 
 
8-(1H-pyrrol-2-yl)octanal (2.86). TPAP (113 mg, 0.32 mmol) was added to a 50 mL 
flame-dried round bottom flask containing a stirred and cooled (0 
o
C) solution of alcohol 
2.94 (625 mg, 3.20 mmol), NMO (750 mg, 6.40 mmol), and 4 A molecular sieves (3 g) in 
dichloromethane (25 mL). The reaction was warmed to room temperature and stirred for 
6 hours. The reaction mixture was filtered through a silica/celite plug that was liberally 
rinsed with dichloromethane. The filtrate was condensed under reduced pressure to give 
2.86 as a pale yellow liquid (580 mg, 88%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.24-1.29 (m, 6H), 1.49-1.52 (m, 4H), 1.80-1.86 
(m, 2H), 2.39 (td, J = 3.2 Hz, 1.8 Hz, 2H), 2.56 (t, J = 8.0 Hz, 2H), 5.87 (s, 1H), 6.08 (dd, 
J = 5.6 Hz, 2.8 Hz, 1H), 6.63 (d, J = 1.6 Hz, 1H), 8.07 (bs, 1H), 9.73 (t, J = 2.0 Hz, 1H).  
 
(5S)-5-methyl-3-(phenylthio)dihydrofuran-2(3H)-one (2.134). To a solution of 
diisopropylamine (21. 8 g, 215.3 mmol) in 145 mL of THF at -78 
o
C was added 160 mL 
(258.3 mmol) of a 1.6M solution of n-BuLi in hexanes. After stirring at -78 
o
C for 15 
min, (phenylthio)acetic acid (14.5 g, 86.1 mmol) in 43 mL of THF was added and the 
mixture was stirred for an additional 15 min. To the resulting solution was added (S)-(-)-
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propylene oxide (5 g, 86.1 mmol) in one portion. The mixture was allowed to warm to 
room temperature over a period of 3 h and was then stirred for 16 h. The reaction was 
quenched with 2M NaOH (100 mL0 and was extracted with Et2O (2 x). The organic 
phase was discarded and the aqueous phase acidified to pH = 3 with 2M HCl. The acidic 
solution was extracted with Et2O (3 x) and the organic phase washed with brine (1 x) and 
dried with MgSO4. Evaporation of the solvent gave a clear oil (18.11 g, 93%) which was 
carried on to the next step without further purification. The oil was dissolved in benzene 
(80mL) and a catalytic amount of p-toluenesulfonic acid (0.76 g, 3.98 mmol) was added 
at room temperature. The solution was stirred overnight, the solvent evaporated, and the 
crude product chromatographed (100% CH2Cl2) to afford 2.134 (12.6 g, 76%) as a 2.8:1 
mixture of stereoisomers. 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.34 (d, J = 6.4 Hz, 2.2H), 1.38 (d, J = 6.0 Hz, 
0.8H), 1.85 (ddd, J = 13.2 Hz, 10.8 Hz, 10.4 Hz, 0.75H), 2.26 (dt, J = 12.4 Hz, 8.4Hz, 
0.25H), 2.38 (ddd, J = 13.6 Hz, 6.2 Hz, 4.0 Hz, 0.25H), 2.74 (ddd, J = 13.2 Hz, 9.0 Hz, 
6.4 Hz, 0.75H), 3.91 (dd, J = 8.4 Hz, 3.6 Hz, 0.25H), 3.97 (dd, J = 10.8 Hz, 8.8 Hz, 
0.75H), 4.48-4.60 (m, 1H), 7.31-7.36 (m, 3H), 7.53-7.57 (m, 2H). 
13
C NMR (CDCl3, 100 
MHz)  (ppm): 174.7, 174.5, 133.4, 133.2, 132.3, 131.9, 129.2, 129.1, 128.6, 128.4, 75.4, 
74.8, 46.5, 45.4, 37.5, 37.3, 21.0, 20.8. 
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(S)-5-methyldihydrofuran-2(3H)-one (2.129). A solution of 2.134 (6.0 g, 28.81 mmol) 
in 30 mL of THF was added to a suspension of Raney nickel (30 g) in 230 mL of THF. 
The flask was purged with Ar (1 x), with H2 (3 x), and then kept under an atmosphere of 
H2. The mixture was vigorously stirred for 16 h at room temperature. The nickel was 
filtered off, the filtrate evaporated, and the crude product chromatographed (1:4 
Et2O/CH2Cl2) to give 2.48 g (86%) of 2.129 as a clear, colorless liquid. 
[]23D = -33.0
o
 (c = 10.0, CH2Cl2) 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.40 (d, J = 6.4 
Hz, 3H), 1.77-1.87 (m, 1H), 2.31-2.39 (m, 1H), 2.52-2.56 (m, 2H), 4.59-4.67 (m, 1H).  
 
(3S,5S)-3-allyl-5-methyldihydrofuran-2(3H)-one (2.135). LiHMDS (1.0M in THF, 
7.83 mmol) was added dropwise to a 0.15 M solution of 2.129 (0.8 g, 7.99 mmol) in THF 
at -78 
o
C. The mixture was stirred for 30 min, and then allyl iodide (1.48 g, 8.79 mmol) 
was added dropwise. The solution was stirred for 1.5 h while maintaining the temperature 
at -78 
o
C. The reaction was quenched by addition of saturated NH4Cl and allowed to 
warm to room temperature. The mixture was extracted with Et2O (3 x), dried over 
MgSO4, the solvent evaporated, and the crude product chromatographed (4:1 
Hex:EtOAc) to give 895mg (80%) of 2.135 as a 6:1 mixture of diastereomers.  
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1
H NMR (CDCl3, 400 MHz)  (ppm): 1.36 (d, J = 6.4 Hz, 2.6H) , 1.41 (d, J = 6.4 Hz, 
0.4H), 1.49-1.57 (m, 0.14H), 1.98 (ddd, J = 17.6 Hz, 0.86H), 2.13 (dt, J = 13.2 Hz, 7.2 
Hz, 0.86H), 2.197-2.30 (m, 1H), 2.40-2.47 (m, 0.14H), 2.52-2.59 (m, 0.84H), 2.60-2.66 
(m, 0.14H), 2.71-2.78 (m, 0.84H), 4.44-4.53 (m, 0.14H), 4.64 (sex, J = 6.4 Hz, 0.86H), 
5.1-5.14 (m, 2H), 5.72-5.82 (m, 1H).  
 
(S)-tert-butyldimethylsilyl 2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl) pent-4-
enoate  (2.137). Allyl lactone 2.135 (2.02 g, 14.41 mmol) was suspended in THF (84 
mL) and cooled to 0 
o
C. A solution of LiOH (0.4 g, 16.7 mmol) in H2O (12 mL) is added 
dropwise. When addition was complete, the resulting solution was stirred for 10 h at 0
o
C. 
The mixture was diluted with water (20 mL) and Et2O (30 mL) and the layers separated. 
The organic layer was discarded and the aqueous layer was carefully acidified (pH = 3) 
with 1M HCl. The aqueous layer was then extracted with ethyl acetate (5 x), dried over 
MgSO4, the solvent evaporated, and the crude product (2.136, 2.24 g, 98%) carried on to 
the next step without further purification. Crude 2.136 (2.24 g, 14.15 mmol) was 
resuspended in CH2Cl2 (58 mL) and the solution was cooled to 0
o
C. Imidazole (4.33 g, 
63.68 mmol) was added in one portion, followed by tert-butyldimethylsilylchloride 
(6.40g, 42.45 mmol). The resulting cloudy, white solution was stirred 16 h at room 
temperature. The reaction was quenched by addition of H2O (20 mL), and the solution 
was extracted with CH2Cl2 (3 x). The organic layer was dried over MgSO4, the solvent 
evaporated, and the crude product chromatographed (6:1 Hex:EtOAc) to give 2.137 
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(5.45g, 100%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.04 (s, 6H), 0.26 (s, 6H), 0.88 (s, 9H), 0.94 (s, 
9H), 1.13 (d, J = 6.0 Hz, 2.6H), 1.15 (d, J = 6.0 Hz, 0.4H), 1.41-1.48 (m, 0.86H), 1.49-
1.54 (m, 0.14H), 1.70-1.77 (m, 0.86H), 1.80-1.87 (m, 0.14H), 2.24-2.37 (m, 2H), 2.52-
2.56 (m, 0.14H), 2.63-2.70 (m, 0.86H), 3.78-3.86 (m, 1H), 5.01-5.08 (m, 2H), 5.69-5.79 
(m, 1H). 
 
(S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)pent-4-enoic acid (2.138). Silylester 
2.137 (1.00 g, 2.59 mmol) was suspended in a solution of MeOH (30 mL), THF (10 mL), 
and H2O (10 mL). K2CO3 (1.07 g, 7.76 mmol), was added in one portion at room 
temperature, and the reaction stirred for 1 h.  The mixture was diluted with Et2O (30 mL), 
the layers were separated and the organic layer discarded. The aqueous layer was 
carefully acidified (pH = 3) and extracted with EtOAc (5 x). The organic layer was dried 
with MgSO4, the solvent evaporated, and the crude product dried in vacuo to give 2.138 
(655 mg, 93%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.88 (s, 9H), 1.14 (d, J = 6.4 Hz, 
2.6H), 1.16 (d, J = 6.4 Hz, 0.4H), 1.50-1.59 (m, 1H), 1.76-1.83 (m, 0.86H), 1.83-1.91 (m, 
0.14H), 2.22-2.31 (m, 1H), 2.36-2.44 (m, 1H), 2.54-2.58 (m, 0.14H), 2.67-2.74 (m, 
0.86H), 3.87-3.94 (m, 1H), 5.04-5.11 (m, 2H), 5.71-5.81 (m, 1H).  
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(S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)-N-methoxy-N-methylpent-4-
enamide (2.139). Acid 2.138 was suspsended in CH2Cl2 (18 mL) and DCC (380 mg, 
1.84 mmol) was added at room temperature, followed by DMAP (22.4 mg, 0.184 mmol). 
The solution was stirred for 15 min, then N,O-dimethylhydroxylamine HCl (179 mg, 1.84 
mmol) and triethylamine (186 mg, 1.84 mmol) were added, and the resulting mixture 
stirred for 4 h at room temperature. The mixture was diluted with water (10 mL) and 
extracted with CH2Cl2 (3 x). The organic layer was dried over MgSO4, the solvent 
removed, and the crude product purified (4:1 Hex:EtOAc) to give 2.139 (498 mg, 86%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.02 (s, 3H), 0.04 (s, 3H), 0.88 (s, 9H), 1.13 (d, J 
= 6.4 Hz, 3H), 1.49-1.55 (m, 2H), 1.83-1.90 (m, 1H), 2.15-2.25 (m, 1H), 2.32-2.39 (m, 
1H), 3.18 (s, 3H), 3.70 (s, 3H), 3.77-3.83 (m, 1H), 4.98-5.07 (m, 2H), 5.70-5.80 (m, 1H).  
 
(S)-S-pyridin-2-yl 2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)pent-4-enethioate 
(2.141). To a solution of acid 2.138 (376 mg, 1.38 mmol) in toluene (7 mL), was added 
PPh3 (435 mg, 1.66 mmol) and 2,2’-bisdipyridyldisulfide (365 mg, 1.66 mmol) at room 
temperature. The solution was stirred for 3 h and then diluted with water (5mL), extracted 
with EtOAc (3 x), and dried over MgSO4. The solvent was evaporated and the crude 
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product purified (2:1 Hex:EtOAc) to give 2.141 (465 mg, 92%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.07 (s, 3H), 0.11 (s, 3H), 0.90 (s, 9H), 1.15 (d, J 
= 6.0 Hz, 3H). 1.54-1.61 (m, 1H), 1.87-1.98 (m, 1H), 2.30-2.37 (m, 1H), 2.49-2.56 (m, 
1H), 2.98-3.05 (m, 1H), 3.87-3.94 (m, 1H), 5.07-5.14 (m, 2H), 5.73-5.84 (m, 1H), 7.25-
7.28 (m, 1H), 7.61 (d, J =8.0 Hz, 1H), 7.70-7.75 (td, J = 8.0 Hz, 2.0 Hz, 1H), 8.60-8.62 
(m, 1H).   
 
(S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)-1-(5-(hex-5-en-1-yl)-1H-pyrrol-2-
yl)pent-4-en-1-one (2.140). MeMgCl (3.0M in THF, 2.11 mmol) was added to a solution 
of alkylpyrrole 2.108 (336 mg, 2.25 mmol) in toluene (11mL) at -45 
o
C. The solution was 
stirred for 0.5 h and then cannulated into a solution of thioester 2.141 (350 mg, 0.957 
mmol) in toluene (9.5mL) at -78 
o
C. The resulting mixture was stirred at -78 
o
C for 0.5 h 
and was then allowed to slowly warm to room temperature and stirred for 1 h. The 
reaction was quenched with saturated NH4Cl, extracted with EtOAc (3 x), and dried over 
MgSO4. The solvent was evaporated and the crude product purified (9:1 Hex:EtOAc) to 
give 2.140 (328 mg, 85%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): -0.11 (s, 3H), -0.03 (s, 3H), 0.84 (s, 9H), 1.12 (d, J 
= 6.0 Hz, 3H), 1.44 (quin, J = 7.6 Hz, 2H), 1.52-1.58 (m, 1H), 1.66 (quin, J =7.6 Hz, 2H), 
1.89-1.99 (m, 1H), 2.08 (q, J = 7.2 Hz, 2H), 2.20-2.27 (m, 1H), 2.40-2.47 (m, 1H), 2.62 
(t, J = 7.6 Hz, 2H), 3.28-3.34 (m, 1H), 3.75-3.79 (m, 1H), 4.93-5.04 (m, 4H), 5.69-5.83 
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(m, 2H), 5.98 (t, J = 3.2 Hz, 1H), 6.83 (t, J = 2.8 Hz, 1H), 9.04 (bs, 1H).  
 
(S)-4-((tert-butyldimethylsilyl)oxy)-1-(5-ethyl-1H-pyrrol-2-yl)pentan-1-one (2.146). 
To a solution of acid 2.137 (363 mg, 1.56 mmol) in toluene (4 mL), was added PPh3 (449 
mg, 1.71 mmol) and 2,2’-bisdipyridyldisulfide (377 mg, 1.71 mmol) at room 
temperature. The solution was stirred for 3 h. MeMgCl (3.0M in THF, 1.79 mmol) was 
added to a solution of 2-ethylpyrrole (192 mg, 2.02 mmol) in toluene (7 mL) at -45
o
C. 
The solution was stirred for 0.5 h and then cannulated into the of solution acid 2.137 at -
78 
o
C. The resulting mixture was stirred at -78 
o
C for 0.5 h and was then allowed to 
slowly warm to room temperature and stirred for 1 h. The reaction was quenched with 
saturated NH4Cl, extracted with EtOAc (3 x), and dried over MgSO4. The solvent was 
evaporated and the crude product purified (9:1 Hex:EtOAc) to give 2.146 (425 mg, 88%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 3H), 0.06 (s, 3H), 0.90 (s, 9H), 1.16 (d, J 
= 6.0 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H), 1.72-1.89 (m, 2H), 2.66 (q, J =6.8 Hz, 2H), 2.68-
2.75 (m, 1H), 2.81-2.89 (m, 1H), 3.86-3.93 (m, 1H), 6.00 (t, J = 3.6 Hz, 1H), 6.82 (dd, J 
= 3.6 Hz, 2.4 Hz, 1H), 9.05 (bs, 1H). 
 
(S)-1-(1-benzyl-5-ethyl-1H-pyrrol-2-yl)-4-((tert-butyldimethylsilyl)oxy)pentan-1-one 
(2.147). NaH (60% in mineral oil, 2.05 mmol) was suspended in DMF (14 mL) and 
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acylpyrrole 2.146 (425 mg, 1.37 mmol) was added at room temperature. The mixture was 
stirred for 0.5 h, then benzylbromide (351 mg, 2.05 mmol) was added and the resulting 
solution stirred for 2 h. The reaction was quenched with H2O, extracted with CH2Cl2 (3 
x), washed with 5% LiCl, dried over MgSO4, and the solvent evaporated. The crude 
product was purified to give 2.147 (520 mg, 95%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.03 (s, 3H) 0.04 (s, 3H), 0.90 (s, 9H), 1.13 (d, J = 
6.0 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H), 1.65-1.83 (m, 2H), 2. 51 (q, J = 7.6 Hz, 2H), 2.72-
2.79 (m, 1H), 2.86-2.94 (m, 1H), 3.80-3.88 (m, 1H), 5.68 (d, J = 3.6 Hz, 2H), 6.05 (d, J = 
4.0 Hz, 1H), 7.05 (d, J = 4.0 Hz, 1H), 7.18-7.27 (m, 5H).  
 
4-((tert-butyldimethylsilyl)oxy)-1-(1-(phenylsulfonyl)-1H-pyrrol-2-yl)butan-1-ol 
(2.155). Diol 2.154 (400 mg, 1.35 mmol) was suspended in CH2Cl2 (14 mL) and cooled 
to 0 
o
C. Imidazole (138 mg, 2.03 mmol) was added followed by tert-
butyldimethylsilylchloride (224 mg, 1.49 mmol) and the resulting cloudy solution was 
stirred for 4 h at room temperature. The reaction was quenched with H2O and extracted 
with CH2Cl2 (3 x). The organic extract was dried over MgSO4, the solvent evaporated, 
and the crude product purified (3:1 Hex:EtOAc) to give  2.155 (494 mg, 89%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.04 (s, 3H), 0.05 (s, 3H), 0.89 (s, 9H), 1.52-1.66 
(m, 2H), 1.81-1.97 (m, 2H), 3.34 (bs, 1H), 3.62 (t, J = 6.0 Hz, 2H), 4.87-4.90 (m, 1H), 
6.26 (t, J =3.2 Hz, 1H), 6.30-6.32 (m, 1H), 7.29 (dd, J = 3.2 Hz, 2.0 Hz, 1H), 7.49 (t, J = 
7.6 Hz, 2H), 7.59 (t, J =7.6 Hz, 1H), 7.78 (d, J =8.0 Hz, 2H).  
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1-(phenylsulfonyl)-2-(tetrahydrofuran-2-yl)-1H-pyrrole (2.156).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.90 (m, 3H), 2.24-2.29 (m, 1H), 3.75-3.81 (m, 
1H), 3.87-3.92 (m, 1H), 5.25-5.28 (m, 1H), 6.22-6.25 (m, 2H), 7.26-7.28 (m, 1H), 7.47 (t, 
J = 7.2 Hz, 2H), 7.57 (t. J = 7.2 Hz, 1H), 7.81 (d, J = 7.6 Hz, 2H).  
 
(E)-2-(4-((tert-butyldimethylsilyl)oxy)but-1-en-1-yl)-1-(phenylsulfonyl)-1H-pyrrole 
(2.161). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.89 (s, 9H), 2.38 (q, J = 7.0 Hz, 2H), 
3.66 (t, J =6.4 Hz, 2H), 5.85-5.97 (m, 1H), 6.20-6.27 (m, 1H), 6.79 (d, J = 15.6 Hz, 1H), 
7.26-7.29 (m, 2H), 7.45-7.50 (m, 2H), 7.45-7.60 (m, 1H), 7.76-7.81 (m, 2H).  
 
(S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)pent-4-en-1-ol (2.180). Silylester 
2.137 (18.8 g, 48.72 mol) was suspended in CH2Cl2 (200 mL), cooled to -78 
o
C, and 
DIBAL-H (1.0M in CH2Cl2) was added dropwise. After addition was complete, the 
mixture was stirred for 1.5 h at  -78 
o
C. MeOH (5 mL) was added very slowly at -78 
o
C 
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until H2 evolution had ceased. The mixture was then warmed to room temperature and a 
saturated solution of Rochelle’s salt (150 mL) was added with vigorous stirring. After 2 
h, the solution had become clear, so was extracted with CH2Cl2 (5 x), dried over MgSO4, 
and the solvent was evaporated to give crude product which was purified (2:1 
Hex:EtOAc) to give 2.180 (11.65 g, 93%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.08 (s, 3H), 0.09 (s, 3H), 0.91 (s, 9H), 1.18 (d, J 
= 4.4 Hz, 3H), 1.43 (m, 1H), 1.60 (m, 1H), 1.88 (m, 1H), 1.96 (m, 1H), 2.08 (m, 1H), 
3.41 (dd, J = 11.0 Hz, 7.2 Hz), 3.55-3.60 (m, 1H), 4.04-4.09 (m, 1H), 5.00-5.07 (m, 2H), 
5.72-5.82 (m, 1H).  
 
(S)-2-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)pent-4-enal (2.174). Alcohol 2.180 
(2.00 g, 7.74 mmol) was suspended in DMSO (10 mL) and CH2Cl2 (30 mL) and cooled 
to 0 
o
C. Triethylamine (7.83 g, 77.37 mmol) was added, followed by sulfur trioxide 
pyridine complex (4.93 g, 30.95 mmol) and the mixture was stirred for 6 h at 0 
o
C. The 
solution was diluted with H2O (20 mL), extracted with CH2Cl2 (3 x), and washed with 5% 
LiCl solution (1 x). The organic layer was dried over MgSO4, the solvent was evaporated, 
and the crude product purified (4:1 Hex:EtOAc) to give 2.174 (1.60 g, 81%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 3H), 0.07 (s, 3H), 0.90 (s, 9H), 1.17 (d, J 
= 6.0 Hz, 3H), 1.55-1.62 (m, 1H), 1.81-1.87 (m, 1H), 2.19-2.24 (m, 1H), 2.44-2.49 (m, 
1H), 2.59-2.63 (m, 1H), 3.92-3.96 (m, 1H), 5.07-5.12 (m, 2H), 5.70-5.79 (m, 1H), 9.66 
(d, J = 2.4 Hz, 1H). 
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7-iodohept-1-en-6-yne (2.176). 6-bromo-1-hexene (15.0 g, 92.0 mmol) was added 
dropwise to a stirred slurry of lithium acetylide –ethylene-diamine complex (14.1 g, 138 
mmol) in DMSO (40 mL) cooled to 0
o
C. When addition was complete, the mixture was 
allowed to warm to room temperature and stirred for 2 h. The reaction was quenched with 
H2O, extracted with Et2O (3 x), washed with 5% LiCl (2 x), and dried over MgSO4. The 
solvent was carefully removed under reduced pressure and the crude product 2.181 
carried on to the next step without further purification. Crude 2.181 was suspended in 
THF (115 mL), cooled to -78 
o
C, and n-BuLi (2.5M in hexanes, 87.9 mmol) was added 
dropwise. After addition was complete, the mixture was stirred for 0.5 h. To the stirred, 
cooled solution was added iodine (23.0 g, 90.4 mmol) in THF (115 mL). After addition 
was complete, the resulting solution was allowed to slowly warm to room temperature 
and stir for 1 h. The reaction was quenched with a saturated NH4Cl solution and extracted 
with Et2O (3 x). The organic layer was dried over MgSO4
 
, the solvent evaporated, and 
the crude product purified (silica, hexanes) to yield 12.7 g of 2.176 (59% over 2 steps). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.48-1.54 (m, 4H), 2.06 (q, J = 7.2 Hz, 2H), 2.37 
(t, J = 6.8 Hz, 2H), 4.94-5.04 (m, 2H), 5.75-5.85 (m, 1H). 
 
Trimethyl(nona-8-en-1,3-diyn-1-yl)silane (2.182). Alkynyl iodide 2.176 (2.0 g, 8.54 
mmol) was suspended in piperidine (13 mL) and cooled to 0 
o
C. Ethynyltrimethylsilane 
(2.18 g, 22.2 mmol) was added, followed by cuprous iodide (146 mg, 0.769 mmol). The 
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solution was stirred at 0 
o
C for 2 h. The reaction was then quenched with saturated NH4Cl 
and extracted with CH2Cl2 (3 x). The extract was washed with brine (2 x), dried over 
MgSO4, and the solvent evaporated. The crude product was purified (silica, hexanes) to 
give 2.182 (1.55 g, 89%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.18 (s, 9H), 1.47-1.59 (m, 4H), 2.06 (q, J = 7.2 
Hz, 2H), 2.28 (t, J = 6.8 Hz, 2H), 4.94-5.03 (m, 2H), 5.73-5.84 (m, 1H).  
 
Nona-8-en-1,3-diyne (2.175). K2CO3 (10.0 g, 72.61 mmol) was added to a solution of 
TMS-diyne 2.182 (3.71 g, 18.15 mmol) in THF/MeOH (23 mL/23 mL) at 0 
o
C, and the 
mixture was stirred for 3 h. The reaction was diluted with H2O (25 mL) and extracted 
with Et2O (3 x). The organic extract was dried over MgSO4, the solvent evaporated, and 
the crude product purified (silica, hexanes) to give 2.175 (2.28 g, 95%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.46-1.60 (m, 4H), 1.96 (t, J =1.2 Hz, 1H), 2.04-
2.09 (m, 2H), 2.27 (td, J = 6.8 Hz, 1.2 Hz, 2H), 4.95-5.04 (m, 2H), 5.74-5.84 (m, 1H). 
 
(4S,5S)-4-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)pentadeca-1,14-dien-6,8-diyn-
5-ol (2.183). Diyne 2.175 1.33 g, 10.06 mmol) was suspended in THF (50 mL), cooled to 
0 
o
C, and treated with EtMgBr (1.0M in THF, 9.93 mmol). The mixture was stirred for 
0.5 h, and then a solution of aldehyde 2.174 (1.72 g, 6.71 mmol) was added dropwise at 0 
o
C. After 1 h, the reaction was quenched with saturated NH4Cl, extracted with Et2O (3 x), 
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and dried over MgSO4. The solvent was evaporated and the crude product purified (silica, 
19:1 Hex:EtOAc) to give 2.183 (2.22g, 85%) as a 1:1 mixture of diastereomers (cis, cis, 
trans : cis, cis, cis). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.07 (s, 3H), 0.12 (s, 1.5H), 0.15 (s, 1.5H), 0.89 (s, 
4.5H), 0.93 (s, 4.5H), 1.15 (d, J = 6.0 Hz, 1.5H), 1.18 (d, J = 6.8 Hz, 1.5H), 1.46-1.57 (m, 
6H), 1.89-1.99 (m, 1.5H), 2.06 (q, J = 7.2 Hz, 2H), 2.11-2.16 (m, 1H), 2.28 (t, J = 6.8 Hz, 
2H), 2.41-2.44 (m , 0.5H), 3.96-4.01 (m, 0.5H), 4.09-4.16 (m, 0.5H), 4.36-4.44 (m, 1H), 
4.94-5.12 (m, 4H), 5.67-5.80 (m, 2H).  
 
(((2S,4S)-4-allyl-5-bromopentadeca-14-en-6,8-diyn-2-yl)oxy)(tert-butyl)dimethyl 
silane (2.173). To a solution of alcohol 2.183 (1.50 g, 3.86 mmol) in CH2Cl2 (40 mL) 
was added CBr4 (2.56 g, 7.72 mmol) followed by pyridine (1.22 g, 15.44 mmol). PPh3 
(2.03 g, 7.72 mmol) was then added and the solution was stirred at room temperature for 
1 h. The reaction was quenched with sat. NaHCO3, extracted with CH2Cl2 (3 x), dried 
over MgSO4, condensed in vacuo, and purified by flash chromatography (19:1 Hex: 
EtOAc) to give 2.173 (1.43 g, 82%) as a clear, colorless, viscous oil. 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.07 (s, 6H), 0.89 (s, 9H), 1.15 (d, J = 6.0 Hz, 3H), 
1.48-1.57 (m, 5H), 1.58-1.66 (m, 1H), 1.72-1.81 (m, 1H) 2.05-2.09 (m, 2H), 2.15-2.27 
(m, 1H), 2.96-2.33 (m, 2H), 3.39-2.46 (m, 1H), 3.88-3.97 (m, 1H), 4.84 (dd, J =14.6 Hz, 
3.2 Hz, 1H), 4.95-5.15 (m, 4H), 5.66-5.84 (m, 2H). 
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(S)-4-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)pentadeca-1,14-dien-6,8-diyn-5-one 
(2.198). Propargyl alcohol 2.183 (1.13 g, 2.92 mmol) was suspended in CH2Cl2 (20 mL) 
with 4 angstrom molecular sieves (3.0 g) and cooled to 0
o
C. NMO (683 mg, 5.83 mmol) 
was added in one portion, followed by TPAP (103 mg, 0.292 mmol). The mixture was 
warmed to room temperature and stirred for 1.5 h. The reaction was filtered, the solvent 
evaporated, and the resulting black residue immediately purified (19:1 Hex:EtOAc) to 
give pure 2.198 (938 mg, 83%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.03 (s, 3H), 0.04 (s, 3H), 0.88 (s, 9H), 1.13 (d, J 
= 6.0 Hz, 3H), 1.48-1.64 (m, 5H), 1.86-1.93 (m, 1H), 2.08 (q, J = 7.2 Hz, 2H), 2.26 (quin, 
J =7.2 Hz, 1H), 2.38 (t, J = 7.2 Hz, 2H), 2.46 (quin, J = 7.2 Hz, 1H), 2.82-2.89 (m, 1H), 
3.78-3.85 (m, 1H), 4.96-5.10 (m, 4H), 5.64-5.74 (m, 1H), 5.74-5.84 (m, 1H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): -4.8, -4.3, 18.0, 19.5, 24.2, 25.9, 27.2, 27.9, 33.1, 36.3, 40.0, 
50.2, 64.1, 66.4, 72.0, 90.2, 114.9, 117.4, 134.7, 138.1, 190.0. 
 
(E)-ethyl 4-(diethoxyphosphoryl)but-2-enoate (2.199). Triethylphosphite (3.13 g, 
18.84 mmol) was added to ethyl-4-bromocrotonate (80%) (5.0 g, 20.72 mmol) at room 
temperature. The solution was stirred at 85 
o
C for 24 h, cooled to room temperature, and 
purified (1:2 Hex:EtOAc) to give 2.199 (5.40 g, 92%).  
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1
H NMR (CDCl3, 400 MHz)  (ppm): 1.27 (t, J = 6.8 Hz, 3H), 1.31 (t, J = 7.2 Hz, 6H), 
2.72 (ddd, J = 24.0 Hz, 8.0 Hz, 1.2 Hz, 2H), 4.06-4.14 (m, 4H), 4.17 (q, J = 7.2 Hz, 2H), 
5.94 (ddd, J = 14.8 Hz, 5.0 Hz, 1.2 Hz, 1H), 6.85 (sex, J = 8.0 Hz, 1H).  
 
(2E,4E)-ethyl-5-((4S,6S)-6-((tert-butyldimethylsilyl)oxy)hept-1-en-4-yl)pentadeca-
2,4,14-trien-6,8-diynoate (2.197). To a solution of phsophonate 2.199 (974 mg, 3.89 
mmol) in THF (40 mL) cooled to -78 
o
C, was added n-BuLi (2.5M in hexanes, 3.46 
mmol) dropwise. The mixture was stirred at -78 
o
C for 10 min then warmed to 0
o
C and 
stirred for 50 min. The mixture was re-cooled to -78 
o
C and a pre-cooled (-78
o
C) solution 
of ketone 2.198 (836 mg, 2.16 mmol) in THF (15 mL) was added dropwise. The mixture 
was allowed to warm to room temperature over 1 h and stir overnight. The reaction was 
quenched with saturated NH4Cl, extracted with EtOAc (3 x), washed with brine, and 
dried over MgSO4. The solvent was removed and the crude product purified (19:1 
Hex:EtOAc) to give 2.197 (324 mg, 31%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): -0.01 (s, 3H), 0.02 (s, 3H), 0.88 (s, 9H), 1.12 (d, J 
= 6.0 Hz, 3H), 1.31 (t, J =6.8 Hz, 3H), 1.51-1.63 (m, 6H), 2.10 (q, J =6.8 Hz, 2H),  2.13-
2.23 (m, 2H), 2.39 (t, J = 6.8 Hz, 2H), 2.47-2.54 (m, 1H), 3.66-3.72 (m, 1H), 4.22 (q, J = 
6.8 Hz, 2H), 4.96-5.05 (m, 4H), 5.64-5.71 (m, 1H), 5.76-5.86 (m, 1H), 5.91 (d, J  = 15.2 
Hz, 1H), 6.42 (d, J = 11.6 Hz, 1H), 7.69 (dd, J = 15.2 Hz, 11.6 Hz, 1H).  
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(2E,4E)-5-((4S,6S)-6-((tert-butyldimethylsilyl)oxy)hept-1-en-4-yl)pentadeca-2,4,14-
trien-6,8-diyn-1-ol (2.200). Ester 2.197 (225 mg, 0.466 mmol) was suspended in CH2Cl2 
(5 mL) and cooled to -78 
o
C. DIBAL-H (1.0M in CH2Cl2, 1.40 mmol) was added 
dropwise to the cooled solution. After addition was complete, the reaction was stirred at  
-78 
o
C for 1.5 h. MeOH (0.5 mL) was added very slowly until H2 evolution had ceased, 
then the mixture was warmed to room temperature and a saturated solution of Rochelle’s 
salt (15 mL) was added with vigorous stirring. After 15 min the solution had become 
clear, so the product was extracted with CH2Cl2 (3 x), dried over MgSO4, and the solvent 
evaporated to give crude product which was purified (8:1 Hex:EtOAc) to give 2.200 (162 
mg, 81%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.01 (s, 3H), 0.03 (s, 3H), 0.88 (s, 9H), 1.12 (d, J 
= 6.0 Hz, 3H), 1.50-1.61 (m, 6H), 2.08 (q, J = 6.8 Hz, 2H), 2.12-2.24 (m, 2H), 2.37 (t, J = 
6.8 Hz, 2H), 2.39-2.45 (m, 1H), 3.70-3.76 (m, 1H), 4.25 (d, J = 5.2 Hz, 2H), 4.96-5.05 
(m, 4H), 5.63-5.74 (m, 1H), 5.76-5.86 (m, 1H) 5.93 (dt, J = 15.2 Hz, 5.6 Hz, 1H), 6.35 
(d, J = 11.2 Hz, 1H), 6.73 (dd, J = 15.2 Hz, 11.2 Hz, 1H).  
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(S)-5-((S)-2-((tert-butyldimethylsilyl)oxy)propyl)-2-(cyclohex-1-en-1-ylethynyl) 
cyclopent-2-enone (2.207). Ketone 2.198 (100 mg, 0.259 mmol) was suspended in 
CH2Cl2 (86 mL) and Grubbs second-generation catalyst (22 mg, 0.026 mmol) was added 
in one portion. The mixture was heated to reflux and stirred for 16 h. The solvent was 
evaporated and the crude product purified (15:1: Hex:EtOAc) to give 2.207 (63 mg, 
68%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.06 (s, 3H), 0.07 (s, 3H), 0.88 (s, 9H), 1.14 (d, J 
= 6.0 Hz, 3H), 1.42 (dt, J =14.0 Hz, 8.0 Hz, 1H), 1.55-1.67 (m, 5H), 1.91 (dt, J = 13.6 
Hz, 4.8Hz, 1H), 2.10-2.14 (m, 2H), 2.16-2.19 (m, 2H) 2.45-2.49 (m, 1H), 2.88-2.97 (m, 
1H), 4.01-4.15 (m, 1H), 6.21-6.23 (m, 1H), 7.64 (t, J = 2.8 Hz, 1H). 
 
3-(benzyloxy)propan-1-ol (2.219). Sodium hydride (5.52 g, 137.98 mmol, 60% 
dispersion in mineral oil) was suspended in anhydrous THF (175 mL) in a flame-dried 
500 mL round bottom flask. The solution was cooled to 0 
o
C and 1,3-propanediol (10.0 g, 
131.41 mmol) was added dropwise. The resulting mixture was stirred for 30 min at 0 
o
C 
at which time benzyl bromide (23.6 g, 137.98 mmol) was added dropwise followed by 
addition of tert-butyl ammonium iodide (4.85 g, 13.14 mmol). The mixture was warmed 
to room temperature and stirred for 4 h. The reaction was quenched by dropwise addition 
of saturated NH4Cl solution. The resulting mixture was extracted with ethyl acetate (3 x), 
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dried over Na2SO4, and concentrated under reduced pressure. The resulting oil was 
purified by flash chromatography (1:1 Hex:EtOAc) to give alcohol 2.219 as a clear, 
colorless oil (12.25 g, 56%). 
 1
H NMR (CDCl3, 400 MHz)  (ppm): 1.87 (quin, J = 5.8 Hz, 2H), 3.67 (t, J = 5.8 Hz, 
2H), 3.79 (t, J = 5.8 Hz, 2H), 4.53 (s, 2H), 7.27-7.38 (m, 5H). 
 
3-(benzyloxy)propanal (2.220). Alcohol 2.219 (6.0 g, 36.10 mmol) was suspended in 
anhydrous dichloromethane and dimethyl sulfoxide (3:1 v/v, 144 mL). The solution was 
cooled to 0 
o
C and triethylamine (50.2 mL, 360.97 mmol), was added followed by sulfur 
trioxide pyridine complex (23.0 g, 144. 39 mmol) in 4 portions. The resulting mixture 
was warmed to room temperature and stirred for 4 h. The reaction was quenched with 
water and extracted with dichloromethane (3x), dried over sodium Na2SO4, and 
condensed under reduced pressure. The crude oil was purified by flash chromatography 
(2:1 Hex:EtOAc) to provide aldehyde 2.220 as a clear, colorless oil (4.21 g, 72 %).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 2.70 (td, J = 6.1, 1.8 Hz, 2H), 3.82 (t, J = 6.1 Hz, 
2H), 4.54 (s, 2H), 7.27-7.38 (m, 5H), 9.80 (t, J = 1.8 Hz, 1H). 
 
5-(benzyloxy)pent-1-en-3-one (2.216). Aldehyde 2.220 (3.50 g, 21.32 mmol) was 
suspended in anhydrous THF (85 mL) in a 250 mL flame-dried round bottom flask and 
the solution was cooled to -78 
o
C. Vinylmagnesium bromide (1.0 M in THF, 25.58 mmol, 
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25.6 mL) was added dropwise and the resulting solution was stirred for 1 h at -78 
o
C. The 
reaction was quenched by addition of saturated NH4Cl solution and warmed to room 
temperature. The mixture was extracted with dichloromethane (2x), dried over anhydrous 
Na2SO4, and condensed in vacuo to provide a pale yellow residue. This residue was 
carried on without further purification and suspended in anhydrous dichloromethane (49 
mL) with 4 angstrom molecular sieves (7.0 g) and cooled to 0 
o
C. N-methylmorpholine-
N-oxide (3.46 g, 29.54 mmol) was added, followed by tetrapropylammonium 
perruthenate (260 mg, 0.74 mmol). The reaction was warmed to room temperature and 
stirred until complete conversion was evident by TLC. The solution was filtered through 
celite and condensed in vacuo to give a dark green residue. This residue was purified by 
flash chromatography (4:1 Hex:EtOAc) to provide enone 2.216 as a clear colorless oil 
(3.12 g, 77%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 2.91 (t, J = 6.5 Hz, 2H), 3.80 (t, J = 6.4 Hz, 2H), 
4.53 (s, 2H), 5.87 (dd, J = 10.5, 1.0 Hz, 1H), 6.24 (dd, J = 17.6, 1.0 Hz, 1H), 6.38 (dd, J = 
17.6, 10.5 Hz, 1H),  7.26-7.36 (m, 5H). 
 
1-(((8-iodooctyl)oxy)methyl)-4-methoxybenzene (2.221). Sodium hydride (1.44 g, 35.9 
mmol, 60% dispersion in mineral oil) was suspended in anhydrous THF/DMF (9:1 v/v, 
(120 mL) in a flame-dried 250 mL round bottom flask. The solution was cooled to 0 
o
C 
and 1,8-octanediol (5.0 g, 34.2 mmol) was added dropwise. The resulting mixture was 
stirred for 30 min at 0 
o
C at which time p-methoxybenzyl chloride (5.62 g, 4.87 mmol) 
was added dropwise followed by addition of tert-butyl ammonium iodide (1.26 g, 3.42 
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mmol). The mixture was warmed to room temperature and then heated to 65 
o
C and 
stirred for 18 h. The reaction was quenched by dropwise addition of saturated NH4Cl 
solution. The resulting mixture was extracted with ethyl acetate (3 x), dried over Na2SO4, 
and concentrated under reduced pressure. The resulting oil was purified by flash 
chromatography (1:1 Hex:EtOAc) to give mono-PMB alcohol as a clear, colorless oil 
(4.81 g, 53%). This alcohol was then carried on to the subsequent reaction. The alcohol 
(2.0 g, 7.51 mmol) was suspended in anhydrous THF (38 mL) and triphenylphosphine 
(2.96 g, 11.3 mmol), pyridine (1.84 g, 23.3 mmol), and iodine (2.67 g, 10.5 mmol) were 
added successively and the mixture was stirred at room temperature for 2 h. The reaction 
was quenched by addition of Na2S2O3, and extracted with Et2O (3x). The organic layers 
were combined, dried over anhydrous Na2SO3, and condensed in vacuo to give an orange 
residue. This residue was purified by flash chromatography (5:1 Hex:EtOAc) to give 
iodide 2.221 a clear, colorless oil (2.16 g, 77%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.28-1.40 (m, 8H), 1.59 (quin, J = 7.2 Hz, 2H), 
1.81 (quin, J = 7.2 Hz, 2H), 3.18 (t, J = 7.1 Hz, 2H), 3.43 (t, J = 6.6 Hz, 2H), 3.80 (s, 
3H), 4.43 (s, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H). 
13
C NMR (CDCl3, 
100 MHz)  (ppm): 7.41, 26.22, 28.59, 29.34, 29.83, 30.54, 33.63, 55.39, 70.22, 72.63, 
113.85, 129.32, 130.88, 159.20.  
 
 
244 
 
 
(3S,5S)-3-(8-((4-methoxybenzyl)oxy)octyl)-5-methyldihydrofuran-2(3H)-one (2.222). 
To a stirring solution of LDA (2.0 M in THF/heptane, 1.05 mL, 2.10 mmol) in anhydrous 
THF (2.0 mL) at 0 
o
C, was added DMPU (960 mg, 7.49 mmol)  dropwise and the 
resulting mixture was stirred for 15 min and then cooled to -78 
o
C. Lactone 2.129 (200 
mg, 2.00 mmol) in THF (5.0 mL) was added dropwise over a 0.5 h period. The reaction 
was stirred for anadditional 0.5 h at -78 
o
C. Iodide 2.221 (902 mg, 2.40 mmol) in THF 
(2.0 mL) was added dropwise and the reaction mixture was stirred at -78 
o
C for 18 h. The 
reaction was quenched by addition of saturated NH4Cl and warmed to room temperature. 
The mixture was extracted with EtOAc (3x), dried over Na2SO4, concentrated under 
reduced pressure, and purified by flash chromatography (5:1 Hex/EtOAc) to give alkyl 
lactone 2.222 as a clear, colorless oil (272 mg, 39 %, 7:1 dr).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.24-1.38 (m, 11H), 1.37 (d, J = 6.5 Hz, 3H), 1.55-
1.62 (m, 3H), 1.78-1.86 (m, 1H), 1.97-2.11 (m, 2H), 2.56-2.65 (m, 1H), 3.43 (t, J = 6.6 
Hz, 2H), 3.80 (s, 3H), 4.43 (s, 2H), 4.65 (sex, J = 6.4 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 
7.26 (d, J = 8.6 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 21.43, 26.34, 27.53, 
29.46, 29.54, 29.92, 30.87, 35.26, 39.51, 55.46, 70.36, 72.69, 75.11, 113.92, 129.40, 
1130.97, 159.27, 179.62. 
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(S)-2-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-10-((4-methoxybenzyl)oxy)decan-1-
ol (2.223). Alkyl lactone 2.222 ( 220 mg, 0.63 mmol) was suspended in THF (10.5 mL) 
and cooled to 0
 o
C. Lithium hydroxide (38 mg, 1.59 mmol) was dissolved in H2O (1.5 
mL) and this solution was added dropwise to the THF solution with vigorous stirring. 
The resulting mixture was stirred for 16 h at 0 
o
C and was then carefully acidified to pH = 
4. The acidified solution was extracted with EtOAc (4x), dried over Na2SO4, and 
condensed in vacuo. The resulting pale yellow oil was carried on without further 
purification. The crude acid  was suspended in dichloromethane (12 mL) Imidazole ( 160 
mg, 2.35 mmol) was added, followed by TBDPSCl (518 mg, 1.88 mmol) at room 
temperature. The resulting mixture was stirred at rt for 4 h at which time the reaction was 
quenched by addition of water and extracted with dichloromethane (3x), dried over 
Na2SO4, and condensed in vacuo to give the TBDPS ether/ester as a pale yellow oil that 
was carried on without further purification. The TBDPS ether/ester (530 mg, 0.63 mmol) 
was suspended in anhydrous dichloromethane (9 mL) and the resulting solution was 
cooled to -78 
o
C. DIBAL-H (1.0 M in CH2Cl2, 2.5 mL, 2.5 mmol) was added dropwise 
and the solution stirred for 2 h at -78 
o
C. The reaction was quenched by addition of a 
saturated aqueous solution of sodium potassium tartrate, warmed to room temperature, 
and stirred for 0.5 h. The mixture was extracted with dichloromethane (3x), dried over 
Na2SO4, condensed in vacuo and purified by flash chromatography (4:1 Hex/EtOAc) to 
provide alcohol 2.223 as a clear, colorless oil (186 mg, 50% over 3 steps).  
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1
H NMR (CDCl3, 400 MHz)  (ppm): 1.06 (s, 9H), 1.08 (d, J = 6.5 Hz, 3H), 1.17-1.28 
(m, 10H), 1.30-1.38 (m, 2H), 1.40-1.53 (m, 2H), 1.59 (quin, J = 7.2 Hz, 2H), 1.63-1.70 
(m, 1H), 3.33-3.48 (m, 2H), 3.43 (t, J = 6.6 Hz, 2H), 3.80 (s, 3H), 4.00 (sex, J = 5.6 Hz, 
1H), 4.43 (s, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.36-7.43 (m, 6H), 
7.67-7.70 (m, 4H).  
 
(S)-2-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-10-((4-methoxybenzyl)oxy)decanal 
(2.224). Alcohol 2.223 (150 mg, 0.254 mmol) was suspended in DCM/DMSO (3:1 v/v, 
5.0 mL) and cooled to 0 
o
C. Triethylamine (257 mg, 2.54 mmol) was added, followed by 
sulfur trioxide pyridine complex (162 mg, 1.02 mmol). The resulting mixture was 
warmed to room temperature and stirred for 4 h. The reaction was auenched by addition 
of water, extracted with dichloromethane (3x), dried over Na2SO4, and condensed in 
vacuo to give a yellow oil. This oil was purified by flash chromatography (5:1 
Hex/EtOAc) to provide aldehyde 2.224 as a clear, colorless oil (135 mg, 90%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.04 (s, 9H), 1.06 (d, J = 4.0 Hz, 3H), 1.19-1.28 
(m, 10H), 1.28-1.35 (m, 2H), 1.47-1.55 (m, 2H), 1.55-1.60 (m, 2H), 1.79-1.90 (m, 1H) 
2.39-2.46 (m 1H), 3.33-3.48 (m, 2H), 3.43 (t, J = 6.6 Hz, 2H), 3.80 (s, 3H), 3.92 (sex, J = 
6.0 Hz, 1H), 4.43 (s, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.35-7.44 
(m, 6H), 7.64-7.69 (m, 4H). 9.44 (d, J = 3.0 Hz, 1H).  
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tert-butyl(((2S,4S)-12-((4-methoxybenzyl)oxy)-4-vinyldodecan-2-yl)oxy)diphenyl 
silane (2.217). Methyltriphenylphosphonium bromide (100 mg, 0.28 mmol) was 
suspended in anhydrous THF (3.0 mL) and the solution cooled to 0 
o
C. KHMDS (0.5 M 
in toluene, 0.52 mL, 0.26 mmol) was added dropwise and the resulting mixture was 
stirred at 0 
O
C for 1h. Aldehyde 2.224 (27 mg, 0.22 mmol) was suspended in anhydrous 
THF (2.2 mL) and added dropwise to the solution of Wittig salt, and then the mixture was 
slowly warmed to room temperature and stirred 2h. The reaction was quenched by 
addition of saturated aqueous NH4Cl, extracted with EtOAc (3x), dried over Na2SO4, and 
condensed in vacuo to give a yellow oil. This oil was purified by flash chromatography 
(6:1 Hex/EtOAc) to give alkene 2.217 as a clear, colorless oil (107 mg, 85%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.02 (d, J = 6.2 Hz, 3H), 1.04 (s, 9H), 1.13-1.34 
(m, 13H), 1.55-1.62 (m, 4H), 2.12-2.19 (m, 1H), 3.43 (t, J = 6.7 Hz, 2H), 3.80 (s, 3H), 
3.82-3.87 (m, 1H), 4.43 (s, 2H), 4.70-4.77 (m, 1H), 4.83 (dd, J  = 10.4, 2.0 Hz, 1H), 5.35-
5.44 (m, 1H), 6.88 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 7.34-7.43 (m, 6H), 7.65-
7.70 (m, 4H).  
 
Methyl 3-(benzyloxy)propanoate (2.228). K2Cr2O7 (2.9 g, 9.9 mmol) was dissolved in 
H2O (5.0 mL). Conc. H2SO4 (2.0 mL) was added dropwise with vigorous stirring. The 
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reaction was cooled to 0 
o
C (15 min) and then a solution of alcohol 2.219 (1.5 g, 9.0 
mmol) in acetone (18.0 mL) was added dropwise to the prepared Jone’s reagent. The 
mixture was then stirred for 2 h. The reaction mixture was diluted with EtOAc and water 
and then extracted with EtOAc (3x). The combined organic layers were dried over 
Na2SO4, condensed in vacuo and carried on to the next step without further purification. 
The crude acid was suspended in methanol (100 mL) and conc. HCl (0.2 mL) was added. 
The reaction was heated to 60 
o
C and stirred for 12 h. The mixture was allowed to cool to 
room temperature and saturated aqueous NaHCO3 was slowly added. The solution was 
diluted with ethyl acetate and water, extracted with EtOAc (3x), dried over Na2SO4, and 
condensed in vacuo to give a yellow-green residue. This residue was purified by flash 
chromatography (2:1 Hex/EtOAc) to provide ester 2.228 as a clear, colorless oil (980 mg, 
54% over 2 steps).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 2.63 (t, J = 6.4 Hz, 2H), 3.70 (s, 3H), 3.75 (t, J = 
6.4 Hz, 2H), 4.54 (s, 2H), 7.27-7.37 (m, 5H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 
35.10, 51.83, 65.69, 73.24, 127.81, 128.52, 138.18, 172.18. 
 
Dimethyl (4-(benzyloxy)-2-oxobutyl)phosphonate (2.225). To a solution of dimethyl 
methylphosphonate (2.40 g, 19.4 mmol) in anhydrous THF (16.0 mL) was added n-BuLi 
(2.5 M in hexanes, 7.65 mL, 19.1 mmol) dropwise at -78 
o
C. The white suspension was 
stirred 1 h at -78 
o
C at which time ester 2.228 (940 mg, 4.84 mmol) in THF (8.0 mL) was 
added dropwise. The reaction was stirred for an additional 1 h at -78 
o
C and was then 
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quenched with saturated NH4Cl and warmed to room temperature. The mixture was 
extracted with ethyl acetate (3x), dried over Na2SO4, condensed in vacuo, and purified by 
flash chromatography (1:9 Hex/EtOAc) to provide phosphonate 2.225 as a clear, 
colorless oil (970 mg, 70%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 2.90 (t, J = 6.2 Hz, 2H), 3.12 (s, 1H), 3.17 (s, 1H), 
3.75 (t, J = 6.2 Hz, 2H), 3.75 (s, 3H), 3.78 (s, 3H), 4.50 (s, 2H), 7.27-7.36 (m, 5H). 
 
(S,E)-1-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-14-((4-methoxy 
benzyl)oxy)tetradec-4-en-3-one (2.215). Phosphonate 2.225 (512 mg, 1.79 mmol) was 
suspended in THF (3.3 mL). Ba(OH)2 (262 mg, 1.53 mmol) was added at room 
temperature, and the resulting mixture was stirred for 1 h. Aldehyde 2.224 (902 mg, 1.53 
mmol) in THF/H2O (40:1 v/v, 5.1 mL) was added dropwsie at room temperature and the 
reaction was stirred 4 h. The reaction mixture was diluted with ethyl acetate and water 
and neutralized by addition of 1.0 M HCl. The mixture was extracted with EtOAc (3x), 
dried over Na2SO4, and condensed in vacuo. The crude product was purified by flash 
chromatography (4:1 Hex:EtOAc) to provide enone 2.215 as a clear, colorless oil (529 
mg, 46%, 58% brsm). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.03 (s, 12H), 1.12-1.37 (m, 12H), 1.55-1.70 (m, 
4H), 2.31-2.37 (m, 1H), 2.72 (td, J = 6.6, 2.4 Hz, 2H), 3.43 (t, J = 6.6 Hz, 2H), 3.72-3.76 
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(m, 3H), 3.80 (s, 3H), 4.43 (s, 2H), 4.50 (s, 2H), 5.79 (d, J = 15.9 Hz, 1H), 6.44 (dd, J = 
15.9, 9.1 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.30-7.40 (m, 11H), 
7.63-7.67 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.38, 24.47, 27.16, 27.20, 
29.59, 29.62, 29.64, 29.90, 35.01, 39.24, 40.32, 44.94, 55.39, 65.63, 67.98, 70.34, 72.64, 
73.35, 113.88, 127.54, 127.61, 127.71, 127.76, 127.82, 128.51, 129.36, 129.63, 129.76, 
130.24, 130.92, 134.21, 134.78, 136.03, 136.06, 138.35, 152.29, 159.23, 198.43. 
 
tert-butyl(hept-6-en-1-yloxy)dimethylsilane (2.227). 6-hepten-1-ol (10 g, 87.6 mmol), 
was suspended in anhydrous dichloromethane (175 mL) in a flame-dried 250 mL round 
bottom flask. Imidazole (8.94 g, 131.4 mmol) was added followed by TBSCl (15.84 g, 
105.1 mmol). The reaction was stirred at room temperature for 4 h and was quenched by 
the addition of water, extracted with dichloromethane (3x), dried over Na2SO4, and 
condensed in vacuo to give a clear oil. This oil was purified by flash chromatography (6:1 
Hex:EtOAc) to provide TBS ether 2.227 as a clear, colorless oil (19.24 g, 96 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.89 (s, 9H), 1.29-1.44 (m, 4H), 1.49-
1.56 (m, 2H), 2.05 (q, J = 7.2 Hz, 2H), 3.60 (t, J = 6.6 Hz, 2H),  4.93 (dm, J = 10.2 Hz, 
1H), 4.99 (ddd, J  = 17.2, 3.6, 1.7 Hz, 1H), 5.81 (ddt,  J = 17.2, 10.2, 6.6 Hz, 1H).  
 
(E)-ethyl 8-((tert-butyldimethylsilyl)oxy)oct-2-enoate (2.228). TBS ether 2.227 (19.24 
g, 82.82 mmol) was suspended in anhydrous CH2Cl2 (207 mL) in a flame-dried 500 mL 
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round bottom flask fit with a reflux condenser under an atmosphere of argon. Ethyl 
acrylate was added (33.2 g, 331.3 mmol), followed by Grubbs’ second generation catalyst 
(703 mg, 0.83 mmol), and the resulting dark red solution was heated to 40 
o
C for 12 
hours. At this time, the dark green solution was exposed to air, condensed under reduced 
pressure, purified by flash chromatography (5:1 Hex/EtOAc), and concentrated in vacuo 
to give ester 2.228 as a clear, colorless oil (24.2 g, 97%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.04 (s, 6H), 0.89 (s, 9H), 1.28 (t,  J = 7.0 Hz, 3H), 
1.32-1.39 (m, 2H), 1.44-1.54 (m, 4H),  2.20 (q, J = 7.0 Hz, 2H), 3.60 (t, J = 6.6 Hz, 2H),  
4.18 (q, J = 7.2 Hz, 2H), 5.81 (d, J  = 15.6 Hz, 1H), 5.81 (dt,  J = 15.6, 7.0 Hz, 1H). 
13
C 
NMR (CDCl3, 100 MHz)  (ppm): -5.10, 14.46, 25.49, 26.15, 28.00, 32.30, 32.67, 60.35, 
62.99, 121.64, 149.23, 166.93.  
 
(E)-8-((tert-butyldimethylsilyl)oxy)oct-2-en-1-ol (2.229). Ester 2.228 (24.2 g, 80.70 
mmol) was suspended in anhydrous dichloromethane (161 mL) in a flame dried 1 L 
round bottom flask and cooled to -78 
o
C. DIBAL-H (1.0 M in CH2Cl2, 201.7 mmol, 
201.7 mL) was added dropwise. The resulting mixture was stirred for 2 h until complete 
conversion was evident by TLC. The reaction was quenched by addition of sodium 
potassium tartrate, warmed to room temperature, and stirred for 2 h until the organic layer 
was clear. The mixture was extracted with dichloromethane (3 x), dried over Na2SO4, and 
condensed in vacuo to give a clear oil. This oil was purified by flash chromatography (4:1 
Hex:EtOAc) to provide allylic alcohol 2.229 as a clear, colorless oil (18.9 g, 91%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.04 (s, 6H), 0.89 (s, 9H), 1.31-1.43 (m, 4H), 1.51 
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(quin,  J  = 7.0 Hz, 2H), 2.05 (q,  J  = 7.0 Hz, 2H), 3.60 (t,  J = 6.6 Hz, 2H),  4.08 (d, J = 
5.4 Hz, 2H), 5.60-5.73 (m, 2H).
13
C NMR (CDCl3, 100 MHz)  (ppm): -5.10, 18.53, 
25.51, 26.14, 29.06, 32.34, 32.83, 63.36, 63.91, 129.15, 133.43. 
 
(E)-tert-butyl((8-iodooct-6-en-1-yl)oxy)dimethylsilane (2.230). Imidazole (2.81 g, 41.3 
mmol) was suspended in dichloromethane (61 mL). Triphenylphosphine (3.97 g, 15.2 
mmol) was added followed by iodine (3.85 g, 15.2 mmol) and the resulting mixture was 
stirred at room temperature for 0.5 h.  Allylic alcohol 2.229 (3.56 g, 13.8 mmol) in 
dichloromethane (55 mL) was slowly added, and the resulting reaction stirred for 1.5 h at 
which time TLC indicated complete conversion. The reaction was quenched by addition 
of saturated NaHCO3 extracted with DCM (3x), dried over Na2SO4, and condensed in 
vacuo to give a yellow oil. This oil was purified by flash chromatography (9:1 Hex: 
EtOAc) to give iodide 2.230 as a clear, colorless oil (3.84 g, 76%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.04 (s, 6H), 0.89 (s, 9H), 1.29-1.42 (m, 4H), 1.51 
(quin,  J  = 7.2 Hz, 2H), 2.03 (q,  J  = 5.2 Hz, 2H), 3.59 (t,  J = 6.4 Hz, 2H), 3.87 (d, J = 
6.4 Hz, 2H), 5.70-5.73 (m, 2H). 
 
(3S,5S)-3-((E)-8-((tert-butyldimethylsilyl)oxy)oct-2-en-1-yl)-5-methyldihydrofuran-
2(3H)-one (2.231). Lactone 2.129 (949 mg, 9.48 mmol) was suspended in anhydrous 
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THF (63.0 mL) in a flame-dried 250 mL round bottom flask and cooled to -78 
o
C. 
LiHMDS (1.0 M in THF, 9.38 mL, 9.38 mmol) was added dropwise over a 0.5 h period. 
The reaction was stirred for an additional 1 h at -78 
o
C. Iodide 2.230 (3.84 g, 10.42 
mmol) in THF (17.0 mL) was added dropwise and the reaction mixture was stirred at -78 
o
C for 2 h. The reaction was quenched by addition of saturated NH4Cl and warmed to 
room temperature. The mixture was extracted with EtOAc (3x), dried over Na2SO4, 
concentrated under reduced pressure, and purified by flash chromatography (5:1 
Hex/EtOAc) to give allyl lactone 2.231 as a clear, colorless oil (2.62 g, 82 %, 8:1 dr).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.04 (s, 6H), 0.89 (s, 9H), 1.31-1.43 (m, 4H), 1.37 
(d,  J  = 6.3 Hz, 3H), 1.51 (quin,  J  = 7.1 Hz, 2H), 1.92-2.03 (m, 3H), 2.08-2.16 (m, 1H), 
2.18-2.25 (m, 1H), 2.45-2.51 (m, 1H), 2.64-2.74 (m, 1H), 3.60 (t,  J = 6.6 Hz, 2H),  4.63 
(sex, J = 6.2 Hz, 1H), 5.44 (dm,  J = 67.9 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz)  
(ppm): -5.10, 18.53, 21.50, 25.50, 26.13, 29.32, 32.65, 32.84, 33.75, 33.35, 39.70, 63.35, 
75.23, 125.83, 134.29, 179.08. 
 
(S,E)-10-((tert-butyldimethylsilyl)oxy)-2-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl) 
dec-4-enal (2.234). Allyl lactone 2.231 (2.52 g, 7.40 mmol) was suspended in THF (64.8 
mL) and cooled to 0
 o
C. Lithium hydroxide (354 mg, 14.8 mmol) was dissolved in H2O 
(9.3 mL) and this solution was added dropwise to the THF solution at 0 
o
C with vigorous 
stirring. The resulting mixture was stirred for 24 h at 0 
o
C and was then carefully 
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acidified to pH = 4. The acidified solution was extracted with EtOAc (4x), dried over 
Na2SO4, and condensed in vacuo. The resulting pale yellow oil was carried on without 
further purification. The crude acid was suspended in dichloromethane (87 mL) 
Imidazole (2.02 g, 29.6 mmol) was added, followed by TBDPSCl (6.10 g, 22.2 mmol) at 
room temperature. The resulting mixture was stirred at rt for 4 h at which time the 
reaction was quenched by addition of water and extracted with dichloromethane (3x), 
dried over Na2SO4, and condensed in vacuo to give the TBDPS ether/ester as a pale 
yellow oil that was carried on without further purification. The TBDPS ether/ester was 
suspended in anhydrous dichloromethane (118 mL) and the resulting solution was cooled 
to -78 
o
C. DIBAL-H (1.0 M in CH2Cl2, 29.6 mL, 29.6 mmol) was added dropwise and 
the solution stirred for 2 h at -78 
o
C. The reaction was quenched by addition of a 
saturated aqueous solution of sodium potassium tartrate, warmed to room temperature, 
and stirred for 0.5 h. The mixture was extracted with dichloromethane (3x), dried over 
Na2SO4, condensed in vacuo and purified by flash chromatography (4:1 Hex/EtOAc) to 
provide alcohol 2.233 as a clear, colorless oil (3.81 g, 88% over 3 steps).  
Alcohol 2.233 (3.81 g, 6.54 mmol) was suspended in DCM/DMSO (3:1 v/v, 65  mL) and 
cooled to 0 
o
C. Triethylamine (6.61 g, 65.4 mmol) was added, followed by sulfur trioxide 
pyridine complex (4.16 g, 26.1 mmol). The resulting mixture was stirred for 6 h at 0 
o
C. 
The reaction was quenched by addition of water, extracted with dichloromethane (3x), 
dried over Na2SO4, and condensed in vacuo to give a yellow oil. This oil was purified by 
flash chromatography (5:1 Hex/EtOAc) to provide aldehyde 2.234 as a clear, colorless oil 
(3.08 g, 72%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.90 (s, 9H), 1.04 (m, 12H), 1.26-
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1.35 (m, 4H), 1.49-159 (m, 3H), 1.79-1.89 (m, 1H), 1.90-2.00 (m, 2H), 2.02-2.14 (m, 
1H), 2.23 (quin, J  = 6.8 Hz, 1H), 2.49-2.55 (m, 1H), 3.60 (t,  J = 6.6 Hz, 2H),  3.95 (sex, 
J = 6.0 Hz, 1H), 5.33 (dm,  J = 65.4 Hz, 2H), 7.35-7.45 (m, 6H), 7.65-7.70 (m, 4H), 9.47 
(d, J = 2.4 Hz, 1H).  
 
(S)-10-((tert-butyldimethylsilyl)oxy)-2-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl) 
decanal (2.235). Aldehyde 2.234 (2.17 g, 3.74 mmol) was suspended in anhydrous ethyl 
acetate (37 mL) in a 50 mL round bottom flask. 10% palladium on activated carbon (199 
mg, 0.19 mmol), was added and the flask was sealed and evacuated then filled with argon 
(3 x). The flask was then evacuated and refilled with hydrogen (3 x) from a balloon. The 
reaction was stirred for 12 h at room temperature until reaction was complete by TLC. 
The mixture was filtered through celite and washed through liberally with ethyl acetate. 
The filtrate was condensed in vacuo to give aldehyde 2.235 as a clear colorless oil that 
was carried on to the next step without further purification (2.16 g, 99%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.90 (s, 9H), 1.04 (m, 12H), 1.23-
1.31 (m, 12H), 1.47-1.55 (m, 3H),  1.63-1.70 (m, 2H), 1.83 (ddd,  J  = 14.2, 9.0, 4.6 Hz, 
1H), 2.41-2.47 (m, 1H), 3.60 (t,  J = 6.6 Hz, 2H), 3.92 (sex, J = 5.8 Hz, 1H), 7.32-7.44 
(m, 6H), 7.63-7.68 (m, 4H), 9.44 (d, J = 2.9 Hz, 1H).  
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(S,E)-1-(benzyloxy)-14-((tert-butyldimethylsilyl)oxy)-6-((S)-2-((tert-butyldiphenyl 
silyl)oxy)propyl)tetradec-4-en-3-one (2.236). Phosphonate 2.225 (1.46 g, 5.11 mmol) 
was suspended in THF (9.3 mL). Ba(OH)2 (845 mg, 4.93 mmol) was added at room 
temperature, and the resulting mixture was stirred for 1 h. Aldehyde 2.235 (2.13 g, 3.65 
mmol) in THF/H2O (40:1 v/v, 12.2 mL) was added dropwsie at room temperature and the 
reaction was stirred 4 h. The reaction mixture was diluted with ethyl acetate and water 
and neutralized by addition of 1.0 M HCl. The mixture was extracted with EtOAc (3x), 
dried over Na2SO4, and condensed in vacuo. The crude product was purified by flash 
chromatography (4:1 Hex:EtOAc) to provide enone 2.236 as a clear, colorless oil (1.22 g, 
45%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.90 (s, 9H), 1.04 (m, 12H), 1.15-
1.37 (m, 16H), 1.46-1.54 (m, 2H), 1.67 (ddd,  J  = 14.2, 8.2, 4.2 Hz, 1H), 2.31-2.40 (m, 
1H), 2.73 (td, J = 6.6, 2.4 Hz, 2H), 3.60 (t,  J = 6.6 Hz, 2H), 3.72-3.75 (m, 3H), 4.51 (s, 
2H), 5.79 (d, J = 16.0 Hz, 1H), 6.44 (dd, J = 16.0, 9.2 Hz, 1H), 7.27-7.42 (m, 11H), 7.63-
7.67 (m, 4H).  
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(3S,6S,E)-1-(benzyloxy)-14-((tert-butyldimethylsilyl)oxy)-6-((S)-2-((tert-butyl 
diphenylsilyl)oxy)propyl)tetradec-4-en-3-ol (2.237). Enone 2.236 (984 mg, 1.32 mmol) 
was suspended in anhydrous THF (13 mL) in a flame-dried 50 mL round bottom flask. 
The solution was cooled to -20 
o
C and R-(+)-2-methyl-CBS oxazaborolidine (367 mg, 
1.32 mmol) in toluene (1.3 mL) was added, followed by dropwsie addition of BH3 THF 
complex (1.0 M in THF, 4.1 mmol, 4.1 mL). The resulting mixture was stirred for 3 h 
and then quenched by addition of water, extracted with ethyl acetate (3x), dried over 
Na2SO4, and condensed in vacuo. The crude product was purified by flash 
chromatography (4:1 Hex:EtOAc) to give alcohol 2.237 as a clear, colorless oil (927 mg, 
94%, >20:1 dr).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.90 (s, 9H), 1.04 (m, 12H), 1.18-
1.29 (m, 14H), 1.47-1.54 (m, 2H), 1.59 (ddd,  J  = 13.8, 8.0, 4.2 Hz, 1H), 1.67-1.73 (m, 
2H), 2.11-2.19 (m, 1H), 3.51-3.65 (m, 2H), 3.60 (t,  J = 6.6 Hz, 2H), 3.79-3.84 (m, 1H), 
4.48 (d,  J = 3.4 Hz, 2H), 5.13 (dd, J = 15.6, 6.0 Hz, 1H), 5.24 (dd, J = 15.6, 8.5 Hz, 1H),  
7.28-7.41 (m, 11H), 7.63-7.69 (m, 4H).  
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(S)-3-(benzyloxy)-1-((2S,3S)-3-((5S,7S)-2,2,5,17,17,18,18-heptamethyl-3,3-diphenyl-
4,16-dioxa-3,17-disilanonadecan-7-yl)oxiran-2-yl)propan-1-ol (2.242). Into a 100 mL 
flame-dried round bottom flask was placed 4 angstrom molecular sieves (1.8 g) and 
anhydrous dichloromethane (11.2 mL). The solution was cooled to -20 
o
C and (+)-
diethyltartrate (276 mg, 1.34 mmol) and titanium (IV) isopropoxide (317 mg, 1.12 mmol) 
were added successively. After 10 min, tert-butyl hydrogenperoxide (5.5 M in decane, 
0.41 mL, 2.23 mmol) was added dropwise. After 30 min, allylic alcohol 2.237 (831 mg, 
1.12 mmol) in anhydrous dichloromethane (11.2 mL) was added dropwise. The reaction 
was stirred at -20 
o
C for 36 h. The reaction was quenched by dropwise addition of 
saturated sodium chloride solution and warmed to room temperature. The mixture was 
extracted with dichloromethane (3x), dried over Na2SO4, and filtered through celite. The 
filtrate was condensed in vacuo to give a yellow oil which was purified by flash 
chromatography (3:1 Hex:EtOAc) to provide epoxide 2.242 as a clear colorless oil (761 
mg, 90%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.05 (s, 6H), 0.90 (s, 9H), 1.03 (s, 9H), 1.05 (d,  J 
= 6.4 Hz, 3H),  1.13-1.30 (m, 14H), 1.46-1.54 (m, 4H), 1.72-1.90 (m, 2H), 2.64 (d, J  = 
6.0 Hz, 2H), 3.59 (t,  J = 6.6 Hz, 2H), 3.68 (dm,  J = 30.0 Hz, 2H), 3.75-3.78 (m, 1H), 
3.99 (q, J  = 6.2 Hz, 1H), 4.52 (s, 2H),  7.27-7.42 (m, 11H), 7.65-7.70 (m, 4H).  
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(5S,7S)-7-((2S,3S)-3-((R)-3-(benzyloxy)-1-methoxypropyl)oxiran-2-yl)-2,2,5,17,17, 
18,18-heptamethyl-3,3-diphenyl-4,16-dioxa-3,17-disilanonadecane (2.244). Epoxide 
2.242 (374 mg, 0.49 mmol) was suspended in anhydrous THF (10.0 mL). The reaction 
was cooled to 0 
o
C and triphenylphosphine (322 mg, 1.23 mmol), 4-nitrobenzoic acid 
(197 mg, 1.18 mmol0, and DIAD (229 mg, 1.13 mmol) were added successively. The 
reaction was warmed to room temperature and stirred for 4 h then quenched with water, 
extracted with ethyl acetate (3x), dried over Na2SO4, and condensed in vacuo to give a 
pale yellow oil. This oil was suspended in THF (1.6 mL) and MeOH (2.0 mL). 2.0 M 
NaOH (1.98 mmol, 1.5 mL) was added, and the resulting mixture was stirred for 1 h at 
which time TLC indicated complete conversion to the hydrolysis product, alcohol 2.243. 
The mixture was diluted with EtOAc and quenched with 1.0 M HCl then extracted with 
EtOAc (3x), dried over Na2SO4, condensed in vacuo, and purified by flash 
chromatography (3:1 Hex/EtOAc) to give alcohol 2.243 as a clear, colorless oil (311 mg, 
83%) 
Alcohol 2.243 (60 mg, 0.079 mmol) was suspended in anhydrous dicholoromethane (1.6 
mL) and powdered 4 angstrom molecular sieves (51 mg) were added. Proton sponge 
(50.7 mg, 0.24 mmol) was added, followed by trimethyloxonium tetrafluoroborate (29 
mg, 0.20 mmol). The resulting mixture was stirred for 2 h at room temperature and then 
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quenched with water, extracted with DCM (3x), dried oer Na2SO4, and condensed in 
vacuo. The crude product was purified by flash chromatography (4:1 Hex:EtOAc) to give 
ether 2.244 as a clear, colorless oil (53 mg, 87 %).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.06 (s, 6H), 0.91 (s, 9H), 1.04 (m, 12H), 1.09-
1.32 (m, 14H), 1.47-1.58 (m, 4H), 1.76 (q,  J  = 6.1 Hz, 2H), 1.67 (ddd,  J  = 14.2, 8.2, 
4.2 Hz, 1H), 2.38 (dd,  J = 7.6, 2.1 Hz, 1H), 2.63 (dd, J = 6.6, 2.2 Hz, 1H), 3.05 (q,  J = 
6.6 Hz, 1H), 3.43 (s, 3H), 3.53-3.57 (m, 1H), 3.60 (t,  J = 6.6 Hz, 2H), 4.00 (sex,  J  = 6.4 
Hz, 1H), 4.49 (s, 2H), 7.27-7.41 (m, 11H), 7.67-7.72 (m, 4H). 
13
C NMR (CDCl3, 100 
MHz)  (ppm): -5.05, 18.57, 19.44, 24.02, 26.00, 26.18, 27.20, 27.29, 29.66, 29.71, 
30.03, 31.85, 32.78, 33.08, 37.48, 43.22, 58.22, 58.70, 63.50, 66.37, 68.20, 73.26, 78.97, 
127.54, 127.59, 127.63, 127.76, 127.80, 127.88, 128.56, 129.55, 129.65, 134.53, 135.07, 
136.05, 136.12, 136.15, 138.57. 
 
(3R,4S,5R,6S)-1-(benzyloxy)-14-((tert-butyldimethylsilyl)oxy)-6-((S)-2-((tert-
butyldiphenylsilyl)oxy)propyl)-5-chloro-3-methoxytetradecan-4-ol (2.245). Epoxide 
2.244 (42 mg, 0.054 mol) was suspended in anhydrous toluene (0.45 mL) and cooled to   
-78 
o
C. Et2AlCl (1.0 M in toluene, 0.16 ml, 0.16 mmol) was added dropwsie and the 
solution was stirred for 10 min. TMS-acetylide in toluene {prepared by addition of n-Buli 
(2.5 M n hexanes, 0065 mL, 0.16 mmol) to TMS-acetylene (17.6 mg, 0.179 mmol) at -78 
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o
C in toluene (0.9 mL) with 0.5 h stirring}was added dropwise to the epoxide solution. 
After 6 h, the reaction was warmed to 0 
o
C, stirred for an additional 6 h, and then warmed 
to room temperature and stirred 12 h. Additional Et2AlCl (0.54 mmol, 0.54 mL) was 
added and the reaction was stirred for 6 h at which time, TLC indicated that complete 
conversion had occurred. The reaction was quenched by addition of NaHCO3, extracted 
with DCm (3x), dried over Na2SO4, and condensed in vacuo. The crude product was 
purified by flash chromatography (2:1 Hex:EtOAc) to provide alcohol 2.245 as the only 
isolated product. 
1
H NMR (CDCl3, 600 MHz)  (ppm): 0.05 (s, 6H), 0.90 (s, 9H), 1.03 (d, J = 3.8 Hz, 3H), 
1.04 (s, 9H), 1.21-1.34 (m, 13H), 1.40-1.44 (m, 1H), 1.51 (quin, J  = 7.0 Hz, 2H), 1.61 
(ddd,  J  = 14.3, 9.3, 3.8 Hz, 1H), 1.68 (ddd,  J = 14.3, 7.8, 3.8 Hz, 1H), 1.86-1.92 (m, 
1H), 1.94-2.00 (m 1H), 2.40-2.43 (m 1H), 3.37 (s, 3H), 3.54-3.63 (m, 4H),  3.89 (t,  J = 
6.4 Hz, 1H), 3.91-3.99 (m, 1H), 4.13 (dd,  J  = 10.2, 1.7 Hz, 1H), 4.52 (d, J = 2.2 Hz, 
2H), 7.27-7.43 (m, 11H), 7.67-7.72 (m, 4H). 
13
C NMR (CDCl3, 150 MHz)  (ppm): -
5.05, 18.58, 19.40, 24.28, 26.03, 26.19, 27.21, 27.24, 27.67, 28.75, 29.70, 29.85, 29.89, 
30.19, 31.12, 33.11, 34.77, 41.35, 58.72, 63.55, 66.40, 66.76, 67.84, 73.28, 73.51, 76.88, 
127.50, 127.53, 127.71, 127.80, 127.90, 128.59, 128.62, 129.57, 129.75, 134.40, 135.18, 
136.07, 136.11, 136.18, 138.42. 
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(3R,5R,6S)-1-(benzyloxy)-14-((tert-butyldimethylsilyl)oxy)-6-((S)-2-((tert-butyl 
diphenylsilyl)oxy)propyl)-5-chloro-3-methoxytetradecan-4-one (2.246). Alcohol 
2.245 (10 mg, 0.0114 mmol) was suspended in anhydrous dichloromethane (1.5 mL). 4 
angstrom molecular sieves (5 mg) were added, followed by 4-methylmorpholine N-oxide 
(2.7 mg, 0.023 mmol) and tetrapropylammonium perruthenate (0.4 mg, 0.0011 mmol) 
and the reaction was stirred for 2 h at rt. The mixture was filtered through celite and 
washed through liberally with dichloromethane. The filtrate was condensed in vacuo to 
give a dark green residue that was purified by flash chromatography (2:1 Hex:EtOAc) to 
give ketone 2.246 as a clear, colorless oil. 
1
H NMR (CDCl3, 600 MHz)  (ppm): 0.06 (s, 6H), 0.90 (s, 9H), 1.03 (s, 9H), 1.05 (d, J 
= 6.5 Hz, 3H), 1.19-1.30 (m, 6H), 1.47-1.58 (m, 8H), 1.78-1.85 (m, 1H), 2.03-2.11 (m, 
1H), 2.26-2.32 (m, 1H), 3.35 (s, 3H), 3.92 (sex, J = 5.8 Hz, 1H), 4.14 (dd,  J = 8.4, 4.0 
Hz, 1H), 4.50 (dd,  J = 27.0, 12.0 Hz, 2H), 4.83 (d,  J  = 4.6 Hz, 1H), 7.28-7.43 (m, 11H), 
7.62-7.69 (m, 4H).  
 
 (S)-tert-butyl(pent-4-en-2-yloxy)diphenylsilane (2.258). A flame-dried 250 mL round 
bottom flask was charged with cuprous iodide (1.64 g, 8.61 mmol) under an atmosphere 
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of argon. Anhydrous THF (17.5 mL) was added and the resulting solution was cooled to -
20 
o
C with vigorous stirring. Vinyl magnesium bromide (1.0 M in THF, 100 mL) was 
cannulated under a positive stream of argon into the stirring cuprous iodide over a 20 
minute period. The resulting black solution was stirred for 30 minutes and a solution of 
(S)-propylene oxide (3.02 g, 43.04 mmol) in anhydrous THF (5.5 mL) was added 
dropwise. The reaction mixture was stirred for 20 hours at -20 
o
C. At this time, the 
reaction was quenched by dropwise addition of saturated NH4Cl and warmed to room 
temperature. The mixture was extracted with diethyl ether (4 x), dried over sodium 
sulfate, and filtered through celite. The organic layer was carefully concentrated under 
reduced pressure to avoid evaporation of the volatile homoallylic alcohol 2.257. The 
remaining solvent was removed by gently blowing air across the surface of the solvent. 
After 20 minutes, the remaining yellow liquid was carried on to the next step without 
further purification. The crude homoallylic alcohol was suspended in dichloromethane 
(108 mL) and imidazole (5.86 g, 86.1 mmol) was added followed by TBDPS-Cl (16.5 
mL, 64.6 mmol) at room temperature. The reaction stirred for 2 hours at room 
temperature and was quenched by the addition of water. The mixture was extracted with 
dichloromethane (3 x), dried over sodium sulfate, and concentrated in vacuo to give a 
thick yellow oil. The crude oil was purified by flash chromatography (9:1 Hex:EtOAc) 
and condensed under reduced pressure to give 2.258 as a clear yellow oil (11.9 g, 85% 
over 2 steps).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.14 (s, 9H), 1.145 (d, J = 3.0 Hz, 3H), 2.22-2.33 
(m, 2H), 3.98 (sex, J = 6.0 Hz, 1H), 5.01-5.06 (m, 2H), 5.84 (dddd, J = 17.0, 11.2, 10.4, 
7.6 Hz, 1H), 7.41-7.49 (m, 6H), 7.75-7.78 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  
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(ppm): 19.38, 22.97, 27.15, 44.08, 69.34, 116.92, 127.57, 127.62, 129.58, 129.64, 134.58, 
134.86, 135.23, 136.00, 136.02. HRMS: C21H28ONaSi, Calculated: [M+H]+, 347.1807, 
Found: [M+H]+, 347.1804. 
 
(S,E)-ethyl 5-((tert-butyldiphenylsilyl)oxy)hex-2-enoate (2.259). Homoallylic alcohol 
2.258 (11.2 g, 34.5 mmol) was suspended in anhydrous CH2Cl2 (138 mL) in a flame-
dried 250 mL round bottom flask fit with a reflux condenser under an atmosphere of 
argon. Methyl acrylate was added (10.8 mL), followed by Grubbs’ second generation 
catalyst (580 mg, 0.69 mmol), and the resulting dark red solution was heated to 40 
o
C for 
12 hours. At this time, the dark green solution was exposed to air, condensed under 
reduced pressure, purified by flash chromatography (17:3 Hex/EtOAc), and concentrated 
in vacuo to give a 2.259 as a clear, colorless oil (12.8 g, 97%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.05 (s, 9H), 1.09 (d, J = 6.0 Hz, 3H), 2.29-2.33 
(m, 2H), 3.72 (s, 3H), 3.96 (sex, J = 5.9 Hz, 1H), 5.76 (ddd, J = 15.7, 1.3, 1.2 Hz, 1H), 
6.92 (ddd, J = 15.7, 7.8, 7.6 Hz, 1H), 7.35-7.45 (m, 6H), 7.65-7.67 (m, 4H).
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 19.32, 23.30, 27.10, 42.27, 51.52, 68.59, 123.16, 127.65, 
127.74, 129.73, 129.81, 134.13, 134.45, 135.99, 145.97, 166.94. HRMS: C23H30O3NaSi, 
Calculated: [M+H]+, 405.1862, Found: [M+H]+, 405.1859. 
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(R)-4-benzyl-3-((S,E)-5-((tert-butyldiphenylsilyl)oxy)hex-2-enoyl)oxazolidin-2-one 
(2.253). Ester 2.259 (11.85 g, 30.97 mmol) was suspended in THF/H2O (7:1 v/v, 155 
mL) in a 250 mL round bottom flask fit with a reflux condenser. Lithium hydroxide (7.42 
g, 309.7 mmol) was added in three portions, and the resulting solution was heated to 55 
o
C for 18 hours. After hydrolysis was complete, the mixture was cooled to room 
temperature and acidified to pH = 2 by dropwise addition of concentrated HCl. The 
acidic solution was extracted with ethyl acetate (3 x), dried over sodium sulfate, and 
condensed in vacuo to give crude carboxylic acid 2.260 (11.4 g, 100%) as a viscous clear, 
yellow oil that was carried on without further purification. 
Carboxylic acid 2.260 (14.26 g, 39.77 mmol) was suspended in anhydrous THF (200 mL) 
in a 500 mL flame-dried round bottom flask under an atmosphere of argon. The solution 
was cooled to -78 
o
C and triethylamine (6.65 mL, 47.73 mmol) was added, followed by 
dropwise addition of pivaloyl chloride (5.48 mL, 44.54 mmol). The resulting milky white 
solution was stirred at -78 
o
C for 15 min, then it was warmed to 0 
o
C and stirred for 45 
min, followed by cooling to -78 
o
C. The solution was cannulated dropwise at -78 
o
C to a 
preformed solution of (R)-(-)-4-benzyl-2-oxazolidinone (7.4 g, 41.76 mmol), n-BuLi (2.5 
M in Hexanes, 41.76 mmol), and anhydrous THF (104 mL) (n-BuLi added to 
oxazolidinone in THF at -78 
o
C and stirred for 25 min). The resulting suspension was 
stirred at -78 
o
C for 20 min and then warmed to room temperature and stirred for 2 hours. 
The reaction was quenched by addition of saturated NH4Cl, extracted with ethyl acetate 
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(3 x), dried over sodium sulfate, and condensed in vacuo to give an orange oil. The 
resulting oil was purified by flash chromatography (3:1 Hex/EtOAc) to yield 
acyloxazolidinone 2.253 as a viscous, pale, yellow oil (17.13 g, 82%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.07 (s, 9H), 1.13 (d, J = 6.2 Hz, 3H), 2.43 (q, J = 
5.6 Hz, 2H), 2.78 (dd, J = 13.0, 9.6 Hz, 1H), 3.33 (dd, J = 13.5, 3.2 Hz, 1H), 4.03 (sex, J 
= 5.9 Hz, 1H), 4.19-4.23 (m, 2H), 4.73 (ddd, J = 13.2, 7.2, 3.4 Hz, 1H), 7.19-7.43 (m, 
14H), 7.68-7.70 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.35, 23.42, 26.49, 
27.12, 38.03, 42.69, 55.42, 66.21, 68.66, 122.49, 127.45, 127.67, 127.77, 129.09, 129.60, 
129.72, 129.80, 134.12, 134.46, 135.54, 135.99, 136.02, 148.22, 153.49, 164.85. HRMS: 
C32H37NO4NaSi, Calculated: [M+H]+, 550.2390, Found: [M+H]+, 550.2393. 
 
(R)-4-benzyl-3-((S)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)hex-5-enoyl) 
oxazolidin-2-one (2.261). Recrystallized CuBr-S(CH3)2 complex (22.2 g, 108.00 mmol) 
was suspended in dimethylsulfide and THF (1:2 v/v, 216 mL) in a flame-dried 500 mL 
round bottom flask and cooled to -78 
o
C. This solution was cannulated into a cooled 
solution (-78 
o
C) of allylmagnesium bromide (1.0 M in Et2O, 86.86 mmol) in a second 
flame-dried 500 mL round bottom flask. The resulting, thick, black solution was 
vigorously stirred for 1 hour at -78 
o
C and then acyloxazolidinone 2.253 (11.46 g, 21.72 
mmol) in anhydrous THF (72 mL) was slowly added over 20 min. The reaction mixture 
was stirred for an additional 1.5 hours at -78 
o
C and was then quenched with saturated 
NH4Cl and warmed to room temperature. The black mixture was extracted with diethyl 
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ether (4 x), dried over sodium sulfate, the solvent volume reduced to approximately 200 
mL by rotary evaporation, and the resulting solid/oil mixture filtered through a celite plug 
with liberal diethyl ether washes. The resulting solution was condensed in vacuo to give a 
turquoise oil that was purified by flash chromatography (5:1 Hex/EtOAc) to provide the 
desired conjugate addition adduct 2.261 as a clear, colorless oil (10.48 g, 85%) and a 
single diastereomer by 
1
HNMR (>20:1).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.05 (s, 9H), 1.12 (d, J = 6.1 Hz, 3H), 1.41 (quin, J 
= 7.0 Hz, 1H), 1.60 (quin, J = 7.0 Hz, 1H), 1.91-2.03 (m, 2H), 2.22 (quin, J = 6.1 Hz, 
1H), 2.63 (dd, J = 17.9, 5.8 Hz, 1H), 2.68 (dd, J = 13.0, 10.0 Hz, 1H), 2.87 (dd, J = 17.9, 
7.2 Hz, 1H), 3.28 (dd, J = 13.4, 3.3 Hz, 1H), 3.92 (sex, J = 6.2 Hz, 1H), 4.10-4.20 (m, 
3H), 4.65 (ddd, J = 13.4, 6.9, 3.2 Hz, 1H), 4.92-4.91 (m, 2H), 5.62 (dddd, J = 16.7, 10.2, 
9.0, 7.2 Hz, 1H), 7.20-7.43 (m, 11H), 7.66-7.70 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  
(ppm): 19.34, 23.57, 26.50, 27.19, 30.43, 38.08, 38.38, 39.53, 43.77, 55.29, 66.19, 67.70, 
77.37, 116.95, 127.48, 127.55, 127.66, 129.04, 129.10, 129.56, 129.63, 134.40, 134.92, 
135.49, 136.09, 136.11, 136.32, 153.49, 172.53. HRMS: C35H43NO4NaSi, Calculated: 
[M+H]+, 592.2859, Found: [M+H]+, 592.2854. 
 
((But-3-en-1-yloxy)methyl)benzene (2.266). Sodium hydride (3.88 g, 97.07 mmol, 60% 
dispersion in mineral oil) was suspended in anhydrous THF (140 mL) in a flame-dried 
250 mL round bottom flask. The solution was cooled to 0 
o
C and But-3-en-1-ol (5.0 g, 
69.34 mmol) was added dropwise. The resulting mixture was stirred for 30 min at 0 
o
C at 
which time benzyl bromide (17.79 g, 104.01 mmol) was added dropwise followed by 
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addition of tert-butyl ammonium iodide (2.56 g, 6.93 mmol). The mixture was warmed to 
room temperature and stirred for 18 h. The reaction was quenched by dropwise addition 
of saturated NH4Cl solution. The resulting mixture was extracted with ethyl acetate (3 x), 
dried over Na2SO4, and concentrated under reduced pressure. The resulting oil was 
purified by flash chromatography (1:1 Hex:EtOAc) to give benzyl ether 2.266 (8.62 g, 
77%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 2.39 (q, J = 6.8 Hz, 2H), 3.54 (t, J = 6.8 Hz, 2H), 
4.53 (s, 2H), 5.06 (d, J = 10.2 Hz, 1H), 5.12 (ddd, J = 17.2, 3.5, 1.5 Hz, 1H), 5.86 (ddt, J 
= 17.2, 10.3, 6.8 Hz, 1H), 7.27-7.38 (m, 5H)..
13
C NMR (CDCl3, 100 MHz)  (ppm): 
34.40, 69.78, 73.06, 116.53, 127.71, 127.81, 135.44, 138.63. 
 
(E)-ethyl 5-(benzyloxy)pent-2-enoate (2.267). Benzyl ether 2.266 (8.62 g, 53.13 mmol) 
was suspended in anhydrous dichloromethane (106 mL) under an atmosphere of argon in 
a flame-dried 250 mL round bottom flask fit with a reflux condenser. Ethyl acrylate 
(21.28 g, 212.54 mmol) was added to the solution followed by Grubbs second generation 
catalyst (902 mg, 1.06 mmol) in one portion. The resulting mixture was heated to 40 
o
C 
and stirred for 12 h. The reaction was cooled to room temperature and concentrated under 
reduced pressure to provide a brown oil which was purified by flash chromatography (2:1 
Hex:EtOAc) to give ester 2.267 a clear, colorless oil (10.46 g, 84 %).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.29 (t, J = 7.2 Hz, 3H), 2.51 (ddd, J = 13.8, 6.6, 
1.5 Hz, 2H), 3.59 (t, J = 6.6 Hz, 2H), 4.19 (q, J = 7.2 Hz, 2H), 4.52 (s, 2H), 5.89 (dt, J = 
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15.7, 1.5 Hz, 1H), 6.98 (dt, J = 15.7, 6.8 Hz, 1H), 7.28-7.37 (m, 5H)..
13
C NMR (CDCl3, 
100 MHz)  (ppm): 14.41, 32.77, 60.36, 68.44, 73.20, 123.09, 127.83, 128.57, 138.24, 
145.70, 166.58. 
 
(E)-5-(benzyloxy)pent-2-en-1-ol (2.268). Ester 2.267 (1.80 g, 7.68 mmol) was 
suspended in anhydrous dichloromethane (31 mL) in a 100 mL round bottom flask. The 
solution was cooled to -78 
o
C and DIBAL-H (1.0 M in CH2Cl2, 19.21 mL, 19.21 mmol) 
was added dropwise. The reaction was stirred for 1 h at -78 
o
C and was then quenched by 
addition of sodium potassium tartrate, warmed to room temperature, and stirred for 1 h 
until the organic layer was clear. The mixture was extracted with dichloromethane (3 x), 
dried over Na2SO4, and condensed in vacuo to give a clear oil. This oil was purified by 
flash chromatography (1:1 Hex:EtOAc) to provide allylic alcohol 2.268 as a clear, 
colorless oil (1.25 g, 85%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 2.36-2.40 (m, 2H), 3.52 (t, J = 6.7 Hz, 2H), 4.08-
4.09 (m, 2H), 4.52 (s, 2H), 5.71-5.74 (m, 2H), 7.27-7.37 (m, 5H). 
13
C NMR (CDCl3, 100 
MHz)  (ppm): 32.57, 63.53, 69.54, 72.85, 127.54, 127.63, 128.32, 129.15, 130.93, 
138.26. 
 
((2S,3S)-3-(2-(benzyloxy)ethyl)oxiran-2-yl)methanol (2.269). Into a 100 mL flame-
dried round bottom flask was placed 4 angstrom molecular sieves (650 mg) and 
anhydrous dichloromethane (32.5 mL). The solution was cooled to -20 
o
C and (+)-
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diethyltartrate (135 mg, 0.66 mmol) and titanium (IV) isopropoxide (130 mg, 0.46 mmol) 
were added successively. After 10 min, tert-butyl hydrogenperoxide (5.5 M in decane, 
2.36 mL, 13.00 mmol) was added dropwise. After 30 min, allylic alcohol 2.268 (1.26 g, 
6.56 mmol) in anhydrous dichloromethane (13 mL) was added dropwise. The reaction 
was stirred at -20 
o
C for 48 h. The reaction was quenched by dropwise addition of 
saturated sodium chloride solution and warmed to room temperature. The mixture was 
extracted with dichloromethane (3 x), dried over sodium sulfate, and filtered through 
celite. The filtrate was condensed in vacuo to give a yellow oil which was purified by 
flash chromatography (1:2 Hex:EtOAc) to provide epoxide 2.269 as a clear colorless oil 
(1.16 g, 86%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.78-1.86 (m, 1H), 1.89-1.98 (m, 1H), 2.97 (quin, 
J =2.4 Hz, 1H), 3.08-3.11 (m, 1H), 3.58-3.62 (m, 3H), 3.88 (dd, J = 12.4, 2.8 Hz, 1H), 
4.52 (s, 2H), 7.27-7.37 (m, 5H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 31.98, 53.67, 
58.44, 61.67, 66.78, 73.02, 127.58, 127.61, 128.35, 138.11. 
 
(2S,3R)-5-(benzyloxy)-3-methoxypentane-1,2-diol (2.270). Epoxide 2.269 was 
suspended in anhydrous methano1 (10 mL) in 25 mL round bottom flask fit with a reflux 
condensor. 2,6-di-tert-butyl-4-methylpyridine (79 mg, 0.38 mmol) was added followed 
by addition of europium (III) triflate (230 mg, 0.38 mmol), and the reaction was heated to 
70 
o
C. After 19 h, the reaction mixture was diluted with water and ethyl acetate, extracted 
with ethyl acetate (3x), dried over Na2SO4, and condensed in vacuo. The crude oil was 
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purified by flash chromatography (1:1 Hex:EtOAc to 100% EtOAc) to give diol 2.270 as 
a clear, colorless oil (430 mg, 93 %, > 20:1 1,3:1,2 diol). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.89 (q, J = 5.2 Hz, 2H), 3.36 (s, 3H), 3.39-3.44 
(m, 1H), 3.54-3.59 (m, 1H), 3.63-3.73 (m, 4H), 4.52 (dd, J = 21.2, 11.6 Hz, 2H), 7.27-
7.37 (m, 5H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 29.68, 57.82, 63.69, 66.13, 72.35, 
73.27, 80.17, 127.72, 127.77, 128.42, 137.68. 
 
(R)-4-(benzyloxy)-2-methoxybutanal (2.271). Diol 2.270 (100 mg, 0.416 mmol) was 
suspended in dichloromethane: pH 7 buffer (1:1 v/v, 5.2 mL). The biphasic mixture was 
vigorously stirred and cooled to 0 
o
C, then NaIO4 (534 mg, 2.50 mmol) was added in 3 
portions and the resulting solution was stirred at 0
 o
C for 4 h. The reaction mixture was 
diluted with water and dichloromethane, extracted with dichloromethane (2x), dried over 
Na2SO4, and condensed under reduced pressure. The product was purified by flash 
chromatography (1:3 Hex:EtOAc) to give aldehyde 2.271 as a clear, colorless oil (83 mg, 
96 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.90-1.98 (m, 1H), 2.00-2.08 (m, 1H), 3.45 (s, 
3H), 3.55-3.64 (m, 2H), 3.76-3.79 (m, 1H), 4.49 (dd, J = 21.0, 11.8 Hz, 2H), 7.27-7.37 
(m, 5H), 9.67 (d, J = 1.5 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 30.80, 58.53, 
65.22, 73.16, 83.18, 127.83, 128.58, 138.32, 203.35. 
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(Z)-4-((4-methoxybenzyl)oxy)but-2-en-1-ol (2.297). Sodium hydride (3.81 g, 95.34 
mmol, 60% dispersion in mineral oil) was suspended in anhydrous THF (185 mL) in a 
flame-dried 500 mL round bottom flask. The solution was cooled to 0 
o
C and 1,4-cis-
buten-1-ol (8.0 g, 90.80 mmol) was added dropwise. The resulting mixture was stirred for 
30 min at 0 
o
C at which time p-methoxybenzyl chloride (15.64 g, 99.88 mmol) was added 
dropwise followed by addition of tert-butyl ammonium iodide (3.35 g, 9.08 mmol). The 
mixture was warmed to room temperature and stirred for 12 h. The reaction was 
quenched by dropwise addition of saturated NH4Cl solution. The resulting mixture was 
extracted with ethyl acetate (3 x), dried over Na2SO4, and concentrated under reduced 
pressure. The resulting oil was purified by flash chromatography (2:3 Hex:EtOAc) to 
give  PMB ether 2.297 ( 13.15 g, 70%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 3.80 (s, 3H), 4.05 (d, J = 6.0 Hz, 2H), 4.15 (d, J = 
6.3 Hz, 2H), 4.45 (s, 2H), 5.76 (dm, J = 35.0 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 7.27 (d, J 
= 8.5, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 55.20, 58.60, 65.28, 72.06, 113.78, 
128.21, 129.43, 129.86, 132.28, 159.24. HRMS: C12H16O3Na, Calculated: [M+H]+, 
231.0997, Found: [M+H]+, 231.0995. 
 
(E)-4-((4-methoxybenzyl)oxy)but-2-enal (2.298). PMB ether 2.297 (8.78 g, 42.16 
mmol) was suspended in dichloromethane (135 mL). Manganese dioxide (73.3 g, 843.18 
mmol) was added in 5 portions and the resulting heterogenous mixture was vigorously 
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stirred for 24 h at room temperature. Additional manganese dioxide (36.65 g, 421.59 
mmol) was added in 3 portions and the reaction was stirred for 12 h. The mixture was 
filtered through celite and condensed in vacuo to give a pale yellow oil. The oil was 
purified by flash chromatography (3:2 Hex:EtOAc) to provide aldehyde 2.298 as a clear, 
colorless oil (5.36 g, 62 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 3.83 (s, 3H), 4.28 (dd, J = 4.1, 1.9 Hz, 2H), 4.54 
(s, 2H), 6.41 (ddt, J = 15.9, 8.0, 1.9 Hz, 1H), 6.86 (dt, J = 15.9, 4.1 Hz, 1H), 6.92 (d, J = 
8.4 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 9.60 (d, J = 7.7 Hz, 1H). 
13
C NMR (CDCl3, 100 
MHz)  (ppm): 55.42, 68.40, 72.83, 114.06, 129.52, 129.58, 131.94, 153.37, 159.59, 
193.48. HRMS: C12H14O3Na, Calculated: [M+H]+, 229.0841, Found: [M+H]+, 
229.0841. 
 
(R)-4-benzyl-3-((2R,3S,E)-2-((4S,6S)-6-((tert-butyldiphenylsilyl)oxy)hept-1-en-4-yl)-
3-hydroxy-6-((4-methoxybenzyl)oxy)hex-4-enoyl)oxazolidin-2-one (2.299). To a 
flame-dried 500 mL round bottom flask was added acyloxazolidinone 2.261 (11.5 g, 
20.18 mmol) and anhydrous dichloromethane (200 mL). After cooling to 0 
o
C, Titanium 
chloride (2.32 mL, 21.19 mmol) was added dropwise and the resulting yellow solution 
was stirred for 15 minutes. At 0 
o
C, diisopropylethylamine (3.87 mL, 22.20 mmol) was 
slowly added and the dark red mixture was stirred for 40 minutes while maintaining the 
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temperature at 0 
o
C. N-methylpyrrolidinone (1.95 mL, 20.18 mmol) was added dropwise 
and the solution stirred for 10 additional minutes. Aldehyde 2.298 (4.35 g, 21.09 mmol) 
in anhydrous dichloromethane (81 mL) was added dropwise at 0 
o
C. After addition was 
complete, the solution was stirred for 1.5 h at 0 
o
C, quenched with saturated NH4Cl, and 
warmed to room temperature. The dark orange solution was extracted with 
dichloromethane (3 x) and filtered through a celite plug. The solvent was removed under 
reduced pressure at rt, and the resulting orange oil was purified by flash chromatography 
(3:2 Hex/EtOAc)  to provide the syn aldol adduct 2.299 (10.15 g, 65%, 10:1 dr). 
 1
H NMR (CDCl3, 400 MHz)  (ppm): 1.05 (s, 9H), 1.07 (d, J = 6.0 Hz, 3H), 1.49-1.56 
(m, 1H), 1.61-1.67 (m, 1H), 1.80-1.86 (m, 2H), 2.01-2.09 (m, 1H), 2.11-2.18 (m, 1H), 
2.48 (dd, J = 13.0, 10.7 Hz, 1H), 3.30 (dd, J = 13.2, 3.2 Hz  1H), 3.79 (s, 3H), 3.97-4.04 
(m, 5H), 4.27 (t, J = 7.5 Hz, 1H), 4.43 (s, 3H), 4.46-4.50 (m, 1H), 4.60-4.66 (m, 1H), 
4.83 (d, J = 17.1 Hz, 1H), 4.90 (d, J = 10.0 Hz, 1H), 5.55 (dddd, J = 16.8, 9.9, 7.2, 5.0 
Hz, 1H), 5.81-5.83 (m, 2H), 6.85 (d, J = 8.6 Hz, 2H), 7.17-7.43 (m, 14H), 7.66-7.71 (m, 
4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.33, 23.12, 27.14, 34.68, 35.21, 38.42, 
40.85, 50.64, 55.40, 55.74, 65.97, 67.65, 69.83, 72.02, 113.90, 117.11, 127.43, 127.60, 
127.72, 129.09, 129.43, 129.46, 129.62, 129.68, 130.17, 130.40, 131.88, 134.52, 134.81, 
135.52, 136.05, 153.84, 159.33, 173.41. HRMS: C47H58NO7Si, Calculated: [M+H]+, 
776.3983, Found: [M+H]+, 776.3982. 
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(2S,3S,E)-2-((4S,6S)-6-((tert-butyldiphenylsilyl)oxy)hept-1-en-4-yl)-6-((4-methoxy 
benzyl)oxy)hex-4-ene-1,3-diol (2.301). Aldol adduct 2.299 (10.4 g, 13.40 mmol) was 
suspended in anhydrous tetrahydrofuran (136 mL) and split into 6 separate 40 mL 
scintillation vials. Methanol (0.36 mL, 8.93 mmol) was added to each of the 6 vials and 
they were cooled to 0 
o
C. LiBH4 was slowly added to each vial (4.53 mL, 2.0 M in THF), 
and the reaction mixtures were stirred for 3 h until the reaction was complete by TLC. 
Water was added dropwise to each vial and all 6 vials were combined and extracted with 
ethyl acetate (4 x), dried over Na2SO4, condensed in vacuo, and purified by flash 
chromatography (1:1 Hex/EtOAc) to give diol 2.299 as a clear, colorless oil  (3.21 g, 
40%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.05 (s, 12H), 1.37-1.44 (m, 1H), 1.55-1.64 (m, 
1H), 1.68-1.74 (m, 2H), 1.90 (quin, 4.0 Hz, 1H), 2.03-2.09 (m, 1H), 2.28-2.35 (m, 1H), 
3.58-3.61 (m, 1H), 3.67-3.72 (m, 1H), 3.80 (s, 3H), 3.93 (sex, J = 6.1 Hz, 1H), 3.99 (d, J 
= 4.2 Hz, 2H), 4.24 (bs, 1H), 4.46 (s, 2H), 4.88-4.93 (m, 2H), 5.56 (dddd, J = 17.0, 10.4, 
9.0, 6.4 Hz, 1H), 5.82-5.85 (m, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 
7.35-7.44 (m, 6H), 7.67-7.70 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.31, 
23.54, 27.15, 33.30, 35.22, 41.85, 47.61, 53.39, 61.67, 68.15, 69.86, 72.19, 74.32, 113.93, 
116.36, 127.56, 127.68, 129.00, 129.47, 129.51, 129.60, 129.69, 130.32, 133.39, 134.44, 
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134.79, 136.03, 137.13, 159.35. HRMS: C37H50O5NaSi, Calculated: [M+H]+, 625.3325, 
Found: [M+H]+, 625.3325. 
 
(5S,7S,8S,9S)-7-allyl-11,11-diethyl-9-((E)-3-((4-methoxybenzyl)oxy)prop-1-en-1-yl)-
2,2,5-trimethyl-3,3-diphenyl-8-(((triethylsilyl)oxy)methyl)-4,10-dioxa-3,11-
disilatridecane (2.303). Diol 2.299 (433 mg, 0.718 mmol) was suspended in anhydrous 
dichloromethane (7.2 mL) in a 25 mL flame-dried round bottom flask. Imidazole (245 
mg, 3.59 mmol) was added followed by TESCl (325 mg, 2.15 mmol). The resulting 
mixture was stirred at room temperature for 4 h and then quenched by addition of water, 
extracted with dichloromethane (2x), dried over Na2SO4, and condensed in vacuo to give 
a clear oil. This oil was purified by flash chromatography (9:1 Hex:EtOAc) to provide 
bis-TES ether 2.303 as a clear colorless oil (573 mg, 96%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.51-0.60 (m, 12H), 0.90-0.96 (m, 18H), 1.01 (d,  
J = 6.0 Hz, 3H), 1.03 (s, 9H), 1.44-1.51 (m, 1H), 1.57-1.67 (m, 2H), 1.77 (dt,  J = 14.0, 
7.8 Hz, 1H), 1.85-1.92 (m, 1H), 2.26 (dm, J  = 14.0 Hz, 1H), 3.54 (dd,  J  = 10.2, 5.6 Hz, 
1H), 3.63 (dd,  J  = 10.2, 5.6 Hz, 1H), 3.81 (s, 3H), 3.91 (sex,  J = 6.2 Hz, 1H), 3.95 (d,  J 
= 2.7 Hz, 2H), 4.32-4.35 (m, 1H), 4.42 (s, 2H), 4.82 (s, 1H), 4.86 (d,  J = 5.6 Hz, 1H), 
5.50-5.60 (m, 1H), 5.69 (d,  J  = 3.4 Hz, 2H), 6.88 (d,  J  = 8.6 Hz, 2H), 7.25 (d,  J  = 8.6 
Hz, 2H), 7.33-7.42 (m, 6H), 7.67-7.72 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 
4.60, 5.30, 7.06, 7.14, 19.37, 23.46, 27.22, 32.69, 35.86, 42.78, 49.86, 55.46, 60.04, 
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68.85, 70.27, 71.69, 72.78, 113.93, 115.40, 127.41, 127.55, 127.63, 129.34, 129.51, 
29.58, 130.78, 134.86, 135.28, 135.90, 136.07, 138.39, 159.30.  
 
(4S,5S,6S,E)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-4-((triethylsilyl)oxy)-5-
(((triethylsilyl)oxy)methyl)nona-2,8-dien-1-ol (2.304). Bis-TES ether 2.303 (533 mg, 
0.641 mmol) was suspended in dichloromethane/ pH 7 phosphate buffer (7:1 v/v, 16 mL). 
The solution was cooled to 0
 o
C and DDQ (153 mg, 0.673 mmol) was added in 2 portions 
and the resulting mixture was stirred for 4 h at 0
 o
C. The reaction was quenched by 
addition of saturated NaHCO3, extracted with dichloromethane (4x), dried over Na2SO4, 
and condesned in vacuo to give a yellow residue. This residue was purified by flash 
chromatography (6:1 Hex:EtOAc) to give allylic alcohol 2.304 as a clear, colorless oil 
(346 mg, 76%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.55 (quin, J = 7.6 Hz, 12H), 0.93 (t, J = 8.0 Hz, 
18H), 1.01 (d,  J = 6.2 Hz, 3H), 1.03 (s, 9H), 1.46 (quin, J  = 6.7 Hz, 1H), 1.59-1.66 (m, 
2H), 1.75 (dt,  J = 14.1, 8.0 Hz, 1H), 1.84-1.92 (m, 1H), 2.25 (dm, J  = 14.1 Hz, 1H), 3.54 
(dd,  J  = 10.2, 5.4 Hz, 1H), 3.62 (dd,  J  = 10.2, 5.4 Hz, 1H), 3.91 (sex,  J = 6.1 Hz, 1H), 
4.07 (d,  J = 4.5 Hz, 2H), 4.33 (t, J = 5.8 Hz, 1H), 4.42 (s, 2H), 4.83 (s, 1H), 4.86 (d,  J = 
3.8 Hz, 1H), 5.50-5.60 (m, 1H), 5.63-5.76 (m, 2H), 7.34-7.43 (m, 6H), 7.67-7.69 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 4.60, 5.30, 7.05, 7.12, 19.38, 23.52, 27.21, 32.63, 
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35.78, 42.68, 49.82, 59.94, 63.48, 68.83, 72.71, 115.47, 127.56, 127.63, 129.51, 129.55, 
129.60, 134.79, 134.91, 135.21, 136.06, 138.57.  
 
(5S,6S,E)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-(hydroxymethyl)-1-((4-
methoxybenzyl)oxy)nona-2,8-dien-4-one (2.306). Diol 2.299 (643 mg, 1.06 mmol) was 
suspended in dichloromethane (18 mL) and manganese dioxide (1.85 g, 21.33 mmol) and 
the resulting heterogenous solution was stirred for 24 h at room temperature. The mixture 
was filtered through celite and condensed under reduced pressure to give a clear oil. This 
oil was purified by flash chromatography (2:1 Hex:EtOAc) to provide enone 2.306 as a 
clear colorless oil (460 mg, 72%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.02 (s, 9H), 1.06 (d,  J = 6.1 Hz, 3H), 1.46 (dt, J  
= 14.0, 6.3 Hz, 1H), 1.58 (quin, J = 6.8 Hz, 1H), 1.82-1.94 (m, 2H), 2.03-2.11 (m, 1H), 
2.83-2.88 (m, 1H), 3.59 (dd,  J  = 11.6, 3.2 Hz, 1H), 3.81 (s, 3H), 3.86 (dd,  J  = 11.6, 7.6 
Hz, 1H), 3.93 (sex,  J = 6.1 Hz, 1H), 4.13 (dd, J = 4.2, 1.8 Hz, 2H), 4.50 (s, 2H), 4.88-
4.94 (m, 2H), 5.46 (ddt, J = 17.0, 10.0 7.1 Hz, 1H), 6.44 (d, J = 15.9 Hz, 1H), 6.84-6.90 
(m, 3H), 7.27 (d,  J = 8.0 Hz, 2H), 7.34-7.43 (m, 6H), 7.66-7.69 (m, 4H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 19.35, 23.34, 27.19, 33.80, 35.10, 41.24, 54.15, 55.48, 
60.35, 68.08, 68.69, 72.78, 114.09, 117.29, 127.66, 127.79, 128.96, 129.58, 129.72, 
129.80, 129.84, 135.94, 136.04, 143.63, 159.58, 203.62.  
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(2S,3S,E)-2-((4S,6S)-6-((tert-butyldiphenylsilyl)oxy)hept-1-en-4-yl)-3-hydroxy-6-((4-
methoxybenzyl)oxy)hex-4-en-1-yl Pivalate (2.308). Diol 2.299 (300 mg, 0.498 mmol) 
was suspended in anhydrous dichloromethane (10 mL) in a flame-dried 25 mL round 
bottom flask. Pyridine (71 mg, 0.897 mmol) was added, followed by pivaloyl chloride 
(63 mg, 0.523 mmol). The reaction was stirred at room temperature for 3 h and then 
quenched by the addition of water and extracted with dichloromethane (3x), dried over 
Na2SO4, and condensed in vacuo to give a pale yellow oil. This oil was purified by flash 
chromatography (3:1 Hex:EtOAc) to provide pivalate 2.308 as a clear, colorless oil (318 
mg, 93%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.04 (m, 12H), 1.15 (s, 9H), 1.43 (dt, J  = 14.0, 6.4 
Hz, 1H), 1.64 (dt, J = 14.0, 6.2 Hz, 1H), 1.72 (dt,  J = 14.4, 8.0 Hz, 1H), 1.84-1.89 (m, 
1H), 1.95-2.01 (m, 1H), 2.22 (dm,  J = 14.0 Hz, 1H), 3.80 (3, 3H), 3.90 (q,  J  = 6.2 Hz, 
1H), 3.97 (dd, J = 9.2, 5.6 Hz, 2H),  3H), 4.06 (dd,  J  = 11.5, 5.6 Hz, 1H), 4.14-4.18 (m, 
1H), 4.43 (s, 2H), 4.90-4.94 (m, 2H), 5.55-5.64 (m, 1H), 5.68-5.82 (m, 2H), 6.87 (d,  J  = 
8.5 Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H), 7.34-7.42 (m, 6H), 7.66-7.70 (m, 4H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 19.36, 23.56, 27.21, 27.36, 32.93, 35.62, 38.84, 41.71, 
45.70, 55.45, 62.66, 68.27, 69.90, 72.05, 72.19, 113.97, 116.27, 127.59, 127.72, 129.04, 
129.52, 129.64, 129.74, 130.42, 133.96, 134.49, 134.92, 136.10, 137.81, 159.39, 178.64.  
 
280 
 
 
(S,E)-2-((4S,6S)-6-((tert-butyldiphenylsilyl)oxy)hept-1-en-4-yl)-6-((4-methoxybenzyl) 
oxy)-3-oxohex-4-en-1-yl pivalate (2.309). Pivalate 2.308 (110 mg, 0.160 mmol) was 
suspended in dichloromethane (8 mL) and manganese dioxide (348 mg, 4.00 mmol) was 
added in 2 portions. The resulting heterogenous solution was vigorously stirred for 24 h, 
then filtered through celite, condensed in vacuo, and purified by flash chromatography 
(4:1 Hex:EtOAc) to provide enone 2.309 as a clear colorless oil (93 mg, 85 %). 
 
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.34, 23.18, 27.19, 27.27, 34.31, 34.91, 38.82, 
40.94, 51.17, 55.47, 62.79, 68.13, 68.68, 72.73, 113.95, 114.07, 114.51, 117.49, 127.65, 
127.77, 127.89, 129.17, 129.53, 129.69, 129.77, 129.82, 129.87, 132.53, 134.33, 134.77, 
135.65, 136.04, 143.12, 159.56, 178.41, 200.31. 
 
(4S,5S,6S,E)-5-(((tert-butyldimethylsilyl)oxy)methyl)-6-((S)-2-((tert-butyldiphenyl 
silyl)oxy)propyl)-1-((4-methoxybenzyl)oxy)nona-2,8-dien-4-ol (2.310). Diol 2.299 
(670 mg, 1.11 mmol), was suspended in anhydrous dichloromethane in a flame-dried 25 
mL round bottom flask. Imidazole (114 mg, 1.67 mmol) was added followed by TBSCl 
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(176 mg, 1.17 mmol). The reaction was stirred at room temperature for 4 h and was 
quenched by the addition of water, extracted with dichloromethane (3x), dried over 
Na2SO4, and condensed in vacuo to give a clear oil. This oil was purified by flash 
chromatography (3:1 Hex:EtOAc) to provide TBS ether 2.310 as a clear, colorless oil 
(762 mg, 96 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.02 (d,  J = 1.4 Hz, 6H), 0.87 (s, 9H),  1.04 (m, 
12H), 1.42-1.49 (m, 1H), 1.58-1.62 (m, 1H), 1.68-1.75 (m, 1H), 1.81-1.86 (m, 1H),  2.08 
(dm, J = 14.4 Hz, 1H), 3.13 (d,  J = 7.0 Hz, 1H), 3.66 (d,  J  = 6.5 Hz, 2H), 3.80 (3, 3H), 
3.89 (sex,  J  = 6.2 Hz, 1H), 4.01 (d,  J  = 3.8 Hz, 2H), 4.23-4.27 (m, 1H), 4.45 (s, 2H), 
4.85-4.91 (m, 2H), 5.52 (ddt,  J  = 17.0, 9.9, 7.0 Hz, 1H), 5.80-5.82 (m, 2H), 6.87 (d,  J  = 
8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.34-7.43 (m, 6H), 7.66-7.69 (m, 4H). 
13
C NMR 
(CDCl3, 100 MHz)  (ppm): -5.47, -5.45, 18.21, 19.36, 23.43, 26.02, 27.21, 33.32, 35.35, 
41.96, 47.36, 55.45, 62.75, 68.28, 70.13, 71.85, 73.66, 113.93, 116.33, 127.61, 127.73, 
128.40, 128.83, 129.43, 129.50, 129.62, 129.73, 130.64, 133.62, 134.51, 134.94, 136.08, 
137.09, 159.32. 
 
(1R,2S,3S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-((S)-2-((tert-butyldiphenyl 
silyl)oxy)propyl)-1-((2S,3S)-3-(((4-methoxybenzyl)oxy)methyl)oxiran-2-yl)hex-5-en-
1-ol (2.311). TBS ether 2.311 (325 mg, 0.45 mmol) was suspended in anhydrous 
dichloromethane (4.5 mL) in a flame-dried 25 mL round bottom flask. The solution was 
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cooled to 0 
o
C and vanadyl acetylacetonate (6.0 mg, 0.023 mmol) was added in one 
portion followed by dropwise addition of tert-butyl hydrogen peroxide (0.25 mL, ~5.5 M 
in decane). The resulting dark red solution was stirred at 0 
o
C for 4 h until reaction was 
determined complete by TLC. The crude reaction mixture was transferred directly to a 
silica column that had been equilibrated with 1% Et3N in hexane and was purified using 
4:1 Hex/EtOAc to give oxirane 2.311 as a clear, colorless oil and a single diastereomer 
by 
1
HNMR (315 mg, 95%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.02 (d,  J = 2.0 Hz, 6H), 0.87 (s, 9H),  1.03 (s, 
9H), 1.04 (d,  J  = 3.0 Hz, 3H),  1.42-1.48 (m, 1H), 1.59-1.65 (m, 1H), 1.68-1.75 (m, 1H), 
1.80-1.86 (m, 1H),  1.88-1.92 (m, 1H), 2.22 (dm, J  = 14.0 Hz, 1H), 2.63 (d,  J = 4.2 Hz, 
1H), 3.05 (dd,  J  = 4.2, 2.4 Hz, 1H), 3.23 (dt,  J  = 6.2, 2.4 Hz, 1H), 3.37 (dd, J = 11.6, 
6.2 Hz, 1H), 3.69-3.73 (s, 2H), 3.76 (dd,  J  = 11.6, 2.4 Hz, 1H), 3.80 (s, 3H), 3.85 (q,  J  
= 4.2 Hz, 1H), 3.91 (sex,  J  = 6.2 Hz, 1H), 4.50 (dd,  J  = 25.4, 11.6 Hz, 2H), 4.86-4.90 
(m, 2H), 5.49-5.59 (m, 1H), 6.87 (d,  J  = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.33-7.43 
(m, 6H), 7.66-7.69 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): -5.42, 18.28, 19.35, 
23.36, 25.92, 26.04, 27.21, 33.01, 35.53, 41.99, 46.81, 54.34, 55.45, 56.71, 61.99, 68.45, 
69.92, 70.05, 73.05, 113.98, 116.14, 127.59, 127.70, 129.61, 129.69, 130.19, 134.53, 
135.00, 136.09, 137.62, 159.45. 
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(5R,6S,7S,9S)-7-allyl-6-(((tert-butyldimethylsilyl)oxy)methyl)-5-((2R,3S)-3-(((4-
methoxybenzyl)oxy)methyl)oxiran-2-yl)-2,2,3,3,9,12,12-heptamethyl-11,11-diphenyl-
4,10-dioxa-3,11-disilatridecane (2.312). Oxirane 2.311 (230 mg, 0.31 mmol) was 
suspended in anhydrous dichloromethane (6 mL) in a flame-dried 25 mL round bottom 
flask. Pyridine was added (99 mg, 1.26 mmol) followed by TBSOTf (248 mg, 94 mmol). 
The reaction was stirred at room temperature for 1.5 h and quenched with water once 
TLC indicated complete conversion. The mixture was extracted with dichloromethane 
(3x), dried over Na2SO4, and condensed in vacuo to give a clear oil. The oil was purified 
by flash chromatography (6:1 Hex:EtOAc) to provide bis-TBS ether (263 mg, 99 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.01 (d,  J = 1.6 Hz, 6H), 0.02 (s, 3H), 0.04 (s, 
3H), 0.86 (s, 9H), 0.87 (s, 9H), 1.01-1.02 (m, 12H), 1.45-1.52 (m, 1H), 1.59-1.75 (m, 
3H), 1.88-1.94 (m, 1H), 2.32 (dm, J  = 14.0 Hz, 1H), 2.80 (dd,  J = 4.8,  2.2 Hz, 1H), 3.09 
(dt,  J  = 6.4, 2.2 Hz, 1H), 3.20 (dd,  J  = 11.5, 6.4 Hz, 1H),  3.63 (d,  J  = 6.4 Hz, 2H), 
3.70 (dd,  J  = 11.5, 2.2Hz, 1H), 3.80 (s, 3H), 3.90 (dd,  J  = 5.0, 3.6 Hz, 1H), 3.96 (sex,  
J  = 6.2 Hz, 1H), 4.47 (dd,  J  = 30.2, 11.5 Hz, 2H), 4.84-4.88 (m, 2H), 5.48-5.58 (m, 
1H), 6.86 (d,  J  = 8.6 Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H), 7.32-7.41 (m, 6H), 7.66-7.71 (m, 
4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): -5.20, -4.79, -4.19, 18.32, 18.38, 19.33, 
23.50, 26.10, 26.11, 27.19, 32.49, 35.61, 43.23, 48.23, 55.45, 55.67, 56.72, 59.77, 68.87, 
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70.32, 70.57, 73.02, 113.96, 115.77, 127.62, 127.64, 129.55, 129.58, 130.31, 134.99, 
135.08, 136.09, 138.05, 159.40. 
 
((2S,3R)-3-((5R,6S,7S,9S)-7-allyl-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2,3,3,9, 
12,12-heptamethyl-11,11-diphenyl-4,10-dioxa-3,11-disilatridecan-5-yl)oxiran-2-
yl)methanol (2.313). Bis-TBS ether 2.312 (248 mg, 0.30 mmol) was suspended in 
dichloromethane/ pH 7 phosphate buffer (9:1 v/v, 10 mL) and the reaction was cooled to 
0 
o
C. DDQ (75mg, 0.33 mmol) was added in one portion and the biphasic mixture was 
vigorously stirred for 4 h at 0
 o
C. The reaction was quenched by addition of saturated 
NaHCO3 and extracted with dichloromethane (4x), dried over Na2SO4, and condensed 
under reduced pressure to provide a yellow oil. This oil was purified by flash 
chromatography (5:1 Hex:EtOAc) to provide alcohol 2.313 as a clear, colorless oil (180 
mg, 83%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.02 (s, 6H), 0.03 (s, 3H), 0.05 (s, 3H), 0.87 (s, 
9H), 1.04 (s, 9H), 1.05 (d,  J  = 6.1 Hz, 3H), 1.48-1.77 (m, 5H), 1.85-1.91 (m, 1H), 2.29 
(dm, J  = 14.0 Hz, 1H), 2.96 (dd,  J = 4.6, 2.2 Hz, 1H), 3.08 (quin,  J  = 2.2 Hz, 1H), 
3.46-3.52 (m, 1H), 3.63-3.65 (m, 2H), 3.85 (ddd,  J  = 12.5, 5.0, 2.4 Hz, 1H), 3.94-3.98 
(m, 2H), 4.84-4.87 (m, 2H), 5.45-5.56 (m, 1H), 7.35-7.44 (m, 6H), 7.68-7.70 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): -5.21, -4.76, -4.23, 18.34, 18.38, 19.34, 23.42, 
26.09, 27.18, 32.53, 35.48, 43.02, 48.26, 56.62, 57.19, 59.77, 61.83, 68.87, 70.31, 115.93, 
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127.62, 127.65, 129.62, 134.93, 135.03, 136.06, 137.79. 
 
(4S,5S,6S,E)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-1-((4-methoxybenzyl)oxy-
5(((triisopropylsilyl)oxy)methyl)nona-2,8-dien-4-ol (2.315). Diol 2.301 (2.16 g, 3.58 
mmol) was suspended in anhydrous dichloromethane (36 mL) in a flame-dried 100 mL 
round bottom flask. Imidazole (1.22 g, 17.91 mmol) was added in one portion, followed 
by dropwise addition of chlorodiisopropylsilane (1.53 mL, 7.17 mmol) at room 
temperature. After 1 h, an additional 1.22 g of imidazole and 1.53 mL of 
chlorodiisopropylsilane were added. After 1 h, 1.53 mL of chlorodiisopropylsilane was 
added and the solution was stirred for an additional 1 h and quenched by addition of 
water after the reaction was determined to be complete by TLC. The mixture was 
extracted with dichloromethane (3 x), dried over Na2SO4, condensed in vacuo, and 
purified by flash chromatography (2:1 Hex/EtOAc) to give triisopropylsilyl ether 2.315 
as  clear, colorless oil (2.39 g, 88%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.04 (s, 33H), 1.44-1.49 (m, 1H), 1.55-1.63 (m, 
1H), 1.71 (quin, J = 7.2 Hz, 1H), 1.87-1.93 (m, 1H), 2.03-2.09 (m, 1H), 3.45 (d, J = 7.2 
Hz, 1H), 3.76 (d, J = 6.8 Hz, 2H), 3.80 (s, 3H), 3.90 (sex, J = 6.2 Hz, 1H), 4.00 (d, J = 
3.0 Hz, 2H), 4.25-4.29 (m, 1H), 4.45 (s, 2H), 4.84-4.91 (m, 2H), 5.49 (dddd, J = 16.9, 
9.8, 7.2, 7.0 Hz, 1H), 5.84-5.85 (m, 2H), 6.87 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 
2H), 7.34-7.43 (m, 6H), 7.66-7.69 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 11.86, 
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18.12, 19.32, 23.36, 27.16, 33.28, 35.12, 41.90, 47.45, 55.41, 63.42, 68.17, 70.11, 71.79, 
73.87, 113.88, 116.43, 127.58, 127.70, 128.46, 129.37, 129.58, 129.69, 130.64, 133.35, 
134.45, 134.88, 136.03, 136.70, 159.26. HRMS: C46H71O5Si2, Calculated: [M+H]+, 
759.4840, Found: [M+H]+, 759.4836. 
 
(1R,2S,3S)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-1-((2S,3S)-3-(((4-
methoxybenzyl)oxy)methyl) oxiran-2-yl)-2-(((triisopropylsilyl)oxy)methyl)hex-5-en-
1-ol (2.316). Triisopropylsilyl ether 2.315 (2.35 g, 3.10 mmol) was suspended in 
anhydrous dichloromethane (16 mL) in a flame-dried 50 mL round bottom flask. The 
solution was cooled to 0 
o
C and vanadyl acetylacetonate (41.0 mg, 0.155 mmol) was 
added in one portion followed by dropwise addition of tert-butyl hydrogen peroxide (1.70 
mL, ~5.5 M in decane). The resulting dark red solution was stirred at 0 
o
C for 4 h until 
reaction was determined complete by TLC. The crude reaction mixture was transferred 
directly to a silica column that had been equilibrated with 1% Et3N in hexane and was 
purified using 4:1 Hex/EtOAc to give oxirane 2.316 as a clear, colorless oil and a single 
diastereomer by 
1
HNMR (2.36 g, 98%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.03 (s, 33H), 1.46 (quin, J = 6.4 Hz, 1H), 1.64 
(quin, 7.2 Hz, 1H), 1.72 (quin, J = 7.2 Hz, 1H), 1.86-1.89 (m, 2H), 2.13-2.18 (m, 1H), 
2.85 (d, J = 4.7 Hz, 1H), 3.08 (dd, J = 4.4, 2.3 Hz, 1H), 3.20 (dt, J = 6.1, 2.2 Hz, 1H), 
3.38 (dd, J = 11.6, 6.2 Hz, 1H), 3.76-3.86 (m, 4H), 3.80 (s, 3H), 3.92 (sex,  J = 6.4 Hz, 
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1H), 4.50 (dd, J = 25.6, 11.6 Hz, 2H), 4.86-4.90 (m, 2H), 5.53 (dddd, J = 19.6, 9.8, 9.2, 
7.4 Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 7.33-7.43 (m, 6H), 7.67-
7.69 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 11.90, 18.13, 19.30, 23.31, 27.15, 
32.92, 35.39, 42.06, 46.96, 54.47, 55.39, 56.52, 62.68, 68.33, 69.86, 70.57, 72.99, 113.91, 
116.18, 127.53, 127.64, 129.54, 129.63, 130.14, 134.47, 134.94, 136.02, 137.34, 159.38. 
HRMS: C46H71O6Si2, Calculated: [M+H]+, 775.4789, Found: [M+H]+, 775.4785. 
 
(5S,7S,8S)-7-allyl-8-((R)-(benzyloxy)((2S,3S)-3-(((4-methoxybenzyl)oxy)methyl) 
oxiran-2-yl)methyl)-11,11-diisopropyl-2,2,5,12-tetramethyl-3,3-diphenyl-4,10-dioxa-
3,11-disilatridecane (2.317). Sodium hydride (60% dispersion in mineral oil) (248 mg, 
6.19 mmol) was suspended in anhydrous tetrahydrofuran (34 mL) in a flame-dried 100 
mL round bottom flask, and the solution was cooled to 0 
o
C.  A solution of oxirane 2.316 
(2.40 g, 3.10 mmol) in THF (10 mL) was slowly added to the sodium hydride solution, 
followed by immediate addition of benzyl bromide (1.47 mL, 12.38 mmol) and tert-
butylammonium iodide (229 mg, 0.619 mmol). The solution was warmed to room 
temperature and stirred for 9 h. The reaction was quenched by the addition of saturated 
NH4Cl, extracted with ethyl acetate (3 x), dried over Na2SO4, and condensed in vacuo to 
give a yellow oil that was purified by flash chromatography (17:3 Hex/EtOAc) to provide 
benzyl ether 2.317 as a clear, colorless oil (2.43 g, 91%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.02 (d, J = 5.4 Hz, 33H), 1.48 (quin, J = 6.7 Hz, 
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1H), 1.61-1.68 (m, 1H), 1.68-1.74 (m, 1H), 1.84-1.91 (m, 2H), 1.96-2.02 (m, 1H), 2.22-
2.29 (m, 1H), 2.91 (dd, J = 5.2, 2.0 Hz, 1H), 3.17 (dt, J = 6.1, 2.4 Hz, 1H), 3.30 (dd, J = 
10.9, 6.5 Hz, 1H), 3.55-3.60 (m, 2H), 3.69 (dd, 10.0, 5.5 Hz,  1H), 3.73-3.78 (m, 1H), 
3.80 (s, 3H), 3.81-3.81 (m, 1H), 3.95 (sex, J = 6.4 Hz, 1H), 4.47 (dd, J = 27.9, 11.9 Hz, 
2H), 4.56 (dd, J= 85.2, 11.5 Hz, 2H), 4.82-4.86 (m, 2H), 5.54 (dddd, J = 17.8, 10.6, 7.8, 
7.6 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 7.22-7.40 (m, 13H), 7.66-7.69 (m, 4H).
13
C NMR 
(CDCl3, 100 MHz)  (ppm): 12.05, 18.21, 19.29, 23.51, 27.13, 32.83, 35.97, 42.83, 
47.51, 55.40, 55.66, 56.39, 60.64, 68.65, 70.21, 73.01, 73.54, 113.91, 115.60, 127.44, 
127.53, 127.59, 128.33, 129.51, 129.54, 134.81, 135.04, 136.02, 138.45, 139.07, 159.37.  
HRMS: C53H77O6Si2, Calculated: [M+H]+, 865.5259, Found: [M+H]+, 865.5259. 
 
((2S,3S)-3-((1R,2S,3S)-1-(benzyloxy)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-2-
(((triisopropylsilyl) oxy)methyl)hex-5-en-1-yl)oxiran-2-yl)methanol (2.318). Benzyl 
ether 2.317 (1.70 g, 1.96 mmol) was suspended in dichloromethane: pH 7 phosphate 
buffer (7:1 v/v, 40 mL) in a 100 mL round bottom flask. The solution was cooled to 0 
o
C 
and vigorously stirred. 2,3-Dichloro-5,6-Dicyanobenzoquinone (535 mg, 2.36 mmol) was 
added in 3 portions and the resulting biphasic solution was vigorously stirred for 2 h at 0 
o
C. An additional 107 mg of DDQ was added and the solution was stirred 2 h at 0 
o
C. The 
reaction was quenched by addition of saturated NaHCO3, extracted with dichloromethane 
(4 x), dried over Na2SO4, and condensed in vacuo to provide a yellow residue that was 
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purified by flash chromatography (5:1 Hex/EtOAc) to provide alcohol 2.318 as a clear, 
colorless oil (1.11 g, 76%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.02-1.05 (m, 33H), 1.44-1.53 (m, 2H), 1.62-1.67 
(m, 1H), 1.68-1.75 (m, 1H), 1.84-1.91 (m, 1H), 1.94-2.01 (m, 1H), 2.21-2.27 (m, 1H), 
3.05 (dd, J = 4.88, 2.2 Hz, 1H), 3.11 (quin, J = 2.3 Hz, 1H), 3.44 (ddd, J = 12.7, 7.4, 5.0 
Hz, 1H), 3.63 (t, J = 5.1 Hz, 1H), 3.68-3.82 (m, 3H), 3.95 (sex, J = 6.2 Hz, 1H), 4.52 (dd, 
J = 55.6, 11.8 Hz, 2H), 4.83-4.87 (m, 2H), 5.54 (dddd, J = 15.3, 10.2, 7.2, 6.2 Hz, 1H), 
7.25-7.42 (m, 11H), 7.68 (d, J = 7.2 Hz, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 
12.07, 18.22, 19.31, 23.50, 27.14, 32.92, 35.94, 42.76, 47.47, 56.72, 56.79, 60.71, 61.77, 
68.65, 73.81, 77.36, 115.73, 127.52, 127.55, 127.60, 128.39, 129.55, 129.58, 134.83, 
135.02, 136.04, 138.32, 139.11.  HRMS: C45H69O5Si2, Calculated: [M+H]+, 745.4684, 
Found: [M+H]+, 745.4681. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-
(((triisopropylsilyl)oxy) methyl)non-8-ene-1,3-diol (2.319). Alcohol 2.318 (1.07 g, 1.44 
mmol) was suspended in anhydrous tetrahydrofuran (96 mL) in a 250 mL flame-dried 
round bottom flask and cooled to 0 
o
C. Sodium bis(2-methoxyethoxy)aluminum hydride 
(65% wt in toluene, 2.68 mL, 8.62 mmol) was added dropwise and the resulting solution 
was warmed to room temperature and stirred for 5 h, until the reaction neared completion 
and the free primary alcohol resulting from TIPS deprotection began to form. At this 
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time, saturated sodium potassium tartrate was added dropwise and the resulting cloudy 
emulsion was diluted with 50 mL of ethyl acetate and stirred for 30 min until the organic 
layer became clear. The product was extracted by ethyl acetate (3 x), dried over Na2SO4, 
and condensed in vacuo to give a thick, clear oil. This oil was purified by flash 
chromatography (7:3 Hex:EtOAc) to provide the desired 1,3-diol 2.319 (670 mg, 63%, 
70% based on recovered starting material) as the only product (
1
HNMR >20:1 1,3 
diol:1,2 diol). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.04-1.09 (m, 33H), 1.49-1.56 (m, 1H), 1.60-1.67 
(m, 1H), 1.74-1.82 (m, 3H), 1.89-1.95 (m, 1H), 2.04-2.12 (m, 1H), 2.16-2.21 (m, 1H), 
2.94 (bs, 1H), 3.51 (t, J = 6.0 Hz, 1H), 3.74-3.89 (m, 5H), 3.95-4.02 (m, 2H), 4.52 (s, 
2H), 4.83-4.87 (m, 2H), 5.37-5.47 (m, 1H), 7.26-7.44 (m, 11H), 7.68-7.71 (m, 4H).
13
C 
NMR (CDCl3, 100 MHz)  (ppm): 12.04, 18.12, 18.15, 19.29, 23.17, 27.12, 31.99, 34.83, 
34.95, 42.33, 46.24, 60.94, 62.56, 68.73, 73.45, 74.56, 82.31, 116.48, 127.56, 127.63, 
127.75, 127.84, 128.50, 129.55, 129.60, 134.72, 134.96, 136.00, 136.79, 138.51.  
HRMS: C45H71O5Si2, Calculated: [M+H]+, 747.4840, Found: [M+H]+, 747.4843. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
hydroxy-5-(((triisopropylsilyl)oxy)methyl)non-8-en-1-yl Pivalate (2.320). 1,3 diol 
2.319 (540 mg, 0.723 mmol) was suspended in anhydrous dichloromethane (36 mL) in a 
100 mL flame-dried round bottom flask. Pyridine was added (0.59 mL, 7.23 mmol) 
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followed by addition of pivaloyl chloride (0.53 mL, 4.34 mmol) at room temperature, and 
the resulting solution was stirred for 2 h. The reaction was quenched by addition of 
saturated NaHCO3, extracted with dichloromethane (3 x), dried over Na2SO4, and 
condensed in vacuo to give a cloudy, white residue. This residue was purified by flash 
chromatography (4:1 Hex:EtOAc) to give pivalate ester 2.320 as a clear, colorless oil 
(596 mg, 99%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.02-1.08 (m, 33H), 1.18 (s, 9H), 1.57 (dquin, J = 
59.8, 6.8 Hz, 2H), 1.69-1.82 (m, 3H), 1.96-2.04 (m, 1H), 2.05-2.12 (m, 1H), 2.16-2.22 
(m, 1H), 3.18 (d, J = 4.9 Hz, 1H), 3.50 (t, J = 6.0 Hz, 1H), 3.73 (dd, J = 10.5, 6.8 Hz, 
1H), 3.81 (dd, J = 10.6, 3.1 Hz, 1H), 3.84-3.88 (m, 1H), 3.97 (sex, J = 6.1 Hz, 1H), 4.16-
4.26 (m, 2H), 4.53 (s, 2H), 4.81-4.85 (m, 2H), 5.38-5.48 (m, 1H), 7.24-7.43 (m, 11H), 
7.67-7.70 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 12.07, 18.17, 18.20, 19.31, 
23.27, 27.14, 27.36, 32.17, 32.70, 35.13, 38.83, 42.65, 46.20, 60.98, 62.35, 68.73, 70.44, 
73.54, 77.36, 82.55, 116.24, 127.57, 127.64, 127.73, 128.47, 129.55, 129.62, 134.77, 
135.03, 136.02, 137.28, 138.74, 178.73.  HRMS: C50H79O6Si2, Calculated: [M+H]+, 
831.5415, Found: [M+H]+, 831.5417. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-(((triisopropylsilyl)oxy)methyl)non-8-en-1-yl Pivalate (2.321). Pivalate 
ester 2.320 (440 mg, 0.53 mmol) was suspended in anhydrous dichloromethane (52 mL) 
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in a 100 mL flame-dried round bottom flask. 1,8-Bis(dimethylamino) naphthalene (680 
mg, 3.18 mmol) was added followed by addition of trimethyloxonium tetrafluoroborate 
(392 mg, 2.65 mmol) in 3 portions at room temperature. The resulting solution was 
stirred at room temperature for 1.5 h until TLC indicated that the reaction was complete. 
The reaction was quenched by addition of saturated NaHCO3, extracted with 
dichloromethane (3 x), dried over Na2SO4, and condensed in vacuo to give a pale yellow 
residue. This residue was purified by flash chromatography (17:3 Hex:EtOAc) to provide 
the desired methyl ether 2.321 as a clear, colorless oil (430 mg, 96%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.00-1.07 (m, 33H), 1.19 (s, 9H), 1.45 (quin, J = 
6.8 Hz, 1H), 1.61-1.74 (m, 3H), 1.82-1.94 (m, 1H), 1.95-2.05 (m, 1H), 2.07-2.13 (m, 1H), 
2.14-2.21(m, 1H), 3.36 (s, 3H), 3.55 (d, J = 9.2 Hz, 1H), 3.60-3.68 (m, 2H), 3.80 (dd, J = 
8.4, 1.7 Hz, 1H), 3.92 (sex, J = 6.1 Hz, 1H), 4.11-4.17 (m, 1H), 4.21-4.27 (m, 1H), 4.70 
(dd, J = 143.5, 11.4 Hz, 2H), 4.78-4.82 (m, 2H), 5.42-5.52 (m, 1H) 7.22-7.41 (m, 11H), 
7.65-7.67 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 12.09, 18.27, 19.30, 23.41, 
27.13, 27.39, 28.89, 32.98, 35.82, 38.81, 43.12, 46,22, 57.49, 61.90, 62.53, 68.69, 74.02, 
77.36, 78.35, 81.37, 115.44, 127.33, 127.50, 127.60, 127.82, 128.27, 129.46, 129.55, 
134.67, 135.15, 136.01, 138.82, 139.21, 178.67.  HRMS: C51H80O6NaSi2, Calculated: 
[M+H]+, 867.5391, Found: [M+H]+, 867.5389. 
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(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-hydroxypropyl)-3-methoxy-5-(((triisopropyl 
silyl)oxy)methyl)non-8-en-1-yl Pivalate (2.323). Ether 2.321 (35.0 mg, 0.041 mmol) 
was suspended in anhydrous dichloromethane (1.0 mL) and added to a solution of 0.01 M 
HCl in methanol (25 mL) at room temperature. The reaction was stirred for 24 h and was 
then diluted with dichloromethane and partitioned with water. The solution was extracted 
with dichloromethane (3x), dried over Na2SO4, and condensed under reduced pressure to 
give a clear residue. This residue was purified by flash chromatography (3:1 Hex:EtOAc) 
to provide the free secondary alcohol 2.323 as a clear colorless oil (22.5 mg, 91 %).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.03-1.06 (m, 21H), 1.16 (d, J = 6.1 Hz, 3H), 1.20 
(s, 9H), 1.25-1.36 (m, 1H), 1.49 (ddd, J = 13.8, 10.4, 3.2 Hz, 1H), 1.61-1.70 (m, 1H), 
1.76-1.83 (m, 1H), 1.85-1.94 (m, 2H), 2.19-1.25 (m, 1H), 2.58 (dm, J = 13.8 Hz, 1H), 
3.08 (s, 1H), 3.46 (s, 3H), 3.61 (t, J = 9.5 Hz, 1H), 3.69 (dd, J = 9.5, 4.6 Hz, 2H), 3.78 (t, 
J = 3.0 Hz, 1H), 3.89-3.97 (m, 1H), 4.12-4.23 (m, 2H),  4.65 (dd, J = 94.6, 11.8 Hz, 2H), 
4.90-4.95 (m, 2H), 5.64-5.74 (m, 1H), 7.27-7.36 (m, 5H).
13
C NMR (CDCl3, 100 MHz)  
(ppm): 12.06, 18.21, 18.25, 23.25, 27.38, 29.86, 30.31, 31.85, 35.98, 38.88, 41.80, 42.13, 
58.31, 61.20, 61.83, 64.47, 73.43, 79.86, 80.17, 115.61, 127.14, 127.75, 127.83, 128.31, 
128.54, 138.70, 138.85, 178.59.  
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(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-
(hydroxymethyl)-3-methoxynon-8-en-1-yl Pivalate (2.322). Methyl ether 2.321 (212 
mg, 0.251mmol) was suspended in anhydrous dichloromethane (25 mL) in 50 mL flame-
dried round bottom flask. Boron trifluoride diethyl etherate (46.5% BF3, 0.133 mL, 0.502 
mmol) was added dropwise at room temperature and the resulting mixture was stirred at 
room temperature for 0.5 h until TLC showed that the reaction had reached completion. 
The reaction was quenched by addition of saturated NaHCO3, extracted with 
dichloromethane (3x), dried over dried over Na2SO4, and condensed in vacuo to give a 
clear oil. This oil was purified by flash chromatography (7:3 Hex:EtOAc) to give the free 
primary alcohol 2.322 as a clear, colorless oil (162 mg, 94%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.02 (s, 9H), 1.03 (d, J = 6.2 Hz, 3H), 1.20 (s, 9H), 
1.46 (quin, J = 6.6 Hz, 1H), 1.61-1.71 (m, 2H), 1.77-1.83 (m, 1H), 1.85 (t,  J = 5.3 Hz, 
1H), 1.88-1.97 (m, 1H), 1.99-2.05 (m, 1H), 2.06-2.12 (m, 1H), 3.39 (s, 3H), 3.51-3.65 
(m, 3H), 3.74 (dd, J = 8.3, 2.2 Hz, 1H), 3.93 (sex, J = 6.1 Hz, 1H), 4.20 (dd, J = 7.7, 5.5 
Hz, 1H), 4.63 (dd, J = 115.4, 11.6 Hz, 2H), 4.84-4.87 (m, 2H), 5.40-5.50 (m, 1H), 7.25-
7.42 (m, 11H), 7.65-7.68 (m, 4H).
13
C NMR (CDCl3, 150 MHz)  (ppm): 19.30, 23.15, 
27.17, 27.40, 29.56, 33.07, 35.46, 38.88, 42.26, 45.96, 57.98, 60.81, 61.97, 68.79, 73.66, 
77.36, 78.98, 80.56, 116.08, 127.55, 127.61, 127.65, 127.98, 128.40, 129.57, 129.65, 
134.56, 134.92, 136.03, 137.92, 138.74, 178.70.  HRMS: C42H60O6NaSi, Calculated: 
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[M+H]+, 711.4057, Found: [M+H]+, 711.4055. 
 
(3R,4R,5R,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-
formyl-3-methoxynon-8-en-1-yl pivalate (2.324). Alcohol 2.322 (170 mg, 0.247 mmol) 
was suspended in CH2Cl2/DMSO (4:1 v/v, 12.5 mL) in a 25 mL flame-dried round 
bottom flask and cooled to 0 
o
C. Triethylamine (0.34 mL, 2.47 mmol) was added 
followed by addition of sulfur trioxide pyridine complex (157 mg, 0.987 mmol) in 2 
portions. The resulting solution was allowed to warm to room temperature and stirred for 
6 h. Additional portions of triethylamine (0.34 mL, 2.47 mmol) and sulfur trioxide 
pyridine complex (157 mg, 0.987 mmol) were added. The reaction was stirred for 10 h 
and then quenched by addition water, extracted with dichloromethane (3x), dried over 
Na2SO4, and condensed in vacuo to give a pale yellow oil. This oil was purified by flash 
chromatography (5:1 Hex:EtOAc) to provide aldehyde 2.322 as a clear, colorless oil (127 
mg, 75%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.99 (s, 9H), 1.01 (d, J = 6.4 Hz, 3H), 1.18 (s, 9H), 
1.50 (ddd, J = 14.4, 7.6, 5.6 Hz, 1H), 1.68-1.78 (m, 2H), 1.80-1.85 (m, 1H), 2.26 (dm,  J  
= 14.0 Hz, 1H), 2.34-2.41 (m, 1H), 2.71 (dt,  J  = 9.8, 2.8 Hz, 1H), 3.19-3.23 (m, 1H), 
3.36 (s, 3H), 3.99 (sex, J = 6.0 Hz, 1H), 4.11-4.20 (m, 3H), 4.66 (dd, J = 123.6, 11.6 Hz, 
2H), 4.90-4.97 (m, 2H), 5.53 (ddt,  J = 23.0, 9.8, 7.2 Hz, 1H), 7.27-7.41 (m, 6H), 7.64-
7.67 (m, 4H), 9.62 (d,  J  = 2.4 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.34, 
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23.44, 27.17, 27.41, 29.35, 32.88, 35.63, 38.90, 41.37, 56.02, 58.04, 61.48, 68.11, 73.99, 
75.54, 81.26, 117.09, 127.59, 127.75, 127.99, 128.48, 129.63, 129.76, 134.31, 134.87, 
136.06, 136.08, 137.03, 138.38, 178.61, 202.94.  
 
(3R,6S,Z)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-formyl-3-methoxynona-
4,8-dien-1-yl Pivalate (2.326). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.03 (d, J = 6.2 Hz, 3H), 1.04 (s, 9H), 1.18 (s, 9H), 
1.69 (quin, J = 7.0 Hz, 1H), 1.79-1.87 (m, 2H), 1.97-2.04 (m, 1H), 2.11-2.17 (m, 1H), 
2.22-2.30 (m, 1H), 2.52-2.59 (m, 1H), 3.18 (s, 3H), 3.84 (sex, J = 6.2 Hz, 1H), 4.10-4.22 
(m, 3H), 4.86-4.90 (m, 2H), 5.47 (ddt,  J = 16.2, 10.6, 7.2 Hz, 1H), 6.24 (d,  J = 8.8 Hz, 
1H), 7.36-7.44 (m, 6H), 7.66-7.68 (m, 4H), 9.34 (d,  J  = 1.6 Hz, 1H). 
13
C NMR (CDCl3, 
100 MHz)  (ppm): 19.33, 23.64, 27.22, 27.38, 29.90, 34.20, 36.35, 37.65, 38.88, 44.03, 
57.13, 60.66, 68.86, 73.94, 116.80, 127.68, 127.77, 127.92, 129.72, 129.79, 134.53, 
134.91, 136.02, 136.52, 136.93, 145.12, 170.52, 178.48.  
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(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-(((triisopropylsilyl)oxy)methyl)non-8-en-1-ol (2.333). Pivalate ester 2.321 
(240 mg, 0.284 mmol) was suspended in anhydrous dichloromethane (28 mL) in a 50 mL 
flame-dried round bottom flask and cooled to -78 
o
C. Diisobutylaluminum hydride (1.0 
M in dichloromethane, 0.85 mL, 0.852 mmol) was added dropwise, and the resulting 
solution was stirred for 1 h until TLC indicated the reaction was complete. The reaction 
was quenched by addition of sodium potassium tartrate, warmed to room temperature, 
and stirred for 0.5 h until the organic layer was clear. The mixture was extracted with 
dichloromethane (3 x), dried over Na2SO4, and condensed in vacuo to give a clear oil. 
This oil was purified by flash chromatography (2:1 Hex:EtOAc) to provide the desired 
free primary alcohol 2.333 as a clear, colorless oil (200 mg, 93%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.1 Hz, 3H), 1.05 (s, 
21H), 1.43 (quin, J = 6.8 Hz, 1H), 1.57-1.63 (m, 1H), 1.65-1.74 (m, 2H), 1.75-1.81 (m, 
1H), 1.98-2.07 (m, 1H), 2.10-2.16 (m, 2H), 2.87 (d, J = 6.3 Hz, 1H), 3.41 (s, 3H), 3.58 
(dd, J = 10.5, 6.2 Hz, 1H), 3.66 (dd, J = 10.7, 3.6 Hz, 1H), 3.71-3.82 (m, 4H), 3.91 (sex, J 
= 6.1 Hz, 1H), 4.69 (dd, J = 156.8, 11.4 Hz, 2H), 4.81-4.85 (m, 2H), 5.42-5.52 (m, 1H) 
7.23-7.41 (m, 11H), 7.65-7.68 (m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 12.05, 
18.24, 19.29, 23.45, 27.11, 31.31, 33.03, 35.55, 42.94, 46.47, 57.01, 61.44, 62.08, 68.64, 
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74.19, 78.20, 84.97, 115.58, 127.46, 127.49, 127.60, 127.97, 128.31, 129.47, 129.56, 
134.62, 135.14, 136.01, 138.62, 138.95.   
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-(((triisopropylsilyl)oxy)methyl)non-8-enal (2.334). Alcohol 3.333 (200 mg, 
0.263 mmol) was suspended in CH2Cl2/DMSO (4:1 v/v, 13 mL) in a 50 mL flame-dried 
round bottom flask and cooled to 0 
o
C. Triethylamine (0.37 mL, 2.63 mmol) was added 
followed by addition of sulfur trioxide pyridine complex (167 mg, 1.05 mmol) in 2 
portions. The resulting solution was stirred for 4 h at 0 
o
C, quenched by addition water, 
extracted with dichloromethane (3 x), dried over Na2SO4, and condensed in vacuo to give 
a pale yellow oil. This oil was purified by flash chromatography (4:1 Hex:EtOAc) to 
provide aldehyde 2.334 as a clear, colorless oil (185 mg, 93%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.99 (s, 9H), 1.02 (d, J = 6.1 Hz, 3H), 1.04-1.06 
(m, 21H), 1.41 (quin, J = 6.7 Hz, 1H), 1.57-1.71 (m, 3H), 2.04-2.11 (m, 2H), 2.54 (dd, J 
= 16.7, 1.5 Hz, 1H), 2.74 (dd, J = 16.7, 3.0 Hz, 1H), 3.39 (s, 3H), 3.57 (dd, J = 10.9, 6.8 
Hz, 1H), 3.66 (dd, J = 10.8, 3.3 Hz, 1H), 3.82 (dd, J = 9.0, 1.8 Hz, 1H), 3.90 (sex, J = 6.2 
Hz, 1H), 4.12 (ddd, J = 8.2, 3.7, 2.1 Hz, 1H), 4.67 (dd, J = 134.0, 11.4 Hz, 2H), 4.80-
4.84 (m, 2H), 5.38-5.48 (m, 1H) 7.22-7.41 (m, 11H), 7.63-7.67 (m, 4H), 9.78 (dd, J = 
2.8, 1.5 Hz, 1H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 11.96, 18.22, 19.28, 23.43, 
27.09, 32.84, 35.33, 42.82, 43.86, 46.77, 57.19, 61.83, 68.50, 74.30, 78.85, 80.12, 115.76, 
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127.50, 127.62, 127.95, 128.34, 129.50, 129.60, 134.53, 135.04, 135.99, 138.36, 138.74, 
202.05.   
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-(((triisopropylsilyl)oxy)methyl)non-8-enoic acid (2.335). To a stirring 
solution of aldehyde 2.334 (182 mg, 0.240 mmol) in tert-butanol (9 mL) was added 2-
methyl-2-butene (0.26 mL, 2.40 mmol). In a separate vial, monobasic sodium phosphate 
(252 mg, 1.82 mmol) was dissolved in water (9 mL) and sodium chlorite (163 mg, 1.80 
mmol) was added in 2 portions. The tert-butanol solution was cooled to 0 
o
C and the 
chlorite/phosphate solution in water was added dropwise. The resulting yellow solution 
was stirred at 0 
o
C for 0.5 h and was then quenched with saturated sodium thiosulfate and 
acidified to pH = 3. The aqueous solution was then extracted with ethyl acetate (4 x), 
dried over Na2SO4, and concentrated in vacuo to give a clear oil. This oil was purified by 
flash chromatography (1:1 Hex:EtOAc) yielding carboxylic acid 2.335 as a clear, 
colorless oil (180 mg, 97%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.3 Hz, 3H), 1.04-1.06 
(m, 21H), 1.43 (quin, J = 6.7 Hz, 1H), 1.59-1.73 (m, 3H), 2.05-2.14 (m, 2H), 2.59 (dd, J 
= 16.5, 3.0 Hz, 1H), 2.73 (dd, J = 16.3, 8.7 Hz, 1H), 3.60 (s, 3H), 3.57 (dd, J = 10.4, 6.4 
Hz, 1H), 3.67 (dd, J = 10.9, 3.9 Hz, 1H), 3.83 (dd, J = 9.0, 1.8 Hz, 1H), 3.90 (sex, J = 6.1 
Hz, 1H), 4.05 (dt, J = 8.2, 2.2 Hz, 1H), 4.68 (dd, J = 141.9, 11.4 Hz, 2H), 4.81-4.85 (m, 
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2H), 5.41-5.51 (m, 1H) 7.23-7.41 (m, 11H), 7.64-7.67 (m, 4H).
13
C NMR (CDCl3, 100 
MHz)  (ppm): 12.02, 18.22, 19.27, 23.42, 27.11, 32.94, 35.08, 35.55, 42.86, 46.51, 
57.47, 61.78, 68.56, 74.49, 77.35, 78.42, 80.90, 115.73, 127.50, 127.54, 127.63, 127.99, 
128.34, 129.49, 129.61, 134.55, 135.08, 135.99, 136.01, 138.43, 138.67, 176.17.   
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-(((triisopropylsilyl)oxy)methyl)non-8-enamide (2.336). Carboxylic acid 
2.335 (225 mg, 0.290 mmol) was suspended in N,N-dimethylformamide (1.5 mL). 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (83.4 mg, 0.44 mmol) and 
1-Hydroxybenzotriazole (58.8 mg, 0.44 mmol) were added subsequently at room 
temperature, followed by addition of diisopropylethylamine (0.20 mL, 1.16 mmol) and 
ammonium chloride (31 mg, 0.580 mmol). The resulting solution was stirred for 6 h at 
room temperature until TLC indicated complete conversion. The reaction was quenched 
by addition of water, extracted with dichloromethane (3 x), dried over Na2SO4, and 
condensed in vacuo to give a pale yellow residue. This residue was purified by flash 
chromatography (1:1 Hex/EtOAc then 1:3 Hex/EtOAc) to give amide 2.336 as a clear 
colorless oil (180 mg, 80%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.1 Hz, 3H), 1.04-1.07 
(m, 21H), 1.44 (quin, J = 6.8 Hz, 1H), 1.63-1.73 (m, 3H), 2.01-2.08 (m, 1H), 2.16-2.22 
(m, 1H), 2.43 (dd, J = 15.8, 3.0 Hz, 1H), 2.53 (dd, J = 15.8, 8.4 Hz, 1H), 3.41 (s, 3H), 
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3.62-3.71 (m, 2H), 3.86-3.95 (m, 3H), 4.67 (dd, J = 124.8, 11.5 Hz, 2H), 4.79-4.84 (m, 
2H), 5.16 (bs, 1H), 5.42-5.52 (m, 1H), 5.98 (bs, 1H),  7.23-7.41 (m, 11H), 7.64-7.66 (d, J 
= 7.6 Hz, 4H).
 13
C NMR (CDCl3, 100 MHz)  (ppm): 12.04, 18.28, 19.30, 23.46, 27.11, 
33.06, 35.82, 36.42, 43.08, 46.05, 57.21, 61.71, 68.63, 74.32, 78.21, 81.02, 115.63, 
127.48, 127.53, 127.63, 127.76, 128.36, 129.51, 129.58, 134.68, 135.03, 136.00, 138.64, 
138.90, 174.12.   
 
(3R,4R,5S,6S,8S)-8-((tert-butyldiphenylsilyl)oxy)-4-hydroxy-3-methoxy-6-propyl-5-
(((triisopropylsilyl)oxy)methyl)nonanamide (2.337). Amide 2.336 (180 mg, 0.232 
mmol) was suspended in anhydrous ethyl acetate (23 mL) in a 50 mL round bottom flask. 
10% palladium on activated carbon (62 mg, 0.058 mmol), was added and the flask was 
sealed and evacuated then filled with argon (3 x). The flask was then evacuated and 
refilled with hydrogen (3 x) from a balloon. The reaction was stirred for 8 h at room 
temperature until reaction was complete by TLC. The mixture was filtered through celite 
and washed through liberally with ethyl acetate. The filtrate was condensed in vacuo to 
give alcohol 2.337 as a clear colorless oil that was carried on to the next step without 
further purification (158 mg, 99%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.77 (t, J = 7.2 Hz, 3H), 0.83-0.92 (m, 2H), 1.03-
1.08 (m, 33H), 1.33-1.40 (m, 1H),  1.41-1.47 (m, 1H), 1.59-1.65 (m, 2H), 1.84-1.90 (m, 
1H), 2.51 (d, J = 5.5 Hz, 2H), 2.68 (d, J = 2.7 Hz, 1H), 3.39 (s, 3H), 3.66-3.74 (m, 2H), 
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3.82  (dd, J = 10.9, 5.1 Hz, 1H), 3.88  (dd, J = 13.5, 6.1 Hz, 1H), 3.93-3.97 (m, 1H), 5.20 
(bs, 1H), 6.01 (bs, 1H),  7.35-7.44 (m, 6H), 7.67-7.72 (m, 4H). 
 
(3R,5S,6S,8S)-8-((tert-butyldiphenylsilyl)oxy)-3-methoxy-4-oxo-6-propyl-5-
(((triisopropylsilyl)oxy)methyl)nonanamide (2.338). Alcohol 2.337 (152 mg, 0.222 
mmol) was suspended in anhydrous dichloromethane (22 mL) in a flame-dried 50 mL 
round bottom flask with 4 angstrom molecular sieves (100 mg). The reaction was cooled 
to 0 
o
C and 4-methylmorpholine N-oxide (52 mg, 0.443 mmol) was added followed by 
tetrapropylammonium perruthenate (15.6 mg, 0.044 mmol). The reaction was warmed to 
room temperature and stirred for 2 h. Upon complete conversion as indicated by TLC, the 
mixture was filtered through celite and washed through liberally with dichloromethane. 
The filtrate was condensed in vacuo to give a dark green residue that was purified by 
flash chromatography (1:3 Hex/EtOAc) to give hydroxyketoamide 2.338 as a clear, 
colorless oil (129 mg, 85 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.67 (t, J = 6.8 Hz, 3H), 0.79-0.93 (m, 3H), 1.02 
(s, 30H), 1.09 (d, J = 6.1 Hz, 3H), 1.25 (ddd, J = 13.7, 8.1, 4.1 Hz, 2H), 1.41 (ddd, J = 
13.7, 8.9, 4.6 Hz, 1H), 1.65-1.73 (m, 1H), 2.37 (dd, J = 14.8, 8.1 Hz, 1H), 2.59 (dd, J =  
15.3, 4.1 Hz, 1H), 3.00 (ddd, J = 8.7, 6.8, 4.8 Hz, 1H), 3.38 (s, 3H), 3.70 (dd, J = 9.5, 4.7 
Hz, 1H), 3.78-3.83 (m, 2H), 4.17 (dd, J = 8.1, 4.0 Hz, 1H), 5.27 (bs, 1H), 5.86 (bs, 1H),  
7.34-7.43 (m, 6H), 7.65-7.68 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 11.97, 
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14.52, 18.10, 18.76, 19.28, 22.83, 27.11, 32.26, 33.98, 37.04, 42.26, 53.06, 58.29, 63.55, 
68.24, 83.87, 127.67, 127.70, 129.68, 134.65, 135.98, 136.02, 171.99, 212.41. HRMS: 
C39H66NO5Si2, Calculated: [M+H]+, 684.4480, Found: [M+H]+, 684.4485. 
 
 
(4R,5R,7S,9S,10S)-4-methoxy-10-(methoxymethyl)-7-methyl-9-propyl-6-oxa-1-
azaspiro[4.5]decan-2-one (2.339).  Hydroxyketoamide 2.338 (68 mg, 0.099 mmol) was 
suspended in anhydrous methanol (30 mL). Concentrated HCl (0.026 mL, 0.3 mmol) was 
added at room temperature and the reaction was allowed to stir for 10 h. After this time 
the reaction was quenched by dropwise addition of NaHCO3 and extracted with ethyl 
acetate (3 x) The organic layers were combined, dried over Na2SO4, and condensed in 
vacuo to give a clear, colorless residue. The crude residue was purified by flash 
chromatograpy (1:6 Hex:EtOAc) to yield the desired marineosin model stereoisomer 
2.339 as a clear, colorless oil (22 mg, 82%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.89-
0.94 (m, 5H), 1.14-1.16 (m, 3H), 1.20 (d, J = 6.6 Hz, 3H), 1.93-1.96 (m, 1H), 2.34-2.37 
(m, 1H) 2.52 (m, 2H) 3.22 (dd, J = 10.4 , 4.4 Hz, 1H), 3.28-3.31 (m, 1H), 3.31  (s, 3H), 
3.44 (s, 3H), 3.74-3.79 (m, 1H), 4.15 (dd, J = 9.6, 8.0 Hz, 1H), 6.23 (bs, 1H). ). 
13
C 
NMR (CDCl3, 150 MHz)  (ppm): 14.0, 22.2, 26.0, 30.6, 35.2, 40.6, 55.9, 58.2, 62.0, 
65.4, 70.4, 72.7, 79.2, 90.3, 175.3.  
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(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-((4-methoxyphenoxy)methyl)non-8-en-1-yl Pivalate (2.342). A 15-20 mL 
microwave vial was charged with triphenylphosphine (298 mg, 1.14 mmol) in anhydrous 
tetrahydrofuran (18 mL) and cooled to 0 
o
C. 4-methoxy phenol (195 mg, 1.57 mmol) was 
added followed by dropwise addition of diisopropylazodicarboxylate (0.21 mL, 1.07 
mmol). The resulting solution was stirred at 0 
o
C for 15 min and alcohol 2.322 (300 mg, 
0.435 mmol) was added dropwise as a solution in tetrahydrofuran (1.8 mL). The reaction 
was warmed to room temperature, stirred for 15 minutes, and then transferred to a heating 
mantle preheated to 80 
o
C. After 0.5 h, the reaction was determined to be complete by 
TLC and was then cooled to room temperature and quenched with saturated NaHCO3. 
The mixture was extracted with ethyl acetate (3 x), dried over Na2SO4, and condensed in 
vacuo to give a pale yellow oil. This oil was purified by flash chromatography (13:7 
Hex:EtOAc) to provide the desired p-methoxyphenyl ether 2.342 as a clear, colorless oil 
(300 mg, 87%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.01 (s, 9H), 1.04 (d, J = 10.5 Hz, 3H), 1.12 (s, 
9H), 1.46 (quin, J = 6.9 Hz, 1H), 1.85-1.94 (m, 1H), 1.95-2.02 (m, 1H), 2.04-2.08 (m, 
1H), 2.18-2.29 (m, 2H), 3.35 (s, 3H), 3.49 (d, J = 9.4 Hz, 1H), 3.77 (s, 3H), 3.78-3.82 (m, 
1H), 3.87-3.97 (m, 1H), 3.99 (d,  J = 9.3 Hz, 1H), 4.20 (dd, J = 7.6, 5.4 Hz, 2H), 4.71 
(dd, J = 143.5, 11.6 Hz, 2H), 4.84-4.90 (m, 2H), 5.46-5.56 (m, 1H), 6.78 (dd, J =  28.8, 
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9.1 Hz, 4H), 7.24-7.40 (m, 11H), 7.65-7.68 (m, 4H).
13
C NMR (CDCl3, 150 MHz)  
(ppm): 19.29, 23.17, 27.16, 27.33, 28.88, 33.14, 35.71, 38.80, 42.25, 43.21, 55.92, 57.70, 
62.08, 66.39, 68.80, 74.11, 77.50, 80.70, 114.81, 115.29, 115.84, 127.46, 127.52, 127.64, 
127.97, 128.33, 129.52, 129.61, 134.55, 134.98, 136.05, 138.49, 139.08, 152.83, 154.04, 
178.67. HRMS: C49H66O7NaSi2, Calculated: [M+H]+, 817.4476, Found: [M+H]+, 
817.4479. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-((4-methoxyphenoxy)methyl)non-8-en-1-ol (2.343). p-Methoxyphenyl 
ether 2.342 (290 mg, 0.365 mmol) was suspended in anhydrous dichloromethane (36.5 
mL) in a 100 mL flame-dried round bottom flask and cooled to -78 
o
C. 
Diisobutylaluminum hydride (1.0 M in dichloromethane, 1.10 mL, 1.094 mmol) was 
added dropwise, and the resulting solution was stirred for 0.5 h until TLC indicated the 
reaction was complete. The reaction was quenched by addition of sodium potassium 
tartrate, warmed to room temperature, and stirred for 0.5 h until the organic layer was 
clear. The mixture was extracted with dichloromethane (3 x), dried over Na2SO4, and 
condensed in vacuo to give a clear oil. This oil was purified by flash chromatography 
(13:7 Hex:EtOAc) to provide the desired free primary alcohol 2.343 as a clear, colorless 
oil (240 mg, 93%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.00 (s, 9H), 1.04 (d, J = 10.1 Hz, 3H), 1.45 (quin, 
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J = 7.0 Hz, 1H), 1.62-1.70 (m, 2H), 1.77-1.84 (m, 1H), 1.98-2.10 (m, 2H), 2.19-2.25 (m, 
2H), 2.59 (dd, J = 7.1, 4.0 Hz, 1H), 3.38 (s, 3H), 3.61 (d, J = 8.6 Hz, 1H), 3.73-3.83 (m, 
4H), 3.77 (s, 3H), 3.92-3.98 (m, 2H), 4.70 (dd, J = 146.2, 11.6 Hz, 2H), 4.85-4.90 (m, 
2H), 5.46-5.56 (m, 1H), 6.79 (dd, J =  33.3, 9.2 Hz, 4H), 7.24-7.41 (m, 11H), 7.65-7.68 
(m, 4H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.29, 23.22, 27.14, 31.59, 33.05, 35.53, 
42.12, 43.35, 55.90, 57.22, 61.37, 66.59, 68.79, 74.15, 77.35, 84.28, 114.84, 115.27, 
115.94, 127.52, 127.55, 127.62, 128.05, 128.36, 129.52, 129.59, 134.55, 134.96, 136.04, 
138.29, 138.84, 152.70, 154.09. HRMS: C44H59O6Si, Calculated: [M+H]+, 711.4081, 
Found: [M+H]+, 711.4080. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-((4-methoxyphenoxy)methyl)non-8-enal. Alcohol 3.343 (220 mg, 0.309 
mmol) was suspended in CH2Cl2/DMSO (4:1 v/v, 15.5 mL) in a 50 mL flame-dried 
round bottom flask and cooled to 0 
o
C. Triethylamine (0.43 mL, 3.09 mmol) was added 
followed by addition of sulfur trioxide pyridine complex (197 mg, 1.24 mmol) in 2 
portions. The resulting solution was stirred for 5 h at 0 
o
C, quenched by addition water, 
extracted with dichloromethane (3 x), dried over Na2SO4, and condensed in vacuo to give 
a pale yellow oil. This oil was purified by flash chromatography (3:1 Hex:EtOAc) to 
provide aldehyde 2.344 as a clear, colorless oil (200 mg, 91%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.01 (s, 9H), 1.04 (d, J = 6.7 Hz, 3H), 1.45 (quin, J 
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= 6.9 Hz, 1H), 1.62-1.71 (m, 2H), 2.01-2.06 (m, 1H), 2.15-2.20 (m, 2H), 2.55-2.63 (m, 
1H), 2.78 (ddd, J = 16.8, 8.0, 2.6 Hz, 1H), 3.35 (s, 3H), 3.73 (dd, J = 10.0, 6.3 Hz, 1H), 
3.77 (s, 3H), 3.84 (dd, J = 10.0, 3.2 Hz, 1H), 3.90-3.98 (m, 3H), 4.69 (dd, J = 126.4, 11.6 
Hz, 2H), 4.83-4.89 (m, 2H), 5.42-5.52 (m, 1H), 6.79 (dd, J =  35.2, 9.0 Hz, 4H), 7.24-
7.41 (m, 11H), 7.64-7.68 (m, 4H), 9.79 (t, J = 2.0 Hz, 1H).
13
C NMR (CDCl3, 150 MHz) 
 (ppm): 19.30, 23.16, 27.16, 32.85, 35.36, 41.92, 43.58, 44.24, 55.91, 57.39, 66.32, 
68.75, 74.31, 78.44, 79.65, 114.85, 115.31, 116.14, 127.55, 127.64, 127.65, 128.05, 
128.40, 129.57, 129.64, 134.56, 134.90, 136.04, 137.93, 138.63, 152.61, 154.13, 201.81. 
HRMS: C44H56O6NaSi, Calculated: [M+H]+, 731.3744, Found: [M+H]+, 731.3745. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-((4-methoxyphenoxy)methyl)non-8-enoic acid (2.345). To a stirring 
solution of aldehyde 2.344 (195 mg, 0.275 mmol) in tert-butanol (14 mL) was added 2-
methyl-2-butene (0.29 mL, 2.75 mmol). In a separate vial, monobasic sodium phosphate 
(289 mg, 2.09 mmol) was dissolved in water (14 mL) and sodium chlorite (187 mg, 2.06 
mmol) was added in 2 portions. The tert-butanol solution was cooled to 0 
o
C and the 
chlorite/phosphate solution in water was added dropwise. The resulting yellow solution 
was stirred at 0 
o
C for 1 h and was then quenched with saturated sodium thiosulfate and 
acidified to pH = 3. The aqueous solution was then extracted with ethyl acetate (4 x), 
dried over Na2SO4, and concentrated in vacuo to give a clear oil. This oil was purified by 
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flash chromatography (1:1 Hex:EtOAc) yielding carboxylic acid 2.345 as a clear, 
colorless oil (188 mg, 96%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.2 Hz, 3H), 1.42-1.49 
(m, 2H), 1.62-1.71 (m, 2H), 2.01-2.07 (m, 1H), 2.15-2.20 (m, 2H), 2.66 (dd, J = 16.3, 3.3 
Hz, 1H), 2.78 (dd, J = 16.2, 8.6 Hz, 1H), 3.40 (s, 3H), 3.73 (dd, J = 9.8, 6.0 Hz, 1H), 3.77 
(s, 3H), 3.85 (dd, J = 9.8, 3.1 Hz, 1H), 3.88-3.99 (m, 3H), 4.70 (dd, J = 131.4, 11.6 Hz, 
2H), 4.85-4.90 (m, 2H), 5.42-5.53 (m, 1H), 6.79 (dd, J =  25.7, 9.0 Hz, 4H), 7.27-7.41 
(m, 11H), 7.65 (d, J = 7.6 Hz, 4H). 
13
C NMR (CDCl3, 150 MHz)  (ppm): 19.28, 23.17, 
29.85, 32.86, 34.83, 35.37, 41.97, 43.49, 55.90, 57.58, 66.19, 68.70, 74.57, 77.85, 80.78, 
114.83, 115.36, 116.20, 127.56, 127.67, 127.74, 128.13, 128.44, 129.58, 129.67, 134.51, 
134.88, 136.03, 136.05, 137.90, 138.39, 152.59, 154.16, 173.69. HRMS: C44H57O7Si, 
Calculated: [M+H]+, 725.3874, Found: [M+H]+, 725.3874. 
 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxy-5-((4-methoxyphenoxy)methyl)non-8-enamide (2.346). Carboxylic acid 
2.345 (170 mg, 0.234 mmol) was suspended in N,N-dimethylformamide (2.5 mL). 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (135 mg, 0.703 mmol) and 
1-Hydroxybenzotriazole (95 mg, 0.703 mmol) were added subsequently at room 
temperature, followed by addition of diisopropylethylamine (0.33 mL, 1.875 mmol) and 
ammonium chloride (50 mg, 0.937 mmol). The resulting solution was stirred for 6 h at 
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room temperature until TLC indicated complete conversion. The reaction was quenched 
by addition of water, extracted with dichloromethane (3 x), dried over Na2SO4, and 
condensed in vacuo to give a pale yellow residue. This residue was purified by flash 
chromatography (1:1 Hex/EtOAc then 1:3 Hex/EtOAc) to give amide 2.346 as a clear 
colorless oil (156 mg, 92%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.01 (s, 9H), 1.03 (d, J = 6.2 Hz, 3H), 1.45 (quin, J 
= 6.7 Hz, 1H), 1.64-1.72 (m, 2H), 2.00-2.05 (m, 1H), 2.13-2.25 (m, 2H), 2.47 (dd, J = 
15.7, 2.8  Hz, 1H), 2.56 (dd, J = 15.6, 8.5 Hz, 1H), 3.39 (s, 3H), 3.74-3.78 (m, 1H), 3.77 
(s, 3H), 3.83-3.90 (m, 2H), 3.93 (sex, J = 6.1 Hz, 1H), 4.00 (dd, J = 8.9, 1.6 Hz, 1H), 
3.88-3.99 (m, 3H), 4.70 (dd, J = 127.3, 11.6 Hz, 2H), 4.84-4.88 (m, 2H), 5.20 (bs, 1H), 
5.45-5.55 (m,  1H), 5.90 (bs, 1H), 6.80 (dd, J =  18.1, 9.2 Hz, 4H), 7.26-7.41 (m, 11H), 
7.64-7.66 (m, 4H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 19.31, 23.31, 27.17, 33.16, 
35.64, 36.81, 42.38, 43.40, 55.90, 57.47, 66.39, 68.74, 74.25, 77.37, 77.72, 81.19, 114.84, 
115.46, 116.02, 127.56, 127.61, 127.66, 127.96, 128.41, 129.56, 129.63, 134.63, 134.95, 
136.04, 138.19, 138.77, 152.70, 154.12, 174.19. HRMS: C44H58NO6Si, Calculated: 
[M+H]+, 724.4033, Found: [M+H]+, 724.4032. 
 
(3R,4R,5S,6S,8S)-8-((tert-butyldiphenylsilyl)oxy)-4-hydroxy-3-methoxy-5-((4-
methoxyphenoxy)methyl)-6-propylnonanamide (2.347). Amide 2.346 (154 mg, 0.213 
mmol) was suspended in anhydrous ethyl acetate (16 mL) in a 15-20 mL microwave vial. 
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10% Palladium on activated carbon was added and the vial was sealed and evacuated 
then filled with argon (3 x). The vial was then evacuated and refilled with hydrogen (3 x) 
from a balloon fit with a needle adapter and needle to pierce the septum. The reaction 
was stirred for 8 h at room temperature until reaction was complete by TLC. The mixture 
was filtered through celite and washed through liberally with ethyl acetate. The filtrate 
was condensed in vacuo to give alcohol 2.347 as a clear colorless oil that was carried on 
to the next step without further purification (132 mg, 98%).  
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.83 (t, J = 7.32 Hz, 3H), 1.04 (s, 9H), 1.07 (d, J = 
6.1 Hz, 3H), 1.37-1.49 (m, 2H), 1.63 (dt, J = 13.4, 5.6 Hz, 1H), 1.89-1.94 (m, 1H), 2.08-
2.15 (m, 1H), 2.32 (d, J = 2.6 Hz, 1H), 2.47 (dd, J = 14.8, 8.8 Hz, 1H), 2.57 (dd, J = 15.2, 
2.9 Hz, 1H), 2.38 (s, 3H), 3.69 (dd, J = 9.7, 7.5 Hz, 1H), 3.73-3.77 (m, 1H), 3.76 (s, 1H),  
3.87 (dd, J = 9.9, 3.0 Hz, 1H), 3.91 (sex, J = 6.2 Hz, 1H), 4.01 (dt, J = 9.4, 2.8 Hz, 1H),  
(quin, J = 6.7 Hz, 1H), 5.23 (bs, 1H), 5.81 (bs, 1H), 6.80 (s, 4H), 7.34-7.42 (m, 6H), 
7.67-7.72 (m, 4H). 
13
C NMR (CDCl3, 150 MHz)  (ppm): 14.64, 19.35, 21.31, 23.77, 
27.17, 29.84, 32.79, 32.82, 35.61, 42.64, 43.52, 55.89, 57.31, 66.73, 68.82, 70.44, 80.45, 
114.82, 115.31, 127.51, 127.63, 129.53, 129.62, 134.50, 135.05, 136.09, 136.14, 152.74, 
154.10, 174.09. HRMS: C37H54NO6Si, Calculated: [M+H]+, 636.3720, Found: [M+H]+, 
636.3723. 
 
(3R,5S,6S,8S)-8-((tert-butyldiphenylsilyl)oxy)-3-methoxy-5-((4-methoxyphenoxy) 
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methyl)-4-oxo-6-propylnonanamide (2.348) Alcohol 2.347 (128 mg, 0.201 mmol) was 
suspended in anhydrous dichloromethane (20 mL) in a flame-dried 50 mL round bottom 
flask with 4 angstrom molecular sieves (150 mg). The reaction was cooled to 0 
o
C and 4-
methylmorpholine N-oxide (48 mg, 0.403 mmol) was added followed by 
tetrapropylammonium perruthenate (7.1 mg, 0.0201 mmol) and the reaction was stirred 
for 1 h at 0 
o
C. After 1 h, the solution was warmed to room temperature and stirred for 3 
h when complete conversion was indicated by TLC. The mixture was filtered through 
celite and washed through liberally with dichloromethane. The filtrate was condensed in 
vacuo to give a dark green residue that was purified by flash chromatography (1:3 
Hex/EtOAc) to give hydroxyketoamide 2.348 as a clear, colorless oil (112 mg, 88 %). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.71 (t, J = 7.1 Hz, 3H), 0.85- 0.98 (m, 3H), 1.03 
(s, 9H), 1.09-1.20 (m, 2H), 1.12 (d, J = 6.1 Hz, 3H), 1.37-1.49 (m, 2H), 1.34 (ddd, J = 
13.7, 7.8, 5.2 Hz, 1H), 1.49 (ddd, J = 13.4, 8.3, 5.2 Hz, 1H), 1.82-1.90 (m, 1H), 2.45 (dd, 
J = 14.7, 7.8 Hz, 1H), 2.62 (dd, J = 15.0, 4.6 Hz, 1H), 3.35- 3.43 (m, 1H), 3.38 (s, 3H), 
3.75 (s, 1H), 3.85-3.91 (m, 2H), 4.06 (t, J = 8.8 Hz, 1H),  4.24 (dd, J = 7.5, 4.7 Hz, 1H),  
5.25 (bs, 1H), 5.80 (bs, 1H), 6.76 (dd, J = 23.0, 8.4 Hz, 4H), 7.34-7.42 (m, 6H), 7.66-
7.68 (m, 4H). 
13
C NMR (CDCl3, 150 MHz)  (ppm): 14.50, 19.03, 19.26, 22.84, 27.10, 
27.14, 32.37, 34.11, 37.00, 42.06, 49.94, 55.84, 58.28, 68.18, 68.30, 83.50, 114.78, 
115.59, 127.66, 127.71, 129.70, 129.71, 134.55, 135.98, 136.00, 152.61, 154.26, 171.86, 
211.75. HRMS: C37H52NO6Si, Calculated: [M+H]+, 634.3564, Found: [M+H]+, 
634.3560. 
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(R)-methyl 3-methoxy-3-((2S,4S)-5-(methoxymethyl)-2-methyl-4-propyl-3,4-dihydro 
-2H-pyran-6-yl)propanoate (2.350). Hydroxyketoamide 2.348 was suspended (53 mg, 
0.0836 mmol) in anhydrous methanol (25 mL) in a 100 mL round bottom flask. 
Concentrated hydrochloric acid (0.041 mL, 0.502 mmol) was added dropwise at room 
temperature and the resulting solution was stirred for 16 h until TLC confirmed complete 
conversion. The mixture was quenched with NaHCO3 and extracted with 
dichloromethane (3 x). The organic layers were combined, dried over Na2SO4, and 
condensed in vacuo to give a pale yellow oil. The crude oil was purified by flash 
chromatograpy (1:2 Hex:EtOAc) to yield the undesired elimination product 2.250 as a 
clear, colorless oil (19.3 mg, 77%).   
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.91 (t, J = 7.2 Hz, 3H), 1.09-1.25 (m, 2H), 1.29 
(d, J = 6.0 Hz, 3H), 1.37-1.49 (m, 2H), 1.51-1.58 (m, 1H), 1.71 (dt, J = 13.7, 2.0 Hz, 
1H), 2.14-2.19 (m, 1H), 2.57 (dd, J = 15.1, 5.5 Hz, 1H), 2.78 (dd, J = 15.1, 8.0 Hz, 1H) 
3.30 (s, 3H), 3.32 (s, 3H),  3.66 (s, 3H), 3.84-3.90 (m, 1H), 3.95 (dd, J = 33.1, 11.5 Hz, 
2H),  4.54 (dd, J = 8.0, 5.7 Hz, 1H). 
13
C NMR (CDCl3, 150 MHz)  (ppm): 14.33, 20.46, 
21.32, 32.76, 33.29, 36.58, 38.86, 51.75, 56.38, 57.95, 67.83, 69.69, 73.60, 112.64, 
149.07, 171.88. 
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5.3. Total Synthesis of Tambjamine K and a Library of Unnatural Analogs. 
 
 
(E)-N-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-N-ethylethanamine (3.17). 
A 100 mL round bottom flask was charged with N,N-diethylformamide (2.86 g, 28.29 
mmol) and 23 mL of dichloromethane. The mixture was cooled to 0 
o
C, and a solution of 
phosphorous oxybromide (10.14 g, 35.36 mmol) in dichloromethane (7 mL) was added 
slowly over 20 minutes. After addition was complete, the reaction mixture was stirred for 
an additional 20 minutes. A solution of 4-methoxy-3-pyrrolin-2-one (7) (2.00 g, 17.68 
mmol) in dichloromethane (18 mL) was added dropwise over 10 minutes, and the 
mixture was stirred for an additional 20 minutes. The flask was then removed from the 
ice bath, transferred to an oil bath, and refluxed (42 
o
C) for 3.5 hours. The reaction 
mixture was then transferred to a 500 mL round bottom flask, cooled to 0 
o
C, and 
quenched by dropwise addition of water (20 mL). Sodium hydroxide (3.0 M in H2O, 230 
mL) was slowly added and the mixture was stirred for an additional 20 minutes. The 
layers were separated and the aqueous layer was extracted with dichloromethane (3 x). 
The combined organic layers were dried over sodium sulfate and concentrated in vacuo. 
The resulting yellow oil was subjected to flash chromatography (4:1 Hex:EtOAc) to give 
3.16 as a tan solid (2.67 g, 59%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.29 (t, J = 7.2 Hz, 3H), 1.30 (t, J = 7.2 Hz, 3H), 
3.40 (q, J = 7.2 Hz, 2H), 3.76 (s, 3H), 4.13 (q, J = 7.2 Hz, 2H), 5.59 (s, 1H), 6.99 (s, 1H). 
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13
C NMR (CDCl3, 100 MHz)  (ppm): 12.4, 14.5, 44.5, 51.0, 57.9, 96.4, 120.7, 133.6, 
138.5, 165.3. IR (KBr) max 2975, 2934, 1629, 1529, 1408, 1290, 1264, 1195, 1116, 
1072, 906, 737 cm
-1
.  HRMS: C10H16N2OBr, Calculated: [M+H]+, 259.0446, Found: 
[M+H]+, 259.0448. 
     
tert-butyl 5'-formyl-4'-methoxy-1H,1'H-2,2'-bipyrrole-1-carboxylate (3.19). 
Pd(PPh3)4 was generated in situ by adding triphenylphosphine (1.22 g, 4.64 mmol) to a 
magnetically stirred suspension of Palladium II Acetate (0.23 g, 1.03 mmol) in degassed 
toluene (5.0 mL) then heating the ensuing mixture at 70 
o
C for 20 minutes under an 
atmosphere of argon. A solution of N-Boc-pyrrole-2-boronic acid (3.26 g, 15.46 mmol) 
and bromoenamine 3.17 (2.67 g, 10.31 mmol) in H2O/1,4-dioxane (1:9 v/v, 86 mL) was 
degassed, purged with argon gas and added to the solution of Pd(PPh3)4 in toluene. 
Anhydrous sodium carbonate (3.28 g, 30.93 mmol) was added and the reaction mixture 
stirred at 85 
o
C. After 3.5 hours, the mixture was cooled and poured into water (150 mL). 
The solution was reduced to pH 7 using 2 M HCl, partitioned with dichloromethane, and 
extracted (4 x). The organic layers were combined, dried over sodium sulfate, and 
condensed in vacuo to give a brown residue that was purified by flash chromatography 
(4:1 Hex:EtOAc) affording aldehyde 3.19 as an orange solid (1.44 g, 48%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.61 (s, 9H), 3.88 (s, 3H), 6.07 (d, J = 3.5 Hz, 1H), 
6.24 (t, J = 3.5 Hz, 1H) 6.66 (dd, J = 3.5 Hz, 1.76 Hz, 1H), 7.33 (dd, J = 3.4, 1.80 Hz, 
1H), 9.53 (s, 1H), 10.73 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 27.8, 57.8, 85.7, 
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94.7, 111.4, 116.8, 118.2, 124.5, 125.9, 130.2, 149.6, 157.6, 174.3. IR (KBr) max 3221, 
2979, 2833, 1735, 1623, 1549, 1502, 1433, 1370, 1330, 1287, 1255, 1140, 1021 cm
-1
. 
HRMS: C15H19N2O4, Calculated: [M+H]+ 291.1345, Found: [M+H]+ 291.1345. 
 
Tambjamine K (3.14).  Isopentylamine (36.0 mg, 0.414 mmol) was added to a stirred 
suspension of aldehyde 3.19 (100 mg, 0.345 mmol) in methanol (5.0 mL) at room 
temperature, followed by 0.87 M HCl in methanol (0.6 mL). After 6 hours, the reaction 
was quenched with saturated sodium bicarbonate, extracted with dichloromethane (3 x), 
and washed with brine (1 x). The organic layers were combined, dried over anhydrous 
sodium sulfate, and concentrated in vacuo to give a dark brown residue. This residue was 
purified by reverse phase chromatography using acetonitrile and 0.1% TFA/water 
(gradient: 15:85 to 55:45) to give Tambjamine K as an orange oil that solidified upon 
standing (58 mg, 65%). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.95 (d, J = 6.8 Hz, 6H), 1.62 (q, J = 6.8 Hz, 2H), 
1.71 (m, 1H), 3.48 (q, J = 6.8 Hz, 2H), 3.93 (s, 3H), 5.98 (d, J = 2.4 Hz, 1H), 6.28 (m, 
1H), 6.75 (m, 1H), 7.09 (m, 1H), 7.33, (d, J = 15.2 Hz), 9.93 (s, 1H). 
13
C NMR (CDCl3, 
100 MHz)  (ppm): 22.1, 25.2, 38.7, 49.2, 58.3, 91.5, 110.5, 110.6, 113.6, 122.2, 124.5, 
140.0, 143.2, 164.0. IR (KBr) max 3234, 2960, 2917, 1674, 1605, 1529, 1463, 1428, 
1368, 1203, 1137, 968, 728, 721 cm
-1
. HRMS: C15H22N3O, Calculated: [M+H]+, 
260.1763, Found: [M+H]+, 260.1764. 
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General method for the synthesis of tambjamine unnatural analogs (3.21): primary 
amine (0.517 mmol) was added to a stirred suspension of aldehyde 16 (30 mg, 0.103 
mmol) in methanol (2.0 mL) at room temperature. 0.87 M HCl in methanol (0.6 mL) was 
subsequently added, and the reaction was stirred for 24 h. Reactions that had not reached 
completion by this time were stirred at 50 
o
C for an additional 24 h period. Reaction 
mixtures were concentrated, and crude compounds were purified by reverse phase 
chromatography using acetonitrile and 0.1% TFA/water to give tambjamine unnatural 
analogs 3.21 in yields ranging from 35–88%. 
 
 
 
 (Z)-N-benzyl-1-(4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methanamine (3.21u). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 3.91 (s, 3H), 4.61 (d,  J = 6.0 Hz, 2H), 5.97 (d,  J 
= 1.9 Hz, 1H), 6.28-6.30 (m, 1H), 6.76 (s, 1H), 7.10 (s, 1H), 7.33-7.42 (m, 6H), 10.44 
(bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 54.11, 58.56, 91.93, 110.91, 111.39, 
114.36, 122.41, 125.04, 128.18, 128.67, 129.35, 135.88, 139.83, 144.18, 164.68. IR 
(KBr) max 3235, 3116, 3034, 2931, 1683, 1603, 1532, 1203, 1163, 1137, 1119, 749 cm
-1
. 
HRMS: C17H18N3O, Calculated: [M+H]+ 280.1450, Found: [M+H]+ 280.1450. 
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(Z)-N-((4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methyl)-1,2,3,4-tetrahydro 
naphthalen-1-amine (3.21b). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 1.83-1.91 (m, 2H), 
1.94-2.00 (m, 2H), 2.12-2.17 (m, 2H), 2.75-2.82 (m, 1H), 2.88-2.96 (m, 1H), 3.89 (s, 
3H), 4.75 (q,  J = 5.8 Hz, 1H), 5.97 (d,  J = 1.9 Hz, 1H), 6.26-6.28 (m, 1H), 6.74-6.75 (m, 
1H), 7.09-7.10 (m, 1H), 7.18-7.30 (m, 6H), 10.09 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz) 
 (ppm): 18.54, 28.66, 30.56, 58.24, 91.62, 110.51, 110.73, 113.83, 122.19, 124.73, 
126.46, 128.44, 129.05, 129.73, 132.28, 138.08, 138.31, 143.44, 164.16. HRMS: 
C20H22N3O, Calculated: [M+H]+ 320.1763, Found: [M+H]+ 320.1760. 
 
(Z)-1-cyclopropyl-N-((4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methyl) 
methanamine (3.21d). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 0.36 (q. J = 5.6 Hz, 2H), 
0.67 (q, J = 5.6 Hz, 2H), 1.07-1.17 (m, 1H), 3.32 (t, J = 6.4 Hz, 2H), 3.93 (s, 3H), 5.98 
(d,  J = 1.8 Hz, 1H), 6.27-6.29 (m, 1H), 6.75 (s, 1H), 7.10 (s, 1H), 7.39 (d,  J = 15.0 Hz, 
1H), 10.04 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  (ppm): 3.90, 11.13, 55.68, 58.54, 
91.80, 110.75, 110.88, 113.90, 122.51, 124.73, 139.87, 143.51, 164.34. IR (KBr) max 
3243, 3013, 2932, 1682, 1606, 1531, 1429, 1245, 1204, 1165, 1138, 967, 834, 720 cm
-1
. 
HRMS: C14H18N3O, Calculated: [M+H]+ 244.1450, Found: [M+H]+ 244.1442. 
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(Z)-N-((4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methyl)-2,3-dihydro-1H-
inden-2-amine (3.21e). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 3.21 (dd,  J = 15.7, 7.0 
Hz, 2H), 3.36 (dd,  J  =15.7, 7.0 Hz, 2H), 3.93 (s, 3H), 4.37 (sex,  J  = 7.0 Hz, 1H), 5.98 
(d,  J = 2.4 Hz, 1H), 6.27-6.29 (m, 1H), 6.76 (s, 1H), 7.10 (s, 1H), 7.20-7.26 (m, 5H), 
7.42 (d,  J  = 15.0 Hz, 1H), 10.13 (bs, 1H).
13
C NMR (CDCl3, 100 MHz)  (ppm): 39.80, 
58.58, 61.39, 91.92, 110.86, 111.29, 114.31, 122.40, 124.85, 125.09, 127.42, 138.57, 
139.72, 144.06, 164.51. IR (KBr) max 3237, 3027, 2924, 1685, 1684, 1601, 1530, 1431, 
1363, 1293, 1201, 1135, 1119, 966, 752, 721 cm
-1
. HRMS: C19H20N3O, Calculated: 
[M+H]+306.1606, Found: [M+H]+ 306.1598. 
 
(Z)-N-((4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methyl)-2-(pyridin-2-yl) 
ethanamine (3.21i) 
1
H NMR (CDCl3, 400 MHz)  (ppm): 3.23 (t, J  = 7.0 Hz, 2H), 3.88 
(s, 3H), 3.98 (t,  J = 7.0 Hz, 2H), 5.91 (s, 1H), 6.26 (s, 1H), 6.72 (s, 1H), 7.05 (s, 1H), 
7.15 (dd,  J  = 7.4, 5.0 Hz, 1H), 7.28 (s, 1H), 7.61 (td,  J = 7.5, 1.6 Hz, 1H), 8.56 (d,  J = 
5.0 Hz, 1H), 9.63 (bs, 1H), 10.84 (bs, 1H).  13C NMR (CDCl3, 100 MHz)  (ppm): 38.18, 
50.07, 58.59, 91.33, 110.88, 110.99, 113.45, 122.14, 122.78, 124.38, 124.48, 136.98, 
140.85, 142.76, 149.70, 157.20, 164.13. IR (KBr) max 3184, 3098, 2926, 2850, 1662, 
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1601, 1528, 1550, 1457, 1312, 1186, 1136, 747 cm
-1
. HRMS: C17H19N4O, Calculated: 
[M+H]+ 295.1559, Found: [M+H]+ 295.1555. 
 
(Z)-N-(2,3-difluorobenzyl)-1-(4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene) 
methanamine (3.21t). 
1
H NMR (CDCl3, 400 MHz)  (ppm): 3.93 (s, 3H), 4.67 (d,  J = 
6.0 Hz, 2H), 5.98 (d,  J  = 2.2 Hz, 1H), 6.28-6.30 (m, 1H), 6.77-6.79 (m, 1H), 7.10-7.22 
(m, 4H), 7.39 (d,  J  = 14.6 Hz, 1H), 10.32 (bs, 1H). 
13
C NMR (CDCl3, 100 MHz)  
(ppm): 47.45, 58.66, 92.06, 111.06, 111.66, 114.79, 117.86, 118.03, 122.31, 125.18, 
125.34, 139.62, 144.78, 165.10. IR (KBr) max 3236, 3117, 3017, 2933, 1683, 1601, 
1533, 1494, 1202, 1138, 957, 756, 748, 721 cm
-1
. HRMS: C17H16N3OF2, Calculated: 
[M+H]+ 316.1261, Found: [M+H]+ 316.1263. 
 
 
Viability assay method: SW620 and H520 cells (2.5 x 10
4
/100 l) were seeded in 96-well 
microtiter plates prior to treatment. Cells were treated with 10 M concentration of 
synthesized compound in quadruplicate for 24 h and 48 h in RPMI 1640 Supplemented 
media and 100 g/ml penicillin–streptomycin. The Quick Cell Proliferation Assay Kit 
from BioVision (Mountain View, CA) was used to measure proliferation. The RPMI 
media is removed and replaced with 100 l of the WST-1/ECS reagent diluted 1:10 in 
RPMI Supplemented media. The plates are incubated for 1 h at 37
o
C in 5% CO2 in the 
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air. The change in proliferation is quantified by measuring the absorbance of the dye 
solution at 450 nm on a microtiter plate reader.  
 
Invasion assay method: SW620 cells (1.0 x 10
6
/ml) were seeded in 6 mm round dish prior 
to treatment. Cells were treated with 10 M concentration of synthesized compound for 
24 h in RPMI 1640 supplemented media and 100 g/ml penicillin–streptomycin. 40 l 
(2.5 mg/ml) of BD Matrigel Basement Membrane Matrix (BD Biosciences, Bedford, 
MA) was added to the top of insert of 24-well transwell permeable support plates with 
polycarbonate membrane (Corning Inc, Corning, NY). Then the cells were trypsinized 
and 3 x 10
5
/250 l cells were added to the top of the chamber in serum free RPMI media, 
and 1 ml of RPMI media with 10% FBS was added to the bottom of the well. Then the 
plates were incubated for 72 h at 37
o
C in 5% CO2 in the air. Then the wells were stained 
with 1% crystal violet in 50% methanol for 1 h and washed in PBS. The membrane was 
cut off, adhered to a slide with glycerol, and analyzed in 20x field via microscopy. 3–20x 
fields were quantified per membrane. 
 
 
 
 
 
 
 
 
321 
 
5.4. Technology Enabled Synthesis and Biological Evaluation of 3,6-disubstituted-  
       [1,24]-triazolo[4,3-b] pyridazines as M1 Antagonists for Treatment of Dystonias 
 
Typical MAOS experimental for 6-chloro-3-p-tolyl-[1,2,4]-triazolo-[4,3-b] pyridazine 
(4.13e). (Method A) To a 5 mL microwave reaction vessel were added 3,6-
dichloropyridazine (100 mg, 0.671 mmol) and p-toluic hydrazide (111 mg, 0.738 mmol) 
in a 3.0 mL solution of 5% AcOH/EtOH. The vial was irradiated in a microwave 
synthesizer at 150 
o
C for 10 min. LCMS (single peak, 2.91 min, m/e, 245.1 (M+1)) 
indicated that all starting material had been consumed affording 131 mg (80%) of 6-
chloro-3-p-tolyl-[1,2,4]triazolo[4,3-b]-pyridazine as a white solid following column 
purification. (Method B) To a 5 mL microwave reaction vessel were added 3,6-
dichloropyridazine (100 mg, 0.671 mmol) and p-toluic hydrazide (111 mg, 0.738 mmol) 
in a 3.0 mL solution of 5% 4 N HCl/EtOH. The vial was irradiated in a microwave 
synthesizer at 150 
o
C for 10 min. LCMS (single peak, 2.91 min, m/e, 245.1 (M+1)) 
indicated that all starting material had been consumed affording 156 mg (95%) of 6-
chloro-3-p-tolyl-[1,2,4]triazolo[4,3-b]pyridazine as a white solid following a silica plug 
and concentration in vacuo.  
1
H NMR  (DMSO-d6, 600 MHz)   (ppm):  2.41 (s, 3H), 7.43 (d, J = 8 Hz, 2H), 7.53 (d, 
J = 9.7 Hz, 1H), 8.19 (d, J = 8.2 Hz, 2H), 8.52 (d, J = 9.7 Hz, 1H); 
13
C NMR (DMSO-d6, 
150 MHz)  (ppm): 21.1, 122.5, 122.8, 127.1, 127.3, 129.5, 140.3, 143.8, 146.8, 149.1; 
LC–MS: single peak, 2.91 min, m/e, 245.1 (M+1). 
 
Typical MAOS experimental for N-(4-methoxybenzyl)-3-p-tolyl-[1,2,4]triazolo[4,3-
b]pyridazin-6-amine. To a 5 mL microwave reaction vessel were added 6-chloro-3-p-
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tolyl- [1,2,4]-triazolo-[4,3-b]pyridazine (50 mg, 0.205 mmol) and 4-methoxy-benzyl 
amine (35 L 6 mmol) in 3.0 ml of ethanol. The vial was heated in a microwave 
synthesizer to 170 
o
C for 25 min. Preparative LCMS afforded 51.6 mg (73%) of N-(4-
methoxybenzyl)-3-p-tolyl-[1,2,4]-triazolo-[4,3-b]pyridazin-6-amineas a white solid.  
1
H NMR (DMSO-d6, 600 MHz)  (ppm): 2.38 (s, 3H), 3.71 (s, 3H), 4.41 (d, J = 5.5 Hz, 
2H), 6.88 (d, J = 9.9 Hz, 1H), 6.92 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 6.7 Hz, 2H), 7.36 (d, 
J = 8.5 Hz, 2H), 7.97 (d, J = 9.8 Hz, 1H), 8.21 (d, J = 8.2 Hz, 2H). 
13
C NMR (DMSO-d6, 
150 MHz)  (ppm): 21.5, 44.7, 55.5, 114.2, 117.0, 124.4, 124.6, 127.0, 129.3, 129.6, 
130.9, 139.4, 143.8, 146.3, 154.1, 158.8; LC–MS: single peak, 3.00 min, m/e, 346.2 
(M+1). 
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Appendix A1: 
 
Spectra Relevant to Chapter 2 
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 Appendix A2: 
 
Spectra Relevant to Chapter 3 
 
 
 
 
 


















